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Thesis abstract 
Vitamin D insufficiency is seasonally endemic in populations north of the 40th parallel, 
and epidemiological data show an association with colorectal cancer risk and prognosis. 
Molecular mechanisms that underpin the relationship are not well established. Vitamin D 
status is shown to be associated with age-related silencing of tumour suppressors in 
colonic stem cells via aberrant DNA methylation, suggesting that insufficiency 
contributes to transformation. In this text, vitamin D’s ability to promote bowel health 
via modification of DNA methylation patterns has been investigated. 
Chronic inflammation drives tumourigenesis, and vitamin D is recognised to promote 
proper immune function. Data presented here confirm that vitamin D differentiates 
monocytes to a tissue-resident macrophage phenotype. D-mediated differentiation is 
associated with hypomethylation of the TNFα promoter and response to LPS. Thus, we 
suggest that vitamin D attenuates aberrant DNA methylation in colonic stem cells by 
promoting resolution of systemic inflammation. 
Mucosal inflammation mediated by PGE2 promotes aberrant DNA methylation. 
Pericryptal myofibroblasts interact with colonic stem cells via their secretomes, which 
are a source of PGE2. Supernatants from primary intestinal myofibroblasts were 
characterised by LC/MS mass spectroscopy in response to vitamin D. Vitamin D 
attenuated TNFα-induced transcription of COX2 and PGE2 secretion. PGE2 induced 
hypermethylation of SOX17 and DKK1 in colonic organoids, and myofibroblast 
supernatants regulated DNA methyltransferase activity in case-matched organoids. 
Furthermore, vitamin D ameliorated established aberrant DNA methylation in organoids 
propagated from inflamed mucosa. Thus, we suggest that vitamin D attenuates mucosal 
inflammation, and the effects of PGE2 driving aberrant DNA methylation in colonic stem 
cells. 
Vitamin D status predicts colorectal cancer survival. The effects of vitamin D sufficiency 
on colorectal cancer cell lines was investigated. Vitamin D-treated cells exhibit a 
modified methylome, reduced transcription of MAP kinases, reduced phosphorylation of 
ERK1 and 2, and inhibition of proliferation. Thus we suggest that vitamin D sufficiency 
improves colorectal cancer prognosis via modification of established aberrant DNA 
methylation. Taken together, data support vitamin D sufficiency promoting bowel health 
via attenuation of aberrant age-related DNA methylation in colonic stem cells. 
  
4 
 
Acknowledgements 
Without question, my sincere thanks are extended first and foremost to Dr 
Nigel Belshaw, not only for his unwavering support in the face of the challenging 
circumstances, but also for providing the insightful theoretical framework that 
forms the basis of this study. Thank you Nigel, for your commitment, lateral 
support, and championship. 
Furthermore I appreciate greatly Professor Ian Johnson fighting my corner; your 
encouragement and objective criticism have enabled me to understand the 
scientific validity and impact of my work in a broader context. Thanks are also 
extended to Drs Giles Elliot, Wing Leung, and Ellen Maxwell for their 
companionship, and initial direction and assistance.  
I’m indebted to Drs Paul Kroon, Nathalie Juge, and Carmen Pin for their pastoral 
care keeping me on track during tricky transitional periods. Thanks especially go 
to my friends Drs Barnabas Shaw, Aimee Parker, and Laura Vaux, for welcoming 
me to their group(s), and for the daily logistical support and encouragement; it’s 
by no means an exaggeration to say that I couldn’t have done it without you! 
I must also sincerely thank UEA and The Institute for the exceptional 
opportunities afforded to me during the course of the project - practicing 
science on no fewer than three continents in as many years. 
Finally I would like to extend warm thanks to my close friends and family, for 
their (apparent) interest in my research and rallying encouragement, which has 
proved indispensable - especially Jemma, whose inspiring words have given me 
the confidence to get the job done on countless occasions. I must also extend a 
debt of gratitude to my original champions, Professor Richard Ball, Drs Danni 
Peat, and Peter Cousens, for holding open the doors that have brought me to 
this juncture; I doubt they’ll ever read this, but it’s true none the less. 
Cheers all - this text is in honour of, and in return for, your investment in me - I 
hope to continue doing it justice. 
  
5 
 
Contents 
Declaration ............................................................................................................................. 2 
 
Thesis abstract ....................................................................................................................... 3 
 
Acknowledgements .............................................................................................................. 4 
 
Contents ................................................................................................................................. 5 
List of figures ..................................................................................................................... 8 
List of common abbreviations ..................................................................................... 10 
 
Chapter 1 .............................................................................................................................. 12 
Abstract ............................................................................................................................ 13 
Vitamin D - an evolutionary perspective ................................................................... 14 
Physiology and molecular biology of vitamin D ....................................................... 16 
Colonic homeostasis and neoplasia ............................................................................ 32 
In summary ....................................................................................................................... 48 
Research questions; ....................................................................................................... 49 
Hypotheses ...................................................................................................................... 50 
Aims and objectives ....................................................................................................... 51 
Notes ................................................................................................................................. 53 
 
Chapter 2 .............................................................................................................................. 54 
Experimental approach .................................................................................................. 55 
Readouts ........................................................................................................................... 59 
Materials ........................................................................................................................... 60 
General methods ............................................................................................................ 60 
 
Chapter 3 .............................................................................................................................. 73 
Preface to the work ....................................................................................................... 74 
Abstract ............................................................................................................................ 76 
Introduction ..................................................................................................................... 77 
Methods ............................................................................................................................ 81 
Results ............................................................................................................................... 84 
Lester’s Oil intervention .......................................................................................... 84 
In vitro verification with THP1 leukemic monocytes .......................................... 89 
Discussion ........................................................................................................................ 97 
In summary ................................................................................................................ 102 
 
  
6 
 
Chapter 4 ............................................................................................................................ 103 
Preface to the work ..................................................................................................... 104 
Abstract .......................................................................................................................... 107 
Introduction ................................................................................................................... 108 
Methods .......................................................................................................................... 111 
Results ............................................................................................................................. 115 
Effect of TGFβ1 on the phenotype of InMyoFib ............................................... 115 
Effect of TGFβ1 on the methylome of InMyoFib .............................................. 120 
Effect of TGFβ1 in combination with Vitamin D .............................................. 126 
Discussion ...................................................................................................................... 132 
In summary ................................................................................................................ 137 
 
Chapter 5 ............................................................................................................................ 139 
Preface to the work ..................................................................................................... 140 
Abstract .......................................................................................................................... 143 
Introduction ................................................................................................................... 144 
Methods .......................................................................................................................... 146 
Results ............................................................................................................................. 149 
Effects of vitamin D in primary myofibroblasts ................................................. 149 
The myofibroblast secretome ............................................................................... 154 
Effects of myofibroblasts supernatants on the epithelia .................................. 160 
Discussion ...................................................................................................................... 170 
Summary .................................................................................................................... 177 
 
Chapter 6 ............................................................................................................................ 178 
Preface to the work ..................................................................................................... 179 
Abstract .......................................................................................................................... 181 
Introduction ................................................................................................................... 182 
Methods .......................................................................................................................... 186 
Results ............................................................................................................................. 189 
Effects of vitamin D in colorectal cancer cell lines ........................................... 189 
Effects of vitamin D on global DNA methylation patterns ............................. 194 
Discussion ...................................................................................................................... 208 
Summary .................................................................................................................... 215 
 
 
  
7 
 
Chapter 7 ............................................................................................................................ 216 
Discussion ...................................................................................................................... 217 
Recommendations for further work ........................................................................ 226 
Concluding remarks ..................................................................................................... 228 
 
References .......................................................................................................................... 229 
 
Appendices ......................................................................................................................... 267 
 
  
  
8 
 
List of figures 
1. Vitamin D physiology and epidemiology …………...……….…… ….……….(20) 
2. Topography of the colonic crypts…………………..…..……………………..(33) 
3. Epithelial homeostasis in the distal bowel……….……..……………………..(38) 
4. Dynamics of DNA methylation………………………………………….……(47) 
5. Graphical abstract ……………………………………………………………(53) 
6. Oncogenic mutations in colorectal cancer cell lines…………………………(57) 
7. Suitability and limitations of selected models ………………………………...(58) 
8. Assays, readouts, and effects measured ……………………………………...(59) 
9. Cell culture conditions ……………………………………………………….(61) 
10. Combined Bisulphite Restriction Analysis …………………………………...(70) 
11. Lester’s Oil trial protocols …………………………………………………...(83) 
12. Lester’s Oil cohort variables at base line ……………………………………(84) 
13. Lester’s Oil results, stratified ………………………………………………...(86) 
14. TNFα promoter DNA methylation status in the Lester’s Oil trial…....……...(88) 
15. The effects of vitamin D in THP1 monocytes ………………………………..(92) 
16. Inducing differentiation in THP1 monocytes………………………………….(95) 
17. Five-methyl cytosine metabolism in THP1 monocytes ………………………(96) 
18. TGFβ1 effects on the phenotype of Intestinal Myofibroblasts ……....……...(117) 
19. Effects of TGFβ1-induced myofibroblast supernatants on colorectal cancer cell 
line phenotype ………………………………………………………………(119) 
20. Methylation array results – sample variability and clustering (TGFΒ1) …….(121) 
21. Pathway analysis and gene ontology of methylation array results ………….(125) 
22. Methylation array results – sample variability and clustering (TGFΒ1 + VITD) 
……………………………………………………………………………….(127) 
23. Transcriptional profiles of vitamin D and TGFΒ1 in combination ……….....(130) 
24. Vitamin D and TGFΒ1 receptor expression ………………………………..(131) 
25. Validation of three human primary myofibroblast lines …………………….(142) 
26. Transcriptional profiles of inflamed myofibroblasts ………………………...(150) 
  
9 
 
27. COX2 transcripts predict secreted PGE2 concentration ………………….(152) 
28. The COX2HIGH/PGE2HIGH phenotype in primary myofibroblasts …………...(153) 
29. Pathway analysis and gene ontology of proteins differentially regulated in 
primary myofibroblasts ……………………………………………………...(156) 
30. Interleukin 6 transcription in the COX2HIGH phenotype …………………...(158) 
31. The inflamed myofibroblast secretome ……………………………………..(159) 
32. Myofibroblast supernatants regulate DNA methylation metabolism in case 
matched organoids ………………………………………………………….(163) 
33. Myofibroblast supernatants regulate vitamin D metabolism in case matched 
organoids ……………………………………………………………………(165) 
34. PGE2 induces Wnt antagonist hypermethylation and regulates DNA 
methylation metabolism and organoid differentiation ……………………...(168) 
35. Vitamin D ameliorates SOX17 promoter hypermethylation in previously 
inflamed colonic organoids ……..…………………………………………...(169) 
36. Preliminary experiments in colorectal cancer cell lines ……………………(180) 
37. Graphical abstract for Chapter Six …………………………………………(186) 
38. Antiproliferative effects of vitamin D in colorectal cancer cell lines    …….(190) 
39. Vitamin D effects differential DNA methylation and 5mC metabolism in DLD1 
cells ………………………………………………………………………….(193) 
40. DNA methylation array results after long term vitamin D sufficiency ……..(197) 
41. DNA methylation array results after long term vitamin D sufficiency 
CONTINUED  ……………………………………………………………...(198) 
42. Wnt antagonist methylation profiles in D-sufficient colorectal cancer cell lines 
……………………………………………………………………………….(201) 
43. Pathway analysis of DNA methylation array results ………………………..(203) 
44. The modified CaCO2 phenotype …………………………………………...(205) 
45. ERK1 and ERK2 phosphorylation Western blots.................................................(206) 
46. 5mC metabolism in in vitro aged, D-sufficient CaCO2 cells...............................(207) 
47. Mutational profiles of colorectal cancer cell lines................................................(209) 
48. Organoids as a model of in vitro ageing...................................................................(225) 
  
10 
 
List of common abbreviations 
5AZA  5-Aza-2'-deoxycytidine 
5hmC  Five Hydroxy Methyl Cytosine 
5mC  Five Methyl Cytosine 
7DHC  Seven De Hydro Cholesterol 
APC  Antigen Presenting Cell/Adenomatous Polyposis Coli 
aSMA  alpha Smooth Muscle Actin 
BCAT  Beta Catenin 
BMI  Body Mass Index 
BMP  Bone Morphogenic Protein 
CAC  Colitis-Associated Cancer 
CAF  Cancer-Associated Fibroblast 
CALP  Calprotectin 
CD  Cluster of Differentiation 
CG  Cytosine-phosphate-guanine (CpG dinucleotide) 
CGI  CG Island 
CGS  Cambridge Genomic Services 
CHIP  Chromatin Immuno Precipitation 
CIMP  CG Island Methylator Phenotype (a sub-type of CRC 
COBRA Combined Bisulphite Restriction Analysis 
COMB  Combined/Combination 
CRC  Colorectal cancer 
CRP  C - reactive protein 
CSC  Crypt/Colonic Stem Cell 
CTRL  Control (vehicle) 
CYC  Cyclin 
Cyp24a1 Catabolic vitamin D enzyme 
Cyp27a1 Anabolic vitamin D enzyme 
DBP  D-binding protein 
DKK  Dickkopf Protein 
DNAm  DNA methylation 
DNMT DNA Methyltransferase (cytosine methylating enzyme) 
ECM  Extra Cellular Matrix 
FAP  Fibroblast Activation Protein 
FBS  Foetal Calf Serum 
GPCR  G-Coupled Protein Receptor 
HDAC  Histone Deacetylase 
IBD  Inflammatory Bowel Disease 
IHC  Immunohistochemistry 
INF  Intestinal Fibroblast 
InMyoFib Intestinal Myofibroblast 
  
11 
 
KB  Kilo-base 
LC/MS-MS Liquid chromatography/Mass Spectroscopy 
LINE  Long Interspersed Nuclear Elements 
LO  Lester’s Oil 
LPS  Lipopolysaccharide (Endotoxin) 
Mac  Macrophage 
MFB  Myofibroblast 
MΦ  Monocyte 
PB  Peripheral Blood 
PBMC  Peripheral Blood Mononucleated Cell 
PBS  Phosphate Buffered Saline 
PGE2  Prostaglandin E2 Synthase 
PMA  Phorbol 12-myristate 13-acetate 
PS  Penicillin Streptomycin 
PTH  Para Thyroid Hormone 
QMSP  Quantitative Methylation Specific PCR 
Q-rt-PCR Quantitative Real Time Polymerase Chain Reaction 
RSPO  r-spondin1 
RXR  Retinoid X Receptor 
SAM  S-Adenosyl-methionine (universal methyl donor) 
SEM  Standard Error of the Mean 
SFRP  Secreted Frizzled Related Protein 
TBST  Tris Buffered Saline-Tween 
TET  Ten-Eleven-Translocation (cytosine de-methylating enzyme) 
TGFΒ1 Transforming Growth Factor Beta One 
TLR  Toll-like Receptor 
TNFα  Tumour Necrosis Factor Alpha 
TRM  Tissue Resident Macrophage 
TRNS  Transfected 
TS  Tumour Suppressor 
TSS  Transcription Start Site 
TUSC  Tumour Suppressor Candidate 
UC  Ulcerative Colitis 
VDR  Vitamin D Receptor 
VDRE  Vitamin D Response Element 
VIM  Vimentin  
VITD  Vitamin D 
WA  Wnt Antagonist 
WIF  Wnt Inhibitory Factor 
 
 
  
12 
 
 
 
 
 
Chapter 1 
 
VITAMIN D STATUS AND COLORECTAL CANCER RISK; 
A ROLE FOR DNA METHYLATION? 
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Abstract 
The secosteroid hormone Vitamin D is recognised to exert pleiotropic anti-proliferative 
and anti-inflammatory effects, and epidemiological data indicate vitamin D status is 
associated with a raft of age-related diseases, including auto-inflammatory and neoplastic 
pathologies of the distal bowel. This raises the possibility that chronic vitamin D 
insufficiency initiates and maintains colorectal pathogenesis. While incidence of severe 
deficiency is relatively rare, asymptomatic insufficiency is seasonally endemic in 
populations north of the 40th parallel, which may be addressed by proper 
supplementation. As such, this represents a significant opportunity for public health 
providers to favourably influence morbidity and mortality due to colorectal cancer 
(CRC). 
Vitamin D’s role as a causative factor in epithelial transformation remains speculative 
due to the paucity of corroborating evidence from clinical interventions. Recently 
however, prospective associations have been reported between vitamin D status and 
aberrant DNA methylation (DNAm) patterns in transformation-prone epithelia, 
suggesting an aetiological role for insufficiency in cancer initiation. In apparently healthy 
mature gut epithelia, aberrant methylation of promoter CG dinucleotides silences 
tumour suppressor antagonists of the Wnt pathway. This results in unchecked 
proliferation of colonic stem cells and tumour formation in the context of acquired 
mutations. Thus, aged epithelia may be thought of as ‘epigenetically primed’ for 
transformation. Vitamin D sufficiency is proposed to attenuate age-related increases in 
aberrant DNA methylation, preserving Wnt tumour suppressor function in later life.  
In this review, the theoretical premise for the thesis is examined, exploring the 
consensus relationship between vitamin D and epithelial homeostasis in the distal bowel, 
as well as speculative epigenetic modes of action by which vitamin D might promote 
bowel health. Aspects of systemic physiology regarding chronic inflammation, chemokine 
signalling in the crypt niche, and autonomous regulation of Wnt with regard aberrant 
DNAm, are addressed. Taken together, the current framework suggests that vitamin D 
promotes bowel health by modulating DNAm in cancer-prone stem cells via 
management of local inflammation and/or 5-methyl-cytosine metabolism - overarching 
hypotheses upon which these experiments were based. 
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Vitamin D - an evolutionary perspective 
 
In 1922, McCollum’s observation - that a fat-soluble compound in cod liver oil 
could resolve childhood rickets - set the scene for the discovery of a novel 
hormone essential for proper skeletal development1. Shortly afterwards, Hess 
and colleagues in Vienna published their lateral observation that sunlight too 
conferred beneficial effects on bone health2. A few years later, Steenbok et al 
linked the two processes, concluding that irradiation of epidermal lipids by 
sunlight yields an active compound intrinsically involved in calcium metabolism3. 
Being the fourth essential nutrient to be discovered, the compound was given 
the unassuming title ‘Vitamine D’, and the hormone entered the collective 
consciousness. 
Ten years later, Windaus and Bock identified the vitamin D precursor 7-
dehydrocholesterol (7DHC), present as an impurity in epidermal cholesterol, 
and shortly afterwards described its structure, for which they were awarded the 
Nobel prize 19384. They went on to establish that irradiation of 7DHC with UV 
light produces minute quantities of  pre-vitamin D (cholecalciferol), and the 
complete photochemistry of the compound was published in 19555. It was 
another 25 years however, until Hollick and his team published their seminal 
paper, detailing the physiology of vitamin D production from 7DHC, in the basal 
strata of the epidermis (figure 1a)6. 
A century on from its discovery, Vitamin D continues to engage researchers 
(figure 1b). In terms of tissue specificity, expression of the nutrient’s cognate 
nuclear receptor - the Vitamin D Receptor (VDR) - is almost ubiquitous, directly 
regulating 1000+ genes exhibiting promoter binding sites, which in turn influence 
many more7. Since its discovery, publications addressing every facet of vitamin D 
metabolism and pathophysiology have increased exponentially and there is no 
indication that interest in the hormone is waning, particularly with contemporary 
insights into the ‘silent’ pandemic of vitamin D insufficiency (serum D <50nM/L) 
and associations with age-related disease 8. 
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In an evolutionary context, vitamin D metabolism is well conserved between 
clades, functioning even in phytoplankton, where it is thought to have conferred 
protection on photosensitive nucleic acids for over 500 million years9. Its role in 
mediating calcium absorption took centre stage during the Palaeozoic era where, 
in the absence of marine electrolytes, novel terrestrial organisms fortified newly 
evolved skeletons through consumption of flora, that in turn derived calcium 
from the soil, allowing them to support the increasingly heavy frames 
necessitated by advancing tissue complexity10. Specifically, bipedal locomotion has 
selected for individuals with an endoskeleton robust enough to endure passage 
through a constricted birth canal, and importantly the vitamin D system is 
thought to have been fundamental in determining skin pigmentation, allowing for 
sufficiency at higher latitudes (the exception being darker skinned Inuit 
populations and others who derive their vitamin D through the consumption of 
oily fish)11.  The aetiology of deficiency itself is a relatively recent development in 
industrialised societies, precipitated by cultural practices that inhibit epidermal 
production of vitamin D, such as garment wearing, urbanisation, and ethnic 
migration – a phenomenon known as environmental mismatch12. 
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Physiology and molecular biology of vitamin D 
 
Endogenously produced, and containing an open steroid ring, vitamin D is 
technically a secosteroid pro-hormone, as opposed to an essential dietary 
vitamin, and the body is capable of synthesizing sufficient quantities of vitamin D 
for proper physiological function. Vitamin D may be derived either from sunlight 
or dietary factors, although proportionally dietary vitamin D (principally dairy, 
oily fish, mushrooms, and fortified cereals) accounts for only 15% of total13. 
Mechanistically, vitamin D is produced by the action of ultraviolet light 
(wavelength 280-230nM) in the basal strata of the epidermis, cleaving 7DHC to 
produce thermodynamically unstable pre-vitamin D. Further isomerisation forms 
the active precursor, cholecalciferol. 
The metabolic activity of the pro-hormone is limited to its interaction with the D 
binding protein (DBP) in the blood, an alpha globulin that binds and transports 
vitamin D and all of its metabolites. Cholecalciferol is either taken up and stored 
in adipocytes, or activated enzymatically by hepatocytes, where it is hydroxylated 
to 25-hydroxy vitamin D (serum calcidiol). The reaction is catalysed by a host of 
feedback-regulated mitochondrial CYP450 enzymes, principally microsomal 
CYP2R1 and mitochondrial CYP27A114-16. 
Clinically, plasma concentrations of calcidiol are considered the most relevant 
marker of vitamin D status due to its long half-life and high serum concentration 
relative to the activated form (~one month vs 24 hours)17,18. Concentrations are 
normally distributed within the range 20–150 nM/L, with insufficiency defined as 
<50-80 nM/L depending on source19. Impaired calcium absorption and risk of 
pathological bone metabolism manifests at levels <30nM/L20,21. Calcidiol 
production by hepatocytes is negatively regulated by feedback from increased 
CYP27A1 expression22. 
The D-binding protein transports calcidiol to the kidneys, whereupon it 
undergoes  terminal hydroxylations in the renal tubules, yielding the biologically 
active form - 1α25(OH)D3 (calcitriol), mediated via the action of CYP27B1
23,24.  
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Given the pivotal role of calcium in cellular signalling (nerve innervation/osteoid 
mineralisation/muscle contraction), stability of interstitial calcitriol is vital for 
robust control of ion gradients across cell-membranes; CYP27B1 activity, and 
thus calcitriol production, are tightly regulated according to the availability of 
calcidiol substrate, parathyroid hormone (PTH), and calcium ion concentration, 
as well as by negative feedback from calcitriol itself25,26. Consequently plasma 
concentrations remain relatively stable, ranging between 20-200 pM/L, with a 
half-life of between 4-36 hours depending on source27,28. Due to its unstable 
nature, a reference range has been difficult to determine, but a cut-off of around 
40 pM/L has been for proposed for health (figure 1c)29. 
Anabolic CYP27B1 activity has also been observed at a variety of extra-renal 
sites not associated with classical vitamin D physiology such as the prostate, 
pancreatic islets, adrenal glands, lymph nodes, brain, lungs, thymus, placenta, 
epidermis, and intestinal epithelium24. The enzyme is also expressed in immune 
cells (macrophages, dendrocytes, & T cells)30, in hyperproliferative inflammatory 
conditions such as psoriasis and sarcoidosis, and in various tumours and cancer 
cell lines31, including colorectal carcinoma32 where it is initially over-expressed in 
early tumourigenesis33 but notably absent in higher grade cancers34. 
Finally, active D is degraded by CYP24A1, which converts vitamin D to water-
soluble calcitroic acid that is subsequently excreted by the kidneys35. Aberrant 
transcription of CYP24A1 may be considered oncogenic, as over-expression in 
neoplastic tissues promotes pathological degradation of calcitriol, abrogating 
vitamin Ds homeostatic effects - as evidenced by over-expression of CYP24A1 in 
aggressive colorectal cancers36,37. 
Asymptomatic vitamin D insufficiency is seasonally endemic 
Seasonal variation in serum vitamin D is reported in populations north of the 40th 
parallel (figure 1e)38. According to a definition for insufficiency  of <75nM/L, it is 
estimated that more than one billion people globally suffer from asymptomatic 
seasonal hypovitaminosis D21. Furthermore, age-related impaired epidermal 
synthesis of vitamin D is exacerbated by chronic immobility in ageing 
populations39. Bioavailability also depreciates in obese subjects due to adipocyte 
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uptake or via reduced duodenal absorption from inflammatory bowel 
conditions40,41. Finally, chronic liver and kidney pathologies - key sites of vitamin 
D synthesis - result in decreased production42. These observations recently 
prompted the UK government to review vitamin D supplementation and issue 
official advice, suggesting that most individuals will benefit from 10ug per day 
seasonal supplementation, with at-risk groups indicated for year-round 
administration.43 
Insufficiency is associated with higher all-cause mortality and implicated in the 
aetiology of several pathologies, increasing the risk of metabolic bone disorders44, 
multiple sclerosis, diabetes45, breast cancer46 and prostate cancer47, as well as 
neurocognitive dysfunction, infection and autoimmunity, and cardiovascular 
disease48. In 1980 Garland and Garland published their seminal paper observing 
the relationship between colorectal cancer rates and geographical location49. 
Subsequently many epidemiological studies have confirmed the inverse 
association between serum D and colorectal cancer risk (figure 1d)50. 
Molecular physiology 
Interstitial vitamin D mediates a rapid genomic response in target cells via plasma 
membrane-associated VDR, enriched at caveolae, which effects prompt 
internalisation and signal transduction51. VDR is expressed ubiquitously 
throughout the body indicating the myriad of cellular activities administered by 
the vitamin D endocrine system. Given its near-universal expression it has been 
suggested that vitamin D directly or indirectly regulates up to 5% of the 
genome52,. Weight has been added to this assertion by array-targeted approaches 
that demonstrate genomic response elements numbering in excess of 2000, 
associated with more than1000 genes involved in 100+ independent pathways53,54. 
Once bound, VDR undergoes conformational change and translocates to the 
nucleus where it forms a heterodimer with retinoid X receptors (RXR)55. Typical 
of steroid hormones, the complex recruits coactivators/repressors, and zinc 
fingers bind DNA at Vitamin D Response Elements in the promoter regions of 
target genes (VDREs)56. VDREs consist of sequential hexameric binding sites with 
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a tri-nucleotide spacer, and target genes have been shown via CHIP-seq to 
contain several response motifs57,58. 
Coactivators induce chromatin accessibility via histone acetylation, and vitamin D 
receptor-interacting protein (DRIP) attracts RNA polymerase. Conversely, 
repression is mediated by VDR-interacting repressor (VDIR) and Williams’s 
syndrome ATP-dependent chromatin remodelling complexes (WINACs) that 
associate with the VDR/RXR heterodimer, recruiting histone deacetylases and 
facilitating gene repression via chromatin remodelling59.  Incidental to this 
project, vitamin D also stimulates a non-genomic response in calcium ion kinetics 
via GPCR binding with speedy RAS-MAPK transduction60, fundamental for muscle 
innervation. Presenting symptoms of severe hypovitaminosis include sporadic 
muscle twitching (fasciculations)61. 
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Figure 1 - Vitamin D physiology and epidemiology A) Photolytic degradation of epidermal 7DHC 
produces pro-hormone cholecalciferol. This is transported by the D-binding protein to the liver, and then 
the kidneys and other target tissues, where activating hydroxylations by Cyp27A and B1 catalyse the 
conversion of cholecalciferol to biologically active calcitriol via calcidiol. Finally, Cyp24a1 – a vitamin D 
regulated product – deactivates calcitriol, and water-soluble calcitroic acid is excreted. Cyp24a1 is 
oncogenic when overexpressed in neoplastic tissues, establishing vitamin D insensitivity, and promoting 
proliferation. B) A Pubmed search for articles containing the term ‘vitamin D’ in their title demonstrates 
an exponential (R2 = 0.9376) increase in the number of publication pertaining to vitamin D since its 
inception in the early 20th century. C) Reference ranges for serum and activated vitamin D derived from 
various publications; there is no global consensus for vitamin D sufficiency, and these values represent the 
most commonly reported concentrations for the preservation of health20,62,63. Insufficiency is typically 
asymptomatic in the acute phase, however may act over the lifetime of an organism to precipitate 
associated health disparities. D) A meta-analysis of nine prospective studies investigating the relationship 
between serum vitamin D (x axis, nM/L) and colorectal cancer risk (y) suggests a dose-response 
association. Adjusted relative risks and 95% CIs (dashed lines) are reported (adapted from64). E) Shows 
proportion of the UK populace who’s serum vitamin D levels seasonally fail to attain the 40nM/L definition 
for sufficiency, adapted from65. Even in summer months, as much as 30% of the English population and 
40% of the Scottish population may be defined as having insufficient vitamin D, leaping to 60%+ at the end 
of winter. Vitamin D insufficiency as a public health concern was addressed recently by the UK 
government’s advisory panel, suggesting supplementation for all citizens during winter months, although 
the necessity and value of this health initiative is contested43,66 
 
A B 
C D 
E 
 
Serum D (nmol/L) 
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Physiology/Pathophysiology 
The classical role of vitamin D in target tissues is to control calcium and 
phosphate metabolism by regulating serum ion concentrations67, promoting 
uptake of dietary calcium in the duodenal epithelium (via induction of calbindin) 
and reabsorption of plasma calcium in the renal tubules68.  This is effected by low 
serum calcium induction of parathyroid hormone (PTH) synthesis in chief cells, 
that stimulates calcitriol production69. Ossification of osteoid collagen, and 
reabsorption of skeletal calcium by osteoclasts, is mediated in harmony with PTH 
and calcitonin via RANK/RANKL signalling, establishing proper mineralisation of 
skeletal bones70,71. 
As predicted by the ubiquity of VDR, vitamin D exerts a variety of non-calcaemic 
effects, particularly with regards to immune function, inflammatory mechanisms, 
and tissue homeostasis, inhibiting proliferation and inducing differentiation and 
apoptosis in a variety of models72. 
Vitamin D acts as an anti-inflammatory and is associated with chronic 
inflammatory pathologies of the distal bowel 
 
Vitamin D status is associated with both adaptive and innate immune functions, 
evidenced by the increased risk of autoimmune disease and infection associated 
with vitamin D deficiency73, and the presence of VDR and CYP27B1 in many 
immune cell types, including macrophages, B and T cells, antigen presenting cells, 
and dendricytes74. Systemically, serum vitamin D is inversely associated with 
serum TNFα in healthy athletes, obese participants, and patients with congestive 
heart failure alike, suggesting a common mechanism underpins the relationship 
between vitamin D and TNFα-mediated inflammatory processes (i.e. not 
associated exclusively with diseased states)75,76. However, the relationship is not 
fulfilled in Crohn’s patients where TNFα levels are independent of vitamin D 
status, but positively associated with anti-inflammatory IL1077, suggesting that 
vitamin D insufficiency in this context promotes resolution of inflammation 
rather than preventing its occurrence. A recent meta-review of vitamin D’s 
effects in PBMCs supports a systemic anti-inflammatory effect both in vivo and in 
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vitro, with researchers routinely reporting inhibition of  cytokine secretion, 
specifically those observed to be elevated systemically in Crohn’s disease, TNFα, 
IL6, and IL1β78. 
The authors postulate mechanisms for the anti-inflammatory effect of vitamin D 
consequent to reduced Toll-like receptor expression in cell membranes (TLR2 
and 4), and reduced cytosolic NFκB phosphorylation. Furthermore vitamin D is 
also reported to suppress NFκB activity via interaction between the VDR/RXR 
complex and IKKβ79. 
Due to its role as a systemic anti-inflammatory, and association with 
inflammatory bowel diseases Crohn’s and ulcerative colitis, vitamin D 
insufficiency is suspected to play a role in the pathogenesis of inflammatory 
conditions in the distal bowel80. However, conversely vitamin D status is 
impacted by impaired absorption of the vitamin D derived from the diet, so the 
true relationship between vitamin D and IBD is not fully resolved81. Tissue 
resident macrophages, recruited from circulating monocyte populations that 
gravitate to beacons of cytokine activity, play a key role in mediating intestinal 
inflammation that is the hall mark of IBD, and numbers increase linearly with 
markers of mucosal inflammation82. The transition from circulating monocyte to 
mucosal macrophage is accompanied by phenotypic changes in the expression of 
cell surface receptors that define degree of differentiation, namely CD14, CD68, 
CD11b, F4/80 and CD16 (addressed in depth in chapter 3)83, and these are 
reported to be regulated by vitamin D - a common bench technique for 
differentiating monocyte-derived macrophages84. Curiously, not all of these 
markers contain vitamin D response elements in their sequences, suggestive of 
non-canonical/non-genomic actions of vitamin D promoting differentiation85. 
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The Cell Cycle and The Hall Marks of Cancer 
Before considering any examples of vitamin D’s anti-neoplastic effect, it is 
pertinent at this juncture to first define their context, by describing routine 
control of tissue growth and cellular proliferation at the molecular level, and the 
consequences for tissue homeostasis when these mechanisms fail. 
At any given moment, the vast majority of somatic cells within an adult human 
are not dividing, and their growth is considered to be arrested (quiescence). In 
order to populate tissues during embryogenesis, or later on in life during wound 
healing or epithelial turnover, external/environmental molecular stimuli (typically 
growth factors) prompt a resting cell to trip back into the cycle of cellular 
division known as mitosis. Conversely, when the healing process nears 
completion, contact inhibition precipitates growth arrest by diametrically 
opposed signalling cascades469. 
Cycling cell goes through four active phases, as well as the semi-permanent 
quiescent/resting phase (detailed in table 1 and figure 1a)470. Well defined 
molecular activities take place during each phase, and at transitional check points 
between phases G1S and G2M. Active phases (DNA synthesis and cell 
division), are preceded by gap phases that allow for the synthesis of 1) proteins 
involved in mediating the anticipated S and M phases (transcription factors, 
phosphorylating kinases), and 2) the raw materials for building a new cell 
(membrane lipoproteins, cytoskeletal filaments). These check points are vital for 
homeostasis, as here regulatory checks on the integrity of the cell and its 
components are performed by maintenance proteins, determining the cell’s 
viability. 
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State Phase Processes 
Quiescent G0 Resting (performing normal tissue and metabolic 
functions) 
Interphase G1 
(1st gap) 
Preparing for DNA synthesis, associated protein 
production, increase in cell volume 
S 
(synthesis) 
DNA synthesis/duplication 
G2 
(2nd gap)) 
Preparing for mitosis, associated protein 
production, increase in cell volume 
Dividing M  
(mitosis) 
Prophase, metaphase, anaphase, telophase, 
cytokenesis 
 
Table I – Phases of the cell cycle. Four phases are observed during cell proliferation. In the 
absence of growth factor signalling, cell exit the cell cycle, differentiate and begin to perform 
normal metabolic function, sometimes for many years. Cells enter the cycle during the first gap 
phase and will not transition to DNA synthesis until regulatory checks are complete. After this 
restriction point and DNA duplication, a second gap phase occurs while proteins are synthesised 
necessary for mitosis. 
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Figure I – Regulation of the cell cycle by cyclins, CDKs and Rb1. A) Interphase defines the period of preparation for M-phase 
(mitosis) when cells actively divide. Quiescent cells enter the cycle during G1. The two gap phases are necessary for protein 
synthesis and regulatory checks. Transition out of gap phases is tightly regulated by a host of cyclin/CDK complex 
phosphorylation events activating transcription factors. B) Mitogenic signals transcribe cyclins that associate with CDK 
enzymes, conferring phosphorylating potential to the complex. Phosphorylation of RB1 frees E2F transcription factors to 
transcribe genes that direct transition from GF-dependant G1 to GF-independent DNA synthesis phase (S-phase). C) Cyclin 
concentration is shown to cycle predictably throughout the cell cycle (as is Rb1 phosphorylation status). Cyclin E is a key 
mediator of G1-S phase transition, after which a cell is committed to dividing, regardless of external signals. 
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Integral to both DNA fidelity and cell cycle progression, is the G1-S phase 
transition check point that occurs towards the end of Gap 1 after preparatory 
growth and protein synthesis. Continuation through the cell cycle is still 
dependent on external growth factors at this point. This transitional period or 
restriction point is when the fate of the cell is determined 
(quiescence/differentiation, division, DNA repair, or death). 
Progression of the cell cycle is positively regulated at each phase by cyclins and 
cyclin-dependant kinases, while negative regulation is performed by Rb1, p53 and 
p21. The interplay between cyclins/CDKs and RB1/p53 and their respective 
phosphorylation states determines whether cells are held at this restriction point 
or are allowed to pass. G1S phase transition is instigated when external 
mitogenic signals promote synthesis of cyclins (figure 1b), that in turn bind and 
activate cyclin-dependant kinases with phosphorylating potential. Primarily, 
phosphorylation of the tumour suppressor Retinoblastoma1 (RB1) prevents it’s 
association with E2F transcription factors that drive the transition to S-phase 
(figure 1b), thus Rb1 phosphorylation state correlates with stages of cell cycle 
progression – hypo-phosphorylated in gap phases, and hyper-phosphorylated 
during synthesis( figure 1c)472. 
During G1-S phase transition, DNA is screened (and repaired where necessary) 
prior to DNA duplication in S phase. This pause for regulatory checks on the 
integrity of the genome also allows the cell to commit programmed cell death if 
errors are deemed unmanageable. Like RB1, down-stream targets of the 
transcription factor p53 also block S-phase transition, while orchestrating DNA 
repair or suicide, earning p53 the moniker ‘guardian of the genome’. This is 
evidenced by the observation that over 50% of all malignant cancers demonstrate 
mutated code or compromised p53 efficiency473. 
By transcribing p21, which binds and inhibits the complexes that drive transition 
to S-phase, p53 may stall the cell cycle while maintenance of the DNA is 
performed by repair proteins that are also under transcriptional control by 
p53474 i.e. Muts-1 which mediates mismatch repair, or DNA glycosylases that 
perform base excisions. Furthermore, p53 may induce apoptosis in compromised 
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cells by activating caspases, via release of cytochrome C from mitochondria 
stimulated by the p53 targets, BID and BAX475 (reviewed in476) Thus, a 
dysfunctional p53 sequence or protein is incapable of bringing about a pause in 
the cell cycle or directing apoptosis, and division proceeds unchecked.  
Once transition to S phase is instigated, a cell is committed to division, regardless 
of variable external GF stimuli, due to a positive feedback loop established by 
E2F transcription factors, and may not quiesce until G1 comes around again after 
division.  
Due to the ability of functional RB1 and p53 proteins to suppress tumour 
formation by negatively regulating the cell cycle, their gene sequences are 
referred to as tumour suppressors (TS). Ergo, mutational silencing or functional 
incompetence of the protein product is observed to result in uncontrolled cell 
proliferation. Conversely, genes that are typically inactive in order to prevent cell 
cycle progression (i.e. switched following after embryogenesis), are termed 
proto-oncogenes. These genes have the potential to initiate tumour formation 
when mutated or over-expressed, which confers true oncogenic properties. 
Examples of proto-oncogene typically include those proteins whose expression 
promotes cell turnover, like Myc, Ras, Raf and CDKs. Classically, oncogenic 
aberrations are tumour-initiating with regards cell cycle, conversely, tumour 
suppressor dysfunction transforms the previously initiated (although as we shall 
explore later, epigenetic silencing of tumour suppressors may prime cells for 
transformation, and precede the initiating oncogenic event). 
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The hall marks of cancer 
When control of the cell cycle is impaired in solid tissues through silencing of 
tumour suppressors, or activation or over expression of proto-oncogenes, a 
benign tumour mass begins to form. Further aberrations that compromise a cells 
ability to execute apoptotic pathways, maintain genome fidelity, or confer the 
ability to migrate from the primary site, mark the transformation of a benign 
lesion to a malignant phenotype (cancer). The diverse and temporally 
spontaneous nature of any particular cancer genome means that individual 
lesions are effectively unique in their molecular profile. However it has been 
asserted that all cancers demonstrate unifying traits with regards their overall 
biological phenotype. Hanahan and Weinberg’s seminal paper – The Hall Marks 
of Cancer477 – surmised six traits common to all cancers (table II), although it is 
important to note that several of these characteristics also apply to benign 
lesions too. Furthermore, while the authors cite multiple examples of specific 
tumours that demonstrate these properties, and detail evidence for the aberrant 
pathways responsible for conferring the cancer phenotype, by their own 
admission, the assertion that all cancers exhibit these features is, for the time 
being, an informed extrapolation of the established paradigm, until the missing 
data is complete. It is also now recognised that several of these traits are 
effected via paracrine regulation of the tumour microenvironment and the 
interstitium by transformed cells i.e. tumours harness the growth-promoting and 
mobilising potential of their non-transformed neighbours. Being effected by non-
transformed cells, the phenotype of the cancer is thus not entirely autonomous 
but requires collusion and cooperation with healthy cells (myofibroblasts, 
immune mediators, vascular tissues etc). In 2011, Hanahan and Weinberg 
published an update, The Hallmarks of Cancer – The next Generation, which 
detailed four additional universal traits of neoplastic tissues that had become 
established in the literature during the intervening period (inflammatory infiltrate, 
evasion of immune detection, deregulated metabolism, and genomic instability)478. 
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Vitamin D exerts pleiotropic effects on the genome via its cognate nuclear 
receptor and ubiquitous response elements. It seems likely that vitamin D might 
thus effect regulation of cell cycle via modulation of the aforementioned tumour 
suppressors, proto-oncogenes, and CDK phosphorylation events that 
orchestrate cell cycle progression. 
 
Characteristic Comment 
Autonomous 
Growth Factor 
signalling 
Paracrine GF signalling is typical of non-transformed proliferating tissues. In 
tumour cells these signals are constitutively activated via mutation to allow 
for autonomous stimulation of the growth response. Furthermore, over 
expression of surface receptors causes GF hypersensitivity. Finally, 
downstream mediators i.e. Ras/Raf, may also become locked on with 
identical consequences for prolioferation479,480 
Resistance to 
programmed cell 
death 
Uncontrolled proliferation does not create a pathological crisis were the 
autonomic mechanisms that initiate cell death remains functional. 
Deregulated caspase activation must also occur to negate apoptosis and 
increase tumour bulk481. 
Insensitivity to 
anti-mitotic 
factors 
Most, if not all, exogenous anti-mitotic growth signalling is transduced via 
phosphorylation of Rb1 by cyclin/CDK complexes. Any disruption to Rb1 
competence is postulated to confer insensitivity to paracrine efforts to 
negatively regulate cell turnover482. 
Transcendence of 
replicative limits 
Telomere shortening due to telomerase insufficiency typically causes 
chromosomal instability during cell division, which, when detected, 
precipitates apoptosis of ‘aged’ cells. Reactivation of telomere catabolism 
allows a cancer cell to permanently avoid this homeostatic mechanism and 
become immortal483    
Promotion 
angiogenesis 
Angiogenesis is essential for supply of nutrients and metabolic respiration 
necessary to support continued growth. Up-regulation of neo-angiogenic 
factors (VEGF) combined suppression of negative angiogenic regulators is 
noted in roughly half of all cancers and is prognositically significant484 
Metastatic 
potential 
Tumours confined to a single organ or tissue may precipitate poor health 
but do not generally effect loss of homeostasis at the whole organism level. 
It is only when a tumour metastasises, first invading the surrounding tissues 
and sub-epithelium, then local lymph and blood networks, and finally to 
distant organs (brain, liver, bone), that whole systems begin to fail, 
endangering life. Mechanisms that promote cell-cell adhesion and cell 
motility are the key effectors of metastatic potential. 
Table II – The Hallmarks of Cancer. Adapted from Hanahan and Weinbers seminal paper of 2011, which has been referenced 
over 25,000 times. Details common properties exhibited by cancer cells regardless of tissue of origin or complexity of 
underlying aberration.  These six physiological quirks combined confer malignant growth on otherwise benign lesions 
(although some properties are also demonstrable in non-cancerous tumours), and arise when normal regulatory mechanisms 
are compromised. 
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Anti-neoplastic effects of vitamin D 
Antiproliferative effects are implied by the vast body of epidemiological data that 
demonstrates serum vitamin D to be inversely associated with the relative risk 
for neoplasia, specifically breast, prostate and colorectal adenomas and 
carcinomas86. While a causal relationship between low vitamin D and epithelial 
tumourigenesis is supported by in vitro studies that demonstrate clear 
antiproliferative and pro-apoptotic effects of vitamin D60, clinical interventions 
that seek to improve vitamin D status do not impact significantly on disease risk, 
implying correlation but not causality, although this could be attributable to 
compromised methodology and relatively short interventions not exceeding an 
average of 3 years66. High-dose Vitamin D as a chemotherapeutic is precluded by 
the risk of hypercalcaemia, that precipitates impaired calcium homeostasis (renal 
calculi, arrhythmias, polyuria/dehydration, and depression)87. 
At the molecular level, vitamin D regulates a variety of pathways in epithelial cells 
that dictate cell cycle progression and growth; the main drivers of vitamin D’s 
antiproliferative effects are cyclins and cyclin-dependent kinases that block 
transition to DNA synthesis phase at G188. A master regulator of the pleiotropic 
c-MYC network89, vitamin D induces P21, P27, TCF4, DKK1, CCND3, CDK4 
and CDK6, all of which act to down-regulate proliferation90-92. Simultaneously in 
glandular epithelia, vitamin D promotes differentiation (improved adhesion) via 
induction of epithelial cadherin (ECAD)93. Enticingly, vitamin D mediates de novo 
expression of ECAD in breast cancer cells via promoter demethylation94. Vitamin 
D also inhibits phosphorylation of the tumour-suppressor RB1, which in turn 
deactivates a host of cell-cycle transcription factors95. Finally, vitamin D may also 
promote p53-dependent (healthy) and independent (tumour) apoptosis, via 
induction of BAX and suppression of BCL296. 
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In vitro evidence is convincing, and growth inhibition and apoptosis have 
consistently been achieved in a variety of colon cancer cell lines and tumour 
explants following treatment with physiologically-relevant concentrations of 
vitamin D97,98,99. Furthermore, expression of VDR inversely correlates with the 
degree of differentiation, such that the antimitotic effects of vitamin D are 
annulled in poorly differentiated, aggressive tumours, due to vitamin D 
insensitivity100. This is consistent with observations that VDR itself binds cytosolic 
β-catenin, downregulating Wnt-mediated proliferation95. 
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Colonic homeostasis and neoplasia 
In order to better appreciate the dynamics of vitamin D promoting bowel health, 
it is first necessary to establish a framework for tissue homeostasis in healthy 
colonic mucosae. 
The large bowel comprises the ascending, transverse, and descending colon, 
terminating distally in the sigmoid rectum. It serves two principal functions; 
storage, mechanical processing, and transit of digested food waste, and the 
recovery of water and other residual nutrients from chyme. Unlike the small 
intestine, the colon is not primarily an absorptive organ, and as such the surface 
is effectively smooth (although pleats exist to allow distension). The surface is 
punctuated by glandular pores known as the colonic crypts, whose primary 
purpose is to secrete goblet cell-derived mucins that lubricate faecal transit, and 
provide a viscous barrier between the luminal contents, permanent microbiota, 
and the epithelium (figure 2)101. 
The epithelial sheet is populated by multipotent crypt stem cells (CSC) that 
reside at the base of the colonic crypts102. These permanent cells are anchored 
to the basement lamina, and marked principally by their expression of LGR5, a 
protein that forms part of the membranous r-spondin receptor complex involved 
in Wnt signal transduction103. Asymmetric division of CSC produces fast cycling 
daughter progeny (termed progenitor or transit-amplifying cells, destined for 
differentiation as they traverse the wall of the crypt), and one replacement stem 
cell, thus maintaining a static population of four or five LGR5+ve cells in  the 
niche104. As progenitors transit the crypt wall, their LGR5 positivity diminishes, 
and markers of terminal differentiation appear. Thus the crypt may be divided 
along its axis into three compartments (figure 3a); the stem cell niche 
(comprising slow cycling CSC and supporting mesenchyme), the proliferative or 
transit amplifying compartment (where rapid division of progenitors produces 
the bulk of cells required to populate the epithelia), and the differentiative 
compartment (where proliferative signals diffusing from the niche fade, 
precipitating terminal differentiation). 
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The epithelial sheet itself is composed of three dominant cell types, absorptive 
enterocytes, mucin-secreting goblet cells, and environment-sensing 
enteroendocrine cells105. 
 
 
Figure 2 – microscopic topography of the colonic crypts a) 3D scanning electron micrograph of glandular 
invaginations comprising the epithelial sheet b) 2D histological cross section reveals numerous goblet cells 
(with prominent mucin filled vacuoles) c & d) cross-sectional schematic detailing the distribution of key 
cell phenotypes and asymmetric CSC division producing transit-amplifying (TA) progenitors that migrate 
along the crypt axis, differentiating to terminal colonocytes at the luminal interface. Adapted from105 & 
106. 
 
  
A B C D 
  
34 
 
Cryptogenesis is consequent to Wnt-mediated stem cell proliferation 
 
To prevent dysplasia, it is essential that the rate cells are produced in the niche is 
balanced by apoptosis at the luminal surface. This is mediated by opposing 
gradients of soluble growth factors and inhibitors secreted along the length of 
the crypt that regulate proliferation, differentiation and apoptosis107. The 
principal signalling cascade that instigates stem cell division is the Wnt pathway 
(figure 3b), the end-point of which is the transcription of the TCF-LEF 
transcription factor targets c-MYC and Cyclin D1 that initiate cycle 
progression108. 
In quiescent cells, in the absence of Wnt stimulation, there is no interaction 
between surface components of the Wnt receptor (Frizzled and LRPs 5 & 6). 
Here, a destruction complex is present in the cytoplasm, formed from APC, 
GSK3β, and AXIN1, which tags cytosolic β-catenin (BCAT) with ubiquitin, 
marking it for degradation by the proteasome109. Typically BCAT, contributes to 
cell adhesion by linking epithelial cadherins to the actin cytoskeleton, thus 
cytosolic concentration of BCAT remains low in quiescent cells, and any free 
cytosolic BCAT is mopped up by the destruction complex. In the nucleus, 
TCF/LEF recruits corepressor Groucho, and histone deacetylases remodel the 
chromatin to inhibit RNA synthesis of target genes, halting proliferation. 
To instigate cell division, ligation of Frizzled by secreted Wnt factors effects 
conformational association with membrane bound LRP5/6 coreceptor 
lipoproteins, potentiating signal transduction; the cytosolic tail of the receptor 
complex attracts Dishevelled, which in turn destabilises and inactivates the 
destruction complex. In the absence of ubiquitin-mediated clearance of BCAT, 
cytosolic concentrations increase to the point of saturation, followed by nuclear 
translocation of BCAT that displaces Groucho. Repression of TCF-LEF targets 
ceases, and transcription of c-MYC/Cyclin D1 initiates S-phase110. 
The epithelium itself is a source of paracrine Wnt ligands that drive cell division 
(r-spondins, Wnt3a)111,112, but neighbouring peri-cryptal myofibroblasts have also 
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been shown to support cryptogenesis via secretion of Wnts113. When Wnt 
signalling from the epithelia is ablated by conditional knock-down of PORCN (a 
protein essential for endoplasmic processing of Wnts), there is no consequence 
for normal cryptogenesis in vivo, indicating redundant, extrinsic sources of Wnt, 
derived from sub-epithelial cell populations114. Wnt signalling is modulated by 
multiple internal and external mechanisms; BMP agonists, secreted by mature 
colonocytes, form an opposing gradient to Wnt diffusing down from the 
epithelium107, and in the niche, secreted frizzled related proteins (SFRPs), Wnt 
inhibitory factor1 (WIF1), and Dickkopf-related proteins (DKKs), bind interstitial 
Wnt ligands and/or outcompete Wnt ligands at Frizzled receptors, reconstituting 
destruction complex activity (figure 3a). Wnt antagonists (WAs) are typically 
TCF-targets, so stem cells modulate proliferation via autocrine feedback 
mechanisms, but they are also expressed by other cell types in the niche, adding 
layers of extrinsic control115,116. 
Wnt-mediated stem cell turn-over is established during embryogenesis to 
propagate epithelial bulk in rapidly expanding tissues. Self-renewal is maintained 
throughout life in somatic tissues to compensate for cell loss due to the routine 
apoptosis of colonocytes (the entire epithelium may be entirely replaced every 
five days)117. Transient colonisation by invading pathogens or toxicity due to 
other pro-inflammatory/necrotic factors, necessitates rapid sloughing of 
compromised cells to limit penetration and protect the stem cell niche, 
concurrent to a loss of crypt architecture and epithelial hypotrophy118. Activation 
of Wnt is thus required to regenerate the epithelia, via symmetrical fission of 
crypts along their axis, and explains why inflammatory cytokines associated with 
chronic inflammation (INF, TNFα) exhibit Wnt-modulating properties, and 
themselves are managed by Wnt following resolution of transient stimuli119,120, 
reviewed in 121. Crypt fission is thought to be responsible for the propagation of 
genetic and epigenetic aberrations originating in individual stem cells (themselves 
the product inflammatory insults) throughout histologically normal epithelia - a 
concept known as the field cancerisation effect122. 
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Deregulated Wnt signalling precedes hyperplasia 
Effective inhibition of Wnt signalling is essential to maintain CSC/progenitor 
proliferation at a rate not exceeding that of cell loss at the lumen. Benign 
adenomatous tumours begin to form when Wnt-mediated proliferation goes 
unchecked, resulting in a net increase in cell number (hyperplasia). Four 
mechanisms by which this can occur are described; 1) loss of the destruction 
complex(DC), via mutation of APC, which is observed in the vast majority of 
sporadic colorectal tumours123. Less commonly, truncation of AXIN124 or 
aberrant phosphorylation  of GSK3b125 impairs DC competence. 2) Gain of 
function due to BCAT mutations that prevent  its association with the 
destruction complex126. 3) Over expression of Frizzled receptors (increasing 
stem cell sensitivity to Wnts)127, and 4), loss of feedback mechanisms that 
interfere with receptor ligation, typically via inactivation of SFRPs, DKKs and 
WIFs due to aberrant promoter methylation that inhibits RNA synthesis128-130. 
Regardless, these effect the same response as Wnt-receptor ligation i.e. 
accumulation of cytoplasmic BCAT, nuclear translocation, and S-phase transition, 
only this time in the absence of sustained Wnt signalling. Constitution of Wnt 
drives the formation of microscopic hyperplastic lesions known as aberrant crypt 
foci - observable histologically by the accumulation of nuclear BCAT that 
precedes macroscopic tumourigenesis131. The dependency of homeostasis on 
proper regulation of Wnt is elegantly demonstrated by the conditional 
inactivation of APC in normal epithelia by RNA interference, which triggers 
polyp formation. Conversely, withdrawal of treatment reconstitutes degradation 
of BCAT,  the rapid regression of established lesions, and a return to normal 
epithelial architeture132. 
Mutational incompetence of Wnt regulation differs temporally to loss of 
redundancy via antagonist inactivation; the former is a consequence of sporadic 
genomic events, while the latter is consequent to creeping deregulation of 
methylation metabolism over time, with no change to the underlying sequence or 
associated protein functionality. Epigenetic silencing of Wnt antagonists (Was) in 
this context is only tumourigenic when alternative options for regulating 
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proliferation have been exhausted. Aberrant DNA methylation, an early 
observation in colorectal tumourigenesis, forms a corner stone of our hypothesis 
and will be discussed in greater depth shortly. 
Importantly, constitutive activation of Wnt signalling in CSC does not necessarily 
transform lesions to a carcinogenic phenotype, with risk of progression being 
age-dependent; around 25% in under 60s and 40% beyond133; APC mutations and 
deleterious DNA methylation are initiating factors in tumourigenesis, but 
typically lesions are well circumscribed, properly differentiated, slow growing, 
and confined to the epithelium134. This is due to an upregulation of compensatory 
anti-proliferative pathways by which CSC control tissue growth, such as the 
RAS/RAF or PI3K/AKT pathways. Due to impaired regulation of Wnt, CSC 
become necessarily dependent on these alternative pathways135. When further 
mutations are effected in compensatory streams, benign adenomas transition to a 
more aggressive phenotype, and proliferation goes into over-drive, resulting in 
large bulky tumours that may obstruct the bowel - a classic presenting symptom 
of an otherwise benign mass136. 
The final insult, conferring true malignancy, is the loss of DNA repair protein 
P53, leading to spontaneous genome instability and the de novo activation of a 
host of dormant activities optimised for tissue growth and motility in 
embryogenesis - encouraging angiogenesis, invasion through the bowel wall, and 
ultimately metastasis to distant organs137. This multistep paradigm of initiation, 
through progression, to transformation was initially proposed by Vogelstein in 
1990, and check-points in the process have since been comprehensively 
characterised (figure 3c)138. The early appearance of epigenetic lesions, suggests 
that preventing initiation by modulating DNA methylation patterns, could 
compensate for activating mutations later, favourably modifying the risk of 
progression139. 
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Figure 3 – Epithelial homeostasis in the distal bowel A) The colonic crypt is comprised of three 
compartments; a stem cell niche containing pericryptal myofibroblasts that provide a source of paracrine 
growth factors and structural proteins to support stem cell function (green cells); a transit amplifying 
compartment with committed progenitors supplying progeny for the epithelia; and a differentiated 
epithelial sheet that emanates Wnt antagonists and BMP agonists, promoting terminal differentiation and 
apoptosis at the luminal interface. Gradients of growth factors are regulated along the crypt axis that 
ensures maintenance of crypt topography. B) The canonical Wnt pathway cycles stem cells – in the 
absence of Wnt ligands the Axin/APC/GSK destruction complex tags cytosolic β-catenin for proteasomal 
degradation. Ligation of membrane LRP attracts frizzled receptors and subsequent dissolution of the 
destruction complex; cytosolic saturation with β-catenin precipitates nuclear translocation and 
transcription of TCF-targets that drive stem cell turnover. The pathway is aberrantly activated in CRC C) 
Adaption of Vogelstein’s multi-hit model of cancer initiation, where aberrant epigenetic silencing of Wnt 
mediators via promoter hypermethylation is an early finding in macroscopically normal epithelia, priming 
cells for transformation in the context of subsequent oncogenic mutations 
A 
B 
C 
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Aberrant DNA methylation in CSC primes the epithelia for transformation 
In the early 21st century, colorectal cancer (CRC) remains a significant health 
burden in developed countries, with lifetime risk of adenoma 40% and malignant 
carcinoma a little over 5%140,141. Importantly, the increase in CRC is associated 
with the evolution of pro-inflammatory Western diets (high in fat and protein, 
and deficient in nutrients, phytochemicals, and fibre), compounded by a shift 
towards sedentary lifestyles, suggesting that risk is dynamic in response to 
environmental exposures142-144. The association of environment with risk is 
evidenced by the mean global rate of colon polyp at 40%; 85% in Westernised 
populations and >2% elsewhere. With over one million cases reported globally, 
CRC accounts for 10% of all new cancer diagnoses each year, two thirds of 
which occur in developed nations145. In Europe and North America incidence is 
approximately 50 per 100,000145 and in the UK it is the 2nd and 3rd highest cause 
of cancer death in males and females, respectively146. 
Importantly, the single biggest risk factor for sporadic CRC is advanced age, with 
rates increasing rapidly in the 50+ demographic, and 90% of all new diagnoses 
occurring in this group147. Medical advances have increased life expectancy during 
recent years, driving an anticipated increase in  CRC incidence that is 
compensated  for by bowel cancer screening programmes, ultimately reducing 
overall mortality due to CRC148. Currently the Dukes (tumour/lymph 
nodes/metastasis) staging system is employed to describe the progression of 
CRC, observing the size and physiological extent of the tumour, and metastatic 
spread, which negatively correlates with prognosis.  Five-year survival rates stand 
at 93% for Dukes A (non-invasive) down to just 6% for Dukes D (distant 
metastases), highlighting the need for early intervention149,150. 
Much work has been done to identify modifiable risk factors for CRC. These 
principally indicate cessation of smoking, increased physical activity, reduced 
consumption of red meat and alcohol151-154. Inflammatory co-morbidities – namely 
Crohn’s and UC, but also obesity-driven inflammation and age-related decline in 
immune function (immunosenescence or inflammageing) - negatively impact on 
lifetime CRC risk155-157. In patients with chronic IBD, the risk of developing a 
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malignant lesion following diagnosis is 1 in 5 over 30 years, killing 50%+ due to 
complications arising from colitis-associated cancer (CAC)158. The risk of CAC is 
attenuated by effective clinical management of the underlying condition159. While 
a role for chronic inflammation in the aetiology of colorectal tumourigenesis is 
well recognised, molecular mechanisms are diverse and incompletely categorised, 
but primarily involve IBD initiation by , followed by persistent elevation of 
mucosal cytokines TNFα, IL6 and IL1β160,161.  
Inflammation is involved in the propagation of CRC at every stage; initiating 
mutations are expedited by sustained DNA damage from reactive oxygen species 
released by inflammatory mediators and/or direct oxidation of mismatch repair 
proteins. Inhibition of the NFκB/COX2/PGE2 pathway is recognised to attenuate 
the molecular signatures of transformation155,162, and vitamin D is shown to 
attenuate NFκB signalling in intestinal epithelium - posited as a mechanism by 
which sufficiency modifies mucosal inflammation and thus CRC risk163. 
Maintenance of sporadic tumours is passively promoted by inflammatory 
cytokines that encourage proliferation and angiogenesis as a means of resolving 
epithelial hypotrophy effected by inflammation. During metastatic progression, de 
novo secretion of chemokines by tumour cells amplifies the inflammatory milieu, 
promoting a brisk T-cell infiltrate and establishing a positive feedback loop164. 
Colorectal tumourigenesis typically follows a well-established progression from 
non-invasive adenoma to malignant carcinoma165. Evidence includes a spike in 
adenoma incidence five years prior to peak CRC rate166, polyps excision reducing 
the incidence of CRC, and adenomas presenting with foci of poorly differentiated 
cells167. Equally, invasive tumours are frequently found to harbour central areas of 
adenoma168. While sporadic mutation of tumour suppressors, activation of 
quiescent oncogenes, and impaired mismatch repair/microsatellite instability, 
initiate tumour formation, epigenetic silencing of Wnt tumour suppressors is 
documented in macroscopically normal epithelium169 – a process itself 
accelerated by inflammatory mediators170. 
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Referring to the fact that the genome may be modified without alteration to the 
underlying nucleotide sequence, epigenetic phenomena allow for the differential 
expression of gene products in a myriad of cell types, with heterogeneous 
phenotypes derived from a common genome. Epigenetic modifications define 
tissue-specificity during embryogenesis, drive differentiation, and confer cellular 
plasticity in response to environmental cues171. Modifications direct transient 
(histone modification, RNA interference) or stable (DNA methylation) 
stereochemical remodelling of the chromatin, and epigenetic management of 
conformation achieves several goals. Practically it allows over two meters of 
DNA to fit within the nucleus, and locks down pernicious retrotransposon 
sequences - acquired over evolutionary time - that sporadically disrupt sequence 
integrity172. Heritable modifications inhibit transcription of sequences not 
contributing to phenotypic function, particularly in the case of imprinting that 
defines sex-linked inheritance during gametogenesis173. To facilitate a plastic 
response to environmental stimuli, acetyl and methyl groups are transiently 
applied to DNA histones by modifying enzymes, recruited by cognate 
transcription complexes - as described for vitamin D. 
Perhaps due to its stability as an epigenetic mark, and binary dynamic, DNA 
methylation is the most studied epigenetic mark, recognised for its role in 
establishing and maintaining phenotype-specific methylomes between successive 
generations of cells174. Succinctly, it involves the enzymatic addition of a methyl 
group to the 5th carbon of cytosine’s central ring (C  5mC) - only 
thermodynamically permissible when the nucleotide occurs directly before a 
guanine i.e. cytosine methylation occurs exclusively in the context of CG 
dinucleotides (although exceptions to this rule are observed during 
embryogenesis and haemopoietic differentiation)175. 
CG cytosines account for less than one percent of all cytosines in the human 
genome, of which some 70% are methylated, typically present in long 
interspersed elements (LINEs), promoting heterochromatin conformation and 
genome stability. Conversely cytosines in coding sequences tend to be 
unmethylated, hinting at their role in transcriptional regulation176. 
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CG frequency throughout the genome is lower than the anticipated 1/16 due to 
the phenomena of CG suppression, where-by methylated cytosines 
spontaneously de-aminate over evolutionary time, mutating to thymine residues. 
Unmethylated cytosines also deaminate, but to uracil residues, which are 
identified by DNA repair mechanisms, unlike 5mC-derived thymines177. 
Sequences where the frequency of CG dinucleotides is conserved, approaching 
the anticipated ratio, are known as CG islands (CGIs),  defined as being between 
200 and 500 bases in length, with a CG content exceeding 50%178. 
Half of all transcribed genes exhibit promoter sequences containing islands 
proximal to their transcription start site, which serve as attachment regions for 
transcriptional machinery and co-modulators176. The established paradigm is that, 
to permit interaction of TFs, promoters must be unmethylated. Methylated 
CGIs, attracts 5mC binding factors (MECP2) and associated corepressors that 
re-model the local chromatin environment through the recruitment of 
HDACs179. However, promoter hypomethylation confers only transcriptional 
competence, as opposed to guaranteeing expression180. The dogma that increases 
in promoter methylation status necessarily correlate with decreased 
transcription, has recently been called into question by novel reports of 
hypermethylated gene promoters being associated with active transcription in 
multiple tissues. Although it is not yet known if conditional demethylation of 
these hyper- sites functionally inhibits transcription, the authors identify distinct 
sequence motifs in hypermethylated sites of active transcription verses hypo- 
sites, suggesting two independent mechanisms are involved in the metabolism of 
5mC and transcription factor binding of hypo- vs hyper- methylated CGIs181. The 
paradigm is further compromised by techniques for methylome analysis not 
biased towards defined CGIs; these reveal additional hypermethylated CG rich 
regions several KB proximal to TSS CGI (termed enhancers, or CG island 
shelves and shores), that are associated both with active transcription, and 
downstream CGI hypomethylation, raising the possibility that the process of CGI 
methylation itself is dependent on upstream motifs or chromatin status182. 
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The idea that de novo methylation of promoter CGIs is dependent on upstream 
events is not a new one, having been speculated by our group and others183. 
Specifically, binding of the transcription factor SP1 in island shelves appears to 
confer protection from de novo methylation of the islands themselves, and it’s 
loss precipitates CGI hypermethylation and inhibition of transcription184. 
With regards de novo promoter CGI methylation in CRC initiation, Belshaw et al 
suggest an all-or-nothing process, supported by others, that shows gene 
promoter regions are found to exhibit methylation values of either less than 10%, 
or more than 90%, of all island CGs (figure 4b)185. Un-characterised upstream 
motifs or binding factors are again implicated by the directional accumulation of 
methyl marks in Wnt antagonist promoters (5’  3’)186. 
Methyl groups required for de novo methylation are provided by s-adenosyl-
methionine (SAM), synthesised from dietary folate187. Recent reports associate 
folate intake and circulating folic acid positively with the rate of aberrant DNA 
methylation in the colonic epithelia188 –  although these findings may be a cause 
for concern, they again bring to light the opportunity to modify methylation 
patterns throughout life via nutritional intervention. 
5mC metabolism is mediated by two classes of enzymes (figure 4a); DNA 
methyltransferases (DNMTs) catalyse the addition of methyl groups to CGs189, 
while ten-eleven translocation enzymes (TETs), demethylate 5mC via oxidation 
of 5-hydroxy-mC intermediates190. There are three DNMTs responsible for 
DNA methylation; DNMT1, 3a, and 3b. Primarily, during gametogenesis, 3a and 
3b cooperate to establish genomic methylation patterns necessary for 
phenotypic specificity on globally hypo-methylated DNA (de novo methylation)191. 
Loss of either or both during embryogenesis maintains embryonic stem cells in a 
pluripotent state192. Once established, DNMT1, which exhibits a preference for 
hemi-methylated DNA strands during mitosis, takes responsibility for somatic 
replication of the pattern on the opposing strand (maintenance of DNAm 
patterns)193, so loss of 5mC  is also consequent to impaired replication fidelity, 
which sees successive reduction in global methylation between iterations of cells 
following deletion of DNMT1194. 
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Conditional knock down of DNMT1 is fatal in embryogenesis, but not necessary 
for survival of CRC in vitro, where surprisingly 80% of methylation is conserved in 
progeny. Furthermore, knock down of either 1 or 3b demonstrates dynamic 
compensatory mechanisms, whereby the effects of deficiency of either appears to 
be annulled by the continued expression of the other, and it is only simultaneous 
knock down that perturbs methylation metabolism sufficiently to effect genomic 
instability via global hypomethylation195,196, i.e. DNMT1 and 3b cooperate to 
effect and maintain DNAm patterns in CRC. 
Metabolism of 5mC is invariably dysregulated in CRC. In fact Baylin et al observe 
that aberrant CGI methylation patterns have been documented for practically 
every known neoplastic disease197. Deregulation falls into three categories; gene-
specific tumour suppressor hypermethylation (macroscopically healthy 
epithelium), global (non-CGI) hypomethylation (healthy mucosae and tumours), 
and a non-specific CGI hypermethylating phenotype in CRC, termed CIMP. 
Global hypomethylation increases with age198, leading to the unlocking of 
transposable elements, chromosomal instability, increased tumour frequency, and 
oncogene activation199. Global methylation status may be assessed by the analysis 
LINEs, which constitute as much as 20% of the genome. Their methylation status 
is therefore assumed to extrapolate to a global view of the DNAm landscape. 
Baba et al have defined a subset of CRCs which exhibit extreme LINE1 
hypomethylation, and more recently LINE1 hypomethylation is shown to be 
associated with proximal colorectal lesions, much like CIMP200-202. 
DNMT3b in particular has an important role to play in CRC aetiology and is 
unique amongst the DNA methyltransferases in that it is represented by a 
number of alternatively spliced isoforms, expressed in a tissue-specific fashion203. 
Aberrant age-related DNAm of Wnt antagonists is well documented in un-
involved mucosae186,204, and is associated with deregulated DNMT3b activity: 
overexpression of 3b in APC mutants increases tumour incidence and size and is 
associated with hypermethylated gene silencing. In contrast overexpression of 
DNMT3a shows no increase in promoter methylation, and tumour burden is 
comparable to control mutants205. DNMT3b expression, effecting 
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hypermethylation of tumour suppressors, typically increases over time in 
multiple cancer-prone tissues206-208. Presumably the two forms of 
hypermethylation (age-related verses CIMP) are independent phenomena, as the 
former is not pathogenic in and of itself, while the latter is associated with rapid 
progression and poor prognosis. 
A corner-stone of our informing hypothesis, Belshaw et al observed that a subset 
of Wnt tumour suppressors (APC, DKK, WIF1, SFRP1, 2, 5) were differentially 
methylated in individual colonic crypts in both an age-dependent fashion, and in 
relation to disease status186. These results are supported by the observations of 
Tapp et al, who correlate age with differential methylation in a cohort of 185 
healthy individuals. Their principal component analysis shows an increase in CGI 
methylation related to age for the panel of genes characterised (figure 4c), and 
supports the theory of aberrant age-dependent gene silencing by 
hypermethylation contributing to epigenetic field effects, that prime the epithelia 
for transformation by removing options by which CSC may regulate constitutive 
Wnt activity209.  
Age-related aberrant DNA methylation of WAs is influenced by nutritional 
factors 
Importantly Tapp et al also correlate a variety of nutritional factors with the rate 
of acquisition of age-related DNA methylation for genes analysed (figure 4d); the 
methyl donor folate, was found to increase methylation of APC, SFRPs1 and 2, 
SOX17, and N33 (aka tumour suppressor candidate 3, TUSC3) in a pattern 
similar to age-related effects. Interestingly folate has previously been linked to 
abnormal methylation of SFRP1 in adenomatous polyps210, supporting the 
hypothesis that age-dependent methylation is a) modifiable by nutritional regimen 
and b) may dispose the colonic epithelia to neoplastic progression.  
Consistent with the paradigm that serum vitamin D has a protective effect 
against colorectal cancer211, and specifically relevant to this project, Tapp et al 
also found that vitamin D status positively influenced age-related DNAm effects 
for HPP1, APC, SFRPs1 and 2, WIF1, MYOD1 and N33, as well as contributing 
to genomic stability by maintaining hypermethylation of LINEs212. 
  
46 
 
Vitamin D has also been shown to down–regulate BMP2 in vitro in bone marrow 
stromal cells via VDR binding in the gene’s promoter, which induced complete 
methylation of the lone CGI in that region, strongly suggesting transcriptional 
repression by vitamin D-mediated DNA hypermethylation, demonstrating a role 
for vitamin D influencing DNAm patterns213. 
The negative association of vitamin D sufficiency with promoter methylation has 
been reproduced in other WAs by Rawson et al, who established an inverse 
linear relationship between vitamin D status and DKK1 methylation in a large 
cohort of CRC patients (n = 992). The same study also established that vitamin 
D favourably influenced the methylation status of WNT5a, an extrinsic Wnt 
antagonist secreted by mature colonocytes, concentrated in the differentiative 
compartment 214.  As well as the attenuation of age-related DNAm, intriguingly 
vitamin D has also been shown to ameliorate established hypermethylation of 
ECAD in epithelial breast cancer cells in vitro, reconstituting its expression and 
promoting cancer cell differentiation94. Vitamin D is also reported to effect 
spontaneous hypomethylation of  MG63 (osteosarcoma), PTEN, RARB2, and 
PDLIM2 (breast cancer)95. Stefanska et al speculate that, as an anti-proliferative, 
vitamin D induces the master transcription factor AP-1, itself a negative regulator 
of DNMT1 - thus vitamin D might effect gradual loss of promoter 5mC via 
passive demethylation associated with impaired DNMT1 copying fidelity215, as 
opposed to inhibiting de novo DNAm.  
Specifically, although vitamin D is observed to be associated with dynamic DNA 
methylation in both healthy and transformed epithelia, there are no reports 
detailing mechanistic aspects by which vitamin D might mediate these effects. 
Elucidation of these is important given the epidemiology of vitamin D 
insufficiency, and potential to mitigate for neoplastic transformation in the 
context of acquired mutation later in life.  
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Figure 4 – Dynamics of DNA methylation a) Methyltransferase enzymes catalyse the conversion of 
cytosine to 5mC during embryogenesis and mitosis. S-adenosyl methionine (SAM) acts as the universal 
methyl donor. Recently 10/11 translocation enzymes (TETs) have been shown to orchestrate active 
demethylation of 5mC via 5hmC b) CG island methylation is demonstrated to be an all-or-nothing 
process, with methyl marks flooding in from the 5’ direction, proximal to the gene body. This work by 
Belshaw et al shows that while average DNAm increases in promoters over time, for individual islands, 
hypermethylation is a spontaneous event, i.e. occurs rapidly and completely, suggestive of a threshold or 
trigger event. C) A principal component analysis by Tapp et al assigns a methylation score, based on the 
methylation status of a panel of surrogate genes in healthy colonic biopsies, which is shown to positively 
correlate with participant age d) Pearson correlation coefficients for the associations between the 
exposure variables (age, vitamin D status, selenium, and the methylation of the nine genes, LINE-1 and 
principal component analysis for all subjects (grey), males only (white) and females only (black). Age 
shows a strong correlation with DNAm in the promoters of all genes, while conversely, vitamin D is 
negatively associated with aberrant, most strongly for HPP1, APC, WIF1 and MYOD1. Sex-effects are 
noted for SFRPs. Adapted from212 
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In summary 
Vitamin D acts as both a systemic and local anti-inflammatory, modulating 
immune function. Sufficiency is well established to be associated with reduced 
rates of inflammatory bowel disease and colorectal neoplasia, and furthermore, 
being prognostically favourable, predicts the course of both diseases. Vitamin D 
insufficiency is prevalent. Vitamin D status is negatively associated with the rate 
of aberrant age-related methylation silencing Wnt tumour suppressors in the 
distal colon, and is shown mechanistically to effect hypomethylation and 
reconstitution of tumour suppressors in transformed epithelia. 
It is not established whether the association of vitamin D status with aberrant 
DNAm patterns in the bowel is consequent to an effect of the compound 
mediating DNAm metabolism or inflammation-associated aberrant DNAm in 
healthy epithelia over time, or conversely, if Vitamin D status is determined 
synchronously by esoteric processes that are coincidentally associated with 
tumourigenesis. 
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Research questions; 
Firstly, is the association of vitamin D with DNAm in healthy epithelia 
recapitulated in vitro, i.e. is vitamin D insufficiency mechanistically responsible for 
the prospective difference observed in DNAm patterns? 
If so, how does vitamin D act to reduce aberrant methylation? As a systemic or 
local anti-inflammatory? By promoting differentiation of immune cells, immune 
function, resolution of inflammation? At the molecular level, does vitamin D 
effect cytokine secretion, or NFκB signalling associated with increased DNAm in 
epithelial cells? Equally, could vitamin D affect toll-like receptor expression or 
signalling implicated in aberrant DNAm of WAs in CSC? 
Does vitamin D act mechanistically to modulate 5mC metabolism, directly 
attenuating effects of inflammation or ageing at the nucleic acid level? Does 
vitamin D effect a gradual loss via impaired DNAm pattern fidelity, inhibit de novo 
DNAm, or promote active demethylation via TET activity?  
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Hypotheses 
In order to determine whether vitamin D specifically exerts a protective effect 
against WA hypermethylation in healthy CSC, and furthermore, whether vitamin 
D might resolve aberrant DNAm patterns in CRC compromising homeostasis, 
the following hypotheses are proposed that require elucidation; 
1) Vitamin D moderates systemic inflammatory mediators shown to drive 
aberrant DNAm in CSC. 
2) Vitamin D mediates inflammatory signalling in the crypt niche responsible 
for aberrant DNAm in CSC. 
3) Vitamin D modulates 5mC metabolism in CSC via regulation of DNA 
methyltransferase and/or TET activity 
4) Vitamin D’s antiproliferative effects in CRC lines in vitro are in part 
effected via amelioration of established pathological DNAm patterns 
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Aims and objectives 
1) With regard systemic inflammatory mechanisms mediated by vitamin D; 
Vitamin D promotes differentiation of circulating monocytes and acts to reduce 
systemic inflammation via regulation of inflammatory cytokines. Differentiation 
and transcription are both regulated in part by permissible DNA methylation 
patterns, and Vitamin D may mediate its effects via modulation of DNA 
methylation; 
Characterise the effect of vitamin D on monocytes in vitro to determine if 
I. Vitamin D promotes their differentiation 
II. Vitamin D regulates cytokine expression 
III. Vitamin D effects differential methylation controlling 
cytokine transcription 
 
2) With regards mitigation of local inflammation in the crypt niche by vitamin D; 
mucosal inflammation is in part mediated by pericryptal myofibroblasts. Mucosal 
inflammation accelerates aberrant DNA methylation in CSC. Vitamin D is 
associated with reduced mucosal cytokine expression; 
Characterise the effect of vitamin D on pericryptal myofibroblasts to determine 
if 
I. Vitamin D modifies their secretory profile 
II. Their secretory profile affects DNAm patterns in CSC 
III. Their secretory profile regulates 5mC metabolic enzymes 
in CSC 
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3) With regards vitamin D mediated attenuation of aberrant age-related DNAm 
in CSC; Vitamin D is associated with the rate of aberrant DNA methylation in 
CSC, although there are no specific reports that demonstrate vitamin D directly 
modulates 5mC metabolism; 
Characterise the effect of vitamin D in CSC to determine if 
I. Vitamin D regulates transcription of WAs 
II. Vitamin D attenuates the acquisition of aberrant DNAm 
III. Vitamin D modulates 5mC metabolism/DNMT activity 
 
4) With regards vitamin D mediated amelioration of established aberrant DNAm 
in CRC; vitamin D acts as an antiproliferative in vitro for most CRC cells lines 
with a functional VDR, although its mechanisms are not completely elucidated. 
Vitamin D sufficiency is associated with reduced mortality and improved 
prognosis following a diagnosis of CRC; 
Characterise the effect of vitamin D sufficiency in CRC cell lines to determine if; 
I. Anti-proliferative effects are sustained beyond treatment 
II. Vitamin D ameliorates WA hypermethylation 
III. Vitamin D modulates 5mC metabolism/DNMT activity 
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Graphical abstract 
 
Notes 
A brief note on terminology – unless stated, hence fourth the term ‘vitamin D’ 
will be used to refer to the biologically active form of the compound (calcitriol), 
while it’s inactive precursor, calcidiol, will be referred to as ‘serum vitamin D’.  
Regarding the methylation status of promoter CGIs analysed in this text, while 
promoter methylation is established by nucleotide-level sequencing as an all or 
nothing process, typically the average DNAm status of multiple alleles is 
reported, which may be hypo- or hyper-methylated in individual cells that 
constitute the sample i.e. a methylation value of 40% refers to the fact that 40% 
of all alleles in the sample were 100% hyper-methylated, and vice versa, and does 
not refer to a partially methylated promoter CGI. 
Figure 5 – Graphical abstract. Detailing cell lines employed to investigate vitamin 
D’s effects promoting bowel health in systemic, mucosal, and epithelial 
environments. 
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Chapter 2 
 
EXPERIMENTAL APPROACH AND GENERAL METHODS 
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Experimental approach 
Given the ubiquitous distribution of the VDR, multi-level molecular effects of the 
compound, and the association of serum vitamin D with a panoply of health out-
comes, a canonical approach to experimental objectives was developed that 
established vitamin D’s effects promoting bowel health, in the broader context of 
whole-organism homeostasis. 
In this respect, concurrent to investigating stem cell-intrinsic effects of vitamin D 
on DNAm, the experimental approach also encompassed systemic effects 
(whole-blood/immune function), and paracrine mediation of the stem cell niche 
by pericryptal myofibroblasts. Furthermore, this comprehensive approach 
included healthy and diseased models, incorporated a variety of tissues, and 
assessed both in vivo and in vitro aspects of vitamin D’s function. 
Systemic effects of vitamin D promoting bowel health 
Chronic inflammatory diseases effecting the distal bowel are characterised in part 
by elevated serum cytokines, and patients are at greater risk from sporadic 
tumour formation216-218. In part this is due to systemic and mucosal inflammation 
accelerating the process of aberrant, age-related DNA hypermethylation in CSC. 
Vitamin D exerts potent anti-inflammatory effects and promotes immune cell 
differentiation, regulating cytokine production. It has been noted that DNAm 
patterns in peripheral blood mono-nucleated cells (PBMCs) regulate cytokine 
transcription and are associated with immune cell differentiation. Furthermore, 
leukocyte ratios in the peripheral blood are associated with aberrant DNAm in 
the colon. These observations led to speculation that vitamin D exerts it’s 
protective effects in the colonic epithelium by acting as a systemic anti-
inflammatory, modulating the leukocyte pool and influencing serum inflammatory 
markers219. In collaboration with The University of Auckland, NZ, the effects of 
vitamin D supplementation (delivered via a randomised cross-over intervention), 
on serum vitamin D, markers of chronic inflammation, and DNA methylation 
patterns in PBMCs, from a small cohort of healthy individuals was investigated. 
The results from these experiments were verified in vitro using the THP1 
monocyte line. 
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Pericryptal myofibroblast regulation of the stem cell niche 
Sub-epithelial pericryptal myofibroblasts (MFBs) interact with CSC via chemokine 
signalling in the niche. In tumour stroma, dysregulation of the fibroblast 
secretome permits carcinogenic transformation by encouraging invasion, 
migration and angiogenesis. Furthermore, vitamin D status is associated with a 
reduced risk for IBD, the hall mark of which is mucosal inflammation mediated in 
part by pericryptal myofibroblasts.  It was speculated that MFBs in 
transformation-prone epithelia might promote aberrant age-related DNAm in 
CSC via a deregulated secretory profile, and that vitamin D indirectly influenced 
DNAm patterns in CSC by moderating inflammatory processes in pericryptal 
myofibroblasts. Culture conditions were optimised to procure three primary 
lines of sub-epithelial myofibroblasts from the uninvolved mucosa of colorectal 
cancer resection specimens, and characterised their secretomes in response to 
TNFα and vitamin D using LC-MS/MS proteomics and sandwich ELISAs. To 
elucidate the effect on DNAm in CSC, colonic organoids (propagated from the 
same biopsies i.e. case-matched), were cultured with MFB supernatants or 
inflammatory mediators for one month, and their DNAm patterns interrogated 
by Illumina methylation array. 
Colonic organoids 
Sato’s revolutionary papers in 2009 and 2011 refined methods for the extraction 
of colonic crypts, and optimised in vitro culture in a three dimensional collagen 
matrix220,221. Here, crypts spontaneously form spherical cysts, later producing 
buds that proliferate and differentiate into functional crypts, with circumscribed 
compartments, a luminal interface, and importantly, static populations of LGR5+ve 
stem cells. Organoids have been comprehensively demonstrated to emulate the 
topography of the colonic epithelia, however this is in the absence of a 
supporting niche, meaning mechanisms of epithelial homeostasis can be 
investigated in isolation. This model was utilised for experiments investigating the 
effects of vitamin D and inflammatory mediator PGE2, on DNAm patterns in 
CSC. Organoid DNA was interrogated on the latest iteration of Illumina’s EPIC 
DNA methylation array that characterises the methylation status of over 850,000 
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CG dinucleotides, reported as a beta-score that equates to percentage promoter 
methylation. 
Colorectal cancer cell lines 
Not only is vitamin D status associated with a reduced risk of developing CRC,  
following diagnosis, those with vitamin D sufficiency show better rates of 
remission and improved over-all five year survival. Having speculated that vitamin 
D might attenuate the process of aberrant DNAm, in light of its prognostic 
properties it was hypothesised vitamin D might also ameliorate DNA 
hypermethylation, thereby reconstituting epigenetically silenced tumour 
suppressors. There are a multitude of validated colorectal cancer cells lines 
available for in vitro studies; four were selected for their mutational diversity and 
discrete phenotypes (figure 6). CaCO2 and DLD1 are of particular interest as 
they exhibit the APC deficiency necessary for hyper-proliferation, but with intact 
BCAT function. CaCO2 cells also show intact alternative pathways which can 
modulate proliferation, so it was anticipated that these cells would be the most 
sensitive to inhibition of Wnt by de novo WA hypomethylation. 
 
 
CaCO2 DLD1 HCT116 HT29 
APC x x Wt xx 
β-CAT Wt Wt x x 
B-RAF Wt Wt Wt x 
K-RAS Wt x x Wt 
TGβr2 Wt x x Wt 
p53 x x Wt x 
 
Figure 6 – Oncogene mutations reported by the manufacturers 
(ATCC) for the cell lines employed in investigations. X = 
heterozygous mutant allele XX = homozygous mutant allele. 
Wt = wild type. 
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Model overview 
 
Model Source 1y Readout Insight Validity Limitations 
PBMCs Peripheral 
blood, 
healthy 
individuals  
Regulation of 
cytokines 
Systemic, 
whole 
organism 
In vivo, human, 
healthy 
cohort 
Heterogeneo
us lineage, 
small cohort  
THP1 
monocytes 
ATCC. 
Peripheral 
blood, AML 
Regulation of 
cytokines  
Systemic, 
whole 
organism 
Verify PBMC 
results 
Neoplastic, 
genomic 
instability 
 
Pericryptal 
MFBs  
Un-involved 
mucosa, 
proximal to 
tumour  
Mucosal 
inflammation, 
GF signalling 
Regulation 
of the 
stem cell 
niche 
Primary, 
Patient-
matched, 
VIM+/αSMA+ 
Aged, 
disease-
associated 
tissue 
Intestinal 
MFBs 
Lonza. 
Embryonic 
Mucosal 
inflammation, 
GF signalling,  
Regulation 
of the 
stem cell 
niche 
Validation in 
healthy cells, 
positive 
control for 
primary MFBs 
Embryonic, 
Replicative 
senescence 
Colonic 
organoids 
Un-involved 
mucosa, 
proximal to 
tumour 
DNA 
methylation 
patterns 
Cell 
intrinsic 
modes, 
protective 
effect 
Primary, non-
transformed, 
niche 
independent 
Aged, 
disease-
associated 
tissue 
CRC cell 
lines 
ATCC. 
Adeno-
carcinoma 
DNA 
methylation 
patterns 
Cell 
intrinsic 
modes, 
restitution 
Established 
Wnt 
antagonist 
hypermethylat
ion 
Not 
translatable 
to healthy 
tissue 
 
Figure 7 – Comparison of models. Table detailing the suitability and limitations of model employed to 
investigate the effects of vitamin D promoting bowel health. 
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Readouts 
In order to investigate the effects of vitamin D, a set of readouts were defined to 
give comprehensive insights into the mechanisms by which end-points were 
brought about. The informing hypothesis in most cases was that dynamic DNA 
methylation in the gene promoter would affect transcription, that in turn would 
influence protein expression, ultimately modulating the phenotype of the cell. 
Thus, it was sought to verify any differential DNAm by consolidating the results 
to RNA and protein readouts, and measurement of some phenotypic 
characteristic. If verification failed at any level, new testable hypotheses are 
indicated to identify the point in the chain that events were disrupted, having 
excluded the primary scenario (for example post translational modifications or 
RNA interference).  Analysis was either performed in a gene-specific fashion 
where likely targets were identified, or using array-based approaches like LC/MS-
MS proteomics and DNAm bead chips. 
 
Assay Readout Effect 
CoBRA Promoter CGI 
methylation status 
DNA methylation 
QMSP Promoter CGI 
methylation status 
DNA methylation 
Illumina Bead Chip Global methylome DNA methylation 
Q-rt-PCR Relative transcripts RNA 
Wnt reporter activity TCF-LEF activity RNA 
WST1 Proliferation Phenotype 
Trypan blue staining Cell viability Phenotype 
Western blot Phospho- status, protein 
quantification 
Phenotype 
LC/MS-MS Semi-quantitative 
secretome 
Phenotype 
Immunohistochemistry Protein 
expression/localisation 
Phenotype 
 
Figure 8 – Assay repertoire. Assays employed to investigate effects of vitamin D promoting bowel 
health, detailing read-outs and the effect they measure. 
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Materials 
A comprehensive list of kits, reagents, and compounds used is included in 
appendix 1, detailing supplier product codes and batch numbers where available. 
Henceforth in the text, only the item and the supplier will be referred to, which 
can be referenced to that sheet. A link to the manufacturer’s instructions online 
is included where available, and detailed in brief here. 
General methods 
Specific treatment regimens are detailed in each chapter; to prevent unnecessary 
repetition later, here general methods employed throughout the project are 
outlined, with examples of optimisation and validation protocols where 
necessary. The methods detailed are routine wet bench techniques for cell 
culture and molecular cell biology techniques used to characterise cell phenotype 
and function - a training PhD project should furnish students with the analytical 
tools to practice independently, and as such this section may also be considered 
as an appropriate record of the training received.  
Cell culture222 
Transformed or immortalised cell lines were cultured in preparation for 
experiments in either 25cm2 or 75cm2 culture flasks (Thermo), passage number 
in most cases was under 20 for transformed lines and under 5 for primary lines. 
Culture was practiced aseptically in a class 2 extraction hood, and all materials 
were disinfected using 70% ethanol spray or 10% Bioguard. Cultures were 
routinely tested for mycoplasma as part of laboratory quality control procedures. 
Cells were incubated at 37°C at 5% CO2. To passage, suspended cells were 
removed, spun at 300G for 5 minutes in a 15 mL falcon tube, and re-suspended 
in an appropriate volume of pre-warmed fresh medium. For adherent cells, 
media was removed, cells washed once with PBS (FBS in the media neutralises 
trypsin), and 2mL of Trypsin/EDTA (0.05%/0.53mM) (Life Technologies) added to 
the flask for 5 minutes at 37°C. Next, flasks were gently agitated to release 
adherent cells, media collected in 15mL falcon tubes, and spun at 300G. Cells 
were suspended in fresh media, and either seeded into new flasks to propagate 
lines, or seeded into cell culture plates (Corning) for experiments. 
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Cell line Medium Additives 
DLD1, CaCO2, HCT116, 
HT29 CRC cell lines (ATCC) 
DMEM F/12 + Glutamax 
(Life Tech) 
10% Foetal Bovine Serum (FBS) 1% 
Penicillin/streptomycin (PS) (Life Tech) 
Intestinal Myofibroblasts 
(InMyoFib) (Lonza) 
Smooth Muscle Basal 
Medium (Lonza) 
SmGM-2 SingleQuot Kit 
THP1 monocytes (ATCC) RPMI 1640 + Glutamax 10% FBS, 1% PS 
 
Figure 9 – Media for cell culture. Cell culture media preparations for transformed/immortal cell lines used to 
investigate the effects of vitamin D promoting bowel health. 
 
 
Participants 
In line with the ethical approval for the project (FMH Ethics committee, 
University of East Anglia, REF 12/1385HT), participants with a diagnosis of recto-
sigmoid adenocarcinoma were consented by authorised gastroenterology 
surgeons. A preference for males over females was specified due to the sex 
associations between CIMPhigh tumours in the proximal colon typical in females, 
versus CIMPlow tumours in the distal colon typical in males223. Advanced age (>65 
years old) was also specified where possible, to increase the likelihood of age-
related DNAm processes having been previously initiated. Preliminary 
experiments optimising the protocol came from participants 1 through 10. 
Organoids and pericryptal myofibroblasts propagated for the arrays came from 
participants 11, 12, and 13. 
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Pathology 
Case 11 - 45 year old male, ulcerating low rectal tumour – grade 2, Dukes B 
equivalent, adenocarcinoma arising on a background of adenoma. Non-invasive 
with no involvement of the nodes or vasculature. Negative for MLH1, MHS2, 
MSH6 with no evidence of microsatellite instability. No idiopathic inflammatory 
bowel disease. Case 12  - 65 year old male, low rectal tumour – grade 2, Dukes 
A equivalent, moderately differentiated adenocarcinoma invading the muscularis 
propria. No lympho-vascular invasion. Evidence of diverticulitis, but otherwise 
unremarkable. Case 13  - 61 year old male, mid rectal tumour – grade 2, Dukes 
B equivalent, moderate and poorly differentiated adenocarcinoma with apparent 
origin from a background adenoma. Invades the meso-rectum. Probable 
lymphatic invasion, no venous invasion. See appendix 3 for participant 
information. 
Sampling and crypt recovery224,225 
[In short, samples were washed with antibiotics, dissected and washed twice with 
antioxidant. 3x5 minute incubations with 2mM EDTA were performed, shaking 
to remove debris, before a final 35 minute incubation at room temp to dissociate 
crypts. 5 fractions were prepared in ice-cold PBS by 5 serial rounds of vigorous 
shaking. Crypts were spun (100G) and re-suspended in wash buffer ASAP to 
prevent crypt deterioration/necrosis] 
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Bowel resections were opened longitudinally and the faecal contents removed. 
The full thickness of the epithelia, mucosa and submucosa, were pinched 
together with forceps, and a ~5mm biopsy sample sliced off. This was 
immediately placed into transport buffer containing anti-biotic/mycotic 
preparations, on ice for at least 15 minutes. Samples were rinsed with ice-cold 
PBS, then dissected into 1mm2 pieces. Pieces were placed in ice-cold DTT buffer 
for 5 minutes, twice. DTT buffer was removed and replaced with 5mL ice-cold 
2mM EDTA for 5 minutes on ice, after which the falcon tube was vigorously 
agitated to release apoptotic debris, faecal matter, and mucous. This was 
repeated until no more single cells or debris were released. Samples were then 
incubated for 30minutes at 37°C for 30 minutes with 2mM EDTA. Vigorous 
shaking of the digested samples in PBS released 1000s of intact crypts, whose 
numbers were visually assessed. 200-300 crypts per well were removed, spun at 
100G, and resuspended in wash buffer prior to seeding into matrigel.
 
Transport buffer 
• 5mL PBS 
• 50uL Fungizone 
• 25uL Gentomycin 
• 50uL Pen Strep 
• 20uL Normycin 
 
 
 
 
1mM DTT wash 
• 10mL PBS 
• 20uL of 0.5M DTT stock 
solution 
 
2mM EDTA buffer 
• 25mL PBS 
• 100uL 0.5M EDTA stock 
solution 
 
 
Re-sus/wash media/buffer 
• 20mL Advanced DMEM 
• 200uL Glutamax 
• 200uL 1M HEPES (pH 
7.4) 
• 200uL Pen Strep 
• 1mL FBS 
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Organoid culture220,221 
Recovered crypts were seeded at 200-300 crypts per well. Crypts were re-
suspended in 25uL of Matrigel (Corning) containing 1uL of Jagged1 (1μM) and 
1uL Y27632 (10mM), and gently pipetted with a P1000 to evenly distribute crypts 
throughout the suspension. 30uL droplets were seeded into 24 well plates and 
cured for 15 minutes at 37°C, after which wells were flooded with 500uL 
organoid growth medium (see appendix 4) (to which treatments were added as 
detailed). Cysts typically form after 2-3 days and persist for up to 14 days, often 
bursting due to luminal turgidity and degradation of the matrigel. Cultures were 
passaged weekly, or as appropriate; media was removed, the well rinsed with 
PBS, the droplet detached and pipetted several times through a p1000 tip to 
breakup matrigel and release organoid fragments. Cultures were spun at 100G 
for 4 minutes at 4˚C, which allowed apoptotic debris to be removed with the 
supernatant, leaving pellet of whole cysts and larger cyst fragments. These were 
digested using 200uL of TrypleE (Life Tech) for 5 minutes at 37°C, neutralised 
with 200uL wash buffer, and then disrupted by vigorous pipetting with a p1000 
tip to dissociate single cells comprising the LGR5+ve population. These were re-
suspended in matrigel and seeded into new plates as described. 
Organoid media: 500uL of wash buffer with the addition of (see reagents list, 
appendix 1 and 4 for supplier) - 
1x     B27    (from x50 stock)  
1x     N2    (from x100 stock)  
1mM     NAC    (from 100mM stock)  
10uM     SB201090   (from 1mM stock)  
1mM    Valporic acid  (from 100mM stock) 
3uM    CHIR   (from 300uM stock)  
140nM    PGE2   (from 14uM stock) 
10mM     Nicotinamide  (from 1M stock)  
50ng/mL   EGF   (from 50ug/mL stock) 
375ng/mL    r-spo1   (from 100ng/mL stock) 
100ng/mL   Wnt3a   (from 100ug/mL stock) 
10nM     Gastrin  (from 1uM stock) 
500nM    A-83-01  (from 500uM stock) 
100ng/mL   Noggin  (from 100ug/mL stock) 
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Primary myofibroblasts culture226,227 
The remaining pieces of mucosa that had been stripped of their epithelium were 
re-suspended in 5mL of wash buffer containing collagenase 1 (1 mg/ml), DNase I 
(0.3 mg/ml), Dispase (500uL), 5uL Ca2+ and 50uL Mg2+, for 30 minutes at 37 °C. 
The digestion buffer was then removed and cold PBS added. Fragments were 
shaken very vigorously for 20 seconds, which released the majority of remaining 
cells. The tissue fragments were removed, and the cells spun at 200G to form a 
pellet, which was re-suspended in Smooth Muscle growth medium and seeded 
into t25 flasks (formulated specifically to promote the growth of intestinal 
myofibroblasts). Media was replaced every 2-3 days to remove suspended 
leukocytes and non-viable cells. The dominant morphological phenotype after 2-3 
weeks were stellate myofibroblasts – confirmed by IHC staining that showed 
homogenous expression of a-Smooth Muscle Actin and Vimentin (SMA, VIM). 
Nucleic acid recovery 
DNA was recovered from PBS-rinsed pellets using the Sigma mammalian 
GenElute DNA mini-prep kit according to the manufacturer’s instructions. 
Alternatively phenol-chloroform extraction was performed. In brief, pellets were 
re-suspended in 100uL of Sigma r-suspension buffer and incubated for 2 minutes 
at room temperature with 20uL of RNase1 (Sigma). 20ul of Proteinase K was 
added to inhibit nucleases, and the cells lysed with NB lysis buffer ((0.2M Tris, 
0.25M NaCL, 25mM EDTA, 0.5% SDS, adjusted to pH 8.5). 340uL of 
phenol:chloroform (equal volume) was added and samples shaken vigorously to 
dissolve nucleic acids, which was then spun at >1000G (4°C) for 5 minutes to 
separate the fractions. The aqueous phase was removed and the process 
repeated with chloroform:isoamyl alcohol (24:1), and finally with pure 
chloroform. DNA was precipitated by adding 1/10th 3M NaOAc pH 5.5, and 1uL 
glycogen, and spinning for 30 minutes at 4°C. The supernatant was removed, the 
DNA pellet rinsed with 70% ethanol, and left to dry at room temperature for 10 
minutes. 
RNA was extracted throughout the project using the Bioline ISOLATE II RNA 
mini kit according to the manufacturer’s instructions, which includes an on-
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column DNase step to eradicate contaminating genomic DNA. Pure RNA was 
re-suspended in 40uL of nuclease-free water and quantified on the Nanodrop. 
Pellets were re-suspended in a final volume of nuclease-free water, and 
concentration quantified using the Nanodrop ND 1000 spectrophotometer, as 
detailed in the manufacturer’s instructions. Samples with a 260:280 ratio 
approaching 1.8 for DNA and 2.0 for RNA were taken to be free from ethanol 
contamination. 
Illumina array and analysis228 
The Infinium Methylation EPIC BeadChip Kit (Illumina) interrogates >850,000 
methylation sites quantitatively across the genome at single-nucleotide 
resolution. The previous iteration works according to similar principals but 
interrogates only 450,000 sites. Both arrays were utilised during the course of 
this project. DNA samples were prepared as outlined, and 500ng dispatched in 
nuclease-free water on dry-ice to Cambridge Genomic Services, where the array 
was executed according to the manufacturer’s instructions. Data were analysed 
by CGS bioinformatics using the RnBeads plugin for ‘R’ studio. P-values were 
computed using hierarchical linear models from the limma package fitted using an 
empirical Bayes approach on derived methylation values. Differential methylation 
was computed based on a variety of metrics. The following quantities for each 
site or region are reported I) the difference in mean methylation levels of the 
two groups being compared, II) the quotient in mean methylation and III) a 
statistical test (t-test or limma depending on the settings) assessing whether the 
methylation values in the two groups originate from distinct distributions. 
Additionally each site was assigned a rank based on each of these three criteria. 
A combined rank is computed as the maximum (i.e. worst) rank among the three 
ranks. 
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Q-rt-PCR 
Primers (appendix 6) were designed using the Roche Probe Library against the 
RefSeq messenger RNA NM number for the gene of interest 
(www.universalprobelibrary.com). Assay parameters stipulated a GC clamp, 18-
27 BPs in length (optimum 20), with a TM of 60°C, and to be intron spanning to 
mitigate for residual contaminating genomic DNA. Where multiple transcript 
variants were identified, a common assay was selected. Reverse transcription was 
performed on 50-500ng of RNA (depending on yield) using Q-Script cDNA 
super mix (Quanta bioscience) according to the manufacturer’s instructions, in 
10uL reactions. These were diluted in 100-200uL of nuclease-free water. 10uL 
Q-rt-PCR reactions were prepared using 3uL of cDNA template, with 7uL of 
reaction buffer containing 5uL of Immomix (Bioline), 1uL of BSA (10mg/mL), 
0.1uL MgCL2 (50mM), 0.0625uL of 1:100 Sybr Green (Qiagen), 0.02uL of each 
primer at a final concentration of 100uM, 0.4uL ROX reference dye (Thermo), 
and 0.4uL of milliQ water. Samples were run on the Applied Bioscience 7300 
RT-PCR system using the following protocol; 95°C dissociation for 10 minutes, 
followed by 40 cycles of [95°C dissociation 30 seconds, 60°C annealing, 30 
seconds, 72°C extension and measurement, 30 seconds]. Primers were validated 
at 60°C using mixed cDNA of serial dilution (1, 1:10, 1:100, 1:1000 and water). 
The gradient of the linear equation was expected to be 3.5 CTs to demonstrate 
>95% efficiency, and a melt curve performed to demonstrate a single 
amplification product. Several house-keeping genes were validated including 18S, 
ACTB, and GAPDH. CT values were normalised to the reference gene to 
mitigate for loading discrepancies (ΔCT), and the relative transcripts determined 
by the equation (2-ΔCT) x100,000. Typically – unless otherwise stated - 
experiments (treatments) were performed in biological triplicate, and technical 
triplicates run on the machine. For each replicate, the mean of the three samples 
was determined +/- the standard error. A three-tailed students T test was used 
to infer the significance of the result of the treatment verses the vehicle control 
without assuming a normal distribution. Significance was assumed if p < 0.05 
(represented by *) or p < 0.01 (represented by **). 
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Combine Bisulphite Restriction Analysis229 
Genomic DNA (200-500ng) was first bisulphite modified using the EZ DNA 
methylation GOLD kit (Zymo) according to the manufacturer’s instructions. The 
principal of the modification is that methylated cytosines undergo demethylation, 
yielding cytosine residues. Unmethylated cytosines on the other hand, are 
converted to uracil residues. This results in a methylation-specific sequence. The 
initial step is to amplify the CG island of interest in the promoter region, using 
primers that lie outside the island that do not incorporate any CGs, so the island 
is amplified regardless - typically a 200-500bp amplicon is generated. The assay 
assumes that all CG sites are methylated in the first instance, and non-CG 
cytosines are converted. Thus restriction enzymes that cleave specifically at a 
single CG in the amplicon can be utilised to cut the fragment in half. This will 
yield two half fragments if the CG site was original methylated in all alleles, one 
whole fragment if the site was 100% unmethylated. Or, if only a percentage of 
alleles were unmethylated, a ratio of cut fragments to uncut fragments can be 
determined, to give a figure for the percentage of methylated to unmethylated 
alleles (figure 10). Assays employed for genes of interest (mainly cytokines and 
Wnt antagonists) are detailed in appendix 5, showing the primers validated, and 
the restriction enzyme for the digestion. The initial amplification is similar to the 
protocol for cDNA, however, in respect of the fact that these amplicons are 
often up to 500BP, the extension time is increased to 1 minute. Commonly only 
35 cycles were performed to mitigate for non-specific amplification of other 
sequences. As the reaction is not quantified, no Sybr Green or ROX reference 
are necessary, and Hot Star Taq (Qiagen) is used for reaction mixtures instead of 
Immomix. 10uL reactions containing 3uL of bisulphite modified DNA (bmDNA) 
template were prepared in technical triplicates from experiments performed in 
biological triplicate. Bisulphite modification was also performed on 20ng of 100% 
and 0% methylated genomic DNA (Zymo, human or mouse as appropriate) as 
controls to demonstrate complete cleavage of the fragment by the restriction 
enzymes. A third control of MilliQ water was also amplified to ensure absence of 
non-specific binding. Once amplified, the amplicon was precipitated as detailed 
using ethanol and Sodium Acetate, rinsed with 70% ethanol, and re-suspended in 
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10uL of the restriction enzyme buffer. Samples were digested at the designated 
temperature for three hours, spun, 2uL of loading dye added, mixed, and then 
loaded into the polyacrylamide gel230. DNA was separated by vertical 
electrophoresis at 200V (approximately three hours). Gels were developed for 2 
hours in the dark using 1:10,000 Sybr Green in 1xTBE buffer (1L MilliQ water, 
54g Trizma, 25,5 boric acid, 4.65g EDTA). The gels were imaged using the Pharos 
FX Molecular imager (BIORAD), and visualised using BIORAD Image Lab 
software (http://www.bio-rad.com/en-uk/product/image-lab-software). Band 
analysis was optimised to subtract the background from each lane, and fragment 
band intensity quantified to determine percent of methylated alleles (total cut 
fragment intensity/total all fragment intensity*100). Data are reported as the 
mean of replicates +/- the standard error.  
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  A 
B 
Figure 10 - Example of a CoBRA polyacrylamide MEGA gel. Figure A is the image of 
the gel, while figure B represents the ratio of the intensity of the cut fragment to the 
whole fragment as a percentage, derived from gel A (n=3 lanes, coloumn is mean +/- 
the SEM.This assay probed the P14ARF promoter region. The promoter amplicon is 
cleaved only where the CG interrogated was originally methylated. Lanes A-F show 
complete cleavage, which equates to 100% methylation at that site. Bands G-L show 
partial cleavage indicating that some alleles are methylated, while others are not, 
while lanes M-X are predominantly un-cleaved, indicating hypomethylation of the CG 
in these cell lines. This assay elegantly demonstrates the heterogeneity of promoter 
methylation in the cell lines selected for experiments. Although the assay only 
interrogates a single CG in the promoter island, promoter DNAm is reported to be an 
all-or-nothing process i.e. the assays assume that the methylation status of the CG 
interrogated represents the entire promoter. Here, there is no difference in P14ARF 
promoter methylation between ethanol controls and vitamin D treated cells. 
Whole amplicon 
Cleaved fragments 
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Protein extraction (whole-cell and fractions). 
Cells were released by trypsin-EDTA chelation, and protein extracted using 
either the Pierce M-PER (for whole-cell extracts) or NE-PER protein extraction 
reagents (for nuclear and cytoplasmic fractions) according to the manufacturer’s 
instructions, which included the addition of HALT protease and phosphatase 
inhibitor cocktail (1:1000) to prevent proteolysis and any further 
phosphorylation events (all items from Thermo). Protein samples were stored at 
-80°C and defrosted on ice for analysis. Samples were quantified using the Pierce 
BCA Protein Assay Kit (Thermo), which includes albumin standards for plotting 
the standard curve. Absorbance was determined on a Bio-Rad Benchmark Plus 
colourimeter as indicated in the manufacturer’s instructions. 
Western blotting 
Proteins were separated by gel electrophoresis in pre-cast graduated NuPAGE 
Bis-Tris polyacrylamide gels following the manufacturer’s instructions 
(Invitrogen). Briefly, to samples containing up to 30ug of protein, 2uL of NuPAGE 
reducing agent and 5uL of LDS buffer were added. Samples were mixed and 
denatured at 70°C for 10 minutes. Pre-stained protein ladder IV (Bioline) and 
samples in triplicate were loaded into wells and run at 200V until appropriate 
separation was achieved. Proteins were transferred to PVDF stacks using the 
iBlot II transfer module (Life Tech). Membranes were rinsed with Tris-buffered 
saline, 0.1% Tween 20 (TBST). The membrane was blocked using 5% BSA in 
TBST for 2 hours at room temperature to prevent non-specific binding, after 
which the membrane was typically incubated with the primary antibody overnight 
at 4°C. Membranes were rinsed several times with TBST, and then developed 
using an appropriate secondary antibody for 2 hours at room temperature. 
Bands were imaged using the ChemiDoc MP imaging system (BioRad) after 5 
minutes incubation with Clarity Western ECL substrate to generate a 
chemiluminescent signal. Bands were quantified using image J (box method), and 
the data reported as the mean +/- the standard error. The ratio of the 
phosphorylated band to the total band is reported for each sample. Membranes 
were stripped by incubation in Reblot Plus membrane stripping solution (Merck) 
and the process repeated for probing with an alternative primary antibody.  
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Proteomics231-233 
Cell supernatants were collected as described and concentrated by 
centrifugation at 14,000G for 2 hours using  protein filters with a MW cut-off of 
3000Da (Merck). Samples were quantified by BCA assay and processed as per 
Western Blot protocols. Samples were run in triplicate on a 10% pre-cast 
polyacrylamide gel (Life tech) for 10 minutes. The lanes were dissected into 1mm 
squares using a razor blade and stored in 500µl water overnight. Gel plugs were 
washed with 1M Ammonium bicarbonate in acetonitrile for 15 minutes, twice, 
and then washed with 1ml acetonitrile to remove excess aqueous solutions.  
Samples were air dried for 10 minutes. Next, samples were incubated for 30 
minutes in a water bath at 60°C with 1ml of 10mM DTT in 50mM Ammonium 
Bicarbonate, then rinsed with 100mM iodoacetamide in 50mM Ammonium 
bicarbonate at room temperature in the dark. Gel plugs were again washed twice 
with 1M Ammonium bicarbonate in acetonitrile for 15 minutes, rinsed with 1ml 
acetonitrile and air dried. Peptides were digested using 5µl (5µg) Trypsin Gold 
(Promega) in 20mM ammonium bicarbonate, incubated overnight in the water 
bath at 37°C. Next, an equivalent volume of 2% formic acid was added before 
freezing on dry ice for 30 minutes. Samples were thawed and the digest solution 
removed and dried down at the Low Drying setting (no heat) on a Speed Vac 
SC110 (Savant), fitted with a Refrigerated Condensation Trap and a Vac V-500 
(Buchi).  The samples were then frozen on dry ice and stored at -80°C for 
Orbitrap analysis. LC MS/MS analysis was executed by IFR’s proteomics 
department. Data were analysed using Scaffold software (version IV). Tandem 
mass spectra were extracted and samples were analysed using Mascot (Matrix 
Science) to search the Uniprot human database. Scaffold was used to validate 
MS/MS based peptide and protein identifications. Peptide identifications were 
accepted if they could be established at greater than 95.0% probability by the 
Scaffold Local FDR algorithm and contained at least 2 identified peptides.  Protein 
probabilities were assigned by the Protein Prophet algorithm. Proteins were 
annotated with GO terms from NCBI. For interventions, Scaffold was instructed 
to perform a two-way analysis of variance on normalised spectra (ANOVA) with 
Hochberg-Benjamini Correction, with significance reported at p<0.05. 
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Chapter 3 
 
VITAMIN D PROMOTES A TISSUE-RESIDENT 
PHENOTYPE IN THP1 MONOCYTES ASSOCIATED WITH 
TNFΑ HYPOMETHYLATION 
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Preface to the work 
Incidence of Inflammatory bowel disease (IBD) is increasing globally in 
Westernised populations, and particularly in New Zealand234,235. The diseases that 
comprise IBD (Crohn’s and UC) are characterised by persistent inflammatory 
lesions in the intestinal mucosa, which frequently foreshadow epithelial 
transformation. While the aetiology of IBD remains incompletely catalogued, 
studies indicate a multifactorial pathogenesis, encompassing immune-regulatory 
defects, perturbation of the commensal microbiota, heritable predispositions 
(genetic and epigenetic), and structural deficiencies impairing barrier integrity. 
The multifactorial nature necessitates a diverse spectrum of expertise, to gain 
sufficiently broad insights to advance community understanding – a diversity not 
always afforded to post-graduate researchers. In this respect, The REINFORCE 
consortium - established by a European grant administered by The University of 
Bologna - seeks to facilitate collaboration-by-exchange between gut health 
researchers around the globe, furnishing PGRs with additional tools and 
experiences beyond their field of expertise - ultimately allowing them to develop 
a broader understanding of the physiological context of their work.  
In light of vitamin D’s established anti-inflammatory and immune modulatory 
effects, taken together with  the association between systemic inflammation and 
aberrant age-related DNA methylation, we pursued an opportunity for a 
REINFORCE collaboration with colleagues at The University of Auckland, NZ, 
investigating vitamin D supplementation as a means of inhibiting systemic 
inflammation. 
Professor Lynette Fergusson and her team in the Faculty of Medical and Health 
Sciences had recently completed a clinical intervention, supplementing a small 
cohort of healthy individuals (n = 30) with Lester’s Oil – a commercially available 
health supplement purported to promote systemic anti-inflammatory effects.  
Their laboratory were commissioned by the manufacturers of Lester’s Oil to 
perform an independent study investigating the bioavailability of the supplement 
and it’s physiological effects - encompassing metabolomics, transcriptomics, and 
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the assay of biomarkers of systemic and local inflammation. It is important to 
note that this premise introduces a conflict of interest by its nature. The group in 
New Zealand designed and executed the study, collected biological specimens, 
and processed PMBCs to recover DNA, and serum to determine vitamin D 
status. The group also furnished us with cohort data for statistical tests. 
The exchange took place in October and November of 2014. Peripheral Blood 
Mononucleated Cell (PBMC) DNA was assayed by CoBRA, to quantify the 
methylation status of genes involved in the pathogenesis of IBD. Preliminary 
experiments raised the possibility that vitamin D status might dynamically 
regulate TNFα promoter methylation and transcription, so we set about 
investigating the relationship between vitamin D and TNFα in vitro. Initially this 
thesis project’s remit was exclusively focussed on epithelial homeostasis, but this 
short exchange has allowed for valuable insight into the nature of chronic 
inflammation, and its relationship with tumourigenesis and transformation.   
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Abstract 
Chronic inflammation accelerates tumourigenesis in multiple tissues, suggesting 
that systemic mediators have a role to play in the aetiology of epithelial cancers. 
Inflammatory bowel pathologies are associated with increased peripheral blood 
monocyte count and elevated cytokines, which in turn are associated with age-
dependent genetic and epigenetic defects that deregulate crypt stem cell 
homeostasis. Specifically, mucosal macrophages, derived from the peripheral 
monocyte pool, express TNFα that contributes to the initiation and maintenance 
of inflammatory lesions. 
Vitamin D’s role as an anti-inflammatory is well established in vitro and in vivo, and 
serum vitamin D is found to be low at presentation in IBD, and prospectively 
associated with CRC risk. Vitamin D promotes monocyte differentiation and 
inhibits TNFα. Furthermore, TNFα transcription is influenced by promoter 
methylation status. 
The effect of vitamin D supplementation on inflammatory biomarkers in a cohort 
of heathy individuals (n=27) was investigated. Supplements improved serum 
vitamin D by 11.3nmol/L (p < 0.001), and inhibited C-reactive protein by 
2.46mg/L (p = 0.04), but not faecal calprotectin, suggesting systemic but not 
tissue-specific effects. In a subset of participants (n = 8), TNFα promoter 
methylation status showed a significant trend towards hypomethylation with 
increasing serum vitamin D (RSQ = 0.37, p = 0.0002). In THP1 monocytes in 
vitro, vitamin D also promoted TNFα hypomethylation, associated with the 
induction of an adherent tissue-resident macrophage phenotype (CD14+, CD68+, 
CD11b+). Conditional demethylation of TNFα by 5AZA was not associated with 
the adherent phenotype, but regression analysis suggests CD11b expression, and 
thus macrophage sub-type, is influenced by TNFα methylation. 
Our data support vitamin D inhibiting systemic inflammation, promoting 
monocyte-to-macrophage differentiation, and modulating TNFα transcription 
independently of DNA methylation status. These effects are proposed to 
regulate mucosal immunity, indirectly affecting DNA methylation patterns in the 
colonic epithelia. Further testing in epithelial models is indicated.   
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Introduction 
The inflammatory bowel diseases comprise Crohn’s Disease (CD) and Ulcerative 
Colitis (UC). Both subtypes are prevalent in Westernised populations at 
approximately 200 per 100,000, representing a considerable public health 
burden. Studies in migrants to the West show a concomitant increase in the rate 
of both UC and CD over time, indicating the environmental component of the 
aetiology236, however it is noted that incidence has plateaued across Europe in 
recent years237, suggesting that rate of diagnosis contributes to the cultural 
discrepancy. 
The aetiology of IBD is multifactorial, representing distinct pathogenic pathways 
that cumulatively effect chronic mucosal inflammation. The hallmark of CD is 
patchy, erythematous lesions throughout the GI tract, while UC presents distally, 
with inflammation involving the whole sheet238. Epithelial hypotrophy precipitates 
ulcerating lesions and granulomatous fibrosis. Both diseases have an autoimmune 
component, marked by leukocytic infiltrates of B and T cells, neutrophils, DCs, 
and tissue-resident macrophages239. Dysbiosis of the commensurate microbiota is 
established in the pathogenesis of IBD, which is compounded by impaired barrier 
integrity240. The conditions are chronic, in that periods of induced remission 
invariable falter. Due to genetic components comprising 100-200 risk loci that 
include infamous NOD2, CARD9, and IL10 SNPs (responsible for dysregulation 
of the host auto-immune response)241,242, - there are presently no curative 
therapies. Thus, pharmaco-intervention focuses on management of inflammation 
and its end points. Specifically, Infliximab, an anti-TNFα monoclonal antibody, is 
indicated in severe refractory disease states, pinpointing TNFα as a key node in 
this complex aetiological network243. The current paradigm for initiation and 
progression is that genetic predisposition impairs the immune response against 
luminal symbionts, which precipitates chronic intestinal inflammation maintained 
by mucosal populations of immune reguators239. 
Regarding prognosis, IBD is associated with an increased risk of overall mortality 
(17 per 1000 verses 11 per 1000 – risk ratio of 1.54)244. Chronic inflammation 
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promotes tumourigenesis, demonstrated by a five-fold increased risk of 
colorectal carcinoma in those diagnosed with IBD relative to healthy controls245.  
Thus IBD models have proved valuable in elucidating the inflammatory 
mechanisms that bring about aberrations found in sporadic tumours of the distal 
bowel. Specifically relevant to this topic, age-related DNA hypermethylation of 
tumour suppressors in colonic stem cells is accelerated by both mucosal and 
systemic inflammation; in their seminal paper from 2001, Issa et al report 
sequential increases in MYOD1, ER, and CDKN2a promoter methylation for 
normal mucosa (non-UC), uninvolved mucosa (UC), and neoplastic lesions (UC), 
demonstrating the association of chronic inflammation in the pathogenesis of 
sporadic lesions246. Another gene frequently reported to be silenced via 
hypermethylation in UC lesions is ECAD, which in turn has implications for Wnt 
signalling, cell-adhesion, and barrier integrity247,248. 
Postulated mechanisms for the increase in DNAm associated with inflammatory 
processes, include over-expression of IL6 in both serum and mucosa of IBD 
patients, which is shown to promote aberrant DNAm via increased DNMT1 
activity in epithelial models249. Aberrant TLR2 expression in the gut epithelia is 
also associated with gene silencing via DNA hypermethylation250, as is increased 
PGE2 in the crypt niche (see chapter 5)251, and anti-inflammatories like Aspirin, 
recognised to modify CRC risk via suppression of NFκB/COX2/PGE2252, have 
recently been reported to favourably influence both age-related and tumour-
associated DNAm patterns in the colonic epithelia253. Tapp et al also allude to 
increased numbers of circulating monocytes as positively associated with age-
related DNAm, for six of the nine genes they interrogated in tumour-prone 
epithelia212, suggesting that modulation of the monocyte pool could be beneficial 
for the epigenetic ageing of colonic stem cells. Notably, while TNFα is recognised 
to be elevated in both serum and mucosa of IBD patients, and mechanistically 
responsible for lesion maintenance and tumourigenesis (via persistent DNA 
damage254), there are presently no studies that correlate serum TNFα with  
aberrant age-related DNAm, although this is implied as TNFα signals via NFκB. 
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Elevated serum and mucosal TNFα is associated with IBD, the principal sources 
of which are circulating monocytes and tissue-resident macrophages respectively. 
Interestingly, Kobor et al observe differential methylation in Peripheral Blood 
Mononucleated Cells (PBMCs) according to the percentage of monocytes they 
contain, suggesting the DNAm has a role to play in the immune-regulatory 
functions of these cells. Indeed, the authors report that DNAm patterns predict 
the cytokine response of PBMCs to stimulation with recombinant TLR-ligands255. 
Global DNAm patterns also vary longitudinally in leukocytes256, but to date, with 
regards cell-type, the majority of studies looking at DNAm in PBMCs have 
focussed on T-cells, not the lesser monocyte contribution257, or are employed as  
systemic markers of epigenetic ageing as opposed to characterising inflammatory 
mechanisms258,259. 
With regards transcriptional control of TNFα, the primary epigenetic events are 
classically histone modifications that are dynamic in response to TLR/NFκB 
signalling. While the TNFα promoter does not contain a defined CG island, a 
single CG 150 BP proximal to the TSS is documented in transcriptional 
competence of the neutrophilic cell line HL60 in the hypomethylated state219. 
Gowers et al report an age-associated decrease in CG methylation in the TNFα 
promoter region, specifically in monocyte-derived macrophages from healthy 
participants, that is associated with increased expression, and thus may 
contribute to age-associated systemic and local inflammatory pathogenesis. 
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As well as a comprehensively described role as a systemic anti-inflammatory260, 
deficiency associations with IBD, aberrant DNAm in CRC212,261, and in vitro 
differentiation of monocyte-derived macrophages84, vitamin D also regulates 
TNFα expression in monocytes262,263. Given access to PMBC DNA from a cohort 
of healthy vitamin D-supplemented participants, it was hypothesised that serum 
vitamin D would be associated with markers of systemic inflammation, the 
macrophage phenotype, and TNFα methylation – plausible mechanisms by which 
vitamin D sufficiency promotes bowel health. We employed THP1 monocytes to 
investigate observed cohort trends in vitro, and report here that the methylation 
status of the TNFα promoter is associated with, but not defined by, vitamin D 
status and macrophage phenotype and function, but not TNFα transcription. 
Hypomethylation was synchronous to regulation of DNMT1 and TET enzymes 
by vitamin D, posited as a mechanism for vitamin D’s epigenetic effects.  
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Methods 
Lester’s Oil intervention 
Thirty healthy individuals from the Auckland metropolitan area were recruited to 
the study. The intervention was of a randomised, double-blinded, placebo-
controlled, cross-over design (figure 11). Blood and faecal samples were 
collected at base line, after intervention 1, after the primary wash-out period 
(before intervention 2), and after intervention 2. Anthropomorphic features 
were also determined at these time points (height, weight). Participants received 
two soft gel caps per day, for 28 consecutive days, containing either Lester’s Oil, 
or encapsulated Canola oil, followed by 28 days of wash-out, and the programme 
was executed between March and June in 2014. Participants were screened to 
include male and females aged between 20 and 65 years, with no history of 
cancer in last 5 years, no history of IBD, not on medication, non-smokers, and 
not currently taking any vitamin D, fish oil/flax seed oil supplements, or eating 
more than 4 servings of oily fish per week. 8.5mL of peripheral blood was 
collected in BD Vacutainer Serum Separation Tubes, which was inverted five 
times, allowed 30 minutes clotting time, and centrifuged for 10 minutes at room 
temperature at 1000-1300G. A 40uL aliquot of serum was pipetted off and 
stored at -80°C for analysis by vitamin D X-press ELISA (ImmuniDiagnostiks). A 
further 4mL of PB was collected with EDTA on ice, PBMCs were separated by 
routine methods, and DNA and RNA extracted using the Qiagen ALL-prep kit, 
for transcriptomics or bisulphite modification using the EZ DNA methylation 
GOLD kit (Zymo). 4.5mL PB was collected with lithium heparin to determine C-
reactive protein (LabPlus). Faecal samples for calprotectin were stored at -80°C. 
TNFα promoter methylation 
500ng of bisulphite modified DNA was amplified by PCR and digested by 
restriction enzyme as outlined in General Methods. Hypo- and hyper-methylated 
control DNA was also included (Zymo). For analysis in Auckland, digested 
fragments were run horizontally on 1% agarose gels as opposed to PAGE. In 
contrast, in vitro verification with THP1 monocyte DNA was performed by PAGE 
as outlined. 
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Cell culture and treatment 
The THP1 cell line (ATCC) was maintained according to the manufacturer’s 
instructions, in RPMI 1640 + 10% FBS + 1% penicillin/streptomycin, at 37°C. To 
induce differentiation, cells were seeded in 12 wells plates at a density of 50,000 
cells per well, to give a final yield of ~400,000 after 6 days (assuming a 48 hour 
doubling-time). After 24 hours to restore homeostatic equilibrium, wells were 
treated in triplicate with either ethanol vehicle at the highest concentration, or 
increasing doses of active vitamin D in ethanol, giving final concentrations 1, 10, 
or 100nM (10x physiological to 1000x physiological relevance). On the final day, 
cells either were recovered for DNA extraction, or were primed with LPS at a 
final concentration of 5ng/mL for four hours prior to RNA extraction. Further 
tests investigating differentiation utilised PMA (200nM final concentration, 24 
hour treatment), IL10, (25ng/mL final concentration, six day treatment), or 
demethylating agent 5-azacytidine (5AZA, 1uM final concentration, six day 
treatment). Treatment was re-applied at 24 hour intervals. On the third day, 
media was removed, the cells collected by centrifugation, and re-suspended in 
fresh media to mitigate for nutrient deficiency. Cell counts to determine the 
ratio of adherent to suspended populations was determined in chamber slides 
using the Cellometre Mini (Nexelom) according to the manufacturer’s 
instructions. 
Q-rt-PCR 
Cell pellets were washed with PBS, and RNA recovered using the Isolate II RNA 
mini-kit (Bioline). 500ng was reverse transcribed using Q-Script (Roche) in 10uL 
reactions as per the manufacturer’s instructions. Assuming a 75% conversion, 
375ng was resuspended in 100uL of RNAse-free water, and Q-rt-PCR reaction 
prepared in technical triplicate (11.25ng cDNA per reaction). Q-rt-PCR was 
executed as detailed in General Methods, and the number of relative transcripts 
(against either 18S or ACTB as a housekeeper) determined by the delta CT 
method. A three-tailed students T-test was used to determine significant 
difference between treatment groups, and data are reported as the mean +/- the 
standard error. Primer pairs specific to this chapter are detailed in appendix 6)  
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Figure 11 – Trial protocol. The cohorts were assigned randomly, and administration was double blinded. 
Participants received either 2 soft gel caps of Lester’s Oil, or 2 gel caps of inert canola oil per day for 4 
weeks. Components of the supplement are also detailed. 
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Results 
Lester’s Oil intervention 
Cohort characteristics 
Of the 30 healthy participants from the NZ cohort supplemented with Lester’s 
Oil, two failed to complete the study and one data set was removed due to an 
ongoing infection during the trial period. Figure 12 details cohort statistics at 
base line. Data were incomplete for a further 3 participants. Our final cohort 
included 11 females and 13 males whose biomarkers exhibited skewed 
distributions, with no significant differences between male and female groups. Log 
transformation corrected significantly skewed variables (BMI and CRP) for 
further testing. Log transformation of the calprotectin data set did not correct 
for the skewed distribution, and so a three-tailed students T-test was applied to 
assume a non-normal distribution. Mean BMI for both males and females 
bordered on overweight (BMI >30) due to the presence of an outlying obese 
individual (BMI > 35) within each group. All other biomarkers measured (vitamin 
D, CRP, CALP) fell within clinical reference ranges. No individuals were deemed 
to be vitamin D deficient (serum D <40nmol/L) at the start of the trial. 
 
Figure 12 – Cohort variables. NZ Lester's Oil cohort variables at t0 (mean +/- SEM). Two or three tailed 
student’s T-tests were applied to normalised data sets as appropriate. 
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Lester’s oil supplements improve serum vitamin D status 
Supplementation with Lester’s Oil significantly improved serum vitamin D status 
concomitant to reduced circulating CRP, suggesting a reduction in systemic 
inflammation. Other biomarkers measured were not significantly affected by 
supplementation. Specifically, the trend for calprotectin in males was positive, 
suggesting that mucosal inflammation in the distal colon was not impacted. 
Detailed in figure 13. Surprisingly, vitamin D was significantly reduced in the 
placebo group, but regression analysis of the relationship between reported 
sunlight hours in Auckland across the trial period, and serum vitamin D in the 
placebo groups, suggested that seasonal variation is responsible for falling serum 
vitamin D in the control participants. 
  
86 
 
 
  
Figure 13 – The effect of Lester’s Oil on various Biomarkers. Detailing cohort response to either placebo 
or Lester’s Oil supplements. BMI does not vary according to treatment, precluding a role for BMI in 
serum vitamin D bioavailability. Circulating vitamin D is significantly increased in the supplemented 
cohort, an increase of 7.4nmol/L in females and 4.6nmol/L in males. There was a modest trend towards 
reduced CRP in this sub-set of participants, which was confirmed by a larger study performed by the 
group in NZ (data not shown). Calprotectin levels trend towards an increase in the Lester’s Oil cohort, 
suggesting that vitamin D’s anti-inflammatory effects were systemic, not mucosal. Vitamin D levels in the 
placebo group fell across the intervention period, our collaborators proposed sequestration of serum 
vitamin D by components of the placebo pill, however, seasonal variation in sunlight hours is suggested as 
an alternative explanation for falling vitamin D levels. NB – this study was performed in the southern 
hemisphere, where seasons are reversed i.e. T1-T4 represent autumn approaching winter. 
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Vitamin D status is inversely associated with dynamic TNFα promoter 
methylation 
 
To investigate any effect of serum vitamin D on TNFα promoter methylation 
status, DNA was extracted from recovered PBMCs at each time point (before 
and after placebo, and before and after intervention) for the first eight 
participants as proof of concept. The TNFα promoter was assayed by CoBRA as 
described. Regression analysis suggested an inverse relationship between TNFα 
promoter DNAm and vitamin D status (figure 14a RSQ=0.367, p = 0.0002). 
When data are stratified according to sample group a non-significant trend is 
observed for the effect of intervention verses placebo on TNFα promoter DNA 
methylation. The intervention in these eight participants significantly increased 
circulating vitamin D. No other trends were observed between TNFα promoter 
status and other biological biomarkers measured. Specifically, age and BMI (both 
associated with DNAm in the distal colonic epithelia) had no effect of TNFα 
methylation in PBMCs in this group. Equally, while intervention and improved 
vitamin D status both decreased CRP levels, CRP itself was not associated with 
any change in TNFα methylation (figure 14b-d). 
Interestingly, TNFα promoter DNAm appeared dynamic within individuals at 
each time point, regardless of intervention i.e. dynamic with regards serum 
vitamin D independent of stratification. This suggested to us that promoter 
methylation status in the context of PBMCs might have a role to play in 
regulating TNFα transcription, as reported elsewhere. Transcriptomics did not 
report any change in TNFα transcripts in PBMC at any time point, regardless of 
vitamin D status, consistent with the contemporary hypothesis that promoter 
hypomethylation need not necessarily drive transcription. 
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Figure 14 – The relationship between serum vitamin D and TNFα promoter methylation in PBMCs. A) 
TNFα methylation status trends towards hypomethylation as vitamin D status improves in this sub-set (n 
= 8). Validation is indicated in a larger cohort. B) When samples are stratified by intervention, serum 
vitamin D is significantly improved in those participants receiving the Lester’s Oil tablet (25ug vitamin D, 
equivalent to 1000IU – the current recommended daily dose is 300IU for comparison) versus the placebo. 
This was associated with reduced CRP, but not CALP, suggesting inhibition of systemic, but not mucosal 
inflammation. C) TNFα methylation in patients receiving LO trends toward a reduction that was not 
significant, in keeping with our regression analysis. D) TNFα methylation status was dynamic within 
individuals according to their vitamin D status (participant number 8 shown), raising the possibility that 
vitamin D directly modulated TNFα methylation in PBMCs.  
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In vitro verification with THP1 leukemic monocytes 
In humans, PBMCs comprise; lymphocytes (~80%), monocytes (~20%), and 
dendricytes (>1%). It was speculated that the weak relationship between vitamin 
D and TNFα methylation in PBMCs, represented a more pronounced 
relationship in one subset of the total cell population. Furthermore, Lester’s Oil 
supplements contain other bioavailable factors which influence systemic 
inflammation (fatty acids264, CoQ10265, carotenoids). To determine if vitamin D 
was mechanistically responsible for the observed trends, in vitro verification was 
proposed. In light of reports that TNFα transcription in monocytes is influenced 
by promoter methylation266, and given their relative abundance in PBMC 
populations, monocytes presented themselves as primary candidates. The THP1 
monocyte cell line was selected as a well differentiated monocyte model267. 
Encouragingly, the methylation status of the TNFα promoter in un-primed THP1 
monocytes in vitro is similar to that documented in the NZ cohort, supporting 
the use of these cells (70.3% +/- 2.6 verses 72.0% +/-1.2). It was further 
speculated that demethylating effects might be passive in nature, given that 
sampling was performed several weeks apart. Thus, cells were treated for six 
days with increasing concentrations of vitamin D, applied every 24 hours, to 
establish dose effects. 
Initially, monocytes were distributed evenly throughout the suspension as single 
cells. By day three, cells began to coalesce into aggregates, and by day six 
approximately 10% of cells were adherent in vehicle-treated wells. In contrast, 
D-treated cells formed larger aggregates sooner, and percent adherence 
increased in a linear fashion with dose. It was hypothesised that the adherent and 
suspended populations represented distinct phenotypes, and so TNFα 
methylation was interrogated in both, by gently removing suspended cells, 
rinsing, and recovering the remaining adherent population. In vehicle controls, 
there was no difference in TNFα methylation between suspended cells and 
adherent cells. Neither did vitamin D affect the promoter status of TNFα in any 
of the suspended populations. However, vitamin D significantly reduced TNFα 
methylation by an average of 8.6% +/-0.4 in all three D-treated adherent 
populations. Unlike the adherent phenotype, the effect was not dose-dependent, 
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suggesting either a spontaneous threshold response, or temporal effect of 
vitamin D (figure 15a).  
Pre-treatment with vitamin D modulates TNFα transcription in 
response to LPS in a phenotype-specific fashion 
 
A reduction in promoter methylation status from 70% to 60%, conversely 
equates to the number of hypo-methylated alleles increasing from 30% to 40%, or 
put succinctly, a 33% increase in the number of hypo-methylated alleles. It was 
hypothesised that if transcription were to be regulated by promoter methylation 
status, adherent vitamin D treated cells would produce more TNFα transcripts 
in response to an inflammatory stimulus than untreated hyper-methylated 
adherent and suspended cells. We repeated the vitamin D protocol at the 
concentration showing the greatest effect (10nM for six days), and then 
stimulated cell populations for four hours with LPS at 5ng/mL, before recovering 
RNA. 
Synchronous to promoter demethylation, vitamin D in isolation inhibited TNFα 
transcription in adherent cells (figure 15b). Naïve adherent cells primed with LPS 
mobilise significantly more TNFα transcripts, which vitamin D attenuates, 
countering our prediction that the demethylating effect of vitamin D would 
enhance the TNFα response to LPS in adherent cells. Furthermore, in suspended 
cells, that experienced no change in their promoter methylation status, the 
pattern is repeated, although it is apparent that TNFα transcription in these cells 
is significantly reduced regardless of environment, in comparison to the adherent 
phenotype. However, it is true that vitamin D-treated adherent cells produce 
more transcripts in response to LPS than vitamin D-induced cells in suspension 
stimulated with LPS, supporting the case for vitamin D promoting an adherent 
phenotype that mobilises more TNFα transcripts due to hypomethylation of the 
TNFα promoter. This suggests that multiple regulatory events prescribe the 
response of TNFα to LPS in a phenotype-dependent fashion. Certainly, vitamin D 
promotes anti-inflammatory effects in THP1 monocytes with regards TNFα 
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transcription, and the compound also appears to encourage an adhesive 
phenotype in these cells. 
Vitamin D induces transcription of biomarkers that define a tissue-resident 
macrophage phenotype 
 
Tissue resident macrophages (TRMs) have an important role to play in the 
resolution of mucosal inflammation in the distal bowel. Populations are recruited 
from circulating monocytes (MOs), and differentiate in situ according to well 
documented schedules, which are both diverse and plastic. Specifically, high 
expression of CD14, CD68, CD16a, F480, and CD11b are documented to 
characterise the tissue-resident phenotype. A significant induction of all of these 
genes in both adherent naive cells and suspended vitamin D-treated cells is 
observed (figure 15c-f). The effect is cumulative in vitamin D-treated adherent 
cells, particularly for CD14 and CD16a which, in keeping with the literature, was 
not detected after 40 cycles in naive suspended cells. Given that both plastic-
adhesion and vitamin D treatment are well-documented bench techniques for 
propagating monocyte-derived macrophages, and in respect of their adhesive 
phenotype and transcriptional profiles, henceforth suspended cells will be 
referred to as MOs and adherent cells as TRMs. 
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Figure 15 – Vitamin D induces TNFα hypomethylation but inhibits transcription in THP1 monocytes over 
6 days. * p<0.05, ** p<0.01. 3 biological replicates, 3 technical replicates. Data represtent the mean +/- the 
SEM. A) The TNFα is hypo-methylated in adherent cells, but not cells remaining in suspension. The effect 
(DNAm ↓8.6% +/-0.4) was not dose-dependent. B) Adherent cells exhibit increased TNFα transcription 
relative to suspended counterparts. Vitamin D acts to inhibit TNFα, and LPS acts to induce, TNFα in 
both phenotypes. Treatment with vitamin D does not promote TNFα transcription when cells are primed 
with LPS, contrary to the founding hypothesis, in fact vitamin D attenuates LPS-induction of TNF, 
supporting vitamin D’s role as an anti-inflammatory, but not effected via modulation of the TNFα 
promoter. C-F) In both suspended and adherent cells, vitamin D induces markers associated with a tissue-
resident macrophage phenotype, consistent with the literature. CD14, CD68, and F4/80 are induced in 
adherent controls and by vitamin D, suggesting a cumulative effect of both plastic adherence and vitamin 
D treatment in the promotion of the TRM phenotype 
A B 
C D 
E F 
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Next we sought to establish if the methylation status of TNFα correlated with 
the degree of differentiation. Two end points were deemed necessary 1) 
optimise  techniques to derive TRMs of varying degrees of differentiation, and 2) 
optimise a technique to demethylate the TNFα promoter, to see if 
hypomethylation precipitates differentiation toward a TRM transcriptional 
profile. Several techniques are reported to promote the differentiation of MOs 
to various TRM phenotypes (including vitamin D) - treatment with phorbol-
myristate-acetate (PMA, 200nM), and treatment with interleukin 10 (IL10, 
25ng/mL) were also selected from the literature465. We also incorporated 
treatment with the demethylating agent 5-azacytidine (5AZA, 1uM). Cells were 
treated for six days, with treatments re-applied every 24 hours with the 
exception of PMA (PMA-treated cells became adherent within 24 hours of the 
initial treatment, and remained adherent for the duration of the protocol). Cells 
were harvested on the sixth day and the ratio of MOs:TRMs determined by 
Cellometre (in triplicate), which show varying degrees of adhesion according to 
treatment regimen (figure 16a). 
The panel of TRM markers was interrogated by Q-rt-PCR to determine the 
phenotype of adherent vitamin D-, PMA-, IL10-, and 5AZA-treated cells. The 
methylation status of the TNFα promoter was also interrogated by CoBRA, to 
investigate its relationship with increased adherence. PMA and 5AZA almost 
completely demethylate the TNFα promoter, but interestingly, while markers of 
the TRM phenotype are induced in these cells, the levels of transcription 
remained relatively low compared with D- and IL10-treated cells (figure 16b and 
c). Specifically, while PMA and 5AZA promoted demethylation, 5AZA did not 
induce adherence during the course of the treatment, suggesting that the change 
in TNFα methylation is not what precipitates the adherent phenotype, thus, in 
this instance the null hypothesis should be accepted - TNFα promoter 
demethylation is associated with an adherent phenotype in previous experiments, 
but not exclusively and does not induce it. Vitamin D induced a trend towards 
demethylation, as previously observed, but this time the effect did not achieve 
significance. Given the modest reduction (<10%), and inclusion of only one 
sample with five technical replicates for comparison, it is strongly advised to 
  
94 
 
repeat this experiment to certify vitamin D’s TNFα demethylating effect in 
adherent THP1 monocytes. 
Although significantly induced relative to controls, F4/80 was expressed at 
negligible levels in treated cells. In retrospect, after further literature searches, 
this marker is not deemed suitable for classification of human macrophage 
populations, typically employed for murine modelling. 
The phenotype of the cells did appear to be defined by treatment regimen, as 
would be anticipated given the TRMs dynamic environment-specific phenotype in 
vivo; all cells show discrete degrees of TNFα methylation and adherence ratios. 
D-treated cells represent a CD14+/CD68+/CD11b+ phenotype. PMA treated cells 
are defined as TRM-markerlow, while IL10 induces a CD14+/CD68++/CD11blow 
(figure 16b). The TRMlow designation applies to both PMA and 5AZA adherent 
cells, which both experience severe TNFα hypomethylation – it may be pertinent 
to explore the effect of these treatments across the THP1 methylome, to be 
correlated with RNA-seq profiles. Validation of the proposed phenotypes by 
IHC, and investigation of associated properties regarding mucosal immunity may 
also bring forth insight into TRM physiology. 
Finally, it was noted that the CD11b transcriptional profile closely matched the 
TNFα methylation status, regardless of treatment; regression analysis raises the 
possibility that the two are inter-dependent, but the trend did not achieve 
statistical significance (figure 16d).   
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Figure 16 – Induction of differentiation by vitamin D, PMA, IL10 and 5AZA. . * p<0.05, ** p<0.01. 3 
biological replicates, 3 technical replicates. Data represtent the mean +/- the SEM. A) Treatments 
increase adherence (% of viable cells) to varying degrees. PMA promoted rapid and permanent adhesion, 
whilst vitamin D and IL10 induce only partial adhesion of the total population. 5AZA did not promote the 
adhesive phenotype B) Treatments were associated with the induction of TRM-specific markers, relative 
to controls where expression was negligible (<1). Adherent vitamin D-treated cells demonstrate modest 
increases in transcription of CD14, CD68, and CD11b. Similarly, PMA induces these genes, suggestive of a 
shift towards a TRM phenotype, however relative expression is low in comparison to D- and IL10 treated 
cells. IL10 exhibits induction of CD14 and specifically CD68. Although TRM markers are induced by 
5AZA, relative levels remain low – taken together with the null effect regarding adhesion, this suggests 
that 5AZA does not promote differentiation, despite hypomethylation of the TNFα promoter C) All 
treatments show trends towards hypomethylation of the TNFα promoter, but the degree does not 
correlate to adherence ratios, suggesting that TNFα promoter methylation status does not regulate the 
adherent phenotype. However, all treatments induce both hypomethylation and markers of TRMs, but 
the true relationship between adherence, biomarker phenotype and TNFα methylation is not resolved 
here. Methylation and transcriptomic arrays are indicated to comprehensively document 
interdependency. D) CD11b transcription appears weakly associated with TNFα methylation status. 
Although the trend was not significant, this finding warrants further elucidation. Immunhistochemical 
assays should also be performed to correlate transcription with variable expression and confirm 
phenotype. 
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Finally, to investigate potential mechanisms by which vitamin D might modulate 
TNFα methylation, we analysed gene transcripts for 5mC metabolic enzymes 
classically associated with DNA hypomethylation (DNMT1, and TETs 1, 2, and 
3). DNMT1 is responsible for maintenance of DNAm during S-phase, and 
deregulation of activity precipitates global hypomethylation. Conversely, TET 
enzymes actively demethylate 5mC via 5hmC intermediates. Encouragingly, 
vitamin D promotes induction of all three TETs (figure 17), raising the possibility 
that activity is deregulated (induction may be driven by vitamin D, or conversely, 
a response to other changes in DNAm metabolism not characterised i.e. a 
feedback response, therefore it is not possible to speculate about the direction 
of activity). Synchronously, DNMT1 is induced – this could be an induced 
homeostatic mechanism, to counter active demethylation by TETs, although this 
hypothesis is speculative. Certainly, transcriptional data strongly implies 
deregulation of normal 5mC metabolism in THP1 monocytes by vitamin D. 
Activity assays (ELISA) are indicated to resolve these effects. 
Figure 17 - 5mC metabolic enzyme transcription in adherent D-treated THP1 monocytes. Vitamin D 
significantly induces DNMT1, TET1, TET2, and TET3. TET1 transcription is relatively low compared to 
the other genes, raising the possibility that responsibility for DNAm metabolism in these cells falls to 
the other TETs analysed. Activity assays are indicated to determine the relationship between 
transcription and enzyme activity to determine any mechanistic effects of vitamin D in regulating 5mC 
methylation and DNAm patterns in THP1 monocytes. Conditional interference will help to resolve the 
relationship between DNAm patterns and differentiation of the TRM phonotype hinted at here by our 
experiments. 
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Discussion 
Vitamin D deficiency, indicated by serum calcidiol (pre-vitamin D) concentration 
<50nmol/L19, is associated with an increased risk of Inflammatory Bowel 
Disease268. Both chronic inflammation and vitamin D deficiency are associated 
with CRC risk, and further associated with aberrant DNA methylation affecting 
Wnt tumour suppressors in the colonic epithelia. To resolve these associations 
mechanistically, it was speculated that vitamin D sufficiency attenuates systemic 
inflammation, thus indirectly attenuating age-related DNA methylation defects 
promoted by inflammatory mechanisms in the colonic epithelia. First,  markers of 
systemic and local inflammation were characterised in a small cohort of healthy 
individuals from Auckland, NZ (n = 27), supplemented with Lester’s Oil, which 
contains 1000 IU (25ug) of vitamin D – 3x the recommended daily intake. 
Versus the placebo, supplementation with Lester’s Oil promoted a significant 
increase in serum vitamin D of 15nmol/L. Given the exponential decrease in 
CRC odds ratio with increasing serum vitamin D269, small improvements in 
circulating vitamin D in deficient patients have a greater impact on health 
outcomes than small improvements where sufficiency is established. As no 
individuals in our cohort were vitamin D deficient at any point during the 
intervention, it may be pertinent to investigate the effects of these supplements 
in a deficient cohort, where the impact on biomarkers should be more 
pronounced. Regardless, the increase in vitamin D in this cohort was associated 
with a significant reduction in serum C-reactive protein (↓2..46mg/L, p = 
0.0423). Although CRP itself is not mechanistically responsible for effecting 
tumourigenesis, it’s clinical usefulness as a marker of systemic inflammation is 
well established, as are its associations with cancer risk270. In fact, Erlinger et al 
report an odds ratio for developing CRC at 1.35-1.38 associated with a 1.02 
mg/L increase in CRP271, so in this respect, correcting for vitamin D deficiency via 
supplementation, where a 2.5mg/L improvement was noted, is proposed to 
favourably impact on CRC risk. 
Conversely, IBD may be diagnosed non-invasively by measuring faecal 
calprotectin (FC)272, which is elevated during inflammation and infection due to 
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neutrophilic infiltration of the mucosa. Contrary to our hypothesis, our cohort 
saw a non-significant trend towards elevated FC following supplementation, and 
when stratified by sex, the increase in males was significant. However, the large 
standard errors associated with these results suggests that caution should be 
exercised in asserting the null hypothesis, particularly in light of recent reports 
that FC is inversely associated with serum vitamin D in IBD, and the relationship 
is strengthened where the disease is in remission, suggesting that for disease-free 
individuals, the association may be even stronger273. In contrast to our findings in 
D-sufficient healthy individuals, Garg et al report serum vitamin D to be inversely 
associated with FC (but not CRP or other markers of systemic inflammation), in 
a cohort of 70 IBD patients, raising the possibility the vitamin D’s mechanisms of 
action are either different in healthy versus disease tissues, or the same but 
impaired in IBD. Inclusive intervention studies that incorporate healthy, D-
deficient, and IBD relapsing/remitting participants may be necessary to resolve 
the associations of serum vitamin D with biomarkers of systemic and mucosal 
inflammation. Certainly our data support larger studies investigating the effects of 
Lester’s Oil on inflammation and disease risk in the distal bowel. 
Tumour necrosis factor-alpha plays a key role in mediating acute phase 
inflammation, and both serum and mucosal concentrations are elevated in 
IBD274,275. Furthermore serum TNFα is positively associated with CRP status276, 
and monocytes from TNFα-high IBD patients produce more TNFα relative to 
TNFα-low patients when primed with LPS218, suggesting that serum TNFα is 
associated with aberrant TNFα transcription in IBD monocytes. We investigated 
the methylation status of a single CG in the TNFα promoter region in a subset of 
the Lester’s Oil participants (n= 8) who’s vitamin D status varied across the trial 
period. Vitamin D was inversely associated with TNFα methylation (P<0.001), 
but not when participants were stratified by treatment regimen, indicating 
analysis in the full cohort should be pursued. The NZ group report no change in 
TNFα transcription for the whole cohort, and transcriptional data was not 
available for our sub-set, which suggests that either our data are insufficient to 
extrapolate to the larger cohort, or that methylation status is independent of 
  
99 
 
TNFα transcription. Equally, TNFα transcription may have varied in our subset, 
but is masked in the full cohort. Determining TNFα transcription in vitamin D-
supplemented participants whose promoter DNAm is dynamic, is essential to 
resolve the epigenetic regulation of TNFα in PBMCs. Methylation of TNFα is 
reported to decrease in PBMCs from obese participants given a calorie-
restricted diet, but in this study of obese men, not only was TNFα methylation 
lower at base line than in our healthy participants, but serum TNFα at baseline 
was positively associated with TNFα methylation status, suggesting that 
hypomethylation does in fact promote TNFα transcription277. Silencing of TNFα 
by promoter hypermethylation is reported elsewhere278. Finally, to confirm the 
dynamic nature of TNFα, one would anticipate D-deficient monocytes to exhibit 
increased promoter methylation. Investigating promoter methylation 
longitudinally in vehicle-treated cells would contribute to our understanding of 
the nature of DNAm in TNFα. 
We sought to a) identify the component of PBMCs contributing variable DNAm 
and b) demonstrate a mechanistic effect of vitamin D specifically versus Lester’s 
Oil, which contains other anti-inflammatory compounds. Monocytes were 
selected for their relative frequency, and role in monocyte-derived TNFα in IBD. 
Treatment with vitamin D reduced TNFα methylation in adherent populations of 
THP1 monocytes, but not those remaining in suspension, which suggested to us 
that methylation status might be associated with an (adherent) tissue-resident 
macrophage phenotype. This appears conclusive in light of our data showing a 
concomitant increase in macrophage markers in adherent cell populations83, 
although expression changes of end-point proteins (CD14 and CD68) should 
ideally be quantified by IHC or Western Blot. However, although conditional 
hypomethylation by 5AZA also showed induction of these markers, relative 
transcripts were low, and adhesion was not the prominent phenotype – this 
could be attributable to transdifferentiating effects of 5AZA, which are reported 
to impair macrophage adhesion279. Perhaps better insights are afforded by the 
PMA-treated cells, which showed severe hypomethylation, increased adhesion, 
and induction of phenotype markers. In support of our findings, TET demethylase 
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transcription is enhanced in D-treated cells, implying modulation of 5mC 
metabolism by vitamin D in THP1 monocytes; activity assays are indicated to 
confirm a functional pathway for vitamin D-mediated hypomethylation of TNFα, 
particularly as we also saw a dose-dependent increase in Interleukin 8 promoter 
methylation in the suspended fraction of D-treated cells (2.7% vs 7.7% p = 0.047, 
data not shown). Our conclusions are strongly supported by a very recent study, 
that fully characterised the methylomes of monocytes and monocyte-derived 
macrophages; the authors conclude that a panoply of genes associated with the 
macrophage phenotype are repressed by hypermethylation in monocytes, and 
that are actively hypomethylated by TETs 2 and 3 during differentiation. When 
TET activity is inhibited, hypermethylation is restored in induced-macrophages280. 
We also noted that TET1 transcription was relatively low compared to 2 and 3, 
and independently predicted their role in hypomethylation in this instance. 
Specifically, Takei et al previously performed very similar experiments to us, 
treating THP1 monocytes with vitamin D and PMA, and determining TNFα 
methylation and transcription in response to LPS. With regards methylation and 
phenotype, the authors’ results recapitulate our findings here, however they 
suggest that hypomethylation by vitamin D increased TNFα transcription both in 
isolation, and in combination with LPS281, as we hypothesised. However we 
observe TNFα to be repressed after having its promoter hypo-methylated, and 
pre-treatment with vitamin D attenuated the response to LPS, rather than 
enhancing it as we predicted. Here the authors use 10ug/mL LPS, not 5ug/mL, 
but they also fail to note the length of stimulation. This contradiction should be 
fully resolved to determine the true role of TNFα promoter methylation status 
in regulating transcription. It is encouraging in a broader context that vitamin D 
appears to inhibit TNFα transcription in THP1 monocytes, supporting vitamin 
D’s role as a systemic anti-inflammatory. 
Several limitations should be considered when interpreting the data presented 
here, firstly the sub-group (n=8) may not represent the cohort, which in turn 
may not represent the broader population, nor D-deficient candidates. Secondly, 
caution is advised against extrapolating data here to the physiology of 
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monocytes/macrophages in IBD, which are established to be dysregulated. 
Thirdly, the contribution of circulating lymphocytes was not addressed; showing 
variable DNAm in monocytes does not preclude a synchronous effect of vitamin 
D on the methylome of T-cells. After all, TNFα methylation status is reported to 
be tissue specific219, although it is posited to define myeloid lineage (when hyper-
), and lymphoid lineage (when hypo-)282, implying our data are representative. 
Further supplementation studies in D-deficient and IBD patients are indicated, as 
is verification in primary models, as opposed to transformed leukemic cells 
(THP1). 
Finally, an important note on the Lester’s Oil trial independent to the results 
from in vitro work; while vitamin D status was observed to correlate with 
markers of systemic inflammation and DNA methylation status in the cohort, 
causation is by no menas demonstrated – The composition of the Lester’s Oil 
supplement also includes other compounds reported to modulate inflammatory 
pathways, for example vitamin E (transrectal lavage) is shown to inhibit TNFα, 
IL1β and IL6 in the colonic epithelium in a model of induced-colitis466, while oral 
vitamin E reduced circulating CRP across 12 trials selected for meta-review by 
>0.5mg/mL468, suggesting that here, that the mechanism of Lester’s Oil 
suppressing CRP are indeed mulitfactorial.  Similarly, oral astaxanthin inhibits 
colitis and modifies CRC risk via down-regulation of inflammatory mediators in 
the colonic mucosa467.  
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In summary 
 
Improving vitamin D status is associated with reduced CRP, taken as a marker of 
systemic inflammation, and may contribute to the attenuation of age-related 
hypermethylation in the distal colon. In support of other studies, our data 
suggests that vitamin D promotes differentiation of monocytes associated with 
TNFα-hypomethylation, and that both the monocyte-derived macrophage sub-
phenotype, and TNFα methylation status, vary according to the differentiating 
stimulus. In vivo studies specifically addressing aspects of systemic inflammation 
and their impact on DNA methylation in the colonic epithelia are warranted to 
elucidate the contribution of vitamin D as an anti-inflammatory in the attenuation 
of age-related DNA hypermethylation. 
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Chapter 4 
 
VITAMIN D ATTENUATES TGFΒ1 MODIFICATION OF 
THE INTESTINAL MYOFIBROBLAST METHYLOME 
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Preface to the work 
 
A fundamental paradox remains regarding vitamin D and its relationship with 
poor health – an epidemiological association between serum vitamin D and a raft 
of diseases, affecting most tissue types, is well documented; were the relationship 
causal, one would expect clinical interventions correcting for insufficiency to 
impact favourably on disease risk. To date, the evidence for this is scant66, 
implying that the observed association of low serum D, is synchronous to, but 
not necessarily a consequence of, poor health.  
Speculative reasons for the dichotomy include the quality and paucity of clinical 
trials data, together with follow-up to interventions not typically exceeding three 
years283. Furthermore, serum D (calcidiol) as a marker of cytosolic bioavailability 
is not well established; activating hydroxylations are managed by enzymes that 
are polymorphic, heterogeneously efficient, and prone to single nucleotide point 
mutation, not to mention transport proteins, other cofactors, and vitamin D’s 
cognate receptor, VDR, all of which have a role to play in active D cytosolic 
bioavailability284,285. Thus low serum D does not necessarily equate to impaired 
cytosolic active vitamin D. 
Alternatively, gastrointestinal absorption of nutrients is typically dysregulated in 
IBD286; this could explain lower serum D found in CRC patients at presentation 
without implying causality. Equally, as a fat soluble compound, obesity might 
precipitate poor health (via chronic adipo-inflammation) and low serum D 
simultaneously40. Finally, the two scenarios are not mutually exclusive; vitamin D 
regulates thousands of genes, and status is associated with diseases of almost 
every tissue and system. Insufficient vitamin D driving pathology in one system 
(e.g. IBD), may be the consequence of impaired function that limits vitamin D 
bioavailability in another (obesity). 
Promisingly, a role for vitamin D sufficiency effecting positive pressure on the 
methylome has not yet been extinguished – if nothing more, vitamin D appears at 
least mechanistically capable of modifying 5mC patterns (granted, in one gene, in 
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one cell type, in a context-specific fashion, in vitro – see chapter 3), possibly via 
transcriptional control of enzymes regulating methylome fidelity (DNMT1, TETs). 
In this respect, we asked if vitamin D’s ability to impact 5mC patterns might be 
extended to other genes in other cell types. 
Having investigated a role for vitamin D in the differentiation and competence of 
circulating monocytes, as a contributing factor to vitamin D’s hypothesised 
effects promoting bowel health, it is now appropriate to turn our attention to 
the microenvironment of the crypt niche, and gain better insight into the 
paracrine relationship between crypt stem cells and their nearest neighbours, the 
pericryptal myofibroblasts. 
It has been suggested that Intestinal Myofibroblasts (InMyoFib) contribute growth 
factors, cytokines, and other signalling molecules to the crypt niche107, indeed, 
these cells promote in vitro culture of colonic organoids113. Reagents for organoid 
culture were a burgeoning cost for the project, so utilisation of primary mucosal 
myofibroblasts as a source of growth factors for experimental procedures was a 
logical extension warranting further investigation. Initial forays into the 
propagation of primary pericryptal myofibroblast (MFBs) –  recovered from the 
uninvolved mucosa of CRC resection specimens – proved prohibitive under 
routine cell culture conditions; primary monolayers took 4-8 weeks to become 
established, frequently senesced prior to analysis, and invariably presented mixed 
populations, primarily comprised of alpha smooth muscle actin negative 
fibroblasts (aSMA positivity being the primary defining feature of an activated 
InMyoFib287). 
To negate these logistical barriers, the addition of soluble growth factors to 
accelerate proliferation was contemplated, but considered uncertain with regards 
clandestine modifying effects on cell phenotype. Searching the literature for 
documented effects of potential growth factors, brought to light a good many 
papers focused on TGFβ1 and its actions converting stromal fibroblasts to 
myofibroblasts associated with the de novo induction of aSMA288. 
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Thus, treatment of mixed primary fibroblast cultures with TGFβ1 was postulated 
as a potential method to rapidly establish ubiquitous aSMA expression and 
phenotype homogeneity. In particular, De Boeck et al allude to the irreversible 
establishment of a MFB phenotype in mesenchymal stem cells treated with 
TGFβ1, that commits naive cells to a MFB phenotype, preventing subsequent 
transdifferentiation289. To us, this suggested that heritable epigenetic 
modifications (DNAm), manifest by TGFβ1, might underpin transcription and 
expression of aSMA and/or other myofibroblast-intrinsic properties. 
Previously, a validated line of primary intestinal myofibroblasts (InMyoFib) had 
been purchased from Lonza, for use as healthy controls when stimulating CRC-
derived MFBs with recombinant cytokines (see chapter 5); it was therefore 
decided, to first characterise the effects of TGFβ1 on the phenotype, 
transcriptional profile, and DNAm status of this cell line and, in keeping with 
project objectives, investigate any role for vitamin D in mediating the effects. 
[Credit for data included in this chapter must be attributed in part to my 
colleague and student, Federico Bernizio, who assisted in the preparation of 
samples and processing of some of the data, as part of a short project funded by 
The Big C cancer charity in the summer of 2015]. 
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Abstract 
Transforming-growth factor beta one signalling is frequently deregulated in colorectal 
tumours, inducing stable de novo expression of aSMA in stromal fibroblasts that in turn 
promote tumour invasion and metastasis via a modified secretome. These cells do not 
transdifferentiate, suggesting TGFβ1induces heritable epigenetic modifications during 
differentiation. Pericryptal myofibroblasts represent healthy mucosal cells expressing 
aSMA that contribute growth factors and ECM components to the crypt niche, and are 
reported to maintain crypt stem cells in vitro. Further to the well-documented 
association between serum vitamin D and incidence of colorectal cancer, vitamin D’s 
cognate receptor, VDR, negatively regulates TGFβ1 signalling in myofibroblasts. In this 
context, it was hypothesised that TGFβ1 remodels the methylome of intestinal 
myofibroblasts to effect cell phenotype and their influence on epithelial homeostasis. 
Once characterised, the ability of vitamin D to mediate the process was investigated. 
TGFβ1 inhibited proliferation of MFBs and transcription of a panel Wnt-associated 
genes, that persisted post-induction. Although induced by TGFβ1, the methylation status 
of aSMA was not affected, precluding a role for dynamic DNAm in transcriptional 
regulation of the gene in this context. Methylation array (Illumina 450K) identified 
candidate genes who’s DNA methylation status was associated with the novel TGFβ1-
intitiated phenotype, synchronous to modulation of TET enzyme activity. Although 
vitamin D partially attenuated TGFβ1-induced DNA methylation, and the consequent 
transcription of affected genes, synergy was observed with other TGFβ1-regulated genes 
not differentially methylated, including TETs 1 and 3, indicating that vitamin D’s effects 
mediating TGFβ1-induction are diverse and highly context specific. TGFβ1 also induced 
VDR, which may account for transcriptional synergy between these agents. The 
methylation status of a single CG in the Fibroblast Activation Protein (FAP) promoter 
significantly correlated with its transcription - an effect attenuated in combination with 
vitamin D – of note because elevated FAP promoted tumourigenesis. 
This work raises the possibility of a role for TGFβ1 signalling in directing the intestinal 
myofibroblast phenotype via a modified methylome and regulation of TET enzymes. 
Vitamin D did not exhaustively attenuate TGFβ1’s effects. Candidate genes regulated by 
DNAm involved in myofibroblast plasticity have been identified and their role in gut 
epithelial homeostasis discussed. 
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Introduction 
In the colonic mucosa, multiple mechanisms are in place locally that allow for 
epithelial plasticity, manifest as regenerative potential that mitigates for 
hypotrophy in the wake of transient inflammation, and redundancy, such that 
control of stem cell turn-over is shared between converging autocrine and 
paracrine signalling cascades. 
The crypt stem cell (CSC) niche is partially comprised of pericryptal, α-smooth 
muscle actin (aSMA) positive myofibroblasts, recognised for their contribution to 
paracrine Wnt signalling that ensures a tight balance between CSC proliferation 
at the base of the crypt, and apoptosis at the luminal interfacereviewed in 290. 
Apportioning a degree of control to neighbouring non-epithelial cells adds a 
further layer of redundancy governing the vital process of epithelial homeostasis. 
Pericryptal myofibroblasts are key contributors to the paracrine signals managing 
Wnt-mediated CSC turnover; antagonism of BMP signalling at the base of the 
crypt is observed in vivo via MFB secreted GREM1 and 2, that inhibits 
differentiation, thus maintaining Wnt-mediated stem cell turnover107. Primary 
MFB cultures have also been shown to support colonoid formation in vitro, and 
express relatively high levels of r-spondins (LGR5 ligands that transduce the 
Wnt-cascade)226. An example of the aforementioned redundancy is demonstrable 
in the small intestine, where conditional deletion of paneth cells, a paracrine 
source of Wnt3a, does not impede stem-cell turnover, suggesting a non-epithelial 
source of growth factors291. However, conditionally blocking Wnt-ligand 
secretion by ablation of PORCN in both the epithelia and submucosa, also fails to 
disrupt cryptogenesis, hinting at further esoteric sources of LGR5 ligands292. 
Finally, inhibition of Wnt may also be effected by other MFB-secreted factors, 
such as DKK1 and SFRP1, who out-compete Wnt agonists by preferentially 
binding LGR5 receptors293,294. 
A phenotypically similar population of aSMA+ve mesenchymal cells are also 
present in colorectal tumour stroma, increasingly recognised as mixed 
populations of trans-differentiated mucosal fibroblasts and bone marrow-derived 
mesenchymal stem cells (MSCs)295. In healthy tissue, the recruitment of elastic 
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myofibroblasts expressing aSMA is a key stage of the wound healing and tissue 
repair process296, and benign transient trans-differentiation of fibroblasts to 
aSMA+ve myofibroblasts is driven principally by controlled TGFβ1 signalling297. In 
a cancer setting this control appears to be deregulated, with the de novo 
expression of aSMA in the stromal compartment documented to be induced by 
both aberrant autocrine and paracrine TGFβ signalling298. Cancer-associated 
fibroblasts (CAFs) promote tumour invasion by a pathologically altered 
secretome that encourages angiogenesis and remodelling of the extra-cellular 
matrix(ECM)299, and there has been a great deal of research looking at 
myofibroblast regulation of ECM components and stromal architecture 
permissive to metastasis. Colorectal CAFs and MSCs (induced to express aSMA 
by TGFβ1 treatment) demonstrate partial overlap of their secretomes (200+ 
proteins), that include components of the ECM, proteases (MMP2 and 3), and 
growth factors (HGF, EGF). In that study, treatment with TGFβ1 fixed the 
phenotype of both MSCs and CAFs, prohibiting trans-differentiation or reversal 
of the established phenotype289.   These observations led us to hypothesise that 
stable epigenetic modifications, precipitated by TGFβ1, induce aSMA 
transcription and changes to the myofibroblast phenotype. Encouragingly, 
inhibition of DNAm was observed to induce aSMA promoter hypomethylation 
associated with de novo aSMA expression in naive lung fibroblasts300.  
It is apparent that pericryptal myofibroblasts and CAFs are distinguishable only 
by virtue of locus and temporal context; pericryptal vs stromal, healthy vs 
disease-associated. Like CAFs, MFBs are mesenchymal in origin, organise their 
local environment via secreted ECM and growth factors, and importantly express 
aSMA. An increasing body of evidence documents the relationship between 
TGFβ1-initiated CAFs, stromal architecture, and the transformed cells they 
interact with. However, there is a paucity of information pertaining to the effects 
of TGFβ1 on healthy pericryptal myofibroblasts and their secretory profiles, 
particularly with regards regulation of Wnt signalling; aberrant activation of Wnt 
is after-all a hall mark of transformation. Furthermore, remodelling of the ECM 
typically precedes a microenvironment permissive to invasion301, and increased 
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levels of TGFβ1 in the lamina propria are noted in chronic inflammatory diseases 
that expedite tumourigenesis302. 
In this context we have investigated the effect of recombinant TGFβ1 on growth 
factor transcription and the epigenome of an aSMA-expressing line of Intestinal 
Myofibroblasts (InMyoFib), and the consequences for epithelial homeostasis. In 
keeping with the over-arching hypothesis that vitamin D promotes bowel health, 
and in light of the observation that vitamin D regulates TGFβ1 signalling in 
activated fibroblasts303, the ability of vitamin D to mediate any effects of TGFβ1 
on the transcriptional profile and methylome of InMyoFib, has also been 
characterised. Primarily we sought to establish if TGFβ1’s effect were indeed 
stable, if they could be attributed to dynamic promoter methylation status in the 
aSMA gene, and if TGFβ1 regulates transcription of enzymes involved in DNA 
methylation metabolism. 
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Methods 
Cell culture 
Intestinal Myofibroblasts (InMyoFib) were purchased from Lonza and cultured by 
routine cell culture protocols according to the manufacturer’s instructions with 
prescribed SmGM-2 Smooth Muscle Growth Medium-2 (cat. no CC-3182). Cells 
were routinely passaged and used between passage numbers 2-6. Induction with 
recombinant (r)TGFβ1 in PBS was achieved at a final concentration of 0.1-
10ng/mL in culture medium. Cells were treated for 48 hours, with refreshed at 
24 hours. 
To assess stability of the induced changes in gene expression, after the initial 48 
hour induction protocol, media was removed, cells washed twice with PBS, and 
fresh media applied. Cells were subsequently cultured for a further 48 hours, 
with an additional wash after 24 hours, to mitigate for residual effects of rTGFβ1. 
Monolayers were then harvested by trypsin-EDTA chelation and cell pellets 
rinsed with PBS prior to nucleic acid extraction. 
For media conditioning experiments, InMyoFib were initiated with TGFβ1 
(10ng/mL) for 48 hours, washed twice over the subsequent 48 hours, and then 
fresh media applied at approximately 80% monolayer confluence, for conditioning 
over the subsequent 24 hours. Supernatants were collected, spun at 300G to 
remove cell debris, and passed through a 20µm filter, before being flash-frozen 
on dry ice and stored at -80°C. Conditioned supernatants were mixed 50:50 
with fresh DMEM/f12 to mitigate for nutrient depletion 
To condition media from HCT116 cells, cells were cultured to 80% confluence in 
75cm2 flasks, and fresh DMEM/f12 conditioned for 24 hours. Collected 
supernatants were spun as before and mixed 50:50 with InMyoFib culture media.  
Biological triplicates were processed for each experiment and technical 
triplicates (Q-rt-PCR) or duplicates (Illumina 450K array) reported as the mean 
+/- the standard error.  
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Nucleic acid extraction and processing 
As detailed in General Methods, RNA was extracted using the Isolate II RNA 
mini-kit from Bioline according to the manufacturer’s instructions, which includes 
an on-column DNase step to digest contaminating genomic DNA. RNA was 
quantified by UV spectroscopy (Nanodrop, Thermo), and 500ng reverse 
transcribed using Q-script from Bioline according to the manufacturer’s 
instructions. Assuming a 75% rate of efficiency for the reverse transcription, 
375ng of cDNA was diluted in 180μL of MilliQ water to give a final 
concentration of 2ng/μL. 
DNA was harvested by phenol-chloroform extraction as outlined in General 
Methods. Samples were precipitated, washed with 70% ethanol, and resuspended 
in water to yield a final concentration of 50ng/uL. Biological triplicates of 500ng 
were interrogated in duplicate by Cambridge Genomic Services on the Infinium 
HumanMethylation450 Bead Chip Kit according to the manufacturer’s 
instructions. 
WST1 and trypan blue assay 
To determine the effect of treatment with TGFβ1 on proliferation of cells, 
InMyoFib were seeded in 96 well plates at a density of 5000 cells per well. After 
observing a 24 hour period to allow cells to adhere and enter log growth phase, 
media, with either PBS vehicle at the highest concentration or rTGFβ1 at the 
specified final concentration, was applied for 48 hours (refreshed after 24). The 
mean absorbance of 10 technical replicates was determined by tetrazolium salt 
assay after 2 hours incubation with 10% WST1 reagent (Roche) according to 
manufacturer’s instructions (absorbance at 450nM). Data were normalised to the 
control and the data displayed as the mean +/- the SEM. A three-tailed T-test, 
assuming non-normal distribution of the data, was performed to determine 
statistical significance. For trypan blue staining, treated cells were harvested by 
EDTA chelation and 20uL of dissociated cells in suspension mixed with 20uL of 
trypan blue. Samples were loaded into cell counting chambers and counted 
(Nexcellom) to determine cell viability. 
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Q-rt-PCR 
Q-rt-PCR were performed in triplicate with 6ng of cDNA  per reaction. Cycle-
threshold (Ct) after 40 cycles was normalised against that for the 18S ‘house-
keeping’ reference gene. The number of relative transcripts, or the fold change 
normalised to PBS vehicle, was determined by the ΔCt or ΔΔCt method, 
respectively304. Intron-spanning primers were designed by using the human 
Universal Probe Library software (Roche) against the NCBI NM RNA reference 
sequences (appendix 6). All Q-rt-PCRs were validated at 60°C. 
RnBeads pipeline for Infinium HumanMethylation450 data 
Data were processed by CGS using the RnBeads plugin for ‘R’ console228. The 
mean methylation (β values between 0 and 1, representing percentage of 
methylated alleles at the site) +/- the SEM of three biological replicates was used 
for comparisons between sample groups. Whilst the array also generates β 
values for non-coding CpG islands (pseudogenes, micro RNA, repetitive 
elements), for the purposes of the analysis, regions of interest were defined as 
single CpG sites associated with functional genes (477,311), gene regulatory 
elements (30,840 promoters), or whole-gene sequences (30,681), limiting read-
outs to regions of methylation effecting transcriptional control, and thus 
verifiable by gene–specific Q-rt-PCR. 
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Quality control 
Control sample data were separately processed by CGS using Illumina’s Genome 
Studio. All variables measures returned values within defined quality parameters 
and accurately predicted sex (male). 
Regional variability 
The variability of a sample group is the span between 5th and 95th percentile of 
β values, averaged over all valid sites and regions. This amounts to a number 
between 0 and 1 and corresponds to the relative area of deviation in the plots 
presented.  
Distribution of β scores 
Methylation score distributions were assessed based on sample group at the 
assigned levels (sites, promoters, genes), to identify shifts in the densities of β 
values associated with treatments. 
Low-dimensional representation and sample group clustering 
Dimension reduction (multidimensional scaling - MDS) was used to visually 
inspect the dataset for a strong signal in the methylation values related to sample 
grouping.  
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Results 
Effect of TGFβ1 on the phenotype of Intestinal 
Myofibroblasts 
 
TGFβ1 reduced proliferation and improved Intestinal Myofibroblast viability 
To determine an appropriate treatment regimen, proliferation of Intestinal 
Myofibroblasts (InMyoFib) was first determined by WST1 tetrazolium salt assay. 
Cells were seeded in 96 well plates at a density of 5000 cell per well, and treated 
for 48 hours during the log-growth phase. TGFβ1 effects a dose-dependent 
response on InMyoFib over 48 hours, reducing proliferation by 35% at 10ng/mL 
relative to PBS vehicle, with no macroscopic effects on cell morphology. The 
antiproliferative effect was not associated with decreased cell viability - rather, 
viability was moderately improved by treatment with TGFβ1, as determined by 
trypan blue staining (figure 18a and b). 
 
TGFβ1 induces a transcriptional profile suggested to antagonise Wnt 
Next, to establish if TGFβ1 might influence the secretory profile of InMyoFib as 
posited, a panel of genes regulating paracrine stem-cell turnover in the niche 
were interrogated by Q-rt-PCR. As a marker of the aberrant phenotype 
documented in cancer-associated fibroblasts, the expression of αSMA was also 
quantified. In keeping with the observation that TGFβ1 reduces proliferation, 
there was a trend toward decreased expression of Ki67 that did not achieve 
statistical significance (p = 0.07).  αSMA was induced 3-fold, and a gene profile 
suggested to antagonise Wnt and promote epithelial differentiation was 
established, showing induction of DKK1 and BMP1 transcripts synchronous to 
the suppression of  secreted growth factor transcription (RSPO1, EGF, HGF and 
JAG1) (figure 18c). 
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The transcriptional profile induced by TGFβI is maintained in the absence of 
TGFβ1 stimulation 
Induction of stromal fibroblasts with TGFβ1 is reported to stably alter their 
secretory profile and associated with de novo expression of αSMA, that persists in 
the absence of continued stimulation305. This raises the possibility that enduring 
epigenetic modifications, such as DNA methylation, inform the MFB phenotype. 
To first determine the persistence of the induced transcriptional profile, 
InMyoFib were activated with TGFβ1 (10ng/mL) as previously described, 
followed by a 48 hour wash-out period to mitigate for direct transcriptional 
effects of rTGFβ1 (media was removed, cells washed twice with PBS, and fresh 
media applied every 24 hours). As before, the transcriptional profile exhibits 
sustained induction of aSMA, DKK1, and BMP1, concomitant with continued 
suppression of other growth factors. Although the effect appears weakly 
diminished for DKK1 and EGF, while HGF and JAG1 transcription are enhanced 
relative to cells actively undergoing rTGFΒ1 stimulation (figure 18d), suggesting 
that the sustained transcriptional profile is not simply a tapering effect. 
Cancer-cell supernatants did not recapitulate the effect of TGFβ1 
Given that TGFβ1 expression is elevated in high-grade colorectal tumours306, it 
was speculated that the induction of the TGFβ1-associated transcription might 
also be initiated by treatment with aggressive CRC supernatants. The HCT116 
cell line represents a poorly differentiated cancer phenotype with invasive 
properties, secreting TGFβ1307. HCT116 cells were cultured to >80% confluence 
in 75cm2 flasks and used to condition InMyoFib culture media for 24 hours. 
Conditioned media was mixed 50:50 with fresh media to mitigate for nutrient 
depletion. As per rTGFβ1 initiation protocol, InMyoFib were cultured for 48 
hours with HCT-conditioned media, followed by a 48 hour wash-out period. 
Transcription of aSMA, RSPO1 and DKK1 was determined during initiation 
(t=48) and after wash-out (t=96). No significant changes in their transcription 
was observed relative to vehicle (data not shown), possibly implicating a flawed 
methodology pertaining to secreted TGFβ1s latent stability/concentration, as will 
be discussed. 
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Figure 18 – TGFβ1 effects on the phenotype and gene transcription in InMyoFib. . * p<0.05, ** 
p<0.01, *** p<0.001. 3 biological replicates, 3 technical replicates. Data represtent the mean fold 
change relative the the control (normalised relative expression) +/- SEM A)  Trypan blue staining 
suggests modest improvements in cell viability at 48 hours. B) After 48 hours proliferation, as 
measured by Wst assay, is concomitantly inhibited by recombinant TGFβ1 verses PBS vehicle, in 
a dose-dependent fashion. C) A transcriptional profile of a panel of epithelial growth factors and 
the lineage marker aSMA was determined at 48 hours, demonstrating induction of aSMA, DKK1 
and BMP1 synchronous to the suppression of growth factors RSPO1, EGF, HGF and JAG1. This 
pattern was hypothesised to negatively regulate epithelial proliferation D) The modified 
transcription profile persists for at least 48 hours post-initiation; samples were treated for 48 
hours with 10ng/mL TGFβ1, washed twice with PBS, and fresh media applied over the subsequent 
48 hours to mitigate for residual rTGFβ1. The transcriptional profile recapitulated effects 
established prior to the wash-out period, with further suppression of HGF and JAG1 
transcription, suggesting that the profile is entrenched and not a diminishing residual effect. 
A 
 
 
 
 
C 
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Supernatants fromTGFβ1-initiated cells reduced CRC cell line proliferation in vitro. 
In order to investigate if the novel transcriptional profile modified the secretory 
phenotype of InMyoFib, colorectal cancer cell lines CaCO2 and HCT116 were 
treated for six days with TGFβ-initiated InMyoFib-conditioned media. After the 
48hr/48hr initiation/washout period, fresh culture media was conditioned for 24 
hours. The supernatant was collected and mixed 50:50 with fresh media to 
mitigate for nutrient depletion. CaCO2 and HCT116 cell lines, selected 
respectively for their well- and poorly-differentiated cancer phenotypes, were 
cultured for six days with either PBS-induced or TGFβ1-induced conditioned 
media, which was replaced every 24 hours. Proliferation was determined by Wst 
assay, and confirmed an antiproliferative effect of supernatants in both cell lines 
relative to PBS-treated control media. The more aggressive HCT116 line 
experienced greater antiproliferative effects (25%) than the better differentiated 
CaCO2 cells (10%) – figure 19a. CaCO2 and HCT116, are reported to be 
resistant to the antiproliferative effects of TGFβ-receptor ligation due to 
mutated signalling pathways307,308, suggesting that the effect observed is a 
consequence of the altered InMyoFib secretory profile, and not residual 
recombinant or secreted TGFβ1.  
TGFβ1-initiated InMyoFib supernatants regulate gene transcription in HCT116 
cells 
To investigate potential mechanisms for the antiproliferative effect of conditioned 
media, a panel of genes demarking cell-cycle, invasiveness, and differentiation, was 
interrogated in the more sensitive HCT116 cells. This time conditioned media 
was applied for four hours, assuming differential transcription precedes the 
antiproliferative response. Relative to vehicle control, TGFβ1-initiated InMyoFib 
media weakly induced a variety of homeostatic markers that, taken together, do 
not provide unifying insight into the antiproliferative effect of the supernatants. 
MUC2 was the only marker to exceed a fold change of two that might dominate 
other changes.  
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Figure 19 – TGFb1-treated InMyoFib media affects CRC cell phenotype in 
vitro . * p<0.05, ** p<0.01. 3 biological replicates, 3 technical replicates. Data 
represtent the mean +/- SEM A) Over six days, supernatants from TGFβ1-
initiated InMyoFib reduced proliferation of CaCO2 and HCT116 cells 10 and 
25% respectively, which is in keeping with the transcriptional profile 
established by TGFβ1-intiation B) HCT116 cells show a two-fold induction of 
MUC2, raising the possibility that conditioned media also promotes 
differentiation in the line. Other markers of proliferation and invasiveness 
were paradoxically raised in response to the conditioned media, but fold-
changes did not exceed a factor of two, so do not specifically preclude an 
overall antiproliferative effect of the media. Modest promotion of TGFβ1 
transcription was also observed in media-treated HCT116 cultures - this 
supports the hypothesis that tumour cells harness stromal fibroblasts to 
promote invasion by establishing a positive feedback loop that amplifies 
aberrant TGFΒ1 signalling. 
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Effect of TGFβ1 on the methylome of InMyoFib 
The novel phenotype was not associated with changes in aSMA DNAm 
 
Persistent induction of aSMA transcripts was hypothesised to be a consequence 
of changes in the methylation status of the gene. Bisulphite modified DNA from 
TGFβ1-induced InMyoFib was interrogated by Combined Bisulphite/restriction 
analysis (CoBRA), to determine any change in promoter methylation status. The 
αSMA promoter region was hypomethylated at base line (<2.1%), and in washed-
out cells after treatment (data not shown). Further analysis of samples on the 
Infinium 450K bead chip array confirmed no significant changes in the 
methylation status of any CpG dinucleotides within the αSMA promoter or gene 
body. These findings preclude a role for dynamic DNAm in the gene sequence 
affecting the InMyoFib phenotype or α-smooth muscle actin transcription in 
Intestinal Myofibroblasts expressing aSMA at base line. 
TGFβ1 induced methylome variability, and samples cluster according to 
treatment 
Having established that, contrary to the informing hypothesis, TGFβ1 establishes 
an InMyoFib phenotype independent of aSMA methylation status, bmDNA was 
interrogated by Methylation 450 Bead Chip Array (Infinium)309 to identify 
esoteric sites differentially methylated elsewhere in the methylome associated 
with the induced phenotype. Relative to vehicle controls, TGFβ1-initiated 
InMyoFib show sustained epigenome-wide β-score variability 48 hours post-
induction (figure 20a-c). Plotting the top 1000 ranking differentially methylated 
regions, it is apparent that hypomethylation occurred more frequently than 
hypermethylation (at all regional levels), but a strong correlation between β-scores 
for sample groups suggests that TGFβ1 does not remodel the bulk of DNAm to 
produce two discrete methylomes (figure 20e-g). Dimensional representation 
indicates modest clustering of samples by treatment regimen that do not overlap 
(figure 20d), but clustering of samples could not be distinguished on β-scores 
heat maps (data not shown). Taken together, the array data suggest that the 
observed phenotypic response may be informed by a smaller subset of dynamic 
region-specific DNAm changes.  
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Figure 20 – Sample variability and clustering . Three biological replicates were pooled and extracted 
DNA probed in technical duplicates A & B) Deviation plots of sample groups. Probes are sorted in 
increasing order of their median methylation and are binned in groups of up to 120. The horizontal 
axis in the plot iterates over probe groups, and the vertical axis measures methylation degree. 
Median β values are depicted by a blue curve, and variability (yellow area) is greater in TGFβ1-
initiated InMyoFib. C) Dimension reduction was used to visually inspect the dataset for a strong 
signal in the methylation values that is related to sample group. The scatter plot visualizes the 
samples transformed into a two-dimensional space using MDS; biological triplicates loosely cluster 
according to treatment regimen, with no overlap. Increased TGFβ1 variability here is represented by 
increased area coverage D,E,F) Scatter plots of β scores for each treatment do not suggest that 
treatment with TGFβ1 gives rise to a distinct methylome at either the site, promoter, or whole gene 
level; correlation values approach 1.0, a clear indication that methylation β scores in control samples 
are largely recapitulated in TGFβ1 samples. Pink markers indicate the top 1000 differentially 
methylated ranking sites for each level. At every level, hypomethylation is over-represented relative 
to hypermethylation in TGFβ1 samples, suggesting that demethylation is the dominant effect of 
TGFβ1 on the methylome of intestinal myofibroblasts under experimental conditions.  
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Differential region-specific DNAm suggests candidate genes associated with the 
modified phenotype 
Indeed, treatment with TGFΒ1 was observed to modify DNAm status at a 
plethora of single CpG sites, gene promoters, and whole genes, across the 
methylome. Data were filtered to exclude; any region not attaining statistically 
significance (p = 0.05), exceeding the acceptable false-discovery rate, not 
achieving a change in β score above the 5% threshold, and, where necessary to 
limit the scope of validation experiments, not ranking in the top 1000 sites. 
Finally Ensembl annotations were mapped to functional genes, thus excluding un-
assigned CpG islands, or those pertaining to miRNAs or pseudogenes. Figure 
21.1 identifies 63 candidate genes differentially methylated at either the site 
(n=23), promoter (n=15) or whole gene (n=25) level, that were associated with 
the TGFβ1-initaited transcriptional profile. Notably, none of the GF genes 
previously characterised in transcriptional profiles experienced differential 
DNAm, precluding a role for dynamic DNAm in their transcription in this 
context. 
Induced-network analyses of the 63 differential methylated candidate genes 
identified other nodes with biological significance, regarding colonic epithelial 
homeostasis and fibroblast differentiation, that might be impacted by an altered 
methylome (figure 21d); amongst others, fibroblast activation protein (FAP), 
interferon gamma (INF), amyloid precursor protein (APP), fibronectin1(FN1), 
the TGFβ-ligand SCUBE3, and Vimentin (VIM). 
Ontology of networks in which these 63 genes occur in, suggested disease 
processes including ‘cancer’, ‘cell cycle’, and ‘focal adhesion’, as well as the ‘Wnt 
pathway’, ‘TGFβ1 signalling’ and ‘colorectal cancer’ (p < 0.05). Biological 
processes include ‘down-regulation of proliferation’, ‘cell-cycle’, and ‘mitosis’ 
(figure 21a-c). 
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Gene Name Delta DNAm p.value 
ACR 5.77 0.03 
AKR1B1 11.44 0.00 
ANKRD20A1 5.70 0.03 
AREG 10.41 0.00 
ARHGAP15 12.24 0.00 
ATP10D -26.04 0.00 
BPIFA3 6.41 0.04 
C1orf195 7.83 0.03 
C3AR1 5.60 0.04 
CCND3 -26.70 0.00 
CDH19 7.60 0.02 
CFHR4 13.22 0.01 
CYP4B1 8.20 0.02 
DCBLD1 12.80 0.00 
DEFB115 -5.30 0.01 
DEFB134 7.15 0.01 
FAM129A -20.68 0.00 
FAP -10.57 0.00 
FRMD4A -10.39 0.00 
GRIA2 8.36 0.01 
HULC -5.02 0.04 
IFI44 6.84 0.03 
ITGAE -22.38 0.00 
ITGB1BP2 5.29 0.05 
LINGO2 5.02 0.04 
LRBA -19.92 0.00 
LRIT3 5.38 0.03 
NAALADL2 8.22 0.01 
NALCN -32.59 0.00 
NAV3 -12.88 0.00 
NBPF20 12.70 0.01 
NPHP1 -11.96 0.00 
OMD 6.89 0.02 
OR10G9 6.49 0.04 
OR4C12 11.89 0.03 
OR4D10 7.32 0.01 
OR5K2 5.40 0.02 
OR6A2 -7.33 0.01 
OR6B1 7.66 0.01 
OR6B2 8.36 0.00 
OSMR -14.30 0.00 
PABPC3 5.01 0.04 
PHLDB2 -11.85 0.00 
PIK3AP1 -10.44 0.00 
PMCH 6.18 0.04 
PRIM2 7.78 0.04 
PROL1 6.65 0.04 
PTHLH -7.08 0.03 
PTPRG -12.34 0.00 
RBM19 12.96 0.00 
RDH12 7.28 0.02 
REP15 5.06 0.03 
RNF148 6.45 0.01 
SERPINA11 -6.67 0.03 
SGIP1 17.69 0.00 
SNTN -5.16 0.03 
SULT1C3 6.29 0.01 
TMPRSS11D 5.34 0.04 
TUSC3 29.63 0.00 
UGT2A2 9.36 0.04 
 
  
Figure 21.1 – Table of candidate genes identified to be 
differentially methylated by TGFβ1 in Intestinal 
Myofibroblasts. Biological triplicates (n=3) were probed in 
technical duplicate. 
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Transcription of enzymes involved in DNAm metabolism is perturbed in 
InMyoFib following TGFβ1-initiation 
Finally, to investigate potential mechanisms for the modification of gene-specific 
DNAm patterns by TGFβ1, InMyoFib were initiated according to the 48/48 hour 
treatment/wash protocol. A panel of markers involved 5mC metabolism (DNA 
methyltransferases and TET enzymes) was interrogated by Q-rt-PCR, to 
ascertain if transcription of methylation machinery might be impacted by TGFβ1-
initiation. In retrospect, these changes most probably occur well in advance of 
changes in 5mC metabolic rate, and proper time course investigation of the 
response of DNAm enzyme transcription and activity is warranted to asses 
mechanistic aspects of the phenotypic observations. 
Regardless, METTL7b, and TET1 were subjected to significant and sustained 
suppression following initiation by TGFΒ1, while TET3 was moderately induced 
(figure 21e), perhaps suggestive of a compensatory mechanism established to 
inhibit the demethylating potential of TGFβ1. Methyltransferase-like 7b has an 
emerging uncharacterised role in 5mC metabolism, of interest here as TGFβ1-
induced METTL7b promoter hypermethylation was noted on the array data, 
associated with transcriptional suppression detailed.   
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Figure 21 – Pathway analysis of differentially methylated genes following TGFΒ1-initiation A) 
Over-represented pathways include GPCR signal transduction and olfactory sensing, an 
anomalous finding in the gut epithelia, however evolutionarily defunct olfactory receptor 
expression is reported  B) Gene ontology supports activation of sensory pathways and GPCR 
activity. C) Transcription factor associations suggests TFs regulating differentially methylated 
genes, amongst others PAX6, FOXD3 and HNF-3. D) Network analysis exhibits seed nodes 
(marked in red) and associated nodes representing colorectal cancer, TGFβ1 signalling and 
Wnt signalling (marked in green). E) Transcription of a panel of genes involved 5mC 
metabolism. Initiation with TGFβ1 suppressed transcription of METTL7b, TET1 and also 
moderately suppressed TET2 at t=48 post stimulation. n = 3. Data represtent the mean of the 
fold change (see appendix x for the relative expression values with associated standard 
errors).TET3 appeared to be induced, but fold-induction did not achieve the 2x threshold for 
an assumed functional effect. METTL7b’s function has yet to be characterised with regards 
DNAm, but roles for TET-demethylases in mediating active hypomethylation suggest that the 
transcriptional effect observed at this time point might be the product of TGFβ1-initiated 
hypomethylation, as opposed to driving it i.e. downregulating enzymes responsible for 
demethylation as a practical response to negate aberrant demethylation. . * p<0.05, ** p<0.01. 
3 biological replicates, 3 technical replicates. Data represtent the mean +/- the SEM. F) KEGG 
pathway analysis of nodes associated with differentially methylated genes predicts 
deregulated pathways. Highlights include cancer, TGFβ and Wnt signalling in keeping with 
hypotheses that TGFβ1 effects DNAm associated with these terms (here, Wnt signalling 
exceeds the acceptable FDR). 
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Effect of TGFβ1 in combination with Vitamin D 
Vitamin D sensitivity is impaired in fibroblasts which effect systemic sclerosis via 
deregulated TGFβ signalling303. Furthermore, there are documented reports of vitamin 
D attenuating TGFβ-induced de novo aSMA expression in interstitial myofibroblasts 
associated with renal pathology310. To investigate the ability of vitamin D to affect the 
TGFβ1-influenced methylome of InMyoFib, cells were pre-treated with vitamin D for 
24h hours prior to 48hr/48hr initiation. Treatment with vitamin D was sustained at 24 
hour intervals for the duration of the initiation period prior to wash-out. DNA 
methylation profiles (Infinium 450K array) were obtained and Beta scores for the 
combined treatments (COMB) were compared against individual TGFΒ and vitamin D 
scores. Criteria for functional effects were adhered to during the analysis i.e. any change 
in DNAm instigated by TGFβ1 should be attenuated by >5% to assume functional 
reversal of effects. 
Pre-treatment with vitamin D attenuated a proportion of the DNAm changes 
induced by TGFβ1 
Pre-treatment with vitamin D modified DNAm at 821 of the 7503 regions differentially 
methylated by TGFβ1 (10.9%). Of the single CG sites hypo-methylated by TGFβ1 (702), 
vitamin D prevented demethylation at 700 of these (99.7%), promoting demethylation at 
only two sites. Conversely, 119 CGs were hyper-methylated by TGFβ1, of which vitamin 
D prevented de novo methylation of 115 (96.6%), promoting the effect of TGFβ1 at only 
four sites. Similarly pre-treatment with vitamin D attenuated hypomethylation at 15 of 
the 147 TGFβ1-affected promoters (10.2%). Only one of these mapped to a functional 
gene, amphiregulin (AREG); AREG is an EGF-receptor ligand, which when expressed in 
colorectal tumours is prognostically significant311. Vitamin D attenuated AREG 
hypomethylation by TGFβ1. While AREG transcripts were relatively low in controls and 
individual treatments, none were detected in combination. Scatter plots suggest that 
TGFβ1’s DNAm modifying effects were partially attenuated by pre-treatment with 
vitamin D, and β score variability across the methylome diminished to levels similar to 
those observed at base line (figure 22a-c). Taken together, these findings raise the 
possibility that vitamin D exerts a weak (~10%) protective effect against TGFβ1 
remodelling of the methylome. 
  
127 
 
  
Figure 22 – Pre-treatment with vitamin D attenuates region-specific differential DNAm initiated by 
TGFβ1. Biological triplicates (n=3) were probed in technical duplicate. a) CpG DNAm in TGFβ1-
initiated InMyoFib experience greater variability than that observed when cells are pre-treated 
with vitamin D prior to initiation b) variability in in the combined treatment is reduced to levels 
similar to that experienced by PBS-initiated controls c) sample groups  cluster according to 
treatment regimen; grouping of the combined treatment (green), is  intermediate to TGFβ1 
(purple) and Vitamin D (pink) clusters, suggesting a protective effect of vitamin D pre-treatment 
that attenuates establishment of the full TGFβ1-initiated methylome d,e,f) Plotting the top 1000 
differentially methylated sites for Vitamin D, TGFβ1, and combined treatments suggests 
hypermethylation dominance for vitamin D, hypomethylation dominance for TGFβ1, and attenuation 
of both effects in combination. 
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Vitamin D and TGFβ1 synergistically induce aSMA and BMP1 transcription. 
Transcriptional profiles for the panel of genes previously interrogated were 
established for the combined treatments. aSMA exhibits an eight-fold induction in 
combination with vitamin D, suggestive of synergy between the two compounds 
regulating aSMA (figure 23a). Synergy was also observed for BMP1. It is of note 
that in isolation Vitamin D suppressed DKK1 while the growth factors were 
unaffected, hypothesised to promote epithelial proliferation if transcriptional 
repression were to translate to a reduction in secreted DKK1. In combination, 
vitamin D attenuated the suppression of RSPO1 by TGFβ1, enough to preclude 
statistical significance versus control. Other growth factors were unaffected in 
combination, remaining significantly suppressed, indicating that, while vitamin D 
may partially attenuate changes in DNAm, the compounds effects do not 
exclusively mitigate for aberrant TGFβ signalling, and in some instances may even 
promote it (figure 23b). 
FAP transcription is associated with the methylation status of a single CpG 
(cg08826839) 
Candidate genes differentially methylated by TGFβ1 were screened by Q-rt-PCR 
to establish any role for methylation status regulating transcription. Fibroblast 
activation protein (FAP) is induced by TGFβ1 in cancer-associated fibroblasts, 
and responsible for their pathological secretory profile312. FAP was observed to 
contain a single CpG site hypomethylated by TGFβ1-initiation (11% decrease). 
Concomitantly, FAP transcription increased three-fold - an induction attenuated 
in combination with vitamin D, which also restored methylation at the site. CpG 
methylation status and relative transcription of FAP correlated tightly, suggesting 
that this single site is fundamental in regulating transcription of FAP (figure 23c).  
Pre-treatment with vitamin D enhances TGFβ1 transcription of TETs 1 & 3 
TGFβ1 was previously observed to inhibit TET1 and METTL7b transcription, and 
weakly induce TET3. In combination with vitamin D, these effects were enhanced 
for TET1 and TET3, where expression was synergistically repressed and 
promoted, respectively. There was concomitant weak suppression of DNMT3b 
not previously observed with TGFβ1 treatment alone (figure 23d). 
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Pre-treatment with vitamin D modulates VDR and TGFβ-Receptor1 
transcription 
Methylation of The VDR promoter increased in the presence of vitamin D, an 
effect not previously reported in the literature, but this did not affect VDR 
transcription in response to vitamin D in isolation (figure 24a and b). Curiously, 
TGFβ1 did mobilise VDR transcripts; although this change was not associated 
with a change in VDR promoter methylation. Increased transcription of VDR by 
TGFβ1 may enhance InMyoFib sensitivity to vitamin D and is thus posited as an 
explanation for the observed synergy in the effects on the expression of some 
genes. 
Having observed synergy between the compounds, taken together with reports 
of convergence of VDR and TGFβ1 on SMAD signalling in a variety of tissues313, 
transcription of TGFβ1 and the TGFβ receptor1 also warranted assessment. 
Treatments in isolation did not impact on the transcription of either ligand or 
receptor, but in combination, a 2.4-fold induction of TGFβ1 occurred. 
Conversely, in combination significant suppression of TGFβR1 was documented. 
TGFβ1 and TGFβR1 promoter DNAm was not affected by either treatment 
(figure 24 c and d). 
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 Figure 23 – Transcriptional profiles established in the combined treatment n=3, * p<0.05, ** p< 
0.01, data represent mean fold change +/-SEM a) vitamin D and TGFβ1 effect synergy in their 
induction of aSMA transcription b) unlike differential DNAm, growth factor transcription 
profiles initiated by TGFβ1 were not largely attenuated in combination with vitamin D, in fact 
vitamin D promoted the induction of BMP1 in combination c) the methylation status (shown as 
% on x axis) of a single CpG in the FAP promoter region was reduced by TGFβ1 treatment; in 
combination vitamin D prevented hypomethylation at this site, and the transcription of FAP 
correlates with methylation status, suggesting that transcription of FAP depends upon DNAm 
at this site. Each point represents the control, vitamin D or TGFb treatments, or in 
combination d) TGFβ1-initiated differential transcription of TET1 and TET3 was promoted 
synergistically by combined treatment with vitamin D, associated with the attenuation of the 
TGFβ1-initiated phenotype.   
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Figure 24 – Vitamin D effects changes in DNAm and transcription of VDR and 
TGFbR1 in InMyoFib. n=3, * p<0.05, ** p< 0.01, data represent mean % methlation  
or fold change +/- SEM a) Vitamin D induced significant hypermethylation of the 
VDR promoter, which was maintained in combination b) this was not reflected by 
a change in VDR transcripts in isolation, however, TGFΒ1 initiation induced a 
three-fold increase in VDR transcripts that was not attenuated by combined 
treatment, raising the possibility that TGFβ1 potentiates the effects of vitamin D 
as an explanation for the observed synergy c) TGFβ1 transcripts are upregulated 
following initiation of InMyoFib when pre-treated with vitamin D. There are 
implications of this late finding regarding autocrine TGFβ1 signalling in InMyoFib 
which will be discussed further d) The TGFβ receptor1 was suppressed following 
initiation with TGFβ1, an effect that persisted in combined treatment samples. 
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Discussion 
In healthy gut mucosae, transforming growth factor-beta 1 exerts 
antiproliferative effects via rSMAD/coSMAD transduction, and downstream 
targets include a host of CDK-inhibitors that precipitate G1-phase arrest314-316. 
However, these properties are highly context-specific, and in particular, 
dysregulated in colorectal tumourigenesis and progression317. Over-expression of 
TGFβ1 in the tumour stroma is documented to induce de novo expression of 
aSMA in stromal fibroblasts287, which is associated with stable phenotypic changes 
and an altered secretome permissive to angiogenesis and invasion289. Healthy 
pericryptal myofibroblasts are similar to CAFs in that they too express aSMA, 
are mesenchymal in origin, and inform their niche environment, organising ECM 
architecture as well as contributing growth factors that modulate Wnt signalling 
in neighbouring crypt stem cells107,113,226. We investigated the effect of TGFβ1 on 
primary intestinal myofibroblasts with regards a limited transcriptional profile, 
genome-wide DNA methylation patterns, and the consequence for epithelial 
proliferation, to ascertain if their CSC-supporting function might also be impaired 
by TGFβ1 activation. 
TGFβ1’s established antiproliferative effects were confirmed in these healthy 
InMyoFib, concurrent with inhibited transcription of several growth factors318. 
Reports detailing exogenous TGFβ1 stimulation of healthy gut myofibroblasts, 
with a focus on proliferation, are limited; our findings raise the possibility that 
the antiproliferative effects of TGFβ1 in this context are mediated via inhibition 
of autocrine GFs. Increased numbers of activated myofibroblasts persist in 
inflamed mucosae, driving fibrosis - a process that is accelerated in TGFβ1-
transfected murine colons. Thus, for TGFβ1-activated myofibroblasts, 
suppressed proliferation following stimulus mitigates for the increased risk of 
fibrosis319,320,321. 
In light of the metastatic effects of TGFβ1-induced CAF supernatants, it was 
anticipated that rTGFβ1 might also promote a secretory profile in InMyoFib that 
accelerated epithelial cell turn-over in a paracrine fashion; surprisingly the 
A     B 
C     D 
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converse was apparent; GF transcription was suppressed, while secreted Wnt 
antagonists DKK1 and BMP1 were induced, suggestive of an antiproliferative 
secretory profile. This hypothesis was supported by reduced activation of the 
TCF-LEF reporter construct by supernatants, and two epithelial CRC cell lines 
treated with conditioned media experiencing antiproliferative effects and 
increased expression of MUC2 and e-cadherin. In direct contrast to these 
results, TGFβ1 is documented to effect increased transcription of Wnt agonists 
in skin fibroblasts during aSMA induction, promoting  epithelial proliferation322. 
Furthermore, suppression of Wnt antagonist transcription is documented in a 
variety of fibrotic tissues, where transgenic reconstitution of TGFβ-silenced 
DKK1 ameliorates fibrosis323. Importantly, reports in the literature refer to 
pathological events, in contrast to the healthy InMyoFib we have characterised, 
consistent with the context specific-effects of TGFβ1 on fibroblast/myofibroblast 
phenotype. Although we did not characterise the entire transcriptome, nor 
quantify secreted proteins, the paracrine antiproliferative effect of the 
supernatants suggests that our limited panel of markers may be representative of 
the overall secretory effect on paracrine regulation of Wnt. However, because 
we did not quantify GF protein secretion, it cannot be resolved if the suppressive 
effect of the supernatants on CRC cell lines was mediated specifically by the 
factors shown to be transcriptionally regulated. Equally, it is possible only to infer 
effects of supernatants on non-transformed cells; the smaller effect on 
proliferation in the more epithelial CaCO2 relative to HCT116 lends itself to the 
notion that the effect might be further diminished in non-transformed CSC, but 
establishing if these antiproliferative effects are recapitulated in non-transformed 
models, and the influence of vitamin D on the outcome, requires robust 
elucidation using in vitro organoid models - a key recommendation for further 
work. 
One hypothesis was resolved however; data suggest that initiation of the novel 
phenotype in these aSMA-expressing cells by TGFβ1 was not associated with 
changes in any of the CpGs documented to play a role in de novo expression of 
aSMA in naive fibroblasts. Although aSMA was induced significantly following 
treatment, we can assume that in this context, as cells are expressing aSMA at 
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base line, the stereo-chemical accessibility of the aSMA promoter is previously 
established as permissible to transcription. Thus, we infer that induction of aSMA 
by TGFβ1 here is associated directly with transcriptional regulation and not 
dynamic gene promoter methylation status. This is supported by the observation 
that TGFβ1 increases aSMA expression and differentiation of lung fibroblasts 
specifically via SMAD3324. DNAm is reported to have a role in aSMA activation 
by TGFβ1 in renal fibroblasts, via hypermethylation of Rasal1 promoter247 – in 
our study Rasal1 DNAm was unaffected by TGFβ1, but as noted, the InMyoFib 
cells studied here already express aSMA.  
Regarding the stability of the TGFβI-initiated profile, we observed sustained 
differential transcription of growth factors at 48 hours post-induction, suggesting 
that initiation by TGFβ1 alone is sufficient to establish the modified methylome 
and phenotype, supporting our informing hypothesis. However we did not 
investigate whether trans-differentiation, or reversal once the phenotype is 
established, might be possible. PDGF and PGE2 are both documented to reverse 
the transient conversion of fibroblasts to myofibroblasts during TGFβ1-mediated 
wound healing325 - this simple experiment is proposed as a suitable addition to 
the data required to conclude  terminal differentiation.  
TGFβ1 was observed to mediate differential DNAm in InMyoFib in a gene-
specific context that did not produce two discrete methylomes, rather DNAm 
deviated modestly at specific locations. This was anticipated; DNAm patterns 
that commit pluripotent stem cells to tissue-specific lineages are largely 
established during embryogenesis326, and a major re-organisation across the 
entire epigenome would likely result in radical dedifferentiation, de novo 
transcription of lethal proteins, and repression of essential ubiquitous house-
keepers, proving ultimately fatal. 
While there are still questions to resolve regarding the secretory phenotype of 
TGFβ1-initiated InMyoFib, the effects on gene-specific DNA methylation were 
clearer; differentially methylated genes tended to be hypo-methylated in response 
to TGFβ1, which is in keeping with observations that TGFβ1 drives SMAD-
mediated promoter hypomethylation in both breast and skin cancer cell lines327. In 
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our study, differentially methylated genes were largely identified by gene 
ontology and network analysis to be involved in the pathogenesis of bowel 
disease, consistent with our informing hypothesis. However similar effects seen 
in ovarian cancers are specifically not associated with the TGFβ1-induced changes 
in TET enzyme transcription that we observed, where expression remains static 
despite deregulated TGFβ1 signalling328. A putative mechanism for TGFβ1’s 
effects on DNA methylation is suggested by the observed promotion of TET3, 
which is a novel finding; the dominance of hypomethylation in the wake of TGFβ1 
stimulation might suggest increased TET activity as opposed to a loss of fidelity 
effected by DNMT1 deregulation, which was unaffected. Vitamin D’s synergy in 
this respect is paradoxical in light of its attenuating effects on TGFβ1-induced 
hypomethylation, however our experiments only looked at transcription of 
DNAm enzymes 96 hours after the initial stimulation of InMyoFib by TGFβ1; as 
noted it is possible that the profile we captured represents the cellular response 
to DNAm modification, not the instigator of it. Whether deregulation of TETs 
drives TGFβ1-initiated hypomethylation in this context, or conversely, is a plastic 
response to it, can only be ascertained by proper time/dose studies, and 
conditional interference with TET activity; suggested to clarify if regulation of 
TETs by TGFβ1 instigates promoter hypomethylation in InMyoFib.  
Vitamin D’s effects on the TGFβ1-initiated methylome were almost exclusively 
inhibitory, but only attenuated about 10% of the differential methylation effected 
by TGFβ1. Furthermore, vitamin D attenuated TGFβ1 hypomethylation and 
induction of FAP. In contrast vitamin D synergistically promoted aSMA, BMP1, 
TET 1 and 3, and TGFβ1 transcription in InMyoFib, creating an apparent paradox 
regarding vitamin D’s role in mediating TGFβ1’s effects. Certainly its effects were 
not exclusively reparative, in the same way that TGFβ1’s effects were not 
exclusively pernicious. Ultimately, phenotype should be the mark of the over-all 
relationship between TGFβ1 and vitamin D, and as we did not investigate vitamin 
D’s effects in combination with regards the secretory profile, or effect on 
epithelial cell line, data is insufficient to resolve this apparent paradox. 
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Fibronectin1 
Pathway analysis of differentially methylated genes identified Fibronectin 1 (FN1) 
as a key intermediary node. TGFβ1-initiation saw a sustained eight-fold induction 
of FN1 (p < 0.0001), which is also observed to be upregulated in metastatic 
CRC329 and detectable in serum and urine, where concentration is prognostically 
significant330. Furthermore FN1 is TGFβ1-inducible independent of SMAD4331; 
enticingly our data raise the possibility that TGFβ1-induction of FN1 may be 
mediated by an altered DNA methylation profile of genes modulating FN1 
transcription. Vitamin D attenuated FN1 induction by 13% but this was not 
statistically significant. 
Fibroblast activation protein 
FAP is over-expressed in the CRC stromal compartment and more common in 
CGI methylator phenotype (CIMP)-high tumours332. We observed a significant 
3.5-fold induction in FAP expression by TGFβ1 that was associated with 
hypomethylation (27.1%  16.6%) of a single CpG (cg08826839). Vitamin D pre-
treatment significantly attenuated both induction and hypomethylation at the site, 
and furthermore, regression analysis suggests that FAP transcription is negatively 
associated with DNAm at this site, not previously reported. Here is our first 
piece of evidence that DNAm patterns may be maintained by vitamin D to 
promote bowel health. 
VDR 
Sustained three-fold induction of VDR by TGFβ1 initiation was unprecedented 
and would not have been investigated had vitamin D treatment in isolation not 
significantly increased VDR promoter methylation. Positive regulation of VDR by 
TGFβ1 is a novel finding; VDR is documented to mediate TGFβ1 signalling in 
sclerosing fibroblasts by complexing with pSMAD3, thus negatively regulating 
transduction, but in these cells, VDR expression is inhibited by TGFβ1303. In 
contrast, in our experiments, combined treatments either saw no change in 
transcription, or synergy between TGFβ1 and Vitamin D, which might be 
explained by the induction of VDR by TGFβ1, increasing sensitivity of the cells to 
vitamin D.  
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An important limitation our work must be observed; the InMyoFib cell line 
employed to interrogate the effects of TGFβ1 is itself embryonic in origin; TGFβ 
superfamily signalling is well documented to play a role in differentiation during 
embryogenesisreviewed in 333, and this limits what can be inferred from our data about 
effects of TGFβ1 in mature colonic pericryptal myofibroblasts. TGFβ1 signalling 
in InMyoFib during embryogenesis may however be recapitulated in healthy adult 
tissues during tissue repair, processes which have similar end goals. In order to 
determine the relevance of our results, effects would have to be recapitulated in 
a mature MFB cell line. 
 
In summary 
As hypothesised, recombinant TGFβ1 exerted modest pressure on the 
methylome of InMyoFib in a gene-specific fashion, associated with a modified 
secretory phenotype, and increased aSMA transcription that was not related to 
its methylation status. Deregulated transcription of factors involved in DNAm 
metabolism is posited as a mechanism by which TGFβ1 might alter the 
methylome in InMyoFib and requires further validation. The permanence of these 
changes was not fully established. Vitamin D partially attenuated TGFβ1’s effects 
on the methylome, but displayed synergy elsewhere regarding gene transcription, 
and so vitamin D’s role in mediating TGFβ1’s effects, and the consequences of 
either treatment for secretory profiles and epithelial homeostasis, requires 
further elucidation. 
Treatment of InMyoFib with TGFβI induced phenotypic changes including 
reduced cell proliferation and modifications to the secretome that affected 
epithelial cell proliferation. These phenotypic changes were associated with 
significant changes to the expression of a number of genes established to play a 
role in epithelial homeostasis. The altered phenotype was sustained following 
withdrawal of TGFβI stimulation suggesting that these changes may be 
permanent. The TGFβI-induced phenotypic changes were associated with 
significant gene-specific changes to the DNA methylome raising the possibility 
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that at least some of the differential gene-specific DNA methylation, is 
responsible for the altered phenotype. Further experiments are required to 
establish this. TGFβI affected the expression of several genes involved in DNA 
methylation highlighting a potential mechanism explaining the observed effects on 
the methylome. 
Pre-treatment of InMyoFib with vitamin D attenuated some of the effects of 
TGFβI on the DNA methylome including the complete inhibition of the TGFβI-
induced demethylation of FAP, which may prove significant in the context of 
bowel health. However, while attenuating some of the effects of TGFβI, vitamin 
D also synergistically enhance other effects including on the expression of a 
number of genes, and so vitamin D’s role in mediating TGFβ1’s effects, and the 
consequences of either treatment for secretory profiles and epithelial 
homeostasis, requires further elucidation. 
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Chapter 5 
 
VITAMIN D MEDIATES THE SECRETOME OF 
PERICRYPTAL MYOFIBROBLASTS, AND DNA 
METHYLATION PATTERNS IN COLONIC ORGANOIDS 
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Preface to the work 
Two over-arching hypotheses are proposed to explain why serum vitamin D 
might affect the rate of aberrant age-related DNA hypermethylation in the 
uninvolved mucosae of colorectal cancer patients; 1) vitamin D attenuates age-
related deregulation of DNAm metabolism directly, via modulation of enzyme 
activity or other cell-intrinsic factors mediating the process 2) Inflammatory 
mediators drive aberrant DNAm via NFκB networks which, as a systemic and 
local anti-inflammatory, vitamin D attenuates, indirectly maintaining DNAm  
patterns within crypt stem cells. As well as characterising the effects of vitamin D 
on DNAm in CSC, it was also deemed pertinent to investigate if vitamin D’s anti-
inflammatory effects might modulate inflammatory networks in the crypt 
microenvironment. 
With regards project objectives, organoid culture from colonic crypts was 
complex, with cultures regularly failing to yield sufficient DNA for methylation 
analysis. Furthermore, these healthy primary cultures are particularly sensitive to 
recombinant protein/hormone concentrations routinely used to stimulate cancer 
cell lines, which by their nature resist apoptotic stimuli. As aberrant DNAm  is a 
processes of aging, it was recognised that in order to try and accelerate the 
process (with inflammatory cytokines), or ameliorate/attenuate the process (with 
vitamin D), cultures would need to be stimulated with physiologically relevant 
concentrations and maintained for extended periods, as opposed to protocols 
typically used with transformed cell lines (high dose, short intervention). 
Although Sato et al report that under appropriate culture conditions, there 
appears to be no threshold population doubling for crypt stem cells, we routinely 
observed a decrease in viable organoids at each passage, suggestive that passage 
technique is a key factor in organoid longevity. 
To mitigate for these logistical hurdles during the early stages of the project and, 
as discussed, to investigate the secretory potential of pericryptal myofibroblasts 
in informing the niche and mediating paracrine stem cell turn over, we focused 
our attention on validating primary lines of mucosal myofibroblasts from the 
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same bowel resection specimens for use in alternative experiments while 
organoid culture efficiency was optimised. 
Specifically pericryptal myofibroblasts represent an actively secreting phenotype 
intermediate to structural fibroblasts (aSMA-ve) and elastic myocytes (Vimentin-ve) 
that disseminate the instructions of inflammatory mediators to effect niche 
architecture and epithelial regeneration in response to stress334. After 
propagating three human lines of morphologically homogenous stellate primary 
mucosal cells, we performed IHC with antibodies directed against both aSMA 
and VIM to demonstrate that all three primary cultures were homogenously 
expressing both structural filaments, defining a pure population of aSMA/VIM+ve 
myofibroblasts (figure 25)17.  
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Figure 25 – Colonic myofibroblast validation. Cell monolayers at passage 2-4 seeded on chamber slides 
were stained with primary polyclonal antibodies against aSMA (Texas Red) or Vimentin (Alexa 448 
green).  aSMA+VE InMyoFib guaranteed by Lonza were used as a positive control.  Smooth muscle actin 
and vimentin filaments are homogenously present in all cells, demonstrating pure cultures of colonic 
myofibroblasts propagated from mucosal biopsies. Cell were used for media conditioning experiments to 
investigate potential mechanism by which pericryptal myofibroblasts might mediate inflammation in the 
stem cell crypt niche. 
aSMA     VIM 
VIM 
IMF 
C11 
C12 
C13 
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Abstract 
 
Chronic inflammation in the distal bowel maintained by TNFα, predisposes the 
epithelia to transformation, and is associated with deregulated 5mC metabolism, 
genomic instability, and silencing of Wnt-tumour suppressors, via age-related 
effects on DNAm patterns in crypt stem cells. We hypothesised that primary 
pericryptal myofibroblasts supporting CSC might contribute inflammatory 
mediators to the crypt niche in response to cytokine stimulation, and that these 
factors in turn effect differential DNAm patterns in case-matched colonic 
organoids. 
To this end, we validated three lines of aSMA+ve/VIM+ve primary colonic 
myofibroblasts, propagated from uninvolved mucosa proximal to rectal tumours 
in mature bowel resections. LC/MS-MS proteomics was employed to identify 
commonly secreted factors at baseline (124), following stimulation with vitamin 
D (one, Laminin2), and following stimulation with TNFα (0). Vitamin D did not 
universally attenuate COX2 transcription, but did inhibit secreted PGE2, 
suggestive of interference via an uncharacterised mechanism. Two MFB lines 
exhibited high levels of COX2 transcripts relative to healthy controls, prompting 
speculation of a COX2/PGE2-high phenotype that was associated with aspects of 
the secretory profile at base line. Supernatants modulated DNMT3a and 3b 
transcription, and were noted to also induce Cyp24a1 transcription, in case-
matched organoids. Interrogation of organoid methylomes by Illumina EPIC array 
was inconclusive, but non-significant trends in Wnt-antagonist promoter 
methylation status do not specifically confirm a null hypothesis and indicate 
experiments with increased power are warranted.  
We show that pericryptal myofibroblasts from diseased colons contribute 
pernicious niche factors that can modulate DNMT transcription in epithelial 
organoids in a context-specific fashion regarding their inflammatory status. 
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Introduction 
It is increasingly recognised that chronic inflammation in the distal bowel 
precedes and predisposes the epithelium to transformation in later years, and 
initiation is invariably associated with microenvironmental changes that promote 
accumulation of activating mutations in intestinal epithelial cells335. Primarily, 
mechanisms have been inferred from models of the inflammatory bowel 
pathologies, Crohn’s and ulcerative colitis (UC), where pathogenesis is foremost 
a complex interplay between the gut micro-flora, mucosal immunity, and 
predisposing genetic factors336. However, over extended periods, persistent, 
asymptomatic, low-level chronic mucosal inflammation, associated with 
environmental (diet) and metabolic (obesity) factors, recapitulates the 
pathological effect of IBDs in non-diseased bowels337-339. 
Regardless of aetiology, chronic inflammation perturbs homeostasis via similar 
mechanisms at the molecular level, instigated in part by networks of 
inflammatory mediators that form the cross-talk between luminal, epithelial, and 
submucosal compartments, to preserve barrier integrity, epithelial function, and 
immune regulation in times of homeostasis reviewed in 340. Tumour necrosis factor 
alpha (TNFα), a pleiotropic cytokine secreted by gut lymphocytes, antigen 
presenting cells, and tissue resident macrophages (as detailed in chapter 3), is a 
primary provocateur, stimulating a cascade of other pro-inflammatory cytokines, 
including IL6, in a paracrine fashion. TNFα mediates its immune-modulatory 
effects via it’s cognate cell surface receptor, in a similar way to pathogen-
stimulated toll-like receptor signalling, that is, via activating serine 
phosphorylations that degrade cytosolic IKK complexes, and rapidly precipitate 
nuclear translocation of the transcription factor NFκB. 
One downstream target of NFκB, consistently over-expressed in both 
inflammatory and neoplastic bowel wall lesions, is Prostaglandin-endoperoxide 
synthase 2 (COX2)341. In uninflamed tissues COX2 over-sees the catabolism of 
prostaglandins - specifically prostaglandin E2 (PGE2) - from arachidonic acid, to 
establish a negative feedback loop that resolves transient inflammation. In 
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chronically inflamed tissues, this process is deregulated, and increased levels of 
PGE2 secretion contribute to the amplification of pro-inflammatory signalling342. 
Not only is COX2/PGE2 dysregulation directly tumouri- and carcino-genic in the 
epithelium343, PGE2 is also shown to modulate DNMT activity in vitro and in 
murine APCmin/+ colons, effecting hypermethylation of MGMT associated with 
tumour promotion344. Selective inhibition of COX2 conversion of arachidonic 
acid to PGE2 by non-steroidal anti-inflammatory drugs is widely recognised to 
favourably influence risk of mortality from CRC345, and vitamin D has also been 
shown to negatively regulate COX2 activity in macrophages,346,347 leading us to 
speculate that PGE2 modulation in the niche might affect DNAm patterns in the 
epithelia. 
Sentinels of the crypt microenvironment, pericryptal myofibroblasts contribute 
niche factors that interact with the epithelium348. PGE2 secretion, stimulated by 
TNFα has been previously reported in gingival fibroblasts, tracheal smooth 
muscle, and synovial fibroblasts349-351, and this led us to speculate that TNFα 
regulation of COX2 in pericryptal myofibroblasts promotes prostaglandin 
synthesis and secretion in the crypt niche. Furthermore, we hypothesised that 
the secretory profile of a TNFα-stimulated myofibroblast might also affect 
aberrant DNA hypermethylation in an organoid model of the colonic epithelia.  
We set out to characterise the secretory profiles of primary MFB from 
transformed colons in respect of TNFα-stimulated COX2 regulation and PGE2 
output. We also investigated the ability of TNFα-inflamed supernatants to affect 
aberrant DNA methylation in case-matched colonoids, and the ability of vitamin 
D to mediate any observed effects, with the informing hypothesis that vitamin D 
might inhibit COX2 transcription, PGE2 secretion, and aberrant effects of 
supernatants on DNAm patterns in epithelial cells. 
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Methods 
Cell recovery and culture 
Mucosal samples were taken from three fresh bowel resection specimens, 20cm 
proximal to rectal adenocarcinomatous tumours, and transported in wash buffer 
on ice. Five minute serial digestions on ice with 2mM EDTA in PBS first released 
apoptotic cell debris and faecal matter and then epithelial crypts (for organoid 
culture). The stripped mucosal remains were further digested in EDTA-dispase 
solution at 37°C and agitated to release a mixed population of mucosal 
fibroblasts, myofibroblasts and other non-adherent tissue resident cell types. 
Pellets were rinsed with PBS and seeded into 75cm2 flasks containing 10mL of 
InMyoFib culture medium (Lonza). Primary cells were propagated to confluence, 
with frequent media changes to remove non-adherent cells, during which time 
adherent cells exhibiting a macroscopic stellate morphology became the 
dominant phenotype (Figure 25). 
Validation of MFB cultures by IHC 
Primary cell cultures were released by trypsin-EDTA chelation, rinsed, and 
seeded on chamber slides. At 80% confluence, adherent cells were fixed with 4% 
para-formaldehyde, permeabilised with Triton X (1:100), blocked with 5% BSA in 
PBST, and incubated over-night at 4°C with primary antibodies anti-aSMA and 
anti-Vimentin (1:300 in PBST, ABCAM ab7817 and ab92547 respectively). 
Secondary fluorescent antibodies (anti-rabbit Alexa 488 green and Texas Red, 
1:500) applied after several washes for 2 hours at room temperature. Finally 
DAPI was applied for 10 minutes to stain nucleic acids blue, before visualisation 
by fluorescent light microscopy.  
TNFα stimulation 
The three validated human lines of MFBs and the commercial InMyoFib line were 
seeded into 12 well plates at 30,000 cells per well. After allowing 24 hours to 
establish, cells were treated with either ethanol vehicle or 1nM vitamin D 
(Tocris, 2551) final concentration for 72 hours. For the final 24 hours, TNFα 
(Sigma, SRP3177) was applied at 1ng/mL to either vehicle or vitamin D pre-
treated wells. Media was collected, spun at 300G, passed through a 20μm filter, 
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before diluting 1:2 in ELISA buffer. Cell pellets were harvested for RNA 
extraction/Q-rt-PCR as previously described in general methods 
Q-rt-PCR 
Typically yields were low from MFBs due to a high cytoplasmic to nuclear ratio 
(even confluent wells only yield about half the RNA of epithelial lines), so here 
100ng was reverse transcribed for Q-rt-PCR, which was carried out as 
previously described. Lists of primers are included in appendix 6. 
PGE2 Elisa 
A 96 well plate monoclonal PGE2 Elisa kit was purchased from Cambridge 
Bioscience Ltd (CAY514010), and executed as per manufacturer instructions. 
Conditioned media samples were diluted by 50% in Elisa buffer to ensure PGE2 
concentration fell within the reliable working range of the standard curve. 
Biological triplicates from each line and each treatment were interrogated in 
technical duplicate, and the data represent the mean of biological triplicates +/- 
the SEM. 
LC/MS-MS Proteomics 
Was performed as detailed in General Methods. Samples for analysis were 
prepared as follows. The three human MFB cases were cultured in 25cm2 flasks 
to 80% confluence. Cells were treated as described with 1nM vitamin D +/- 
1ng/mL rTNFα. To mitigate for albumin interference, FBS was removed during 
TNFα stimulation, and it is noted that this introduces a necessary discrepancy 
relative to the PCR data. Media was harvested and processed to remove debris, 
and inhibitor cocktail added. Conditioned media was spun for 2 hours at 14,000g 
through a 3K AmiconUltra4 protein filter (Merck,). Protein concentration was 
determined by BCA assay as described, and 15μg triplicates separated for 10 
minutes by PAGE electrophoresis at 200V (Novex). Lanes were visualised by 
Coomassie blue and dissected into 1mm pieces. Peptides were digested with 
20mM Ammonium Bicarbonate added to 5µl (5µg) Trypsin Gold (Promega) in 
50mM Acetic Acid. The gel pieces were washed with 50% acetonitrile (Fisher) to 
recover digested peptides from the gel. The extracted samples were then dried 
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at room temperature on a Speed Vac SC110 (Savant) and frozen on dry ice to be 
stored at -80°C. 
Organoid culture 
Pure crypts from case 11, 12 and 13 mucosal biopsies were seeded in 25uL 
drops of Matrigel (Corning 354230) containing 1:1000 JAG1 (1uM) and 1:1000 
Y27632 (10mM) in 24 well plates with 500uL of routine organoid culture 
medium. Stimulated myofibroblast culture medium was prepared as previously 
described without inhibitor cocktail and concentrated through 3K protein filters. 
Triplicate wells of organoids for each case were treated for 30 days with either 
vehicle- vitamin D- TNFα- or combined treatment-matched myofibroblast 
supernatants (500ng). Media were replaced every 2-3 days for the duration of 
the protocol. Organoids were passaged at days 10, 20, and 30, and following the 
final passage, all treatments were removed and fresh routine media added for a 
48 hour washout period. Treatment replicates were pooled for DNA extraction 
as described and 500ng of genomic DNA dispatched for EPIC array analysis. 
InnateDB analysis 
Ensembl codes for proteins identified by secretomics and genes identified by 
EPIC array were uploaded to InnateDB to determine statistically over-
represented biological pathways and molecular interaction networks between 
seed genes. InnateDB interrogates public curated databases of biological 
interactions including KEGG, Reactome, NetPath, INOH, BioCarta and PID. For 
analysis and visualisation, the recommended hypergeometric algorithm with 
Benjamini Hochberg correction was selected.  
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Results 
 
Effects of vitamin D in primary myofibroblasts 
Vitamin D inhibits TNFα induction of COX2 and IL1β transcripts in a dose-
dependent fashion 
 
To establish a suitable protocol to inflame pericryptal myofibroblasts, un-
validated homogenous cultures propagated from case 1 were incubated at 80% 
confluence for four hours with 10ng/mL of rTNFα as a test case. For combined 
treatments, MFB were pre-treated with 10nM (COMB1) or 100nM (COMB2) of 
vitamin D, for 48 hours prior to stimulation with TNFα. COX2, and IL1β 
transcripts were quantified by Q-rt-PCR to demonstrate the pro-inflammatory 
effect of TNFα in these cells. In keeping with the hypothesis that MFBs 
contribute Wnt ligands to the niche environment, the transcription of RSPO1 
and WNT3a (essential components of organoid culture medium) were also 
interrogated. 
Vitamin D inhibited COX2 transcription, but not IL1β. TNFα significantly 
induced COX2 (two-fold) and IL1β (50-fold) transcripts. Combined treatment 
with vitamin D attenuated the effect in a dose-dependent fashion for both COX2 
and IL1β, with statistical significance being achieved at the higher concentration 
(figure 26a and b). Regarding Wnt agonist transcription, base line Wnt3a 
transcripts were relatively low (CT values approaching the 40 cycle threshold 
limit and thus not detectable in all replicates), precluding statistical analysis – 
included here because the trend reflects the pattern observed for RSPO1; in 
isolation and in combination, both TNFα and vitamin D significantly induce 
RSPO1 transcription (figure 26c and d). This suggests that were these changes to 
translate to increased RSPO1 secretion by MFBs, increased epithelial turnover 
may be induced in response to both vitamin D treatment and TNFα-mediated 
inflammation in the crypt niche. 
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Figure 26 – Vitamin D and TNFα modify gene transcription in primary myofibroblasts. 1 MFBs 
Heterogeneous intestinal myofibroblast cultures (case 1) in the log growth phase were treated 
with either ethanol vehicle, vitamin D (100nM, 48 hours), rTNFα (10ng/mL, 4 hours), or in 
combination (COMB1; 10nM vitamin D + 10ng/mL rTNFα. COMB2; 100nM vitamin D + 10ng/mL 
rTNFα). RNA was reverse transcribed and interrogated by Q-rt-PCR to determine gene 
transcription. Data show relative transcripts determined by the ΔCT method +/- SEM. n=3, * 
p<0.05, ** p< 0.01. A) Inflammatory mediator COX2 transcription is repressed by vitamin D, 
induced by TNFα, and attenuated in a dose-dependent fashion in combination B) To confirm the 
pro-inflammatory effect of TNFα on MFB, IL1β transcription was also assessed, again showing a 
dose-dependent attenuation in combination with vitamin D. C & D) Secreted Wnt ligand RSPO1 
is significantly induced by both vitamin D and TNFα, a trend recapitulated for Wnt3a 
transcription, another recombinant ligand utilised in organoid culture, raising the possibility that 
both vitamin D and TNFα promote stem cell turn-over via increased paracrine signalling in the 
crypt niche. 
A B 
C D 
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COX2 transcription correlates with, and vitamin D inhibits, myofibroblast-
secreted PGE2 
 
Secreted prostaglandin E2 is an end point of COX2 regulation and is shown to 
promote tumourigenesis via aberrant DNAm in colonic epithelia. In light of 
COX2 regulation by TNFα, it was hypothesised that stimulation might also 
increase secreted PGE2 from myofibroblasts, and that vitamin D might attenuate 
this.  
To ensure sufficient conditioning of the media by inflamed MFBs following COX2 
induction observed at four hours, the treatment protocol was extended; in 
respect of the dose-dependency of the combined treatments, and to better 
reproduce the situation in vivo, three validated MFBs lines (case 11, 12 and 13) 
were pre-treated for 48 hours with a lower concentration of vitamin D (1nM – 
10x physiological sufficiency). Preliminary experiments with InMyoFib – employed 
as a healthy control against the MFBs recovered from CRC resections – 
indicated that 10ng/mL of TNFα was comprehensively fatal at 24 hours, so it was 
decided to also reduce the TNFα stimulus to 1ng/mL for the extended 
conditioning period. Supernatants were collected and processed as previously 
described to remove cellular debris, diluted as appropriate, and the 
concentration of PGE2 determined by ELISA according to the manufacturer’s 
instructions.  
Vitamin D in isolation (1nM for 72 hours) significantly reduced PGE2 in the 
conditioned media in three of the four MFB cell lines, and the trend was evident 
in the fourth. Data were pooled and normalised to the control (to allow for 
comparisons between cell lines), and suggest that vitamin D for 72 hours at 1nM 
significantly reduces PGE2 secreted by intestinal myofibroblasts by approximately 
25% (figure 25a). Similarly, stimulation with TNFα significantly increases PGE2 
concentrations 3.5-fold in intestinal myofibroblasts, as anticipated. However, in 
combination, a 48 hour pre-treatment with vitamin D was not able to 
significantly attenuate the increase, as was suggested by vitamin D’s ability to 
down-regulate COX2 transcripts. 
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In this respect, it is of note that, at base line, cases 11 and 12 MFBs exhibit a 
four-fold increase in secreted PGE2 relative to healthy InMyoFib and case 13, 
raising the possibility that in vivo, these cells had previously acquired an inflamed 
phenotype (figure 28b).  
Due to the apparent discrepancy between results from the preliminary 
experiments, regarding vitamin D’s attenuation of TNFα-induced COX2 not 
reflected by diminished PGE2 secretion, RNA was harvested from all four lines 
after media conditioning to re-establish the relationship between COX2 
transcription and secreted PGE2. Supporting the developing hypothesis that case 
11 and 12 represent an inflamed phenotype distinct to case 13 at base line, 
COX2 transcripts are significantly raised in these two cases relative to case 13 
MFBs and InMyoFib at base line (figure 28a). While TNFα still significantly 
induced COX2 under the new protocol, vitamin D was not able to attenuate it’s 
induction in any line, consistent with results for secreted PGE2. In fact, vitamin D 
in isolation induces COX2 in the two basally inflamed lines, supporting a modified 
‘inflamed’ phenotype relative to the two other lines. Finally, regression analysis of 
data from each line shows a strong correlation between relative COX2 
transcripts and secreted PGE2 in response to TNFα stimulation (figure 28a).  
Figure 27 – PGE2 production by inflamed myofibroblasts. Secreted PGE2 was determined by ELISA 
for InMyoFib and case 11, 12 and 13 MFBs. Biological triplicates were treated with either ethanol 
vehicle, 1nM vitamin D (72 hours), 1ng/mL TNFα (24 hours), or in combination. A) When data are 
pooled from the four lines interrogated (normalised to the control), VITAMIN D treatment 
significantly suppresses PGE2 secretion by ~25%. Similarly rTNFα induces a 3.5-fold increase in 
secreted PGE2. In combination, pre-treatment with vitamin D did not attenuate TNFα-induced 
PGE2 secretion. B) Regression analysis shows a significant correlation between COX2 transcription 
and secreted PGE2 following stimulation with TNFα (RSQ = 0.99, p = 0.0075, suggesting that TNFα-
stimulated PGE2 secretion is consequent to COX2 induction. n=3, * p<0.05, ** p< 0.01, data 
represent mean +/- SEM. 
A B 
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Figure 28 - COX2 transcription verses secreted PGE2 in intestinal myofibroblasts. Cells were 
treated with either 1nM vitamin D for 72 hours, rTNFα at 1ng/mL for 24 hours, or in 
combination A) COX2 transcription is observed to be increased case in 11 and case 12 MFBs at 
base line relative to InMyoFib and case 13 MFBs at this time point. In the two basally inflamed 
cases, VITAMIN D does not ameliorate COX2 transcription, and only partially ameliorates it in 
the other two. TNFα significantly induces COX2 in all four lines, however, combined treatment 
does not attenuate TNFα induction of COX2 in any line. B) PGE2 concentration in conditioned 
supernatants is elevated in the two COX2-high MFB lines relative to the two COX2-low lines. 
Vitamin D treatment ameliorates secreted PGE2 in all four lines, and rTNFα significantly 
induces PGE2 secretion. However, in combination, vitamin D in not able to attenuate TNFα-
induced PGE2 secretion. Data suggest that case 11 and 12 represent a COX2/PGE2-high basal 
phenotype. n=3, * p<0.05, ** p< 0.01, data represent mean +/- SEM 
B 
A 
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The myofibroblast secretome 
To further qualitatively investigate any differences in secretory protein profiles 
mediated by vitamin D or TNFα treatment, LC/MS-MS proteomics analysis of the 
conditioned media from cases 11, 12 and 13 was performed. The protocol was 
repeated as detailed, with the exception that for the final 24 hours of 
conditioning foetal calf serum was removed from the media, to mitigate for 
albumin interference. In brief, supernatants were spun to remove cell debris, and 
passed through a 20um filter. Next protease/phosphatase inhibitor cocktail was 
added, and 5mL of conditioned media spun through a 3K protein filter to 
concentrate the supernatants. Technical triplicates of 15ug for each treatment 
were separated by PAGE electrophoresis and each lane dissected and digested 
with trypsin, washed, and precipitated to yield desiccated peptides for mass-spec 
analysis. Peptides were compared against the Uniprot human database using 
Scaffold proteome software to identify secreted proteins. Scaffold applies a 
student’s T-test to sample groups with Hochberg-Benjamini correction of 
normalised total spectra to determine statistically significant differences between 
treatments. 
In respect of the fact that, under the modified protocol, pre-treatment with 
vitamin D failed to attenuate TNFα-induced COX2 transcription or PGE2 
secretion, the analysis focused exclusively on the secretome in response to 
Vitamin D (1nM, 72hours), or TNFα (1ng/mL, 24 hours) in isolation relative to 
vehicle control, for each of the three validated human lines of MFBs. As vitamin 
D inhibition is suggested to be dose-dependent, extrapolation of the combined 
effect may be inferred. 
The basal MFB secretome supports niche architecture and chemokine 
signalling. 
Secretomics for case 11 procured the most diverse secretory profile of the three 
cases; 491 unique proteins in MFB supernatants were identified at base line 
(76.6% demarked as extra-cellular), reported to be involved in immune system 
processes (n = 105), establishment of localisation (n = 94), biological adhesion (n 
= 60), locomotion (n = 53), growth (n = 11), and cell killing (n = 6). 
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In case 12, there were 318 unique proteins identified at base line (65.5% 
demarked as extra-cellular), involved in localisation (n = 75), immune system 
processes (n = 35), biological adhesion (n = 34), locomotion (n = 21), growth (n 
= 4), and cell killing (n = 3). 
In case 13, there were 209 unique proteins identified at base line (70.1% 
demarked as extra-cellular), involved in localisation (n = 59), immune system 
processes (n = 32), biological adhesion (n = 22), locomotion (n = 20), growth (n 
= 3), and cell killing (n = 2). 
Consistent with the developing concept of heterogeneous secretory profiles 
represented at base line, case 11 and 12 exhibit an expanded panel of secreted 
proteins relative to case 13, with considerable over-lap between the two panels 
(81 common to the COX2-high phenotype) – more than were shared by case 13 
with either line (19 and 28 respectively). 
Regardless, 124 proteins were identified as common to all three validated MFB 
lines (figure 29a). Not surprisingly the most prevalent in terms of total spectra 
comprised extra-cellular structural components such as keratins, collagens, 
fibrilin1, ECM1, and, again fibronectin1, as well as matrix metalloproteases and 
MMP inhibitors (TIMP1 and 2). Curiously, all three MFB lines were found to 
secrete the Vitamin D-binding protein at relatively low levels in the un-primed 
state, which raises possible implications for vitamin D bioavailability in the crypt 
niche. In respect of the fact that these uninvolved myofibroblasts were recovered 
from diseased colons, network analysis was employed to identify biological 
processes associated with the common secretory profile at base line. The 124 
common seed nodes were associated with 34 ‘colorectal cancer’ nodes (p = 
1.19e-10), 48 ‘TLR-signalling’ nodes (p = 2.61e-7), and 53 nodes involved in ‘Wnt 
signalling’ (p = 0.00157, figure 29b-d). Network analysis of the 81 proteins 
common to COX2/PGE2-high MFBs did not reveal notably different profiles in 
terms of gene ontology or pathway over-representation (data not shown) but 
did reveal that these MFBs were secreting IL6 at base line, recognised for its role 
in IBD, but the COX2-low case 13 was not, providing support for a more 
inflamed phenotype for these two MFB lines.  
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Pathway Expected Hits P.Value 
Pathways in cancer 79.2 167 2.27E-28 
MAPK signalling 67.7 123 3E-14 
Focal adhesion 51.1 110 1.08E-19 
Chemokine signalling 48.3 74 1.85E-05 
Actin cytoskeleton 46.5 87 3.3E-11 
Wnt signalling 36.8 53 0.00157 
Insulin signalling 35 68 6.72E-10 
Cell cycle 31.7 60 2.38E-08 
TLR signalling  24.8 48 2.61E-07 
CRC 12.5 34 1.19E-10 
ECM-receptor int. 21.4 39 2.39E-05 
Figure 29 – The basal myofibroblast secretome. A) 491, 318 and 209 unique proteins were identified 
respectively in case 11, 12 and 13 MFB supernatants. Secretomes exhibit individual diversity at base 
line, however considerable over-lap of commonly secreted proteins is noted (124, indicated in grey 
area).  B) KEGG pathway analysis returns top hits for anticipated biological function of pericryptal 
myofibroblasts; colorectal cancer, chemokine, Wnt, and TLR signalling, cell cycle, ECM, and actin 
cytoskeleton. C) Pathway over-representation analysis (Innate DB) of secreted proteins posits roles 
for MFBs in ECM degradation and organisation, and D) GO term over-representation analysis 
(Innate DB) returns the top seven gene ontology terms as pertaining to extracellular functions. 
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Vitamin D and TNFα independently modify the myofibroblast secretome 
 
Effect of vitamin D 
 
Of 504 identified proteins from case 11, 124 (24.6%) produced differential counts 
of total spectra following treatment with vitamin D. Vitamin D treatment 
completely eliminated seven proteins and induced de novo secretion of a further 
seven proteins (appended in 8).  Of the 295 unique proteins identified from case 
12, 86 (28.9%) show differential counts of total spectra following treatment with 
vitamin D. Twenty four secreted proteins were not present following vitamin D 
treatment, but no de novo proteins were identified (appended in 9). Lastly, only 
12 of the 209 proteins secreted by case 13 exhibit differential counts of total 
spectra following treatment with vitamin D (5.7%). Three proteins were 
eliminated by vitamin D, and none were induced (appended in 10). 
Of the de novo proteins effected by vitamin D, none were common to all three 
MFB lines, and so validation focussed on proteins reported as either ‘high’ or 
‘low’ relative to vehicle in vitamin D treated samples. Proteins identified to be 
differentially secreted following vitamin D treatment show limited commonality 
between lines. Specifically Laminin subunit alpha two (LAMA2) was the only 
protein detected in all three supernatants that was consistently suppressed by 
vitamin D treatment (figure 31a and b). LAMA2 is a basement membrane laminin 
that mediates stromal communication with the epithelium, and is found to be 
over-expressed in inflamed UC mucosae352. The effect of vitamin D (repressed or 
induced) was also consistent between lines for proteins common to C11 and 12; 
(collagen 5-A2, complement factor-H, prostaglandin D2-syntahase, and moesin), 
common to C11 and C13; (heat shock protein 90-AA1 and super-oxide 
dismutase 2); and common to C12 and C13 (keratin 10).   
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Effect of TNFα 
 
In isolation, TNFα exerted a potent inflammatory effect on intestinal 
myofibroblasts in terms of COX2 transcription and PGE2 secretion. 
Consequently secretomic LC/MS-MS analysis of TNFα-induced myofibroblast 
supernatants was performed, to identify proteins that might be increased in the 
niche in chronically inflamed mucosae; TNFα effected statistically significant 
differential secretion of 103, 45 and 44 proteins respectively, however none of 
these were common to all three MFB lines (figure 31c). 13 proteins were 
common to COX2 -high MFBs following rTNFα stimulation, including IL6, 
SERPINE1, PGD2, leukaemia inhibitory factor (LIF) and TNFα-stimulated gene 6 
(TSG6). Differences in total spectra counts for these proteins, recognised for 
their role in bowel pathogenesis, were consistent across both MFB lines 
following TNFα stimulation (figure 31d-f). Qualitative total spectra counts for IL6 
from COX2-high MFB lines were validated by Q-rt-PCR; both lines show 
significant induction of IL6 transcripts following stimulation with rTNFα (figure 
30). Transcripts were recorded in case 13 MFBs at base line, but not identified by 
mass spec, suggesting that post-translational modifications activate secretion of 
IL6 in COX2high MFBs. 
 
Figure 30 – Interleukin 6 transcription in MFBs. TNFα at 1ng/mL for 24 hours significantly induces IL6 
transcripts in COX2/PGE2-high MFBs relative to COX2/PGE2-low (case 13) MFBs. This supports the 
observed increase in IL6 total spectra detected in case 11 and 12 supernatants. n=3, ** p<0.01, *** 
p<0.001. Data represent mean +/-SEM. 
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Figure 31 – The secretome of stimulated intestinal myofibroblasts lines n=3, *P<0.05, ** p< 0.01. Data 
represent the mean +/- the SEM. a) Venn diagram of secreted proteins differentially expressed following 
treatment with 1nmol VITAMIN D for 72 hours. Only 1 protein, lamanin2 (LAMA2) was common to all 
three lines b) LAMA2 total spectra are highest in case 11 at base line, and treatment with vitamin D 
ameliorates LAMA2 secretion in all three MFB lines c) No over-lap of any secreted protein was observed 
between lines treated with TNFα (1ng/mL) for 24 hours, however basally inflamed case 11 and 12 share 13 
commonly secreted factors following TNFα induction. Three of these were identified to be both over 
expressed in IBD, and induced here by rTNFα. d) Interleukin 6 was weakly secreted at base line in both 
cases, treatment with TNFα (1ng/mL) for 24 hours significantly increases IL6 concentration in 
supernatants e) SERPINE1 (Plasminogen activator inhibitor-1)  is over-expressed in inflammatory 
conditions, promoting fibrosis. Here, TNFα treatment induced significant increase in secreted SERPINE1 
in both basally inflamed MFB lines, but was not detectable in case 13 supernatants. f)  TNF-stimulated 
gene 6 protein (TSG6) is inducible in a variety of inflammatory conditions. In case 11 and 12 MFBs, TNFα 
stimulated TSG6 secretion from both basally inflamed MFB lines, but was not detected in case 13 MFBs. 
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Effects of myofibroblasts supernatants on the epithelia 
MFB supernatants modulate DNAm profiles in case-matched colonic 
organoids and regulate DNMT transcription 
The informing hypothesis is that mediators in the crypt niche, secreted by 
inflamed pericryptal myofibroblasts, accelerate age-dependent aberrant DNAm in 
cycling crypt stem cells. To investigate the consequence of a perturbed MFB 
secretome on uninvolved gut epithelia, the experimental protocol was repeated 
to condition media for use in routine organoid culture. Importantly, although 
TNFα peptides were not detected in any of the MFB supernatants, it must be 
noted that metabolites of rTNFα may still be present in supernatants at t=24 
hours. Again, organoid methylomes were characterised after a wash out period 
to mitigate for transient effects on DNAm. 
Case 11 and Case 12 matched organoids were cultured as described in biological 
triplicates for 30 days with the addition of 500ng/mL of concentrated MFB 
supernatants from either vehicle, vitamin D, or TNFα treated MFBs. Media were 
refreshed every 48 hours, and organoids were passaged every 10 days to 
increase yield, and encourage mitosis and propagation of DNAm patterns. 
Triplicate wells were pooled and recovered, DNA was bisulphite modified and 
interrogated by Infinium EPIC methylation bead chip. Infinium’s updated chip 
determines DNAm status of 841,684 CpG sites (verses 486,428 in the previous 
iteration). 
[A caveat must be observed to accompany the results; case 12 organoids treated 
with vehicle-induced MFB supernatants (CTRLs) failed to yield DNA suitable for 
the array. Analysis was focussed on results from case 11 organoids alone and, 
where trends identified, assessed in case 12 organoids using data substituted 
from control organoids not treated with MFB supernatants but after 30 days in 
culture (also included on the array). Loci-specific comparisons between the two 
cases are intended only to support observed trends, but should not imply 
validation of observations].  
In case 11, average gene promoter DNAm status was significantly reduced by a 
small percentage in matched organoids treated with supernatants from vitamin 
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D-induced-MFBs. Surprisingly, TNFα-induced-MFB supernatants also precipitated 
a methylome-wide decrease in promoter DNAm status. Both changes were 
attenuated in combination (figure 32a). Whether this is useful in determining the 
validity of the hypothesis is questionable, however the trend is consistent with 
observations discussed subsequently detailing DNMT transcription. 
A total of 14,182 single CpG sites (1.6%) that were hyperdynamic in response to 
vitamin D and TNFΑ supernatants consistent to the hypothesis were identified. 
The top 1% of these differentially methylated CpGs mapped to 11 assigned 
genes, of which two experience attenuation of TNFα-induced hypermethylation 
when treatments were combined; CCBE1, a tumour suppressor found to be 
silenced by hypermethylation in breast cancer(figure 32b)353, and POU3F4, which 
was shown to be hypermethylated in lung cancer354. Furthermore, the variable 
DNAm at these sites was recapitulated in case 12 organoids, raising the 
possibility that the effects of vitamin D and TNFα on DNAm in these genes 
might be ubiquitous in inflamed mucosae. 
With regards differentially methylated promoters, filtered according to 
previously defined criteria, 1918 (4.3% of the total interrogated) were hyper-
methylated (+5% or more) by TNFα. Supernatants from the combined treatment 
attenuated TNFα-induced DNA hypermethylation of 1060 of these gene 
promoters (55.3%), suggestive that vitamin D may indirectly protect 
inflammation-mediated DNAm. Pathway analysis of vitamin D rescued genes 
revealed three regulating Wnt signalling (SFRP1, FRZB and FZD5), and two 
involved in vitamin D bioavailability (Klotho, frequently silenced in cancer by 
promoter hypermethylation, attenuated in combination here, and S100G), but 
variable DNAm of these genes observed in case 11 was not recapitulated in case 
12 organoids. 
The methylation status of the top 20 promoters hyper-methylated by TNFα in 
case 11, that were attenuated in combination, were mapped in case 12; six of 
these promoters also experience variable DNAm, but promoters represented 
un-assigned locations or pseudo-genes. The other 14 promoters were unaffected 
in case 12 organoids. 
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Finally, in both cases promoter methylation status was determined for the panel 
of genes identified by Tapp et al, whose methylation status in epithelial biopsies 
was associated with serum vitamin D. None of these promoters were 
significantly dynamic in either line with regards to MFB supernatant treatment, 
however four (SFRPs 1, 2, and 4, and MYOD1) exhibit non-significant trends 
supportive of the hypothesis that TNFα-stimulated MFB supernatants drive 
aberrant DNAm of Wnt antagonists (figure 32c and d). 
To investigate a potential mechanism by which vitamin D/TNFα stimulated MFB 
supernatants might mediate aberrant DNAm patterns in organoids, matched 
organoids were treated for 24 hours with supernatants at a final concentration of 
500ng/mL from all three validated MFB lines. RNA was interrogated to 
investigate transcription of DNA methyltransferases 1, 3a and 3b, and TET1. 
Transcripts for TET1 were not detectable in any of the three organoid lines, and 
DNMT1 transcription remained static in response to MFB supernatants. 
DNMT3a and 3b were both suppressed at 24 hours by vitamin D- and TNFα- 
stimulated MFB supernatants, consistent with the modest but significant effect 
each treatment had on over-all promoter DNAm status. The effect was 
significantly attenuated in all three organoid lines in response to the combined 
treatment supernatants (figure 32e and f). Lastly, to demonstrate that vitamin D 
was no longer present in MFB supernatants, CYP24a1 transcripts in the 
organoids were quantified. Cyp24a1 is the principal catabolic enzyme of vitamin 
D and is directly inducible as part of regulated feedback355. As well as treating 
case-matched organoids with MFB extracts, all three organoid lines were treated 
with an increasing dose of vitamin D. Cyp24a1 was induced in a dose-dependent 
fashion in all three organoid lines, as anticipated. In contrast, MFB supernatants 
from vitamin D-treated cells weakly suppress Cyp24a1 relative to vehicle 
controls. Theoretically this would increase epithelial sensitivity to vitamin D, and 
is consistent with the over-arching hypothesis that vitamin D promotes bowel 
health. It is of note that relative to untreated control organoids, vehicle-
stimulated MFB supernatants significantly induce Cyp24a1 transcription in all 
three organoid lines, raising the possibility that the secretome of pericryptal 
MFBs may inform epithelial sensitivity to vitamin D (figure 33b).  
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Figure 32 – Myofibroblast supernatants effect partially differential DNAm patterns in case-
matched colonic organoids. Case 11 and 12 organoids were cultured in biological triplicate 
for 30 days +/- 500ng/mL of supernatants, from either ethanol vehicle, 1nM vitamin D, 
1ng/mL TNFα, or combined treatment stimulated MFBs. A two day washout period was 
observed prior to DNA extraction. DNAm patterns were determined by Illumina EPIC 
array. A) Case 11 gene promoters in colonoids exhibit a modest but significant reduction in 
average DNAm status after incubation with both vitamin D and TNFα stimulated MFB 
supernatants, attenuated in combination B) A single CpG in the CCBE1 sequence exhibits a 
trend toward vitamin D-supernatant-mediated hypomethylation and TNFΑ-supernatant-
mediated DNA hypermethylation (DNAm heterogeneity between C11 and C12 precludes 
statistical significance). C & D) Promoter DNAm in Wnt antagonists frequently 
hypermethylated in CRC - SFRP2 and MyoD1 shown - trends towards hypermethylation in 
both cases after incubation for 30 days with TNFα-stimulated MFB supernatants E&F) DNA 
methyltransferase transcription is suppressed in colonic organoids (average of three cases) 
after 24 hour stimulation with case matched MFB supernatants. vitamin D and TNFΑ-
stimulated MFB supernatants both suppress DNMT3a and B transcription, attenuated in 
combination.  
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Finally, in respect of the observed increase in IL6 transcription and secretion 
from TNFα stimulated COX2-high myofibroblasts, the effect of exogenous 
recombinant IL6 on DNA methylation patterns in case 11 organoids was 
investigated, to determine if increased IL6 signalling in the crypt niche might 
affect aberrant DNAm in the epithelium. Organoids were seeded in Matrigel in 
biological triplicates, and treated for 6 days with the addition of either PBS 
vehicle, or increasing doses of rIL6 at 10, 100 and 1000pg/mL final concentration 
in the media. Triplicates were pooled, and harvested DNA bisulphite modified 
for interrogation by Infinium EPIC methylation array. Gene promoter 
methylation status was correlated to LOG transformed IL6 concentration. 
Statistical significance was determined by applying a students’ 2-tailed T 
distribution to the correlation coefficient. 
The average gene promoter methylation status in case 11 organoids was not 
affected by treatment with IL6 at any concentration, remaining static at 49.3% +/- 
0.2%. However, recombinant IL6 significantly increased promoter DNAm in a 
dose-dependent fashion for 972 of the 44,848 genes interrogated (2.2%). Of 
these, 159 increased their promoter DNAm by more than 5% at the highest 
concentration, an ominous finding at a low concentration over a short period of 
time, relative to the in vivo paradigms commonplace in IBD. Pathway analysis 
suggests many of the genes differentially methylated by a short incubation with 
IL6 are regulated by Myc, a key transcription factor involved in proliferation and 
survival (figure 33a and c). It is of note that most of the genes susceptible to 
hypermethylation by IL6 under this protocol, were already partially methylated at 
base line; only 135 (13.8%) were hypo-methylated at base line. This raises the 
possibility that IL6 exacerbates an underlying CIMP-high phenotype affecting 
aberrant DNAm in these organoids recovered from diseased colons. 
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Figure 33 – The effect of matched myofibroblasts conditioned media on epithelial organoids. a) KEGG 
pathway analysis of the 1060 genes in case 11 identified as hypermethylated by TNFα-stimulated MFB 
supernatants, and attenuated in the combined treatment. Suggested upregulated pathways and 
implicated differentially methylated genes include; apoptotic signalling pathway (BMPR1B, SFRP1, 
ZSWIM2), vitamin D binding (KL, S100G), and Wnt activated receptor activity (FRZB FZD5 SFRP1). B) 
Vitamin D increases Cyp24a1 transcription in 3 human colonic organoid lines in a dose-dependent fashion 
(average across three lines +/- SEM). Myofibroblast supernatants (CTRLm) increased transcripts of 
Cyp24a1 in all cell lines, proposed to inhibit epithelial sensitivity to vitamin D, whereas vitamin D treated 
MFB supernatants (vitamin Dm) suppress Cyp24a1, confirming an absence of vitamin D in the conditioned 
media used to treat organoids, and suggested to potentiate epithelia to vitamin D’s antiproliferative 
effects. C) Induced network analysis suggests a Myc as a master regulator of gene promoters 
hypermethylated in a dose-dependent fashion in response to treatment with rIL6 (seed nodes in black 
text, purple line denotes transcriptional control of protein product). 
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Vitamin D attenuates de novo DNA methylation and ameliorates 
hypermethylation in murine colonoids 
In respect of vitamin D’s ability to regulate PGE2 production by pericryptal 
myofibroblasts, the effect of PGE2 on DNA methylation patterns in both murine 
and human colonic organoids was investigated. As a proof of concept, organoids 
were generated from an 24 week old C57BL/6 mouse, and cultured in triplicate 
with either ethanol vehicle, vitamin D (1nM), PGE2 (100mM, 10x physiological 
dose), or in combination. Cultures were maintained for four weeks and passaged 
where appropriate to propagate material for interrogation. The methylation 
status of DKK1, SOX17, SFRP1 and WIF1 were determined by CoBRA. 
SFRP1 and WIF1 remained hypomethylated in all samples at the end of the 
treatment regimen. Vitamin D treated organoids exhibit a reduction in DKK1 
promoter methylation from 29.9% in vehicle controls to 14.7% in the D-treated 
wells. DKK1 methylation status was not determined at base line, so it isn’t 
possible to speculate about the effect of IVA here; either vitamin D has 
attenuated an IVA-associated increase in DKK1 Methylation seen in the controls, 
or vitamin D has ameliorated methylation that was previously established. The 
PGE2-treated organoids show a trend towards DKK1 hypermethylation (p = 
0.0502), and again in organoids cultured with both vitamin D and PGE2, 
DKK1methylation is reduced by a similar degree to that of the vitamin D 
treatment in isolation (figure 34a). The pattern for SOX17 did not reflect these 
observations; here, SOX17 is hypomethylated in both the controls and the D-
treated organoids, with no meaningful difference between the two. However, 
PGE2 treated organoids show an increase of 12.2% (p < 0.0001) of the SOX17 
promoter after four weeks, which is attenuated in in combination with vitamin D 
(figure 34b). These observations are encouraging in that they suggest a direct 
effect of both PGE2 and vitamin D on WA promoter DNAm, but questions are 
raised regarding the mechanism of the effect, which appears gene-specific in this 
instance. It is strongly recommended to attempt replication of these 
observations in other murine organoids. 
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Gene transcripts were quantified for several genes of interest, although at this 
time no validated Q-rt-PCR assay were available for murine SOX17 or DKK1. 
Curiously, DNMT1 and 3b are both suppressed by PGE2, an effect attenuated in 
combination with vitamin D, consistent with the observations regarding DNAm 
(figure 34c and d). Paradoxically, vitamin D induces LGR5 transcription, implying 
a promotion of the stem-like phenotype, but also induced MUC2, suggesting a 
move towards a more differentiated phenotype (figure 34 e and f). This may be 
explained as vitamin D simply exerting normal homeostatic mechanisms in these 
cells relative to the vitamin D-deprived controls, i.e. this is nothing more than 
media containing vitamin D allowing for routine cell metabolism. CyclinD1 was 
interrogated next as an indicator of TCF-LEF activity; vitamin D suppressed 
CYCD1 in isolation and in combination, supporting the observations regarding 
vitamin D’s status as an anti-proliferative. PGE2 did not affect CYCD1 
transcription (figure 34 g and h).  
Finally, organoids were cultured from an 11 week old C57BL/6 mouse 
transfected via tail vein injection to conditionally over-express TNFα in liver 
hepatocytes. Elevated serum TNFα in vivo was confirmed via monoclonal TNFα 
ELISA (figure 34a). These organoids were cultured in triplicate for four weeks +/- 
vitamin D (1nM). D-treated cultures exhibited a decrease in the ratio of cystic 
spheroids to organoids with budding crypt like structures (figure 35b). This was 
attributable to increased organoid count (of any kind) in control wells, consistent 
both with vitamin D promoting differentiation and inhibiting proliferation. The 
ratio of cysts to differentiated organoids was estimated by light microscopy using 
image J. SOX17 methylation status was determined by CoBRA. Vehicle controls 
show a similar level of hypermethylation to the level effected by PGE2 previously 
(23.1% in vivo TNFα versus 18.1% in vitro PGE2). Encouragingly, treatment with 
vitamin D for four weeks shows a reduction in promoter methylation to 8.0% 
(figure 35c) p = 0.0334). Again a caveat must be observed that baseline 
methylation was not interrogated, making it impossible determine if the effect 
was to ameliorate, or attenuate in this instance. 
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Figure 34 – Healthy murine organoids cultured +/- vitamin D (1nM) and +/- PGE2 (x10 physiological). A) 
Vitamin D reduces DKK1 promoter methylation. There was an insignificant increase in PGE treated 
organoids, which was attenuated in combination. B) Similarly, PGE2 promotes hypermethylation of 
SOX17, attenuated in combination. C and D) surprisingly, in light of PGE2 promoting de novo DNAm, 
PGE2 inhibits DNMTs 1 and 3b, which vitamin D attenuates in combination. DNMT3b transcripts are 
relatively low in these organoids. E and F) Paradoxically, both LGR5 and MUC2 are induced by vitamin D, 
speculated to exert opposing effects on cell phenotype, both towards and away from a differentiated 
phenotype. However, it is true that goblet cells populate the transit amplifying compartment, although 
LGR5 shouldn’t be present here. G) Cyclin D1 transcripts are relatively high in these actively proliferating 
organoids. Vitamin D inhibits CYCD1 in isolation and in combination, supporting an antiproliferative 
effect. It is not possible to assign the effect to hypomethylation of DKK1 or SOX17 without further 
conditional experiments. H) Vitamin D induces LEF1, which seems counterintuitive, although there are 
reports that LEF1 targets promote differentiation of epidermal stem cells. n=3, * p<0.05, ** p< 0.01, data 
represent mean +/- SEM 
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Figure 35 – Organoids from a systemically inflamed mouse transfected to over-express TNFα. A) Serum 
TNFα was determined by monoclonal ELISA for non-transfected mice from the same cohort. Serum 
TNFα is elevated in the transfected model prior to dissection. B) The ration of differentiated organoids is 
increased relative to spheroid cysts in D-treated samples. C) Culture for one month with 1nM vitamin D 
reduced DNAm in the SOX17 promoter, consistent with previous effects in un-inflamed models. D) 
Spheroid cyst in control wells E) differentiated organoids showing multiple branching crypt-like structures 
F) Control wells contained greater numbers of spheroid in comparison to G) D-treated wells where yield 
was depressed. Thick-walled differentiated organoids were more frequently observed in these wells.   
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Discussion 
 
Vitamin D is a potent anti-inflammatory and promotes immune cell 
differentiation, mediating cytokine secretion and resolution of transient 
inflammation356. Pericryptal myofibroblasts contribute factors that inform crypt 
niche architecture and ECM, and have a modest role in secreted paracrine 
signalling that regulates Wnt-mediated stem cell turn-over and crypt 
homeostasis107. Chronic inflammation in the colonic mucosa is well described in 
IBD and associated with increased risk of transformation and aberrant age-
related DNA methylation, silencing autocrine Wnt antagonists in crypt stem cells 
via promoter hypermethylation170. Furthermore, sub-epithelial myofibroblasts in 
the oesophagus were recently demonstrated to secrete pro-inflammatory 
cytokines, including IL6, in response to stressors via NFκB activation357. In this 
context it was sought to establish if TNFα, routinely found to be over-expressed 
in inflamed mucosal lesions358, might precipitate a modified secretome in 
pericryptal myofibroblasts lines propagated from uninvolved mucosa of 
colorectal cancer bowel resections. Furthermore, it was set out to investigate if 
the secretory profile of TNFα-stimulated myofibroblasts impacted on DNA 
methylation patterns in case-matched colonoids, propagated from the same 
samples, and the ability of vitamin D to mediate any effects. 
Tumour necrosis factor alpha is a key mediator of transient inflammation and 
repair in the colonic mucosae, with a well-documented role in IBD pathogenesis. 
So pivotal is TNFα signalling in instigating and maintaining IBD, that anti-TNFα 
chemotherapy that inhibits TNFα-mediated inflammation, is indicated in Crohn’s 
disease and Ulcerative Colitis, inducing remission  even in severe refractory 
disease states (TNFα-sequestering agent, Infliximab)359. At the paracrine level, 
TNFα-receptor signalling activates phosphorylation of IKKb complexes, nuclear 
translocation, and transcription of NFκB target genes via response element 
binding sites. COX2 possess one such site, and is demonstrated to be 
upregulated via NFκB activation in TNFα-stimulated gingival fibroblasts349. 
Furthermore, COX2 modulation via inflammatory stimuli is widely accepted to 
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promote PGE2 secretion, with pathological implications for homeostasis in the 
colonic mucosa343.  
An aetiological role for COX/prostaglandins in bowel disease is evidenced by a 
vast body of data that shows long-term inhibition of both COX1 (constituitive) 
and COX2 (inducible) by aspirin, that favourably influences incidence and 
mortality of CRC360. Vitamin D and analogues have been shown to inhibit COX2 
in several macrophage models346,347, although evidence of COX2 inhibition by 
vitamin D specifically in intestinal myofibroblasts is absent from the literature. 
Our findings in four validated primary intestinal myofibroblast lines support the 
first observation; that TNFα promotes PGE2 secretion via induction of COX2, 
and this is consistent with reports that both TNFα and IL1β modulate secreted 
PGE2 in colonic fibroblasts361. PGE2 concentration in supernatants correlates 
well with TNFα-induced COX2 transcripts, raising the possibility that inhibition 
of TNFα-mediated COX2 transcription in intestinal myofibroblasts (by any 
means) might lower PGE2 concentrations in the crypt niche to promote bowel 
health  
Regarding vitamin D’s role, COX2 was only suppressed in embryonic InMyoFib. 
The trend was evident in case 13 MFBs, whose base line level of COX2 
transcription was most similar to the embryonic line, but vitamin D did not 
suppress COX2 in the other two lines exhibiting relatively high levels of COX2 
in the basal state. It may be that 1nM vitamin D for 72 hours in this instance 
wasn’t powerful enough to redress the relatively high level of COX2 
transcription, and proper dose/time dependency should be investigated in this 
respect – COX2 may in fact be suppressed by vitamin D at an earlier time point, 
as assessed in the test case. Importantly however, vitamin D did inhibit PGE2 
secretion in all four lines, suggestive of a non-canonical or indirect mode of 
action, whereby vitamin D interferes with the secretory pathway downstream of 
COX2 regulation; this has in fact been previously documented in lung fibroblasts, 
where vitamin D reduces PGE2 secretion, but not COX2 transcription. Instead, 
vitamin D mediates degradation of PGE2 via induction of HPDG362, and 
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verification of this alternative mechanism warrants investigation in our primary 
lines. 
Myofibroblast lines were recovered from the uninvolved mucosa of colorectal 
cancer resection specimens. Given that these epithelia have already 
demonstrated a propensity to transformation (field cancerisation effects), and the 
role of CAFs in promoting tumourigenesis, it is rational to speculate that these 
pericryptal myofibroblasts may already have adopted a modified phenotype, 
relative to counterparts not associated with a cancer-prone epithelium 
(embryonic InMyoFib for example). InMyoFib supernatants were not 
characterised, however, relative to case 11 and 12, exhibit a COX2- and PGE2-
low profile at base line, similar to case 13, and these respond as predicted to 
vitamin D treatment. 
The base line levels of both COX2 transcripts and PGE2 secretion prompted a 
hypothesis that COX2-high MFBs represent a distinct phenotype to COX2-low 
MFBs with regards their inflammatory/secretory status. However a caveat must 
be observed regarding PGE quantitation; although supernatants were collected 
from 80%+ confluent wells following treatment, it is within the realms of 
possibility that the designation of PGE2-high secretion at base line - determined 
by ELISA - is an artefact of unspecified differences in monolayer density. 
Normalising the data to the control accounts for this discrepancy in the pooled 
data, but interpretation of individual levels of PGE2 secretion should take this 
into account. Thus, data are reported as pg/mL of conditioned media, and not 
pg/number of cells/24 hours. However, the synchronous COX2-high status in 
these two lines implies that this cautionary note may in fact be redundant, as 
transcription results are normalised twice during Q-rt-PCR protocols.  
Prior to any stimulation, mass spec proteomics was employed to characterise the 
base line secretory profile of disease-associated myofibroblasts. Pathway analysis 
of the 124 commonly secreted factors showed top hits including ECM and 
collagen degradation. This is consistent with findings in tumour stromal CAFs in 
cervical, lung, and colorectal cancers289,363,364, although in our case the MFBs are 
not true CAFs, and so may represent a transitory phenotype in the uninvolved 
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but predisposed stroma. On average 15.9% of all secreted proteins were 
associated with gene ontology for regulation of immune function, supportive of a 
role for MFBs in mediation of inflammation in the intestinal crypt niche365. 
Key to our informing hypothesis, vitamin D mediated a significant reduction of 
one secreted protein from all three MFB lines – Laminin 2 (LAMA2). Cytokine 
mediated dysregulation of laminin class protein transcription contributes to 
impaired barrier integrity in IBD366, and specifically, LAMA2 is reported once in 
the literature to exhibit a 4.5-fold increase in expression in UC mucosae relative 
to healthy controls (although it’s cellular origin was not identified)367. Further 
investigation is indicated to establish if this observation is both ubiquitous in 
inflamed mucosal myofibroblasts, and aetiological in loss of epithelial 
homeostasis; firstly, validation by Western blot and ELISA, secondly, 
recapitulation in other intestinal fibroblasts or CAF lines, and finally, elucidation 
of the effects of both recombinant LAMA2 and conditional LAMA2 knock-down 
on DNAm in intestinal  epithelial models The immune response to LAMA2 in 
tissue-resident immune-cells should also be investigated.  
The concept of dual phenotypes is supported by a greater diversity of proteins 
identified in COX2-high MFB supernatants that included pernicious soluble 
factors not detected in COX2-low MFB supernatant; IL6, SERPINE1, PGD2, LIF, 
and TSG6. Secreted IL6 is consistent with previous reports that aSMA+ve 
tumour stromal fibroblasts encourage inflammation and angiogenesis via IL6 
secretion299. The role of IL6 in IBD driven carcinogenesis is reported to 
attenuate apoptotic pathways via induction of BCL-XL368. Our data suggest that 
the tumour promoting effects of IL6, secreted by MFBs in the niche, may be 
exacerbated by TNFα. The serine protease inhibitor SERPINE1 is over expressed 
in epithelium of UC patients, and associated with microsatellite instability in 
colorectal cancer369,370, however ours is the first indication of a further non-
epithelial source of SEPRINE1. Prostaglandin D2 synthase is another COX2-
mediated protein involved in pathological prostaglandin metabolism, activated in 
Crohns disease371. Finally  TNFα-stimulated gene six is recognised to mediate an 
anti-inflammatory effect372, and it’s presence here may contribute to negative 
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feedback in response to the underlying inflamed phenotype, evidenced by 
resolution of intestinal inflammation in mice injected with TSG6-secreting 
mesenchymal stem cells that localise to the peritoneum373. In both cases, 
SERPINE1 and PGD2 were inhibited by vitamin D, but the trend was not 
statistically significant. IL6 and TSG6 were not affected by vitamin D. All four 
proteins exhibit increased total spectra counts following TNFα stimulation of 
COX2-high MFBs.  
The increase of secreted IL6 was validated by Q-rt-PCR, although the mass spec 
secretomic approach is considered qualitative only and so further validation of 
these findings should be performed by ELISA and/or Western blot. It would also 
be pertinent to explore the COX2-high hypothesis in MFBs in non-transformed, 
adenomatous, and carcinogenic mucosa alike, to determine if transition from 
healthy pericryptal myofibroblast to disease-associated myofibroblast is linear 
and/or associated with initiation and tumourigenesis. 
It is of note that none of the previously discussed growth factors were identified 
in MFB supernatants, and less than 2% of identified proteins were associated with 
GO term ‘growth’. This suggests either that the ability of MFBs to contribute 
those growth factors specifically used for organoids culture (RSPO1, JAG1, 
Wnt3a) has been over stated here and elsewhere226, or that they fall beneath 
detectable levels in supernatants via the mass spec approach. This observation 
lends support to the alternative hypothesis that the regulation of GF 
transcription observed in MFBs (mediated by TGFβ1, TNFα and vitamin D) acts 
in an autocrine fashion to regulate MFB proliferation, not in a paracrine fashion 
to drive stem cell turn-over as previously hypothesised (paracrine effects being 
mediate by uncharacterised esoteric factors). 
Data pertaining to DNAm profiles modified by inflamed MFB supernatants in 
case matched organoids must be considered with extreme caution; it was 
originally intended that the three propagated human colonic organoid lines would 
comprise three biological replicates for statistical comparison on the array – not 
only did two lines fail to yield sufficient DNA for analysis, stochastic variation 
between the lines in gene-specific DNAm (possibly established in the original 
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epithelia due to field effects) precluded significance – a finding not unanticipated 
given the difference between participants chronological age (45yo verses 65yo). 
This presents a fundamental flaw in the methodology for determining statistical 
significance; in retrospect, increasing the sample pool included on the array 
would better power analyses to reveal impacted genes. 
However, it is encouraging that identified genes have been documented 
elsewhere in transformed epithelia; Collagen and calcium-binding EGF domains 1 
(CCBE1) may poses a single CpG hypermethylated by inflamed supernatants that 
was attenuated by vitamin D-treated MFB supernatants in both case 11 and 12. In 
ovarian cancers, CCBE1 is poorly expressed compared to healthy cells. 
Knockdown of CCBE1 in ovarian cancer cells promotes migration and invasion, 
and the gene’s promoter is frequently found to be hypermethylated in these 
cancers353. Similarly, the transcription factor POU3F4, required for Wnt-
mediated proliferation of neural stem cells374,375, experienced hypermethylation of 
a single CpG in organoids treated with inflamed MFB supernatants, an effect 
diminished with supernatants from the combined treatment. POU3F4 is 
hypermethylated in 55% of non-small cell lung cancers; if our results can be 
verified, chronic inflammation perpetuated by COX2-high MFBs may have 
implications for Wnt-mediated regulation of stem cell turnover in the colon.  
With respect to findings of Tapp et al, that underpin this thesis hypothesis, it is 
encouraging that DNAm patterns in a number of genes identified in their paper 
appear to show a similar induction of hypermethylation here in response to 
inflamed MFB supernatants, although the trend was not significant for reasons 
outlined. MYOD1 is of particular interest because that was the gene with the 
most significant correlation with vitamin D status in their paper. Furthermore, 
suppression of DNMT3a and 3b by both TNFα-inflamed and vitamin d-quenched 
supernatants from all three MFB lines in matched organoids is in keeping with the 
modest but highly significant reduction in average gene promoter methylation 
status experience by case 11 organoids after one month in culture. Although 
DNMT3b typically mediates de novo DNAm, if control organoids are prone to 
hypermethylation (CIMP), the reduction observed relative to controls could be a 
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passive consequence of inhibited DNMT3b activity, that means controls advance 
their methylation over the 30 days, rather than stimulated supernatants 
ameliorating it. The case for a predisposition to DNA hypermethylation (CIMP-
high) is supported by the observation that the average methylation status of the 
panel of Wnt antagonists outlined was 30.1% +/- 7.5% in both cases at base line, 
and only three were hypo-methylated according to our definition. Furthermore, 
CIMP-high typically presents in the proximal colon376 - both samples were 
recovered 20cm proximal to recto-sigmoid tumours. 
Finally, TET1 was silenced in all three organoid lines, consistent with reports 
elsewhere that TET1 down-regulation is an early finding in transformation. TET1 
mediates its tumour suppressor effects by stereochemical association with gene 
promoters, inhibiting aberrant DNA hypermethylation at those sites363. Loss of 
TET1 in these organoids supports the CIMP-high hypothesis. 
Lastly, a short note on vitamin D sensitivity; we demonstrate an anticipated dose 
dependent increase in Cyp24a1 in response to exogenous vitamin D in the three 
organoid lines. However, we also saw a significant induction of this vitamin D-
deactivating enzyme in case matched organoids treated with vehicle-stimulated 
MFB supernatants – an effect attenuated by treatment with vitamin D; this 
suggests that disease-associated MFBs such as these might reduce epithelial 
sensitivity to vitamin D’s antiproliferative effects by encouraging its catabolism – 
a novel finding not reported previously, but in keeping with observations that 
Cyp24a1 is routinely over-expressed in poorly differentiated CRC, and that 
conditional silencing potentiates vitamin D’s anti-tumourigenic properties in 
CaCO2 cells377,378 
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Summary 
 
Primary myofibroblasts from the uninvolved mucosa of colorectal cancer 
resections show an inflamed secretory profile at base line hypothesised to 
increase inflammatory signalling in the stem cell niche. Vitamin D partially 
attenuates, and TNFα promotes the secretory profile, and a COX2-high 
phenotype is proposed to explain differences between primary lines, at base line 
and in response to stimulation. It is not verified that an altered MFB secretome 
manifests aberrant DNA hypermethylation in epithelial Wnt antagonists, 
however observational data do not exclude the possibility. Enticingly, MFB 
supernatants are able to regulate methyltransferase transcription in matched 
epithelial cells, and the altered secretome may even pathologically promote 
vitamin D insensitivity of the epithelia via inactivation by Cyp24a1 – a finding that 
warrants further investigation. Vitamin D treated MFB supernatants resolved the 
induction of Cyp24a1, contributing another previously unrecognised role for 
vitamin D in promoting bowel health via indirectly increasing epithelial sensitivity 
to vitamin D’s antiproliferative effects.  
Experiments conducted in murine colonoids give an indication that PGE2 
promotes hypermethylation of WAs in a phenotype or gene specific fashion. It is 
highly recommended that attempts are made to recapitulate these findings in 
other epithelial models.  
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Chapter 6 
 
PHYSIOLOGICAL VITAMIN EXERTS ANTI-CANCER 
EFFECTS IN CACO2 CELLS VIA A MODIFIED 
METHYLOME  
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Preface to the work 
The novel finding that vitamin D ameliorates SOX17 hypermethylation in 
previously inflamed tissues, raises the possibility that vitamin D might also 
possess the ability to resolve pathological patterns of acquired DNAm in 
transformed cells. It is well established that vitamin D status predicts the clinical 
course of CRC following diagnosis, and its actions as an anti-proliferative are 
comprehensively documented in vitro for a variety colorectal cancer cell lines. 
Specifically vitamin D inhibits proliferation via down regulation of Wnt signalling, 
and these effects are mediated in part by induction of tumour suppressors that 
antagonise Wnt379. We considered if these effects could be consequent to 
demethylation of promoter CGI mediated by vitamin D. 
Preliminary experiments with four CRC cell lines (DLD1, HT29, HCT116, and 
CaCO2, selected for their genetic and epigenetic diversity, and differing degrees 
of differentiation), suggested that under optimised conditions vitamin D might be 
able to redress acquired DNAm (figure 36a-d). 
The CaCO2 cell line became the focus of longer-term incubations due to 
anomalous results from a basic WST1 assay used to determine time/dose effects 
of treatment; cells cultured from high passage number stocks (passage 30 
onwards) demonstrate phenotypic insensitivity to vitamin D in this respect. 
Surprisingly, subsequent Q-rt-PCR experiments, for which CaCO2 cells were 
incorporated as a negative control, showed that vitamin D also regulated 
transcription in these cells. The transcriptionally responsive cells were re-
interrogated by WST1 assay, which suggested that, in cells with lower passage 
numbers (under 10), vitamin D’s anti-proliferative effects remained intact. This 
raised the possibility that in vitro ‘ageing’ - specifically forced mitosis through 
repetitive passage (itself a stressful procedure for cells to endure) - might 
accelerate ongoing aberrant DNAm events across the methylome, driving 
progression and resistance to vitamin D. 
As a proof of concept, we aged CaCO2 cells for ten weeks under routine 
conditions, and then stimulated them with supra-physiological vitamin D to 
investigate if extended culture effected C-MYC transcription (as a measure of 
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Wnt activity) and vitamin D sensitivity (figure 36 e and f). Encouragingly these 
experiments suggested that CaCO2 cells undergo transcriptional changes in the 
absence of vitamin D and establishes vitamin D insensitivity at higher passage 
number. We speculated that transcriptional variability could be due to ongoing 
aberrant methylation events typical in transformed epithelial cells, and set about 
characterising the effects of in vitro ‘ageing’ and vitamin D sufficiency on the 
methylome of colorectal cancer cell lines. 
Figure 36 – Preliminary experiments with cancer cell lines. n=3, *p<0.05, **p<0.01. Data represent mean 
+/-SEM. A-D) DLD1 and CaCO2 cells were cultured for 6 days +/- 100nM vitamin D (supra-physiological). 
Bisulphite modified DNA was interrogated by CoBRA, and show modest, non-significant trends towards 
demethylation for APC, DKK1, SFRP2 and SFRP5, suggesting hypomethylation might be achieved under 
optimised conditions E) Vitamin D (100nM, 4 hours) suppresses C-MYC transcription in ‘young’ CaCO2 
cells, but not in the same cells after ten passages, suggesting that in vitro ageing precipitates vitamin D 
insensitivity. F) This is supported by impaired suppression of VDR, a vitamin D responsive gene, in ‘aged’ 
cells. NB, aged cells in the un-primed state increase their sensitivity to vitamin D by increasing VDR 
transcription over time. 
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Abstract 
Vitamin D status is associated with relative risk for bowel cancer. Furthermore, 
serum vitamin D at presentation is associated with survival and CRC-associated 
morbidity. In vitro vitamin D is shown to potentiate chemotherapies and 
independently inhibit constitutional activation of Wnt, via multi-level repression 
of autocrine signalling. Antagonists of the Wnt pathway are frequently inactivated 
in CRC via aberrant promoter methylation, and vitamin D status is inversely 
associated with rates of aberrant age-related DNAm. De novo expression of 
epigenetically inactivated tumour suppressors by vitamin D has been documented 
in other epithelial cancers. Furthermore demethylating agents such as azacytidine 
and decitabine are indicated in myelodysplastic disease, inhibiting DNMT1 activity 
that precipitates a loss of CGI methylation and reconstitution of epigenetically 
silenced genes. It was speculated that vitamin D sufficiency might ameliorate 
aberrant DNA methylation patterns in CRC cell lines, and set about 
characterising the effects of vitamin D sufficiency on the phenotype and 
methylome of CRC cell lines. 
CaCO2 and DLD1 cells were cultured under routine conditions for ten weeks 
+/- 500pM vitamin D (~5x biological sufficiency). After treatment, a four day 
wash-out period was observed to mitigate for transcriptional effects of vitamin 
D. DNA was interrogated by Illumina 450K methylation bead chip array, and 
reveals genome-wide modifications to 5-methyl-cytosine patterns synchronous 
to induction of DNMT1 and 3b. In CaCO2 cells this was associated with 
inhibited proliferation, viability, RPS6Ka3 transcription, and ERK1 and 2 
phosphorylation. Sufficiency did not ameliorate DNAm in the promoter regions 
of genes associated with aberrant DNAm in colorectal cancer (Wnt antagonists 
and CIMP+ genes), although supra-physiological vitamin D reduced SFRP5 
methylation status in DLD1 cells, with trends in other Wnt antagonists. Aberrant 
DNAm was observed to increase in control cells from both lines, termed in vitro 
ageing. 
Taken together, our data suggest that vitamin D improves CRC prognosis via 
epigenetic modifications that inhibit proliferation.  
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Introduction 
Risk of neoplasia in any tissue typically increases with age, and the paradigm holds 
for colorectal cancer, with incidence peaking at 1 per 23, in the 7th decade of life 
onwards380. In  Europe, this  demographic is the fastest growing, with the disease 
representing the 3rd  most prevalent cancer after prostate and lung cancer for 
men, and breast and lung cancer for women381. Treatment regimen, prognosis, 
and mortality depend largely upon factors that describe the tumour at clinical 
presentation. Tumours are staged according to the Duke’s system which 
considers the size and extent of the tumour, the involvement of mesenteric 
lymph nodes or vasculature (which forebodes metastasis), and sites of distant 
metastasis (typically the liver, the ultimate destination for enteric blood and 
lymph). Duke’s staging is a strong predictor of 5 year survival, being  93.2% and 
6.6%  for stage 1 tumours verses stage 4 tumours, respectively382. 
Several histological biomarkers are also used to predict the clinical course of the 
disease, pertaining to critical mutations or indicators of cancer phenotype (Ki67, 
EGFR, VEGF, and P53), with over-expression  associated with an ~50% reduction 
in five year survival383. Other independent biological predictors of prognosis 
include lymphocytic infiltrate, microsatellite instability (MSI), chromosomal 
instability (CIN), and importantly, established aberrant DNA methylation 
patterns384.  
Pathogenic DNAm is reported in virtually every neoplastic tissue, and three 
forms are commonly reported in CRC; age-related gene specific hypermethylation, 
age-related global hypomethylation (both preceding transformation, but present 
throughout), and CG island methylator phenotype (subsequent to 
transformation), reported in up to 25% of sporadic CRCs385. The methylator 
phenotype describes tumours with wide-spread non-specific gene promoter 
hypermethylation in advancing tumours. Associations are noted with MSI, kRAS 
and bRAF mutations, maintained p53 functionality, proximal location, female sex, 
and older age386. The association of CIMP with MSI is an important one, as it is 
thought that hypermethylation of MLH1, a DNA mismatch repair protein 
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invariably silenced in CIMP tumours, is the driving aberration that precipitates 
MSI387. 
Importantly, MLH1 methylation is independent of the aforementioned age-
related hypermethylation of tumour-suppressors, and as such defines the CIMP 
phenotype with a few other genes not affected in an age-dependent fashion 
(CDKN2A, RUNX3)388  
Regardless, all three forms of aberrant DNAm are associated with rate of 
recurrence, 5 year survival, and for CIMP+ve tumours, their response to 
chemotherapy198,389,390. Presumably, resolution of aberrant DNAm patterns in 
cancer cells could potentiate a regain of control over constitutional pathway 
activation driving uncontrolled proliferation, preferable to chemotherapies that 
non-specifically block proliferation or induce apoptosis. After all, due to their 
dynamic nature, epigenetic modifications are potentially reversible, and unlike 
mutations, DNAm must be actively maintained during mitosis, making the 
process an attractive target. These observations have fuelled research into the 
use of DNA methyltransferase inhibitors, mainly cytidine analogues like 5-aza 
cytidine and 5-aza-2 deoxy-cytidine (decitabine), to induce passive 
hypomethylation at sites of aberrant CGI methylation over successive 
generations391. These are shown to be effective at promoting demethylation in 
colorectal cancer cell lines in vitro, potentiating the effects of 
chemotherapeutics392, but are not currently indicated for solid gastrointestinal 
tumours due to toxicity at the effective dose, and non-specific effects that are as 
likely to reconstitute an aberrantly silenced Wnt tumour suppressor, as they are 
to re-activate a necessarily silenced oncogene393,394. 
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It has also been observed that serum vitamin D sufficiency is not only associated 
with reduced rate of cancer incidence, but favourably predicts prognosis too395; 
higher pre-diagnosis serum vitamin D is associated with a significant 
improvement in overall survival396, which is supported by observational studies 
demonstrating improved prognosis when CRC is diagnosed at the end of 
summer, when serum vitamin D levels peak, compared with winter 
presentation397. The relationship is maintained post-operatively, where serum D 
correlates with survival for stage 1 through 3 cancers. Here the authors also 
identify an interaction of recurrence with VDR polymorphisms, suggestive of a 
causative mechanism by which vitamin D influences the course of the disease398. 
Even in stage 4 metastatic CRC, serum vitamin D sufficiency still appears to 
enhance survival399. Conversely, impaired vitamin D metabolism in epithelial 
cancers is a negative prognostic indicator; over-expression of vitamin D-
deactivating enzyme Cyp24a1 correlates with invasive depth, lymph node 
metastasis, reduced survival, and increased recurrence400. 
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Vitamin D exerts a variety of anti-proliferative and pro-apoptotic effects on 
colorectal cancer cells in vitro, which are speculated to be in part due to vitamin 
D modulating aberrant DNA methylation patterns60. For example, vitamin D is 
documented to induce DKK1 and inhibit DKK4 transcription in SW480 CRC 
cells, simultaneously orchestrating nuclear export of BCAT via it’s interaction 
with VDR, with consequent repression of TCF targets379. Vitamin D also down-
regulates Wnt signalling via induction of ECAD in CRC in vitro, which effects 
BCAT stabilisation and differentiation91. There are isolated reports that vitamin 
D mechanistically reconstitutes expression of hyper-methylated ECAD in several 
VDR-competent breast cancer cell lines, promoting differentiation. The effect is 
recapitulated by treatment with demethylating agent 5AZA, and synergistic when 
the two treatments are combined. The authors report synchronous 
demethylation, induction, and differentiation, that is abrogated by conditional 
interference with VDR94. Similarly, vitamin D instigates demethylation and de novo 
transcription of epigenetically silenced PDLIM2, again in breast cancer cells. The 
protein functions in a similar way to ECAD, promoting cell-cell adhesion, and 
inhibiting migration401. Tapp et al report an apparent protective effect against de 
novo DNAm in macroscopically normal mucosa, but to date the ability of vitamin 
D to reverse established aberrant DNAm in transformed cells has yet to be 
investigated. 
CaCO2 and DLD1 colorectal cancer cells were cultured for 10 weeks under 
routine conditions, with and without vitamin D at a physiologically relevant 
concentration. After a wash out period, bisulphite modified DNA was 
interrogated by Illumina 450K DNA methylation array, to identify differentially 
methylated regions governing gene transcription manifested by vitamin D. 
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Methods 
Cell culture 
For the main experiments, colorectal cancer cell lines CaCO2, DLD1, HCT116 
and HT29 (form ATCC) were cultured under routine conditions detailed in 
General Methods. Passage number at the start of the extended culture period 
was 2 for CaCO2 cells and 9 for DLD1 cells. To establish a single lineage, cells 
were cultured to 80% confluence in a T75 flask, which was split by routine 
passage into six T25 flasks; three were treated with ethanol vehicle, and the 
other three received 500pM vitamin D (Tocris) final concentration (biological 
triplicates). Media was refreshed every 2-3 days. 
Flasks were maintained for ten weeks, passaged once per week with a 1:10 split. 
Cell pellets at passage 2, 4, 6, 8, and 10 were rinsed, protease inhibitors added, 
and snap frozen on dry ice for subsequent RNA extraction and Q-rt-PCR 
(methods detailed previously). At the end of the treatment regimen, cells were 
seeded into new T25 flasks for a wash out period of 96 hours, which were 
washed with PBS every 24 hours and fresh media applied. Alternatively, cells 
were seeded at an appropriate density for WST1 assay on the fourth day to 
determine proliferation and viability (trypan blue). Washed-out cells from flasks 
were either collected for bisulphate modification/DNA interrogation, or whole-
cell extract protein blots, probing for BCAT and ERK phosphorylation. 
 
Figure 37 – Graphical methods for CRC cell line in vitro ‘ageing’ and vitamin D sufficiency. Cells were 
passaged once per week by routine methods and fresh treatment/media applied every 2-3 days for the 
duration of the experiment. 
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Infinium HumanMethylation450 bead chip array 
DNA samples were prepared by phenol-chloroform extraction, rinsed with 70% 
ethanol, and resuspended in nuclease-free water. Concentration was determined 
from Nano-drop UV spectroscopy, and 500ng dispatched on dry ice for analysis 
using the RnBeads plugin for ‘R’ console as previously described. Data represent 
the mean of the three biological replicates for each line and treatment. 
Western blot 
Whole-cell protein extracts were prepared from one sample of each ‘aged’ 
washed-out CaCO2 treatment as previously described. Technical triplicates of 
20ug protein were run by PAGE on a graduated density gel, and probed for total 
ERK1 and total ERK2 (NEB 9102, 1:2000 in 5% BSA), and phosphoERK1 and 
phosphoERK2 (NEB 4370 1:2000 in 5% BSA). Band intensity was calculated using 
ImageJ, and the normalised ratio of pERK : tERK reported as the mean of the 3 
samples +/- the standard error.  
Q-rt-PCR 
RNA was extracted from washed-out samples and 500ng processed to cDNA as 
previously described. The primer sets used are detailed in appendix 6). Biological 
replicates were run in technical duplicate and CT values normalised to GAPDH. 
Data represent the mean +/- the standard error of the relative transcripts 
(determined by the delta CT method), and a non-parametric students T-test 
applied to the normalised CT values to determine significance. 
CoBRA assays for Wnt antagonists 
To reduce standard errors precluding significance for minor changes in WA 
promoter DNAm, 12 rather than 3 biological replicates of DLD1 cells were 
cultured for six days +/- 100nM vitamin D. The harvested DNA was bisulphite 
modified, amplified by bench-top PCR, and digested by 5mC-specfic restriction 
enzymes using the protocols for APC, DKK1, SFRP1, 2 and 5 in appendix 5. 
LINE1 was interrogated independently by QMSP as detailed in the general 
methods.  
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WST1 assay 
The WST1 Assay (Roche) was performed in 96 well plates as outlined previously 
by the manufacturer’s instructions. Cells were seeded at an appropriate density 
to ensure interrogation during the log-growth phase at either 2, 4, or 6 days post 
vitamin D treatment. Six technical replicates were used to determine statistical 
significance. 
Pathways analysis 
Lists of Ensembl codes for differentially methylated genes mapping to functional 
proteins, were uploaded to www.inateDB.com to determine which biological 
pathways  and gene ontology terms that were significantly over-represented 
(represented more than expected by chance) in the lists. InnateDB incorporates 
pathway annotation from major public databases including KEGG, Reactome, 
NetPath, INOH, BioCarta and PID and is thus one of the most comprehensive 
sources of pathways available. A Gene Ontology (GO) over-representation 
analysis (ORA) examined the lists for the occurrence of GO annotation terms 
which are more prevalent in the dataset than expected by chance. For analysis 
and visualisation, the recommended hypergeometric algorithm with Benjamini 
Hochberg correction was selected.  
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Results 
 
Effects of vitamin D in colorectal cancer cell lines 
Vitamin D reduces proliferation of colorectal cancer cell lines in a dose-
dependent fashion 
Colorectal cancer cell lines CaCO2, DLD1, HCT116 and HT29 were selected 
for their diverse mutational and epigenetic profiles, to investigate if vitamin D’s 
well established antiproliferative effects were recapitulated in these lines. 
Proliferation was interrogated by tetrazolium salt reduction assay (WST1) in 
replicates treated with either ethanol vehicle at the highest concentration, or 
increasing doses of vitamin D (10, 100 and 1000nM respectively) for 6 days. The 
concentrations used represent the supra-physiological range employed by others 
against these lines99,402.  Data are reported as the mean +/- the standard error, 
normalised to the control. 
After six days, all four cell lines exhibit dose-dependent inhibition of proliferation 
(figure 38). The DLD1 and HT29 lines show enhanced vitamin D sensitivity at the 
lowest concentration, not apparent in CaCO2 and HCT lines. Ultimately, the 
assay is a reflection of the ratio of actively proliferating cells, and while cells are 
seeded at identical densities, vitamin D is also reported to promote apoptosis, 
therefore it is not possible to determine whether impaired proliferation or 
impaired viability reduces cell numbers. In preliminary experiments, vitamin D 
was observed to induce transcription of FAS ligand and caspases 3 and 7 (cell line 
dependent), while sporadically suppressing FOS/MYC/JUN at various time points 
(data not shown), consistent with vitamin D acting via multiple phenotype-
specific pathways to inhibit tumour cell growth in vitro403.  
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Figure 38 – Anti-proliferative effect of vitamin D in CRC cell lines. Vitamin D demonstrates a dose-
dependent reduction in proliferation as determined by WST1 assay. Vitamin D sensitivity in DLD1 and 
HT29 cells appears to be greater than in CaCO2 and HCT116 cells. Cells were treated for six days, with 
media and treatments refreshed every 24 hours in respect of vitamin D’s relatively short biological half-
life. Data represent the mean of six technical replicates +/- the standard error, normalised to the control, 
for each line investigated. 
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Vitamin D effects SFRP5 promoter demethylation, increases LINE1 
methylation, and is associated with sustained suppression of DNMT3b 
transcripts. 
Previously, a modest, non-significant trend towards SFRP5 promoter 
demethylation was observed in DLD1 cells, treated for six days with 100nM 
vitamin D, and these cells show increased sensitivity to vitamin D over other 
lines. It was hypothesised that the methylation effect was true, but too weak to 
attain statistical significance due to error associated with insufficient replicates. 
Consequently the number of biological replicates was increased from 3 to 12, 
increasing the total number of data points for statistical comparison (non-
parametric students T-test) from 9 to 36. Again, SFRP1 and 2 show an 
insignificant trend towards hypomethylation, but SFRP5, which showed the 
biggest response previously, experiences significant demethylation at this 
concentration over 6 days. The effect was concomitant to a modest but 
significant increase in global DNAm, as determined for LINE1 (figure 39a).  
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Synchronous to these experiments, DLD1 cells were also cultured with 100nM 
vitamin D and RNA harvested for Q-rt-PCR, to investigate DNMT3b 
transcription. Cells were harvested every 24 hours during the experimental 
protocol, and exhibit suppression of DNMT3b transcripts at every time point, 
except on the 3rd day when the suppression was not significant (figure 39b). 
Taken together, these data raise the possibility that vitamin D prevents the 
acquisition of de novo DNAm in the SFRP5 promoter, as opposed to ameliorating 
established DNAm, although it has been shown elsewhere that DNMT3b 
cooperates with DNMT1 in the maintenance of DNAm patterns, so the 
observed effect could be consequent to impaired replicative fidelity (DNMT1 
transcription was not determined, and SFRP5 transcripts remain undetectable at 
40 cycles). Interestingly, DNMT3b shows a linear decrease in control samples 
across the treatment period, also noted for D-treated cells. This raises the 
possibility that its transcription is enhanced in cells following passage insult, 
which diminishes as cells recover homeostasis and enter the log growth phase. If 
cellular stress really does elicit aberrant DNMT activity, there may be 
deleterious consequences for the methylomes of cell lines that are subject to 
frequent passage (termed in vitro ‘ageing’ - IVA). 
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Figure 39 – Vitamin D effects differential methylation of SFRP5 and LINE1, synchronous to suppressed 
DNMT3b transcription. A) Bisulphite modified DNA was interrogated by CoBRA. Data represent the 
mean of 12 biological replicates, analysed in technical triplicate. SFRP1 and SFRP2 again exhibit a weak 
trend towards reduced promoter DNAm. SFRP5 promoter experiences significant suppression of DNAm, 
and vitamin D increases global 5mC as determined by LINE1 methylation, hypothesised to increase 
genomic stability B) DNMT3b transcription diminishes across the treatment period in both vehicle and D-
treated cells, suggesting that transcription is increased in recently passaged cells prior to log growth 
phase. Regardless, vitamin D exerts suppressive effects on DNMT3b transcription relative to vehicle 
controls, postulated as a mechanism by which vitamin D modifies SFRP DNAm. Presumably, the 
mechanisms for decreasing gene-specific DNAm are independent of the mechanism by which vitamin D 
promotes LINE1 increased DNAm, as the effects oppose each other. *p<0.05, **p<0.01. 
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Effects of vitamin D on global DNA methylation patterns 
 
Vitamin D modifies the cancer methylome, but does not affect methylation 
status of a panel of CRC-associated genes 
To investigate in vitro ageing, and vitamin D’s ability to modify the CRC 
methylome, CaCO2 and DLD1 cells were cultured under routine conditions for 
10 weeks +/- 500pM vitamin D (at the top end of vitamin D’s physiological 
reference range). Cells were passaged at 80% confluence and split 1:5 once per 
week. Media was replaced every 48 hours. Samples were collected for Q-rt-PCR 
at weeks 2, 4, 6, 8, and 10, prior to a wash-out period of four days, to mitigate 
for genomic effects of vitamin D. Samples were prepared in biological triplicate, 
and 500ng of washed-out bisulphite modified DNA interrogated on the Illumina 
450K DNA methylation bead chip array. Data are reported as the mean +/- the 
standard error. 
Exploratory analysis showed minimal variation between β-scores for treated and 
untreated samples. Predictably, given the provenance of the two cell lines, multi-
dimensional scaling of the four sample groups suggests that CaCO2 and DLD 
5mC patterns represent distinct methylomes with no overlap. However, both 
cells lines show weak clustering by treatment regimen with considerable overlap, 
suggesting modest effects of vitamin D on DNAm at the whole genome level. 
The effect is consistent in both lines (figure 40a). Scatter plots of the top 1000 
differentially methylated single CG sites and top 1000 promoters, shows a trend 
toward hypermethylation as the dominant effect of sufficiency on both cell lines 
(figure 40b), recapitulated when results are filtered for statistically significant 
promoters experiencing differential DNAm of 5% or more; after wash out, 
CaCO2 cells exhibit 51 hyper-methylated promoters, but only 7 with reduced 
DNAm. Similarly DLD1 genome shows 41 promoters where DNAm increases, 
but only 10 that were ameliorated. Four hypo-methylated promoters from each 
line mapped to protein coding sequences, whose biological significance in CRC 
has not previously been reported elsewhere (figure 41 c and d). 
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Finally, these observations are supported by a 0.5% overall increase in the 
average methylation status of all 477,289 CGs interrogated across the genome (p 
< 0.00001), for both cell lines. No differences were noted for the average 
methylation status of either whole genes, gene promoters, or CG islands in non-
coding sequences, which raises the possibility that the small increase in CG 
methylation translates to a larger increase in global (non-coding) methylation, 
masked by the null effect incorporated into the average figure from CGIs (figure 
41 a and b). LINE1/surrogates for global methylation are not incorporated on the 
array for comparison. 
To address the hypothesis that vitamin D ameliorates acquired gene-specific 
DNAm, data were extracted for a panel of genes frequently reported to be 
hypermethylated in CRC, representing those pertaining to age-related DNAm, 
and those associated with the CGI methylator phenotype404. No significant 
differences were noted for any of the genes selected after 10 weeks of vitamin D 
sufficiency, strongly suggesting that the null hypothesis should be accepted with 
regards these genes, and in contrast to the informing preliminary experiments 
(figure 42a). Control samples show severe hypermethylation of both WAs and 
CIMP-associated genes that are more frequently observed in the DLD1 cell line, 
in keeping with its mutational profile and poor degree of differentiation relative 
to the CaCO2 phenotype. 
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Regarding in vitro ageing (IVA); surprisingly, when samples are interrogated from 
t=0, several genes in this panel experience increases in promoter methylation in 
untreated controls over the ten passages, supportive of the concept of IVA. 
Certainly the methylome is not static, although it is not possible to elucidate if 
this is an effect of the cancer phenotype exerting persistent age-related aberrant 
DNAm, an effect of the ethanol vehicle, or if this is a consequence of passage 
stress/IVA. Notably, in DLD1 cells, CDKN2b experiences a 77% increase in 
promoter methylation over the ten passages (CDKN2a DNAm also increased in 
CaCO2 cells by 11.3%), and in general DLD1 cells experience greater increases 
in methylation (5/15, average increase of 23%) relative to CaCO2s (3/15, average 
increase of 3%). It was not possible to determine significance for these data as 
only one baseline sample was included on the array retrospectively for 
comparison. Having observed an epigenetic effect of IVA in both lines warrants 
further investigation in other lines, and may have important ramifications, 
particularly with regards replicative senescence in non-transformed cells. 
Perturbation of DNMT3b activity following passage, is posited as a potential 
mechanism for IVA. 
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Figure 40 – Exploratory analysis of CRC methylomes in response to physiological vitamin 
D for 10 weeks after a wash out period of four days. Biological triplicates were probed in 
technical duplicate A) Multidimensional scaling – CaCO2 and DLD1 methylomes cluster 
separately (as anticipated). D-treated samples cluster separately to control samples, but 
demonstrate large overlap, suggestive of only weak effects mediated by vitamin D. B) The 
trend for both cell lines and single CG sites and promoter CGI was towards 
hypermethylation. Pink dots indicate the top 1000 ranking CGs and gene promoters, which 
cluster towards hypermethylation in all D-treated samples. 
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Figure 41 – Gene-specific effects of vitamin D sufficiency in DNAm after a 4 day wash out period a) 
VITAMIN D increases total 5mC by ~0.5% in CaCO2 cells, recapitulated in DLD1 cells (B). Although 
small, the change was highly significant (P<0.000001), and may actually represent a greater increase in 
global DNAm as this figure includes promoter island CGs in coding sequences, which, when determined 
separately show no over-all change in DNAm status. C) Four hypo-methylated gene promoters were 
identified in CaCO2 cells that mapped to functional proteins. D) Four hypo-methylated gene promoters 
were also identified in DLD1 cells that mapped to functional proteins. All of these genes meet the criteria 
for being partially methylated, and so may represent ongoing aberrant DNAm events. E) The four highest 
ranking single CG sites experiencing differential methylation in CaCO2 cells are represented F) The four 
highest ranking single CG sites experiencing differential methylation in DLD1 cells are represented. 
Biological significance of these is not well established for CRC, suggesting that these are anomalous or 
incidental findings which should be anticipated in any genomic array approach. n=3, *p<0.05, **p<0.01. 
Data represent mean +/-SEM. 
A B 
C D 
E F 
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Ignoring the criterion for a decrease of 5% or more (to allow more significant 
hits from database interrogation), and extracting promoters that were 
significantly differentially methylated (regardless of direction), 279 promoters are 
identified in CaCO2 cells, and 437 in DLD1 cells (p<0.05), of which 12 were 
common to both (figure 42b). Of these, only three mapped to RNA coding 
sequences and experienced a change in methylation in the same direction; 
vasoactive intestinal peptide (VIP), (↓1.0% in CaCO2, p=0.03, ↓3.2% in DLD, 
p=0.02); Schlafen-like1 (SLFNL1) (↑2.1% in CaCO2, p=0.04, ↑3.4% in DLD1, 
p=0.02); and MicroRNA 2355 (↑6.0% in CaCO2, p=0.004, ↑0.6% in DLD1, 
p=0.007). These small changes are assumed to be biologically negligible, but 
consistency between lines hints at a universal mechanism effected by vitamin D in 
CRC for these genes. 
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Over representation and gene ontology analysis was performed for the lists of 
differential methylated promoters, which reveals top hits in both cell lines 
specifically for olfactory (chemokine) sensing, and GPCR signal transduction, 
suggesting that vitamin D might affect these functions via methylome modification 
in CRC cells in general (figure 43a). Differentially methylated regions were not 
over represented on any particular chromosome when adjusted for size, 
suggesting that vitamin D effects are not chromosome-specific in this context. 
After excluding promoters not assigned to functional sequences, CaCO2 cells 
exhibit 86 significantly differentially methylated promoters, and DLD1, 142 – 
appended in 11. Several genes of biological relevance to colorectal cancer, 
DNAm, and/or vitamin D physiology were contained in these lists, detailed in 
figure 42b.   
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CACO 
      
DLD1 
    
 
CTRL 
t=0 
CTRL 
(t=10) 
VIT D 
(t=10) 
ΔDNAm 
(IVA) 
ΔDNAm 
(VIT D)   
CTRL 
t=0 
CTRL 
(t=10) 
VIT D 
(t=10) 
ΔDNAm 
(IVA) 
ΔDNAm 
(VIT D) 
WIF1 92.5 96.7 96.5 4.2 -0.2 
 
WIF1 84.1 96.3 96.5 12.2 0.2 
DKK1 5.1 3.9 4.5 -1.2 0.6 
 
DKK1 86.2 90.4 91.0 4.2 0.6 
SFRP1 91.0 91.7 92.7 0.6 1.1 
 
SFRP1 81.1 85.1 85.7 4.0 0.6 
SFRP2 90.2 92.3 93.2 2.1 0.9 
 
SFRP2 91.5 93.8 94.2 2.3 0.5 
SFRP5 49.7 59.6 59.7 9.9 0.1 
 
SFRP5 90.6 92.1 92.3 1.4 0.3 
APC 24.1 31.2 31.4 7.1 0.2 
 
APC 16.6 27.3 27.3 10.7 -0.1 
MYOD 76.0 79.2 79.2 3.2 0.0 
 
MYOD 88.9 91.0 91.7 2.1 0.7 
HPP1 73.0 70.5 70.9 -2.5 0.4 
 
HPP1 89.1 84.5 85.5 -4.6 1.0 
SOX17 92.5 96.8 96.9 4.4 0.1 
 
SOX17 92.5 96.0 96.2 3.5 0.2 
MLH1 4.1 4.8 5.4 0.7 0.6 
 
MLH1 10.6 12.6 12.6 2.0 0.0 
CDKN2 15.1 26.4 26.1 11.3 -0.3 
 
CDKN2 14.7 91.9 92.4 77.2 0.5 
MGMT 38.9 40.0 40.3 1.1 0.3 
 
MGMT 54.1 60.4 60.6 6.3 0.2 
CDH1 16.0 13.1 13.0 -2.9 -0.1 
 
CDH1 12.8 14.0 13.8 1.2 -0.2 
RUNX3 88.3 88.1 89.6 -0.2 1.5 
 
RUNX3 89.8 91.9 92.4 2.1 0.5 
WNT5A 69.6 74.0 76.0 4.3 2.0 
 
WNT5A 32.6 41.7 44.6 9.1 2.9 
 
 
Figure 42 – Promoter methylation status (%) of epigenetically relevant genes in D-aged CRC cell lines. A) 
There was no significant reduction in either age-related hypermethylated genes or CIMP+ related 
hypermethylated genes, strongly suggesting that under experimental conditions, the null hypothesis 
should be accepted – Data do no support vitamin D sufficiency ameliorating gene-specific 
hypermethylation of epigenetically silenced genes in CRC as contributing to the association of sufficiency 
with prognosis. It is of note that most genes underwent increases in promoter methylation as a 
consequence of in vitro ageing alone, although this is only observational, as base line t0 samples were not 
analysed in replicate. Interestingly, CDKN2a appears to experience relatively spontaneous 
hypermethylation, also documented in CIMP+ tumours, raising the possibility that a transitional 
epigenetic event in DLD1 cells representing phenotype progression was observed. To a lesser extent, this 
was also observed in CaCO2 cells (+11.3%). B) Significantly differentially methylated promoters not 
achieving the 5% threshold or decreasing in value, reveal 12 CGI that were consistent between lines, that 
mapped to three functional sequences (VIP, SLFNL1 and MIR2355), not suggestive that a universal 
mechanism underpins vitamin D’s methylome modifying effects in this context. Unique to CaCO2 and 
DLD1 separately, several genes of biological importance to CRC initiation are noted. 
CACO CTRL VIT D ΔDNAm p.val 
IL21 45.6 53.5 7.9 0.03 
TLR2 82.1 86.2 4.2 0.03 
TUSC7 83.7 87.8 4.1 0.05 
     DLD1 CTRL VIT D ΔDNAm p.val 
RHOA 11.2 14.5 3.4 0.04 
CASP4 20.4 15.9 -4.5 0.01 
CGA 70.1 76.1 6.0 0.01 
LRP4 55.2 57.3 2.1 0.04 
A 
B 
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Filtering the array for single CG sites that were significantly hypomethylated, as 
per the informing hypothesis, revealed 70 unique sites in CaCO2 cells, which 
mapped to 58 functional gene products (appended in 12). Pathway analysis of 
these components identifies RPS6Ka3 as a key hub in the network (figure 43b). 
Ribosomal protein S6 kinase acts to phosphorylate members of the MAP 
kinase/ERK cascade, which is frequently up-regulated in CRC, driving 
proliferation405. While the RPS6Ka3 promoter itself only experienced a modest 
2.5% reduction in methylation, the association with multiple differentially 
methylated genes suggested that its transcription might none-the-less be 
impacted by small cumulative changes across the network. Given that all nodes in 
this network experience hypomethylation, increased RPS6ka3 transcription was 
anticipated, however the converse was observed (figure 44d).   
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Figure 43 - Pathway analysis of vitamin D-aged CRC cell lines a) Gene ontology terms associated with 279 
differentially methylated genes in CaCO2 cells show significant associations with olfactory receptor 
activity and G-protein coupled receptor activity. The GO association is recapitulated by the 437 
differentially methylated genes identified in DLD1 cells. Over represented pathways support these 
association in both cell lines, suggesting that the vitamin D modified methylome of CRC cells affects 
olfactory receptor function and GPCR signal transduction. B) Single CGs differentially methylated in 
CaCO2 cells were present in 70 protein coding sequences. Pathway analysis of these 70 genes (black text) 
converge via intermediary proteins (pink text) on RPS6Ka3, recognised for it’ role in ERK phosphorylation 
and thus MAPK signalling. Green dashes depict biochemical interactions, orange lines gene regulatory 
events, and purple lines indicate genetic interactions. Un-connected nodes not shown. 
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Vitamin D sufficiency effected tapering phenotypic changes in CaCO2 cells, 
but not DLD1. 
To investigate any associated changes to the phenotype of the cells, proliferation 
was measured by WST1 assay at the end of the treatment regimen, prior to 
wash out (i.e. cells still under transcriptional regulation by vitamin D), and after a 
four day washout period, during which cells were rinsed with PBS and fresh 
media applied at 24 hour intervals (figure 44a). Proliferation was mildly inhibited 
in DLD1 cells before the washout regimen (8% reduction, not statistically 
significant), but this diminished after four days with repeated washes (data not 
shown). CaCO2 cells however, experienced a 35% reduction in proliferation at 
the end of the experiment, which was sustained at 29% inhibition after the 
washout period, suggesting that their modified methylome (also interrogated at 
this time point) could be suppressing proliferation here. Consistent with this 
observation, cultured cells exhibit reduced viability at day two during the 
washout period, and day four (again, not observed for the DLD1 line). Similarly, a 
tapering effect, with a regain of viability, is apparent at day four (figure 44b). 
Supporting the observation of tapering inhibited proliferation, Ki67 transcription 
was suppressed following the washout period at t=48 but not at t=96 hours 
(figure 44c). Similarly, RSP6Ka3 transcription was inhibited, which persisted at 
t=96 hours, and suggests that MAP kinase signal transduction might be down 
regulated via reduced ERK phosphorylation, as a means to explain the reduced 
proliferation of CaCO2 cells (figure 44d). Whole cell extracts were prepared 
from washed out IVA cells and probed by Western blot for pERK1 and 2, 
normalised to total ERK1 and 2 (20ug from each sample run in technical 
triplicate). Consistent with the hypothesis that reduced RPS6ka3 activity 
prevents ERK phosphorylation, a significant reduction in the ratio of both pERK1 
and pERK2 relative to total ERK1 and 2 is observed (figure 44e and f). 
Incidentally, transcription of ERK2 was also inhibited at t=48, but not at t=96. In 
preliminary experiments an insignificant trend towards increased BCAT 
phosphorylation was also noted in washed-out cells, hinting at inhibition of Wnt 
signalling associated with the D-induced methylome (data not shown). 
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Figure 44 - In vitro ageing of CaCO2 cells shows a tapering phenotype is established by vitamin D 
sufficiency. n=3, *p<0.05, **p<0.01. Data represent mean +/-SEM. A) Cells under transcriptional regulation 
of vitamin D exhibit suppressed proliferation that is maintained, but trending toward reconstitution 96 
hours after the withdrawal of treatment. B) This observation is supported by weakly decreased viability at 
48 hours post-vitamin D, that persists, but is diminished, at 96 hours post treatment. C) Consistent with 
the above, Ki67 transcription is suppressed in D-aged cells, which is ameliorated after the full 96 hour 
washout period. Taken together, these data suggest that the antiproliferative effects of vitamin D 
sufficiency are genomic in action. D) In contrast, RSP6Ka3 – identified as a key node in the D-modified 
methylome, is consistently suppressed at 96 hours. The differences between relative Ki67 and RSP6kKa3 
transcripts in un-primed cells may be an effect of cellular plasticity as cells re-establish ‘routine’ function 
following passage at t=0 i.e. t=48 represents lag growth phase, vs t=96 in log growth phase. E and F) 
Western blot of whole cell extracts (n=2, in triplicate with SEM) shows reduced phosphorylation of ERK1 
and 2 normalised to total ERK, at 96 hours post-treatment in vitamin D aged-cells, consistent with 
sustained inhibition of MAPK signalling as a consequence of the modified methylome (RPS6Ka3 
inhibition). 
Ki67 RPS6Ka3 
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Figure 45 – Phosphorylation of ERK1 and ERK2 in CaCO2 in response to vitamin D 
culture. Band analysis revealed significantly reduced phosphorylation of both ERK1 
and ERK2 in treated cells as a ratio of the total ERK present in whole cell extracts as 
detailed in 44E and F. n=2 (samples 1 and 2), technical triplicates. Validation of this 
result is strongly suggested to consolidate data with gene expression results to 
confirm a causal effect. 
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Finally, 5mC enzyme transcription was interrogated in CaCO2 cells at passages 
2, 4, 6, 8, and 10 to investigate potential mechanisms; DNMTs 1 and 3b are 
initially suppressed in D-treated cells (similar to the effect in DLD1s over a short 
incubation), which rebounds half way through the experiment, both being 
significantly induced following passage 8 and 10 (figure 45). TET1 transcription 
was not altered, implying that any demethylation witnessed is passive in nature, 
or consequent to attenuation of further de novo DNAm. Vitamin D also 
promoted ECAD transcription in a similar fashion to the DNMTs, suppressed to 
begin with, but increasing over time, hypothesised to promote differentiation.  
Figure 46 – Methyltransferase transcription is modulated by vitamin D sufficiency a) DNMT1 transcription 
after 2 weeks in culture is decreased in D-cultured CaCO2 cells. This is recovered over subsequent 
passages, and is significantly increased prior to wash out, hypothesised to improve maintenance fidelity 
during DNA replication b) a similar pattern is noted in DNMT3b transcripts, where the significant 
increase in expression at passage ten may contribute to the effect inferred from a small but highly 
significant increase in de novo global DNAm (0.5%). Weak promotion of DNMT3b activity may thus serve 
to reconstitute global genome stability. C) TET1 transcription remains static relative to EtOH vehicle, 
precluding a role for its dynamic transcription in weak demethylation of gene promoters documented. D) 
E-cadherin transcription is promoted by vitamin D towards the later stages of the 10 week experiment, 
proposed to promote differentiation by improving cell adhesion, and sequestering cytosolic BCAT, down-
regulating TCF targets. The ECAD promoter was not observed to be hyper-methylated (13%) in 
untreated cells, suggesting that this transcriptional response to vitamin D sufficiency is via classical VDR 
/VDRE interaction. NB Patterns of transcription for all genes interrogated (and others not shown) appear 
to dip and recover between passages 4 through 8; this is suggestive of an artefact due to sampling 
discrepancies, perhaps lag vs log phase growth, or sampling technique/efficiency, and may not properly 
reflect the chronological relationship between the cells. This is inconsequential for comparisons between 
treatments at specific time points, which should be considered relevant.  
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Discussion 
Although limited in their scope as a model for investigating the prevention of 
disease, validated CRC cells lines may be employed to identify chemo-
therapeutics and mechanisms that mitigate for disease processes. Four CRC cell 
lines displaying mutational diversity were selected to investigate vitamin D’s 
anticancer properties with regards established pathological DNAm. All four lines 
characterised during preliminary experiments are reported to demonstrate 
constitutional activation of Wnt signalling, uncontrolled proliferation, replicative 
immortality, and active paracrine secretion of Wnt ligands making them ideal 
candidates to investigate epigenetic regulation of Wnt by vitamin D in a 
neoplastic context (figure x). Importantly, Oksana et al recently reported that 
despite truncation of APC in CaCO2 and DLD1 cells, DC architecture and 
BCAT phosphorylation functionality is maintained, albeit somewhat impaired406.  
It is well established that vitamin D exerts antiproliferative effects in CRC cell 
lines in vitro407. Multiple pathways have been characterised as regulated by 
vitamin D in transformed cells408. In particular vitamin D is a potent modulator of 
Wnt signalling, even in cells with mutational incompetence of the BCAT 
destruction complex, suggesting that vitamin D also inhibits Wnt via non-
canonical mechanisms. Indeed, vitamin D is reported to enhance ECAD 
transcription, which sequesters cytosolic BCAT at the plasma membrane, thus 
promoting differentiation and inhibiting TCF targets simultaneously. The VDR-
RXR transcription complex also binds cytosolic BCAT, and classically, vitamin D 
is reported to induce DKK1 – frequently found to be hypermethylated in 
transformation prone epithelia and associated with vitamin D status91,129,214,409. 
Ultimately this results in a net decrease of c-MYC transcripts and blockade of 
transition to S-phase410. Our preliminary experiments confirmed inhibition of 
MYC by vitamin D in low-passage number CaCO2 cells, but the effect appeared 
diminished in older cells, which led us to investigate the effects of in vitro ageing 
in these cells. The DLD1 line was also selected in light of vitamin Ds 
antiproliferative effects at lower concentrations to HCT and HT29 cells, and 
furthermore SFRP promoters trended towards demethylation in preliminary 
experiments.  
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Serum vitamin D at presentation is established as a prognostic biomarker for 
CRC mortality399,411. Taken together with reports that sufficiency attenuates 
aberrant age-related DNA hypermethylation of WAs212, and experimental data 
presented here suggesting amelioration of inflammation-induced hypermethylation 
and DNMT modulation in epithelial models, it was hypothesised that sufficiency 
might in part exert Wnt regulatory activities by effecting gradual reparation of 
the transformed CRC methylome, reconstituting WA transcriptional 
competence and/or genomic stability via improved global DNAm.  
 
CaCO2 DLD1 HCT116 HT29 
APC x x Wt xx 
β-CAT Wt Wt x x 
B-RAF Wt Wt Wt x 
K-RAS Wt x x Wt 
TGβr2 Wt x x Wt 
p53 x x Wt x 
 
Figure 47 – Mutational profiles of colorectal cancer cell lines employed. X = heterozygous mutation, XX 
homozygous mutations, Wt = wild type. CaCO2 cells exhibit fewer late-stage mutations (with the 
exception of carcinogenic p53), suggesting that alternative pathways may be utilised to regulate 
proliferation. This is consistent with the slower-growing and better differentiated phenotype of these cells 
relative to DLD1 cells. Both lines are heterozygous for APC and are reported to have impaired but 
functional DC competence. 
 
In respect of our informing hypothesis, for the cell lines interrogated the null 
hypothesis should probably be accepted; we saw no significant changes in 
promoter methylation status of CRC-associated genes relevant to this thesis, so 
it is unlikely their reconstitution contributed to the observed phenotypic effects 
suppressing proliferation. The implication is that, once established, these 
deleterious methyl marks become entrenched and may not be conditionally 
targeted by vitamin D via active or passive demethylation, despite vitamin D 
modulation of DNMTs. 
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Aguilera et al report DKK1 hypermethylation in 17% of CRC in their cohort 
analysis129, and note that its induction by vitamin D is not via classical VDRE 
binding409. Rawson et al demonstrate an association with vitamin D status with 
DKK1 methylation in transformation-prone colonic epithelia; DKK1 was hypo-
methylated in CaCO2 cells and hyper-methylated in DLD1, which was not 
corrected by vitamin D sufficiency, in support of the null hypothesis. Similarly 
ECAD is reported to be aberrantly methylated in breast cancer and expression is 
restored by vitamin D treatment94. Here, ECAD was hypomethylated in the basal 
state in both lines, which means comparisons cannot be made in this context. 
The ECAD promoter is also reported by others to be hyper-methylated in CRC, 
which suppresses its expression in ~50% of colitis-associated cancers412, so 
validation of a primary line exhibiting ECAD hypermethylation to resolve its 
relationship with vitamin D is feasible and warranted - after all we observed 
induction of ECAD in D-aged cells, however ECAD is an established vitamin D 
target413, raising the possibility that vitamin D induces ECAD transcription via 
dual genetic/epigenetic mechanisms. 
This is not to say that vitamin D cannot favourably modify the cancer 
methylome; indeed we observed modest changes in a variety of genes that might 
impact on tumour progression given sufficient time. In preliminary experiments 
at a higher dose we also note reduced SFRP5 methylation, but this reduction was 
not sufficient to re-establish transcription as determined by Q-rt-PCR after 40 
cycles (data not shown), nor determined after an appropriate wash-out. In this 
respect results are encouraging, given the relatively short intervention and use of 
a physiologically-relevant concentration; small epigenome-wide effects due to 
sufficiency might cumulatively contribute to cancer inhibition over longer periods 
if sustained. For example, interleukin 21 was noted to experience a 7.9% increase 
in promoter methylation (p = 0.03); IL21 is observed to be over-expressed in 
colitis-associated cancer, amplifying the inflammatory milieu in lesions414 - should 
the change in methylation inhibit IL21 expression, an anticancer effect might be 
anticipated in time. This seems plausible in respect of reports that IL21 
transcription inversely correlates with its expression in B-cell lymphoma415, 
suggesting transcriptional regulation by promoter DNAm. 
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In both cell lines, gene ontology and pathway analysis identified GPCR signal 
transduction and olfactory receptor (OR) expression (themselves class A 
Rhodopsin-like GPCRs), as being over-represented in the lists of epigenetically 
modified genes. This raises the possibility that vitamin D sufficiency may exert 
anticancer effects via promotion of appropriate environmental sensing by CRC 
cells, particularly increasing sensitivity to growth-inhibiting hormones or anti-
inflammatory cytokines, classical GPCR ligands. Very recently, ectopic olfactory 
receptor expression has been documented in colonic epithelial cells, and nutrient 
sensing by ORs is an emerging field416, however, given that there are over 1000 
functional OR genes403, whose expression appears  sporadic and is not 
determined to be tissue-specific417, a functional interpretation here may be 
tenuous. 
Our phenotypic data show that the vitamin D-associated methylome in CaCO2 
cells was synchronous to antiproliferative effects, concomitant to a predicted 
inhibition of RPS6ka3 transcription and ERK phosphorylation, but the effect 
appeared to taper across the washout period. This could simply mean that 
observations are consequent to residual classical genomic effects (i.e. induction 
of ECAD/BCAT sequestration). Equally, sufficiency may need to be maintained to 
exert persistent modification of the methylome. Conversely, in the absence of 
vitamin D, pathological processes that effect aberrant DNAm in CRC may re-
assert themselves to reconstitute methylation in those genes ameliorated by 
vitamin D – after all, we saw lower DNMT 1 and 3b transcription in D-deficient 
CaCO2 cells, and equally, an increase in methylation for genes of interest in 
control cells over the course of the experiment, supporting ongoing aberrant 
DNAm events (IVA).  To establish if the phenotype effect was indeed caused by 
vitamin D’s methylome modifying action and not by its regular transcriptional 
function, conditional knock-down of DNMTs in CRC lines might resolve this 
dichotomy, and further studies investigating the broader stability of the modified 
methylome are also indicated (we only probed the methylome once after 96 
hours).  
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Regardless of stability, physiological vitamin D was able to effect demethylation of 
several genes that was sustained for at least 96hours post-treatment. In CaCO2 
relaxins RLN1 and RLN2 were both significantly hypo-methylated. These 
proteins are over-expressed in a variety of neoplastic conditions418. Transcription 
of RLN1 was inhibited in CaCO2 cells after 48hours, and trended towards 
decreased expression at 96 hours, consistent with the tapering effect (data not 
shown). Its suppression here may contribute to the antiproliferative effect seen, 
and conditional interference should be investigated to reveal any contribution of 
relaxin expression to the CaCO2 phenotype. 
Global DNA methylation in the colonic epithelia is associated with vitamin D 
status212, and we saw a modest increase of LINE1 methylation in DLD1 cells at 
high dose over six days. In both CaCO2 cells and DLD1 cells, we also see a 
highly significant increase in total 5mC, so it is lamentable that no measure of 
non-CGI global methylation is included on the Illumina array, which means a 
genome-stabilising effect cannot fully be stated. Investigation of LINE1 
methylation in response to vitamin D sufficiency in both cell lines is a key 
recommendation for further work. 
Finally, an important observation regarding in vitro epigenetic ageing of cells must 
be addressed; both cell lines demonstrate advancing DNAm in the promoters of 
WAs and CIMP-associated genes, specifically CDKN2a, APC and WNT5a. DNA 
de novo hypermethylation of CDKN2b and RUNX3 is reported to effect 
replicative senescence in vitro in mesenchymal stem cells419, and tumour 
suppressor silencing via DNAm is reported more frequently in cancer cell lines 
compared to in vivo counterparts420, implying that these events are consequent to 
in vitro culture. This could be due to their redundancy in the ex vivo environment 
(use-it-or-lose it-hypothesis), or due to the fact that cells suited to lab culture 
are more likely to exhibit hyper-methylating tendencies. Enticingly, CDKN2a 
methylation is associated with Dukes CRC stage421, supporting the idea that 
methylation of this gene advances relatively quickly in vivo. A new hypothesis is 
proffered, that passage number is associated with increasing hypermethylation, 
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which could be succinctly investigated in CRC cell lines and organoid models of 
healthy epithelia. 
Incidentally, it was noted during the array analysis that the vitamin D receptor 
was hyper-methylated in both cell lines independent of treatment (92.1% in 
CaCO2 and 86.9% in DLD1). The two human epithelial cases included on the 
array demonstrate VDR promoter methylation at 53.9 +/- 0.04%, suggesting VDR 
might be aberrantly methylated in cancer-prone tissues. Insensitivity to vitamin D 
via VDR hypermethylation is noted in breast cancer, melanoma, hyperthyroidism 
and HIV infection422-425, and oestrogen inhibits induced colorectal carcinogenesis 
via decreased VDR methylation and increased VDR transcription in a mouse 
model426. Miyamoto et al report three CGI proximal to the VDR transcription 
start site that also contain SP1 regulatory elements, posited to regulate DNMT 
activity at the site427. Conversely we note that hypermethylation of VDR in 
CaCO2 and DLD1 does not inhibit VDR transcription, which we observed by Q-
rt-PCR in both lines on multiple occasions (average cycle threshold under 25), in 
clear contrast to the defunct paradigm that promoter hypermethylation silences 
genes. Our cells were responsive to vitamin D in terms of phenotype 
(proliferation), DNA methylome, and gene regulation. Thus, the mechanism by 
which vitamin D/VDR mediates its effects in CRC warrants further elucidation. 
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A linear increase in VDR transcripts in vitamin D deficient CaCO2 cells over the 
10 passages (RSQ = 0.66), not associated with any meaningful change in DNAm, 
was also determined (data not shown), suggesting that cells increase VDR 
expression to enhance their vitamin D sensitivity in times of deficiency. This 
observation also warrants investigation in non-transformed models, as it suggests 
that low serum vitamin D might not impair cytosolic active vitamin D, if 
deficiency improves sensitivity. This might explain why correcting for low serum 
D fails to modify CRC disease risk, despite the overwhelming epidemiological 
association of serum sufficiency with disease risk. Thus low serum D may not 
equate to impaired vitamin D genomic functions (we also noted exponential 
suppression of Cyp24a1 in D-deficient cells over time (RSQ = 0.940), which 
would further increase D-sensitivity, and supports the idea that low serum D 
need not necessarily be aetiological in CRC initiation). 
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Summary 
 
Physiological vitamin D effected modest remodelling of both the CaCO2 and 
DLD1 methylomes that was associated with a variety of postulated anticancer 
effects. In CaCO2 cells, proliferation and cell viability were inhibited, with an 
associated tapering effect on MAP kinase signalling. Supra-physiological vitamin D 
was able to ameliorate SFRP5 hypermethylation, but not sufficiently enough to 
reconstitute its expression in DLD1 cells. Vitamin D was able to modulate 
DNMT transcription in CaCO2 cells over time, and so DNMT activity assays 
should be deployed to investigate this further. Both cell lines underwent 
progressive in vitro aberrant DNA methylation in the un-primed state, raising 
questions about the effects of routine laboratory culture on primary cell 
methylomes, also noted in organoid models, warranting further investigation. 
Taken together, results presented here support a mechanistic role for vitamin D 
sufficiency improving CRC prognosis via its modulation of 5mC patterns and 
DNMT activity. 
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Chapter 7 
 
GENERAL DISCUSSION 
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Discussion 
Vitamin D status is rigorously established to have an inverse association with 
colorectal cancer risk428-430. The NHNAES-III study in 2007 assessed a total 
cohort of 16,000 participants, and concluded that CRC mortality is reduced by 
up to 72% (95% CI 32-89%), when serum vitamin D exceeds 80 nmol/L relative 
to sub-50 nmol/L popualtions431. 
The relationship came to the attention of the scientific community through 
epidemiological studies in the late 70s and early 80s that suggested, once other 
factors were corrected for, that CRC risk increased with distance of the 
population from the equator, and by mean daily UVB exposure. While Garland 
and Garland’s seminal paper of 1980 was the first to posit the association with 
sunlight hours and thus vitamin D status432, the pair were undoubtedly influenced 
by earlier prophetic studies; these noted associations with over-all cancer risk by 
sunlight hours as early as 1941433, that hypovitaminosis vitamin D-induced rickets 
occurred more frequently in urbanised areas versus arable communities in the 
tropics434, and others postulated vitamin D deficiency as an aetiological factor in 
the racial disparity of CRC rates435. 
There are no studies that report either no association of CRC risk with serum 
vitamin D, or a positive correlation. Two opposing hypotheses are apparent, 
which remain unresolved even today; the first suggests that low vitamin D 
predisposes the colonic epithelia to transformation, either directly via vitamin D 
signalling in epithelial cells, or indirectly via other cell types and autocrine 
signalling factors that deregulate epithelial homeostasis. The alternative is that 
those mechanisms that bring about tumourigenesis (inflammation), 
simultaneously impair vitamin D metabolism. It is recognised that established 
disease, and to an extent age, compound chronic deficiency via impaired 
synthesis at key metabolic sites, and/or absorption in the gut436, however these 
are independent of deficiency as a risk factor, which is observed to precede 
pathogenesis430. A great number of studies have endeavoured to resolve the 
dichotomy, investigating molecular mechanisms by which vitamin D might exert 
an anti-cancer effect. 
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The compounds direct genomic actions are well established to effect anti-
proliferative, pro-apoptotic, and pro-differentiative effects in vitro and ex vivo437, 
which are confirmed in vivo in the mouse438. Equally vitamin D is reported to 
enhance DNA mismatch repair mechanism in colonic crypts via induction of 
MLH1 and MSH2439. Similarly, vitamin D acts to reduce both systemic and local 
inflammation via prescribed pathways encapsulating TLRs, NFκB and cytokine 
production, as well as promoting immune function via proper leukocyte 
differentiation440, all of which are shown to be associated with aberrant age-
related DNAm too441. Vitamin D’s genomic actions, via its cognate receptor VDR 
and hexameric response element, are discussed in detail previously, so it is not 
necessary to restate them here in their entirety. Suffice to say that vitamin D 
represses Wnt signalling in epithelia, and NFκB across the immune system, at 
multiple levels91,356,442. It seems reasonable that these whole-organism, 
multifactorial, pleiotropic modes of action, are likely to act cumulatively to 
contribute to epithelial and immune homeostasis, resulting in the consensus 
association of serum D with bowel health. Data presented here regarding vitamin 
D’s effects on the methylome in a variety of cell types and models, are proposed 
in addition to the established genomic actions, to promote bowel health during 
aging.  
However, these data have not (yet) been confirmed clinically. In 2015, Autier et 
al conducted a meta-analysis of vitamin D trials to date, and concluded that 
modulation of serum D via supplementation does not impact on CRC disease 
risk, and that further attempts to elicit causality would prove futile66. In respect 
of the background discussed, taken together with other data,  this assertion 
should be considered with caution – Tapp et al report an inverse association 
with serum D and age-related DNAm in their cross-sectional study, and DNAm 
patterns are observed to vary longitudinally over the life time of organisms (from 
early childhood onwards)258,443,444; in light of these findings, it could be argued that 
the epigenetic component of vitamin D’s action is modest at physiological 
concentrations in healthy epithelia, and thus status should be maintained over the 
lifetime of the organism to reap beneficial effects in older age; the longest 
intervention surmised by Autier was 8 years. 
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It is also premature to assume a null effect of supplementation as evidence for 
reverse causality; for example, deficiency at any point prior to intervention might 
impart irreversible homeostatic/metabolic deficits, regardless of future vitamin D 
status - a caveat overlooked by the authors. However, a more recent study by 
Skaaby et al report associations between vitamin D status and BMI, alcohol 
intake, physical activity, and diet, suggesting that lifestyle factors known to be 
associated with disease risk, also determine vitamin D status445. This is in support 
of Autier’s reverse causality hypothesis. Thus, caution should be exercised in this 
respect until better trials, which do not conflate deficiency and insufficiency 
(where the effects are undoubtedly more pronounced and subtle respectively), 
are completed.  
Tapp et al report that vitamin D status is associated with hypomethylation of 
WAs in the distal colon, and increased LINE1 methylation. In this context, it was 
set out to investigate if vitamin D exerted a protective effect against age-related 
DNA hypermethylation in the epithelia. Although the vast majority of 
mechanistic studies looking at vitamin D’s anti-cancer effects in the bowel utilise 
transformed cell lines, there are also multiple reports that these are 
recapitulated in healthy epithelial models99,403. Aberrant DNAm across the 
epithelial sheet (field effects) are propagated by crypt fission446,447, and the crypts 
themselves are populated by LGR5+ve stem cells in the crypt niche. It is 
established that the epigenetic defects detected in colonic biopsies are initially 
derived in these cells186, which indicated that studies should ideally be performed 
exclusively in an epithelial model that maintains sufficient populations of 
LGR5+ve cells. In 2009 Sato published his revolutionary paper with detailed 
methods to procure and propagate colonic organoids from healthy mucosal 
biopsies220,221, which have been utilised for this investigation.  Although colonic 
organoids proved easy enough to establish, the number and quality of individual 
organoids rapidly diminished with subsequent passage. This study had set out to 
use a physiologically relevant dose of vitamin D over a longer period of time in 
order to allow for extrapolation to the in vivo environment, but in retrospect, in 
light of the propensity of cultures to fail over time, perhaps a larger dose for a 
shorter period would have been a better place to start as a proof-of-concept. 
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In support of these observations regarding longevity, since Sato, vast numbers of 
papers replicating his success have been published, however it should be noted 
that the majority utilise a) small intestine verses large intestine b) mouse 
organoids verses human, and c) interventions or transfections typically <7 days. 
Sato did not observe replicative senescence in their human colonic organoids, 
and this study endeavoured to replicate their culture and passage methods 
verbatim, but feel that for longer interventions with human colonic organoids, 
optimising the methods for procuring sufficient yields is a major barrier to 
overcome. The technique is still in its infancy, and it is likely that organoids will 
prove exceptionally useful for aging studies in the future. However, a concerning 
observation, is noted albeit in only one cell line; that DNAm patterns showed 
considerable variation between the crypts, organoids at passage 0 and at passage 
4 in vehicle treated cells (ethanol <0.001% final dilution), implying an effect of in 
vitro culture on DNAm. Alcohol intake predisposes to CRC via acetaldehyde 
toxicity448, and is noted to perturb folate/SAM metabolism448, and be associated 
with age-related DNA methylation449. Perhaps the effect of ethanol, but certainly 
the effect of IVA, on colonic organoids in culture is worth exploring further, and 
may have implications for the validity of organoids as an ex vivo model of healthy 
gut epithelia. The effects of IVA are established in hyper-mutable transformed 
cell lines, recapitulated here – it seems plausible that the underpinning 
mechanisms may also be at play in organoids, so efforts should be made to 
determine if this is indeed the case, although their primary nature may afford 
greater plasticity, and it could be that the cancer phenotype drives IVA, not the 
in vitro environment. 
Differential methylation was observed in primary human organoid models 
treated with inflamed myofibroblast supernatants, treated with vitamin D, 
treated with PGE2, and treated with IL6. Vitamin D attenuated the TNFα-
induced production of both PGE2 and IL6, and also improved CRP status in a 
small intervention trial, and regulated TNFα in monocytes.  Amelioration of 
SOX17 and DKK1 DNAm was also observed in healthy and inflamed mouse 
organoids. This suggests that Tapp’s prospective findings are indeed due to a 
mechanistic deficit in D-deficient participants. 
  
221 
 
While data are in support of the primary hypotheses, firstly conditional 
interference with either DNMT activity or VDR competence in any of these 
models, is necessary to finally conclude a mechanistic effect. Secondly, an effect 
on phenotype should be established to demonstrate a functional effect of a D-
modified methylome; this ideally would incorporate measures of proliferation 
(BRDU/WST1 assays, crypt length, and organoid morphology), and regulation of 
transcription and expression associated with differentially methylated genes. 
Furthermore, it is proposed that the effects of vitamin D are multifactorial, 
influencing systemic, niche, and autocrine inflammation and regulation of 5mC 
metabolism. It would be laborious to separate out the size of the anti-
inflammatory effect versus the cell-intrinsic effects, which would require total 
repetition in models with impaired immune function (TLR knock down/ MYD88-/- 
mice). A key finding of Tapp et al was that vitamin D promoted maintenance of 
LINE1 hypermethylation; although the Illumina methylation arrays employed here 
do not include LINEs, it was possible to extrapolate an effect on global DNAm 
when no change in promoter or CGI DNAm was present, which together with 
preliminary data in CRC cell lines, suggested that vitamin D might improve LINE1 
methylation. This is promising, and should be properly investigated in non-
transformed epithelial models. 
There are RNA samples available, collected during the treatment schedules of 
primary organoids, which would be useful to verify the impact of differential 
DNAm on the regulation of the genes affected. Furthermore, investigation of 
5mC enzyme transcripts is warranted in these samples; perhaps the strongest 
indication of a pathway by which effects are manifest, is the non-tissue specific 
(monocytes, organoids, and CRC lines) regulation of the DNMTs and TET 
enzymes by vitamin D. Only about half of the genes reported to be regulated by 
vitamin D contain a catalogued response element. An eloquent and simple 
addition to these data would be the identification of vitamin D response 
elements in 5mC metabolic enzyme sequences, and work is under way to this 
end. 
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Two incidental observations also warrant separate elucidation in the future; the 
expression of the vitamin D-deactivating enzyme, Cyp24a1, is frequently 
dysregulated in CRC. Initially in early stage tumours, Cyp24a1 is down regulated, 
assumed to be a plastic response of the tumour as it struggles to moderate 
rampant proliferation, thereby increasing its sensitivity to vitamin Ds 
antiproliferative effects. In advanced tumours, the relationship is reversed – 
Cyp24a1 becomes aberrantly over-expressed, promoting vitamin D 
insensitivity378,450,451. It is noted that inflamed myofibroblast supernatants were 
able to regulate Cyp24a1 transcription. Despite their accepted role in informing 
stem cell metabolism107,452, there are no reports in the literature detailing the 
effect of the pericryptal myofibroblasts regulating vitamin D metabolism in the 
epithelia. This would make for an exciting and novel project, particularly utilising 
protocols that optimised here for the recovery of myofibroblasts from the same 
biopsies used to propagate colonic organoids, allowing for case-matched 
investigation that truly emulate mucosal topography. These data suggest that the 
role of the pericryptal myofibroblast is incompletely characterised; classically 
myofibroblasts are considered architectural in nature, providing growth factor 
support, and protection for the stem cell niche. The proteomics data raises the 
possibility that pericryptal myofibroblasts also act in a sentinel fashion, re-
interpreting and distributing the TNFα inflammatory message locally. The 
inflammatory role of pericryptal myofibroblasts in IBD has rarely been discussed 
– deregulated expression of TGFβ1, 2, and 3 has been reported in CD MFBs 
versus those recovered from the normal epithelium, even several weeks after 
their removal, suggesting a phenotype modification, not a transient response to 
local signals453. Pro-inflammatory TP12 expression is also deregulated in CD 
MFBs, leading to elevated COX2/PGE2, supporting the results presented here 
and the idea of functional diversity454. Their role as inflammatory mediators in the 
colonic epithelium may have been overlooked while more central players are 
investigated (de novo leukocyte infiltrates), and their ability to regulate CSC 
proliferation via Wnt ligand and WA secretion is still being catalogued455. 
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It was also noted that the VDR promoter was hypermethylated (80 %+) in 
CaCO2 and DLD1 cancer cells, and partially methylated in the two organoid 
lines (50 %+), yet all four models demonstrate vitamin D sensitivity and VDR 
transcripts. Silencing via hypermethylation of VDR promotes vitamin D 
insensitivity in breast and adrenal tumours422,456. The discrepancy here warrants 
further investigation, and may reveal alternative non-canonical modes of action 
by which vitamin D may signal in intestinal epithelial cells.   
With regards the suitability of the models used here; organoids were cultured 
from the uninvolved mucosa 20cm or more, proximal to recto-sigmoid 
adenocarcinomas. Vitamin D status was not determined for these patients. The 
ages were 45 and 65 years old respectively for cases 11 and 12 interrogated. We 
include organoid methylation values at base line for comparison with Tapp’s data 
(figure 47). It is important to note that these patients had developed tumours, 
unlike Tapp’s, who were determined to be disease-free during sampling. 
Consistent with this discrepancy, hypermethylation of ESR1 and N33, and partial 
methylation of WIF1 and SFRP2 is observed in the organoids relative to the 
means reported by Tapp. The two cases generally show increased DNAm in 
comparison, but the obvious caveat is that DNAm has only been determined in 
two instances. The small standard error reported suggests methylation was 
similar for all the genes between the two organoid lines. In retrospect, 
experiments utilising colonoids cultured from healthy, young patients (screened 
by colonoscopy) would presumably generate organoids with intact WA 
hypomethylation, which would allow an investigation of the ability to attenuate, 
as opposed to an investigation of the ability to ameliorate DNAm. In light of the 
mosaic nature of field effects, sampling throughout the length of the colon might 
also be considered pertinent in future. Furthermore, DNA methylation patterns 
are different in colonic stem cells to terminally differentiated counter parts at the 
luminal interface457,458; in these studies the genes that exhibit variable methylation 
were associated with phenotype, so it may be that whole-organoid DNAm 
correlates well with LGR5+ve DNAm patterns, but this could be resolved via 
FACS 
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One final adaption might be considered for any further in vitro work;  the effect 
of vitamin D was investigated at 500pM, in comparison to a basal culture medium 
which is reported by the manufacturers to be vitamin D and metabolite free. 
This would be considered an extreme outlier in the normal physiological 
reference ranges, but is within the realms of possibility in light of confidence 
limits. It was just argued that deficiency drives aberrant DNAm; future 
experiments should include vitamin D-deficient organoids as a control (10pM), 
compared against vitamin D insufficient (30pM), and vitamin D sufficient (90pM), 
which would allow for better parallels to be drawn against the in vivo 
environment reported to be associated with aberrant DNAm. It seems likely in 
respect of the data presented here, that the complete absence of vitamin D in 
cell culture mediums is as likely to be associated with deleterious cell-intrinsic 
effects as would be experienced by an organism devoid of the compound. 
An interesting phenotype was observed at base line in two of the three 
myofibroblast lines validated for experiments, termed COX2high. Implicit with this 
discovery is that chronic inflammation in the mucosa, reported to accelerate age-
related DNA hypermethylation, is in part mediated by the inflamed myofibroblast 
phenotype. Should this finding be recapitulated in further primary MFB cultures 
from uninvolved mucosa, new avenues for the treatment of inflammatory bowel 
disease and attenuation of colitis-associated tumourigenesis may reveal 
themselves. It is encouraging that the observed attenuation of PGE2 secretion by 
vitamin D in four separate primary lines,  is consistent with the prevailing 
consensus by which aspirin modifies colorectal cancer morbidity and mortality 
via inhibition of COX2459. However, aspirin use is itself associated with an 
increased risk of haemorrhagic stroke (0.03% to 0.04% per year) and 
gastrointestinal bleeds 0.7% to 1.4% per year)460. It would be pertinent to 
investigate serum vitamin D with regards the myofibroblast phenotype in vivo, as 
outlined in Recommendations for further work. Vitamin D supplementation at 
the levels required to boost serum vitamin D into the sufficient range are not 
associated with toxicity or hypercalcaemia461 and so might offer an alternative, or 
act synergistically with a lower dose of aspirin for the prevention of colorectal 
cancer. 
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Figure 48 – Comparison of DNAm status in WAs; healthy biopsies versus organoid 
models. All genes in our two organoid lines show increased methylation relative to 
Tapp’s modelling, specifically in the SFRPs, WIF1 ESR1 and N33. This implies that 
organoids cultured from uninvolved mucosa in CRC exhibit the field effects of age-
related DNAm, and as such may not be the go-to option for investigating the 
attenuation of aberrant DNAm (conversely they are deemed suitable for 
investigating the amelioration of aberrant DNAm). Characterisation of the 
differences between crypts, and young and old organoids in terms of DNAm (IVA) is 
strongly advised.  
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Recommendations for further work 
 
One of the key findings was that vitamin D appeared to ameliorate 
hypermethylation of DKK1 in an uninflamed mouse, and SOX17 in a TNFα-
transfected mouse. The organoids were propagated from non-transformed 
colons. Although the results may be statistically significant within these 
individuals, ultimately n = 1. The prospect that improving vitamin D status could 
attenuate, or even ameliorate aberrant age-related or inflammation-associated 
DNAm (regardless of mechanistic route), is an enticing one, with broad 
translational implications for promotion of longevity. Such a study would have a 
significant sociological impact and contribute a good deal to community 
understanding of vitamin D status’ relationship with health. Therefore, an 
intervention study in mice supplemented with vitamin D is proposed. Using a 
mouse model negates having to consider physiological relevance of the control 
group, as vitamin D is provided for in the whole organism, unlike cell culture. It 
would also be possible to recover other tissues and cell types (MFBs), for 
correlation of biomarkers with methylation status of an appropriate panel of 
genes identified here as likely to be differentially methylated. Array-based analysis 
of methylomes versus transcriptomes would yield all the necessary data to target 
genes for verification at the bench. These technologies are not presently available 
for murine models, but may soon be. Furthermore, in recent years epigenetic 
clocks that interrogate individual CG sites, whose methylation status strongly 
predicts biological age, have been developed258; these are a useful tool for 
researchers investigating the effects of any compound or intervention on the 
attenuation of DNAm ageing. 
  
  
227 
 
Perhaps a shorter experiment to complement these findings here, as opposed to 
recapitulating them in vivo, could investigate the necessity of aberrant DNAm for 
progression; typically, up to 80% of benign polyps present with an APC 
mutation462, but aberrant DNAm is also known to be established in these 
tumours463. The CRISPR-Cas9 genome-editing system has recently been utilised 
to insert classic mutations (specifically APC, SMAD4, TP53, KRAS, and PIK3CA) 
into organoids propagated from healthy colonic epithelia. Here the authors 
investigated the ability of the organoids to proliferate in the absence of niche 
signalling and self-maintain when transplanted into common sites of metastasis464. 
By mutating APC in healthy organoids, it would be possible to investigate the 
transformative effects of DNA hypermethylation by means reported here (PGE2, 
IL6, MFB supernatants, IVA), or by conditional over-expression of DNMTs. 
Finally the ability of vitamin D (or other nutrients or anti-inflammatories) to 
attenuate the transformation could be characterised. 
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Concluding remarks 
 
In this observational study the effects of vitamin D on DNA methylation patterns 
in multiple cell types have been characterised. The results presented suggest that 
the association between vitamin D status and aberrant DNAm in the 
transformation-prone colonic epithelial is causal, and that vitamin D exerts 
pleiotropic effects to promote bowel health that include the resolution of 
systemic and mucosal inflammation, and modulation of DNMT and TET enzyme 
transcription. These effects are postulated to contribute to the association of 
vitamin D status with colorectal cancer risk and prognosis. Further work is 
therefore indicated to validate these observations. 
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Appendices 
1- Reagents and compounds 
 
Supplier Description    
CALTAG-MEDSYSTEMS LIMITED CoEpiCM (Colonic Epithelial Cell Medium)    
VWR INTERNATIONAL GMBH 100 RXN Q SCRIPT CDNA SUPERMIX    
R & D SYSTEMS EUROPE LTD 10mg Wnt 3a    
CALTAG-MEDSYSTEMS LIMITED 1L21    
R & D SYSTEMS EUROPE LTD 25MG R-SPONDIN1    
SIGMA-ALDRICH CO LTD 5-AZA-2'-DEOXYCYTIDINE    
BIOLINE REAGENTS LTD 50 PREPS ISOLATE II RNA MINI KIT    
BIOLINE REAGENTS LTD 500RXNS IMMOMIX    
CAMBRIDGE BIOSCIENCE LIMITED 96 WELL PROSTAGLANDIN E2 EIA KIT    
SIGMA-ALDRICH CO LTD ACRYLAMIDE/BIS-ACRYLAMIDE, 40% SOLUTION    
THERMO FISHER SCIENTIFIC (HEMEL) Advanced DMEM/F-12    
MERCK CHEMICALS LTD Amicon Ultra-4 Centrifugal Filter Unit with Ultracel-3 membrane    
ABCAM LTD Anti-GPCR GPR49 antibody [EPR3065Y]    
ABCAM LTD Anti-TATA binding protein TBP [1TBP18] antibody    
CALTAG-MEDSYSTEMS LIMITED APP    
THERMO FISHER SCIENTIFIC (HEMEL) B-27® Supplement (50X), serum free    
CALTAG-MEDSYSTEMS LIMITED B-ACT    
THERMO FISHER SCIENTIFIC (HEMEL) BCA Protein Assay Kit    
NEW ENGLAND BIOLABS (UK) LTD beta-Catenin 6B3 Rabbit mAb    
R & D SYSTEMS EUROPE LTD CALCITRIOL 1.25 DIHYDROXYVITAMIN D3    
NEXCELOM BIOSCIENCE LTD Cell count slides with protective film    
SIGMA-ALDRICH CO LTD CORNING COSTAR CELL CULTURE PLATES,    
VWR INTERNATIONAL GMBH Corning® Matrigel® Basement Membrane Matrix, growth factor reduced (GFR)    
CALTAG-MEDSYSTEMS LIMITED DCLK1    
LIFE TECHNOLOGIES LTD INVITROGEN 
DIV 
DMEM F12 + Glutamax    
NEW ENGLAND BIOLABS (UK) LTD DNase I Reaction Buffer    
CAMBRIDGE BIOSCIENCE LIMITED EZ DNA Methylation Kit Gold for 200 DNA modifications. Supplied with capped 
columns 
   
NEW ENGLAND BIOLABS (UK) LTD Gel Loading Dye Blue 6X    
SIGMA-ALDRICH CO LTD GenElute MAMMALIAN GENOMIC DNA MINIPREP    
NEW ENGLAND BIOLABS (UK) LTD HinfI    
NEW ENGLAND BIOLABS (UK) LTD HpyCH4IV    
PEPROTECH EC LIMITED HS RECOMBINANT NOGGIN    
PEPROTECH EC LIMITED Human recombinant TGFβ1    
THERMO FISHER SCIENTIFIC (HEMEL) iBlot® 2 Transfer Stacks, PVDF, regular size    
BIOLINE REAGENTS LTD IMMOMIX 500RXNS    
LONZA VERVIERS SPRL InMyoFib-Intestinal Myofibroblasts    
BIOLINE REAGENTS LTD Isolate II mini kit 50 preps    
PROMEGA UK LTD Luciferase Assay System with Reporter Lysis Buffer    
CALTAG-MEDSYSTEMS LIMITED mettl7b    
THERMO FISHER SCIENTIFIC (HEMEL) N2 supp. x100    
NEW ENGLAND BIOLABS (UK) LTD NF-kappaB1 p105p50 D7H5M Rabbit mAb    
NEW ENGLAND BIOLABS (UK) LTD Non-phospho Active beta-Catenin Ser3337Thr41 D13A1 Rabbit mAb    
SIGMA-ALDRICH CO LTD PHOSPHATE BUFFERED SALINE TABLET,*TRU-ME    
THERMO FISHER SCIENTIFIC (HEMEL) Pierce beta-Galactosidase Assay Reagent    
GILSON SCIENTIFIC LTD Pipette Tip Holder for PIPETMAN P10    
CAMBRIDGE BIOSCIENCE LIMITED Prostaglandin E2 EIA Kit - Monoclonal    
4TITUDE LIMITED qPCR seals    
VWR INTERNATIONAL GMBH qScript™ cDNA SuperMix, 25 reactions    
R & D SYSTEMS EUROPE LTD r-spondin1    
ABCAM LTD Rabbit monoclonal [EPR3776] to Vimentin - Cytoskeleton Marker - 10uL    
PEPROTECH EC LIMITED Recombinant Human DKK-1    
PEPROTECH EC LIMITED Recombinant Human TGF-β1 (HEK293 derived)    
CALTAG-MEDSYSTEMS LIMITED RSPO1 Antibody    
SIGMA-ALDRICH CO LTD S-ADENOSYL-L-METHIONINEP-TOLUENESULFONAT    
SIGMA-ALDRICH CO LTD SB 202190    
CALTAG-MEDSYSTEMS LIMITED SCUBE3    
LONZA VERVIERS SPRL SmGM-2 BulletKit (CC-3181 & CC-4149)    
LONZA VERVIERS SPRL SmGM-2 BULLETKIT (CC-3181 & CC-4149) AS PER     
FISHER SCIENTIFIC LIMITED TC Flask EasyFlask angled neck    
CALTAG-MEDSYSTEMS LIMITED TSLP Antibody    
CAMBRIDGE BIOSCIENCE LIMITED Universal Methylated Mouse DNA Standard and Control Primers    
R & D SYSTEMS EUROPE LTD Valporic acid    
R & D SYSTEMS EUROPE LTD WNT-3A 10MG    
ROCHE DIAGNOSTICS LTD WST-1 assay reagent    
MERCK CHEMICALS LTD y27632    
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2- Links to relevant online materials 
 
Cell Proliferation Reagent WST-1 (Roche, product number 11644807001) 
https://pim-eservices.roche.com/LifeScience/Document/c4c412ae-96ed-e311-
98a1-00215a9b0ba8 
EZ DNA Methylation-Gold™ Kit (Zymo, product number D5006) 
https://www.zymoresearch.com/epigenetics/dna-methylation/bisulfite-
conversion/ez-dna-methylation-gold-kit 
Prostaglandin E2 ELISA Kit – Monoclonal (Cayman, product number 514010) 
https://www.caymanchem.com/pdfs/514010.pdf 
ISOLATE II RNA Mini Kit (Bioline, product number BIO-52072) 
http://www.bioline.com/us/downloads/dl/file/id/885/isolate_ii_rna_mini_kit_prod
uct_manual.pdf 
GenElute™ Mammalian Genomic DNA Miniprep Kit Protocol (Sigma Aldrich, 
prosuct number G1N70) 
http://www.sigmaaldrich.com/content/dam/sigmaaldrich/docs/Sigma/Datasheet/7/g
1n70dat.pdf 
Pierce™ BCA Protein Assay Kit (Thermo Fischer Scientific, product number 
23225) 
https://tools.thermofisher.com/content/sfs/manuals/MAN0011430_Pierce_BCA_
Protein_Asy_UG.pdf 
M-PER™ Mammalian Protein Extraction Reagent (Thermo Fischer Scientific, 
product number 78510) 
https://tools.thermofisher.com/content/sfs/manuals/MAN0011378_MPER_Mamm
al_Protein_Extract_Reag_UG.pdf 
NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (Thermo Fischer 
Scientific, product number 78833) 
https://tools.thermofisher.com/content/sfs/manuals/MAN0011398_NEPER_Nuc_
Cytoplasmic_Extract_Reag_UG.pdf 
Infinium MethylationEPIC BeadChip Kit (32 samples) (Illumina, product number 
WG-317-1002) 
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3- Participant information for organoid cultures 
 
 DATE AGE SEX DIAGN
OSIS 
LOCATI
ON 
SAMPLE MFB ORGS POLYPS BX 
CASE1 15.1.1
4 
77 m acrc hep 
flex 
10cm 
prox 
y  n n n 
CASE2 24.1.1
4 
46 f acrc rec sig 15cm 
prox 
y  n n n 
CASE3 29.1.1
4 
57 f acrc sig col 20cm 
prox 
y  y n n 
CASE4 26.2.1
4 
59 m acrc sig col 15cm 
prox 
n n n NNU
H TB 
(MW) 
CASE5 17.3.1
4 
81 f acrc sig col 20cm 
prox 
n y n NNU
H TB 
(MW) 
CASE6 1.5.14 54 f acrc rec sig 10cm 
prox 
n n n NNU
H TB 
(MW) 
CASE7 20.5.1
4 
72 f acrc rec sig 10cm 
prox 
Proces
sed 
n n NNU
H TB 
(MW) 
CASE8 2.6.14 53 m acrc rectal 25cm 
prox 
Proces
sed 
n n NNU
H TB 
(MW) 
CASE9 8.9.14 74 m acrc rectal 10cm 
prox 
n y y NNU
H TB 
(MW) 
CASE1
0 
2.2.15 70 m acrc sig col 20 cm 
prox 
n n n NNU
H TB 
(MW) 
CASE1
1 
22.6.1
5 
45 m acrc rec sig 20cm 
prox 
y y n NNU
H TB 
(MW) 
CASE1
2 
29.6.1
5 
65 m acrc rectal 20cm 
prox 
y y n NNU
H TB 
(MW) 
CASE1
3 
2.7.15 61 m acrc rectal 20cm 
prox 
y y n NNU
H TB 
(MW) 
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4 - Reagents for organoid culture 
 
Supplier Cat. No. Item Description Supplier 
12587-010  10ML B27 SUPPLEMENT  
LIFE TECHNOLOGIES LTD 
INVITROGEN DIV  
17502-048  N2 SUPPLEMENT  
LIFE TECHNOLOGIES LTD 
INVITROGEN DIV  
688000  1MG Y - 27632  MERCK CHEMICALS LTD  
P0409  1MG PROSTAGLANDIN E2  SIGMA-ALDRICH CO LTD  
120-10C  
20UG RECOMBINANT 
HUMAN NOGGIN  
PEPROTECH EC LIMITED  
F9665  500ML FETAL BOVINE SERUM  SIGMA-ALDRICH CO LTD  
734-1100  
10ML BD MATRIGEL 
BASEMENT MEMBRANE 
MATRIX  
VWR INTERNATIONAL 
GmbH  
734-1312  
100ML BD DISPASE 5000 
CASEINOLYTIC UNITS  
VWR INTERNATIONAL 
GmbH  
734-0107  
100ML BE CELL RECOVERY 
SOLUTION  
VWR INTERNATIONAL 
GmbH  
PHG0311  EGF RECOMBINANT HUMAN  
LIFE TECHNOLOGIES LTD 
INVITROGEN DIV  
GIN70-KIT  
GENELUTE MAMMALIN 
GENOMIC DNA MINIPREP  
SIGMA-ALDRICH CO LTD  
CLS3516-50EA  
COSTAR CELL CULTURE 
PLATES 6 WELL  
SIGMA-ALDRICH CO LTD  
CLS3524-
100EA  
CORNING COSTAR CELL 
CULTURE PLATES  
SIGMA-ALDRICH CO LTD  
S7067-5MG  SB 202190  SIGMA-ALDRICH CO LTD  
2815    
VALPROIC ACID SODIUM 
SALT 
R & D SYSTEMS EUROPE 
LTD 
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5 - CoBRA assay protocols 
 
HUMAN 
GENE FWD REV ANN
EAL 
ENZY
ME 
TEM
P 
TNFΑ GGAAGTTAGAAGGAAATA
GATTATAGATT 
 
ACAAACATCAAAAATACCCCT 58 HINF
1 
37D
EG 
IL8 TGTGGAGTTTTAGTATTTT
AAATGTA 
 
TGTATAAGTTTTTTAGTAGGG
TGAT 
60 XMN
1 
37D
EG 
APC GGAGTAAAGATTAGAAGAG
AGGAA 
AAACCACTCCTCACTCCA 58 FAU1 55D
EG 
DKK1 AGAGGGAGGTTGTAGAGA
GTTATTATTGT 
 
CTAATAACCCACACTCTAAAA
TAAACTAAACA 
59 MAE1
1 
37D
EG 
SFRP5 GTTTAGGTGGGTGGTAGTT
TG 
 
AAAAAACAAAAAACCCTAAAA
AAAA 
55DE
G 
BSIE1 60D
EG 
SFRP1 AGGTTAAGAAAATTTTGGT
TGTGTTT 
 
CCTACTCCAACACCTCCTTCA
TA 
60 HINF
1 
37D
EG 
SFRP2 GTTTTTTAAGGGGTGTTGA
GT 
CAAACTTCCAAAAACCTCC 59DE
G 
FAUI 55D
EG 
 
MOUSE 
GEN
E 
FWD REV ANN
EAL 
ENZY
ME 
TEM
P 
SOX
17 
AGATTGTAGGGTTTGGTTTG
A 
 
CCTCAAAATCTACCTCTAAAAA
CA 
58 BSIE1 60D
EG 
DKK
1 
AGAGGGAGGTTGTAGAGAG
TTATTATTGT 
 
CTAATAACCCACACTCTAAAAT
AAACTAAACA 
59 MAE1
1
  
37D
EG 
WIF
1 
TGGGGGGAAAGGGATTATA 
TCTAAATCATCACTCAAACC
TCCT 
TCTAAATCATCACTCAAACCTC
CT 
60 HINF
1 
37D
EG 
SFRP
5 
GGAGGTGAGGGGGATTA 
 
TCCAAACCACCCACATA 58 MAE1
1 
37D
EG 
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6 - Q-rt-PCR assays 
Human 
GENE DIR SEQUENCE ANNEAL 
CYP24A1 FWD ATGAGCACGTTTGGGAGGAT 60 
CYP24A2 REV TGCCAGACCTTGGTGTTGAG  
VDR FWD CTGACCCTGGAGACTTTGAC 60 
VDR REV TTCCTCTGCACTTCCTCATC  
MYC FWD GCCACGTCTCCACACATCAG 60 
MYC REV TGGTGCATTTTCGGTTGTTG   
Ecad FWD TGAAGGTGACAGAGCCTCTGGAT 60 
Ecad REV TGGGTGAATTCGGGCTTGTT  
LGR5 FWD accagactatgcctttggaaac 60 
LGR5 REV ttcccagggagtggattctat  
VIM FWD Tggtctaacggtttccccta 60 
VIM REV Gacctcggagcgagagtg  
aSMA  FWD ctgttccagccatccttcat 60 
aSMA  REV tcatgatgctgttgtaggtggt  
RSPO1 FWD CCCTTAAAGGACGGGAGAAA 60 
RSPO1 REV AAAGTCCTCCTTTATAGCTGACCA  
IL6 FWD GATGAGTACAAAAGTCCTCGATCCA 60 
IL6 REV CTGCAGCCACTGGTTCTGT  
actb FWD CTGGAACGGTGAAGGTGACA 60 
actb REV AAGGGACTTCCTGTAACAATGCA  
gapd FWD TGCACCACCAACTGCTTAGC 60 
gapd REV GGCATGGACTGTGGTCATGAG  
TGFβ1r-1 FWD gcagacttaggactggcagtaag 60 
TGFβ1r-2 REV agaacttcaggggccatgt  
cd14 FWD gttcggaagacttatcgacca 60 
cd14 REV atcgtccagctcacaaggtt  
cd68 FWD gtccacctcgacctgctct 60 
cd68 REV cactggggcaggagaaact  
f4/80 FWD tgcagctgtcaagttggatt 60 
f4/80 REV tgcacattcatccacgtctt  
tet1 FWD tctgttgttgtgcctctgga 60 
tet1 REV gcctttaaaactttgggcttc  
cd16a FWD gggggctttttgggagta 60 
cd16a REV ggttgacactgccaaacctt  
cd11b FWD ggcatccgcaaagtggta 60 
cd11b REV ggatcttaaaggcattctttcg  
jag 1 FWD ggcaacaccttcaacctca 60 
jag 1 REV gcctccacaagcaacgtatag  
fn1 FWD gaactatgatgccgaccagaa 60 
fn1 REV ggttgtgcagatttcctcgt  
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FAP FWD TGGCGATGAACAATATCCTAGA 60 
FAP REV ATCCGAACAACGGGATTCTT  
Mettl7b FWD cgcaagatggagagcaaga 60 
Mettl7b REV ggctcctgtaagccccttta  
RPSKA3 FWD gacagcgctgagaatggac 60 
RPSKA3 REV tgtgtgattgcaatttctttgat  
TNFα FWD gacaagcctgtagcccatgt 60 
TNFα REV tctcagctccacgccatt  
dnmt1 FWD cagccaacagaggacaacaa 60 
dnmt1 REV ccggctatccaggtcctc  
dnmt3b FWD ggaaattagaatcaaggaaatacga 60 
dnmt3b REV aatttgtcttgaggcgcttg  
TET1 FWD tctgttgttgtgcctctgga 60 
TET1 REV gcctttaaaactttgggcttc  
TET2 FWD acgcttggaagcaggagat 60 
TET2 REV aaggctgccctctagttgaa  
TET3 FWD cgcctctatccgggaact 60 
TET3 REV tccccgtgtagatgaccttc  
EGF FWD tggttgtggttcatccattg 60 
EGF REV tcacagcctccgttttgata  
HGF FWD cagcatgtcctcctgcatc 60 
HGF REV tcttttcctttgtccctctgc  
BMP-1 FWD accctgggcagctacaagt 60 
BMP-1 REV tgaggaatccgccacaag  
kI67 FWD AAGTTCACACGGACGTCAG 60 
kI67 REV GATGCTCTTGCCATCTCC  
MUC2 FWD TGGGTGTCCTCGTCTCCTACA 60 
MUC2 REV TGTTGCCAAACCGGTGGTA  
VEGF FWD cctccgaaaccatgaacttt 60 
VEGF REV atgattctgccctcctcctt  
ICAM1 FWD ccttcctcaccgtgtactgg 60 
ICAM1 REV agcgtagggtaaggttcttgc  
TGFΒ1 FWD actactacgccaaggaggtcac 60 
TGFΒ1 REV tgcttgaacttgtcatagatttcg  
COX2 FWD cttcacgcatcagtttttcaag 60 
COX2 REV tcaccgtaaatatgatttaagtccac  
ERK1 FWD ccctagcccagacagacatc 60 
ERK1 REV gcacagtgtccattttctaacagt  
ERK2 FWD caaagaactaatttttgaagagactgc 60 
ERK2 REV tcctctgagcccttgtcct  
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Mouse 
Gene DIR SEQUENCE ANNEAL 
Mouse Muc2 FWD GCTGACGAGTGGTTGGTGAATG 60 
Mouse Muc2 REV GATGAGGTGGCAGACAGGAGAC  
Mouse Mki67 FWD ACGTATACATATGCCAGGGGA 60 
Mouse Mki67 REV AAAGCTTTGATATCCTCACACTCA  
Mouse Lgr5 FWD GCCTGAACTAAGAACACTGA 60 
Mouse Lgr5 REV CTGGGGAAGAGATGAGAT  
Mouse Lgr5_2 FWD GACGACGGCAACAGTGTGGAC 60 
Mouse Lgr5_2 REV AGGCGAGCACTGCACCGA  
Mouse dnmt1 FWD TGGTGCTGAAGCTCACACTG 60 
Mouse dnmt1 REV CCATACTGTCCAGCCTGGAG  
Mouse dnmt3a FWD CGGCAGAATAGCCAAGTTCA 60 
Mouse dnmt3a REV CTGGTCTTTGCCCTGCTTTA  
Mouse dnmt3b FWD CCAGTCTTGGAGGCAATCTG 60 
Mouse dnmt3b REV CTG GAG ACC TCC CTC TTA GAC AG  
GAPDH FWD TGTGTCCGTCGTGGATCTGA 60 
GAPDH REV TTGCTGTTGAAGTCGCAGGAG  
ACTB FWD CCACTGCCGCATCCTCTTCC 60 
ACTB REV CTCGTTGCCAATAGTGATGACCTG  
RNA Pol II FWD GACAAAACTGGCTCCTCTGC 60 
RNA Pol II REV GCTTGCCCTCTACATTCTGC  
LEF1 FWD ACAGCTGCCTACATCTGAAACA 60 
LEF1 REV CTGGGGTTTCAACAAGCTTC  
CCND1 FWD ATTTGCTCTGAGTCTCCGGT 60 
CCND1 REV AGCACTGCAGCTGGCTT  
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7 – Basal myofibroblast secretome protein ontology 
 
Myofibroblast secretory profiles (BIOLOGICAL PROCESS) 
Case 11 
 
Case 12 
 
Case 13 
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Myofibroblast secretory profiles (CELLULAR COMPONENT) 
Case 11 
 
Case 12 
 
Case 13 
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Myofibroblast secretory profiles (MOLECULAR FUNCTION) 
Case 11 
 
Case 12 
 
Case 13 
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8 – Case 11 MFB, proteins induced by vitamin D (n=124 p<0.05) 
 
6-phosphogluconate dehydrogenase, decarboxylating OS=Homo sapiens GN=PGD PE=1 SV=3 
Amyloid beta A4 protein OS=Homo sapiens GN=APP PE=1 SV=3 
Aspartate aminotransferase, cytoplasmic OS=Homo sapiens GN=GOT1 PE=1 SV=3 
Aspartate aminotransferase, mitochondrial OS=Homo sapiens GN=GOT2 PE=1 SV=3 
ATP-citrate synthase OS=Homo sapiens GN=ACLY PE=1 SV=3 
Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 
Actin, alpha skeletal muscle OS=Homo sapiens GN=ACTA1 PE=1 SV=1 
Agrin OS=Homo sapiens GN=AGRN PE=1 SV=5 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 
Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 
Fructose-bisphosphate aldolase C OS=Homo sapiens GN=ALDOC PE=1 SV=2 
Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform OS=Homo sapiens GN=PPP2R1A 
PE=1 SV=1 
Complement factor B OS=Homo sapiens GN=CFB PE=2 SV=1 
Cytochrome c (Fragment) OS=Homo sapiens GN=CYCS PE=1 SV=1 
Dipeptidyl peptidase 1 OS=Homo sapiens GN=CTSC PE=1 SV=2 
Cathepsin L1 OS=Homo sapiens GN=CTSL PE=1 SV=2 
Cathepsin Z OS=Homo sapiens GN=CTSZ PE=1 SV=1 
Carbonyl reductase [NADPH] 1 OS=Homo sapiens GN=CBR1 PE=1 SV=3 
CD109 antigen OS=Homo sapiens GN=CD109 PE=1 SV=2 
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 
Chitinase-3-like protein 1 OS=Homo sapiens GN=CHI3L1 PE=1 SV=2 
60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 
Chloride intracellular channel protein 1 OS=Homo sapiens GN=CLIC1 PE=1 SV=4 
Collagen alpha-1(IV) chain OS=Homo sapiens GN=COL4A1 PE=1 SV=3 
Collagen alpha-1(V) chain OS=Homo sapiens GN=COL5A1 PE=1 SV=3 
Collagen alpha-2(V) chain OS=Homo sapiens GN=COL5A2 PE=1 SV=3 
Collagen alpha-3(VI) chain OS=Homo sapiens GN=COL6A3 PE=1 SV=5 
Complement component C7 OS=Homo sapiens GN=C7 PE=1 SV=2 
Coactosin-like protein OS=Homo sapiens GN=COTL1 PE=1 SV=3 
UPF0556 protein C19orf10 OS=Homo sapiens GN=C19orf10 PE=1 SV=1 
Hepatocyte growth factor activator OS=Homo sapiens GN=HGFAC PE=3 SV=1 
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 OS=Homo sapiens GN=DDAH1 PE=1 SV=3 
Glutamate dehydrogenase 1, mitochondrial OS=Homo sapiens GN=GLUD1 PE=1 SV=2 
Dickkopf-related protein 3 OS=Homo sapiens GN=DKK3 PE=1 SV=2 
Dipeptidyl peptidase 3 OS=Homo sapiens GN=DPP3 PE=1 SV=2 
Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2 
Epididymal secretory protein E1 OS=Homo sapiens GN=NPC2 PE=1 SV=1 
Kaliocin-1 OS=Homo sapiens GN=LTF PE=1 SV=1 
Thrombospondin-4 OS=Homo sapiens GN=THBS4 PE=4 SV=1 
Puromycin-sensitive aminopeptidase OS=Homo sapiens GN=NPEPPS PE=1 SV=1 
Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 
Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 
EMILIN-1 OS=Homo sapiens GN=EMILIN1 PE=1 SV=2 
Endoplasmic reticulum aminopeptidase 1 OS=Homo sapiens GN=ERAP1 PE=1 SV=3 
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 
Farnesyl pyrophosphate synthase OS=Homo sapiens GN=FDPS PE=1 SV=4 
Ferritin heavy chain OS=Homo sapiens GN=FTH1 PE=1 SV=2 
Ferritin light chain OS=Homo sapiens GN=FTL PE=1 SV=2 
Cartilage oligomeric matrix protein OS=Homo sapiens GN=COMP PE=4 SV=1 
Glucose-6-phosphate 1-dehydrogenase OS=Homo sapiens GN=G6PD PE=1 SV=4 
Glucose-6-phosphate isomerase OS=Homo sapiens GN=GPI PE=1 SV=4 
Neutral alpha-glucosidase AB OS=Homo sapiens GN=GANAB PE=1 SV=3 
Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens GN=GNB2L1 PE=1 SV=3 
Rho GDP-dissociation inhibitor 1 OS=Homo sapiens GN=ARHGDIA PE=1 SV=3 
Glia-derived nexin OS=Homo sapiens GN=SERPINE2 PE=1 SV=1 
1,4-alpha-glucan-branching enzyme OS=Homo sapiens GN=GBE1 PE=1 SV=3 
Glucosamine-6-phosphate isomerase 1 OS=Homo sapiens GN=GNPDA1 PE=1 SV=1 
N-acetylglucosamine-6-sulfatase OS=Homo sapiens GN=GNS PE=1 SV=3 
Glypican-1 OS=Homo sapiens GN=GPC1 PE=1 SV=2 
Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 
Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 
Hypoxanthine-guanine phosphoribosyltransferase OS=Homo sapiens GN=HPRT1 PE=1 SV=2 
Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 
Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 
Heat shock 70 kDa protein 13 OS=Homo sapiens GN=HSPA13 PE=1 SV=1 
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Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5 
Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 
Isocitrate dehydrogenase [NADP] cytoplasmic OS=Homo sapiens GN=IDH1 PE=1 SV=2 
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3 
Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens GN=ITIH3 PE=1 SV=2 
Low-density lipoprotein receptor (Fragment) OS=Homo sapiens GN=LDLR PE=1 SV=1 
Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4 
Laminin subunit alpha-2 OS=Homo sapiens GN=LAMA2 PE=1 SV=4 
Laminin subunit beta-2 OS=Homo sapiens GN=LAMB2 PE=1 SV=2 
L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 
Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 
Leukemia inhibitory factor OS=Homo sapiens GN=LIF PE=1 SV=1 
Lumican OS=Homo sapiens GN=LUM PE=1 SV=2 
Malate dehydrogenase, mitochondrial OS=Homo sapiens GN=MDH2 PE=1 SV=3 
Lactadherin OS=Homo sapiens GN=MFGE8 PE=1 SV=2 
Moesin OS=Homo sapiens GN=MSN PE=1 SV=3 
Alpha-N-acetylgalactosaminidase OS=Homo sapiens GN=NAGA PE=1 SV=2 
Protein NOV homolog OS=Homo sapiens GN=NOV PE=1 SV=1 
Group XV phospholipase A2 OS=Homo sapiens GN=PLA2G15 PE=1 SV=2 
Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 
Programmed cell death 6-interacting protein OS=Homo sapiens GN=PDCD6IP PE=1 SV=1 
Protein disulfide-isomerase OS=Homo sapiens GN=P4HB PE=1 SV=3 
Phosphatidylethanolamine-binding protein 1 OS=Homo sapiens GN=PEBP1 PE=1 SV=3 
Phosphoglycerate mutase 1 OS=Homo sapiens GN=PGAM1 PE=1 SV=2 
Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 OS=Homo sapiens GN=PLOD3 PE=1 SV=1 
Purine nucleoside phosphorylase OS=Homo sapiens GN=PNP PE=1 SV=2 
Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2 
Peptidyl-prolyl cis-trans isomerase B OS=Homo sapiens GN=PPIB PE=1 SV=2 
Peptidyl-prolyl cis-trans isomerase C OS=Homo sapiens GN=PPIC PE=1 SV=1 
Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 
Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 
Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 
Vitamin K-dependent protein S OS=Homo sapiens GN=PROS1 PE=1 SV=1 
Proteasome subunit beta type-4 OS=Homo sapiens GN=PSMB4 PE=1 SV=4 
Prostaglandin-H2 D-isomerase OS=Homo sapiens GN=PTGDS PE=1 SV=1 
Nucleoside diphosphate kinase OS=Homo sapiens GN=NME1-NME2 PE=1 SV=1 
Spliceosome RNA helicase DDX39B OS=Homo sapiens GN=DDX39B PE=1 SV=2 
Translationally-controlled tumor protein OS=Homo sapiens GN=TPT1 PE=1 SV=1 
Selenium-binding protein 1 OS=Homo sapiens GN=SELENBP1 PE=1 SV=2 
Serpin H1 OS=Homo sapiens GN=SERPINH1 PE=1 SV=2 
Superoxide dismutase [Mn], mitochondrial OS=Homo sapiens GN=SOD2 PE=1 SV=2 
Cornifin-A OS=Homo sapiens GN=SPRR1A PE=1 SV=2 
Erythrocyte band 7 integral membrane protein OS=Homo sapiens GN=STOM PE=1 SV=3 
Transaldolase OS=Homo sapiens GN=TALDO1 PE=1 SV=2 
Tubulin alpha-1A chain OS=Homo sapiens GN=TUBA1A PE=1 SV=1 
Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 
Thyroxine-binding globulin OS=Homo sapiens GN=SERPINA7 PE=1 SV=2 
Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 
Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 
Thioredoxin reductase 1, cytoplasmic OS=Homo sapiens GN=TXNRD1 PE=1 SV=3 
Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 
Thrombospondin-2 OS=Homo sapiens GN=THBS2 PE=1 SV=2 
Protein tweety homolog 3 OS=Homo sapiens GN=TTYH3 PE=1 SV=3 
Thioredoxin domain-containing protein 17 OS=Homo sapiens GN=TXNDC17 PE=1 SV=1 
Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3 
WD repeat-containing protein 1 OS=Homo sapiens GN=WDR1 PE=1 SV=4 
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9 – Case 12 MFB, proteins induced by vitamin D (n=86 p<0.05) 
 
Nidogen-1 OS=Homo sapiens GN=NID1 PE=1 SV=3 
Laminin subunit gamma-1 OS=Homo sapiens GN=LAMC1 PE=1 SV=3 
Proteasome subunit alpha type OS=Homo sapiens GN=PSMA6 PE=1 SV=1 
Chondroitin sulfate proteoglycan 4 OS=Homo sapiens GN=CSPG4 PE=1 SV=2 
Phosphoglycerate kinase 1 OS=Homo sapiens GN=PGK1 PE=1 SV=3 
Moesin OS=Homo sapiens GN=MSN PE=1 SV=3 
78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 
Procollagen C-endopeptidase enhancer 1 OS=Homo sapiens GN=PCOLCE PE=1 SV=2 
Heparan sulfate proteoglycan 2 (Perlecan), isoform CRA_b OS=Homo sapiens GN=HSPG2 PE=4 SV=1 
Xaa-Pro dipeptidase OS=Homo sapiens GN=PEPD PE=1 SV=3 
Proteasome subunit beta type-6 OS=Homo sapiens GN=PSMB6 PE=1 SV=4 
Glutamate dehydrogenase 1, mitochondrial OS=Homo sapiens GN=GLUD1 PE=1 SV=2 
Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 
Protein disulfide-isomerase OS=Homo sapiens GN=P4HB PE=1 SV=3 
Tyrosine-protein kinase receptor OS=Homo sapiens GN=SDC4-ROS1_S4;R32 PE=2 SV=1 
Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 
Transforming growth factor-beta-induced protein ig-h3 OS=Homo sapiens GN=TGFΒI PE=1 SV=1 
Keratin, type II cytoskeletal 75 OS=Homo sapiens GN=KRT75 PE=1 SV=2 
cDNA FLJ55694, highly similar to Dipeptidyl-peptidase 1 (EC 3.4.14.1) OS=Homo sapiens PE=2 SV=1 
Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=1 
Glypican-1 OS=Homo sapiens GN=GPC1 PE=1 SV=2 
Laminin subunit beta-1 OS=Homo sapiens GN=LAMB1 PE=1 SV=1 
Lysosomal Pro-X carboxypeptidase OS=Homo sapiens GN=PRCP PE=1 SV=1 
Aspartate aminotransferase, cytoplasmic OS=Homo sapiens GN=GOT1 PE=1 SV=3 
Collagen alpha-2(V) chain OS=Homo sapiens GN=COL5A2 PE=1 SV=3 
L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 
Sulfhydryl oxidase 1 OS=Homo sapiens GN=QSOX1 PE=1 SV=3 
Decorin OS=Homo sapiens GN=DCN PE=1 SV=1 
Pentraxin-related protein PTX3 OS=Homo sapiens GN=PTX3 PE=1 SV=3 
Calreticulin OS=Homo sapiens GN=CALR PE=1 SV=1 
EGF-containing fibulin-like extracellular matrix protein 1 OS=Homo sapiens GN=EFEMP1 PE=1 SV=2 
Insulin-like growth factor-binding protein 4 OS=Homo sapiens GN=IGFBP4 PE=1 SV=2 
Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 
Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 
Aldose reductase OS=Homo sapiens GN=AKR1B1 PE=1 SV=3 
Prolow-density lipoprotein receptor-related protein 1 OS=Homo sapiens GN=LRP1 PE=1 SV=2 
Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 
Lumican OS=Homo sapiens GN=LUM PE=1 SV=2 
Prosaposin (Variant Gaucher disease and variant metachromatic leukodystrophy) variant (Fragment) OS=Homo sapiens 
PE=2 SV=1 
Dihydrolipoyl dehydrogenase, mitochondrial OS=Homo sapiens GN=DLD PE=1 SV=2 
Serine/threonine-protein phosphatase CPPED1 OS=Homo sapiens GN=CPPED1 PE=1 SV=3 
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 
Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 
Laminin subunit alpha-2 OS=Homo sapiens GN=LAMA2 PE=1 SV=4 
Complement C1s subcomponent OS=Homo sapiens GN=C1S PE=1 SV=1 
Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4 
Glucose-6-phosphate isomerase (Fragment) OS=Homo sapiens GN=GPI PE=1 SV=1 
Lactoferrin OS=Homo sapiens PE=2 SV=1 
Putative uncharacterized protein DKFZp686M0562 (Fragment) OS=Homo sapiens GN=DKFZp686M0562 PE=2 SV=1 
Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3 
Collagen alpha-1(VI) chain OS=Homo sapiens GN=COL6A1 PE=1 SV=3 
Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 
Transketolase (Fragment) OS=Homo sapiens PE=2 SV=1 
Neuropilin-1 OS=Homo sapiens GN=NRP1 PE=4 SV=1 
Alpha-actinin-4 OS=Homo sapiens GN=ACTN4 PE=1 SV=2 
Lysosomal protective protein OS=Homo sapiens GN=CTSA PE=4 SV=1 
Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 
Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 
L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2 
Cathepsin L1 OS=Homo sapiens GN=CTSL1 PE=2 SV=1 
Laminin, alpha 4, isoform CRA_b OS=Homo sapiens GN=LAMA4 PE=4 SV=1 
Collagen alpha-1(XII) chain OS=Homo sapiens GN=COL12A1 PE=1 SV=2 
YWHAE/FAM22A fusion protein (Fragment) OS=Homo sapiens GN=YWHAE/FAM22A fusion PE=2 SV=1 
Collagen alpha-1(XIV) chain OS=Homo sapiens GN=COL14A1 PE=1 SV=3 
Macrophage colony-stimulating factor 1 OS=Homo sapiens GN=CSF1 PE=1 SV=2 
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Tripeptidyl-peptidase 1 OS=Homo sapiens GN=TPP1 PE=1 SV=2 
Glutathione reductase, mitochondrial OS=Homo sapiens GN=GSR PE=1 SV=2 
Tryptophan--tRNA ligase, cytoplasmic OS=Homo sapiens GN=WARS PE=1 SV=2 
Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 
Phosphoserine aminotransferase OS=Homo sapiens GN=PSAT1 PE=1 SV=2 
Keratin, type II cytoskeletal 1b OS=Homo sapiens GN=KRT77 PE=2 SV=3 
Fumarylacetoacetase OS=Homo sapiens GN=FAH PE=1 SV=2 
Metalloproteinase inhibitor 2 OS=Homo sapiens GN=TIMP2 PE=1 SV=2 
72 kDa type IV collagenase OS=Homo sapiens GN=MMP2 PE=1 SV=2 
Selenium-binding protein 1 OS=Homo sapiens GN=SELENBP1 PE=1 SV=2 
Endothelial protein C receptor OS=Homo sapiens GN=PROCR PE=1 SV=1 
Suprabasin OS=Homo sapiens GN=SBSN PE=2 SV=2 
Complement component 1, r subcomponent variant (Fragment) OS=Homo sapiens PE=2 SV=1 
Protein-glutamine gamma-glutamyltransferase E OS=Homo sapiens GN=TGM3 PE=1 SV=4 
Transitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=4 
Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 
Beta-hexosaminidase subunit beta OS=Homo sapiens GN=HEXB PE=1 SV=3 
Collagen alpha-1(V) chain OS=Homo sapiens GN=COL5A1 PE=1 SV=1 
Neogenin OS=Homo sapiens GN=NEO1 PE=1 SV=2 
Phosphatidylethanolamine-binding protein 1 OS=Homo sapiens GN=PEBP1 PE=1 SV=3 
 
10 – Case 13 MFB, proteins induced by vitamin D (n=12 p<0.05) 
 
Fibrillin-1 OS=Homo sapiens GN=FBN1 PE=1 SV=3 
Superoxide dismutase [Mn], mitochondrial OS=Homo sapiens GN=SOD2 PE=1 SV=2 
Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 
Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=1 
Laminin subunit alpha-2 OS=Homo sapiens GN=LAMA2 PE=1 SV=4 
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 
Spondin-2 OS=Homo sapiens GN=SPON2 PE=1 SV=3 
Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 
Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 
Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 
Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 
Stromelysin-1 OS=Homo sapiens GN=MMP3 PE=1 SV=2  
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11 – Vitamin D differentially methylated promoters CaCO2 and DLD1 
(array 1, experiment 2) 
 
86 coding promoters differentially methylated by vitamin D in CACO2 
id Chromosome symbol CACO_CTRL CACO_VIT_D mean.diff comb.p.val 
ENSG00000184227 chr14 ACOT1 0.47 0.48 0.00 0.04 
ENSG00000196344 chr4 ADH7 0.88 0.92 -0.04 0.02 
ENSG00000187546 chr7 AGMO 0.64 0.76 -0.12 0.02 
ENSG00000225556 chr1 C2CD4D 0.53 0.53 0.00 0.04 
ENSG00000243715 chr3 CACNA2D3-AS1 0.67 0.75 -0.07 0.04 
ENSG00000205021 chr17 CCL3L1 0.81 0.85 -0.04 0.04 
ENSG00000113240 chr5 CLK4 0.34 0.27 0.06 0.05 
ENSG00000188603 chr16 CLN3 0.95 0.96 -0.01 0.04 
ENSG00000182372 chr8 CLN8 0.60 0.67 -0.07 0.02 
ENSG00000186115 chr19 CYP4F2 0.79 0.84 -0.05 0.03 
ENSG00000077279 chrX DCX 0.61 0.74 -0.13 0.02 
ENSG00000088367 chr20 EPB41L1 0.33 0.39 -0.05 0.05 
ENSG00000182473 chr17 EXOC7 0.93 0.94 -0.01 0.05 
ENSG00000155875 chr9 FAM154A 0.82 0.87 -0.04 0.04 
ENSG00000162746 chr1 FCRLB 0.18 0.25 -0.07 0.04 
ENSG00000171049 chr19 FPR2 0.20 0.23 -0.03 0.04 
ENSG00000164946 chr9 FREM1 0.94 0.92 0.02 0.04 
ENSG00000144820 chr3 GPR128 0.91 0.92 -0.01 0.05 
ENSG00000182793 chr6 GSTA5 0.67 0.69 -0.02 0.05 
ENSG00000181211 chr7 HECW1-IT1 0.03 0.05 -0.02 0.05 
ENSG00000138684 chr4 IL21 0.46 0.54 -0.08 0.03 
ENSG00000151364 chr11 KCTD14 0.15 0.09 0.06 0.05 
ENSG00000197084 chr1 LCE1C 0.12 0.17 -0.05 0.00 
ENSG00000179676 chr18 LINC00305 0.58 0.67 -0.09 0.03 
ENSG00000248307 chr4 LINC00616 0.86 0.90 -0.04 0.03 
ENSG00000224382 chr10 LINC00703 0.62 0.71 -0.08 0.04 
ENSG00000246898 chr16 LINC00920 0.45 0.47 -0.02 0.04 
ENSG00000130368 chr6 MAS1 0.81 0.80 0.01 0.05 
ENSG00000211520 chr2 MIR216B 0.88 0.90 -0.02 0.03 
ENSG00000253008 chr2 MIR2355 0.86 0.92 -0.06 0.00 
ENSG00000199127 chr8 MIR383 0.38 0.48 -0.10 0.03 
ENSG00000266705 chr2 MIR4437 0.74 0.81 -0.07 0.02 
ENSG00000264319 chr4 MIR4801 0.14 0.21 -0.06 0.02 
ENSG00000207629 chr19 MIR526A1 0.59 0.64 -0.05 0.05 
ENSG00000199165 chr9 MIRLET7A1 0.83 0.86 -0.04 0.05 
ENSG00000172680 chr8 MOS 0.75 0.80 -0.05 0.04 
ENSG00000102891 chr16 MT4 0.60 0.66 -0.06 0.05 
ENSG00000138386 chr2 NAB1 0.97 0.98 -0.01 0.03 
ENSG00000162599 chr1 NFIA 0.27 0.42 -0.15 0.01 
ENSG00000260305 chr15 NTRK3-AS1 0.52 0.61 -0.09 0.00 
ENSG00000255582 chr14 OR10G2 0.74 0.80 -0.06 0.05 
ENSG00000196248 chr11 OR10S1 0.21 0.28 -0.07 0.01 
ENSG00000186306 chr1 OR10T2 0.06 0.05 0.01 0.02 
ENSG00000196944 chr1 OR2T4 0.06 0.08 -0.02 0.02 
ENSG00000176895 chr11 OR51A7 0.22 0.29 -0.06 0.04 
ENSG00000180785 chr11 OR51E1 0.78 0.83 -0.05 0.04 
ENSG00000232268 chr11 OR52I1 0.21 0.27 -0.06 0.01 
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ENSG00000179626 chr12 OR6C4 0.91 0.93 -0.03 0.02 
ENSG00000172381 chr11 OR6Q1 0.05 0.10 -0.05 0.00 
ENSG00000172487 chr11 OR8J1 0.14 0.22 -0.08 0.01 
ENSG00000172199 chr11 OR8U1 0.15 0.23 -0.08 0.01 
ENSG00000149090 chr11 PAMR1 0.82 0.88 -0.06 0.02 
ENSG00000172840 chr16 PDP2 0.96 0.98 -0.01 0.03 
ENSG00000230082 chr3 PRRT3-AS1 0.28 0.23 0.05 0.05 
ENSG00000172780 chr3 RAB43 0.94 0.96 -0.02 0.04 
ENSG00000130701 chr20 RBBP8NL 0.17 0.18 -0.02 0.04 
ENSG00000134533 chr12 RERG 0.35 0.43 -0.08 0.02 
ENSG00000111445 chr12 RFC5 0.18 0.30 -0.12 0.01 
ENSG00000107018 chr9 RLN1 0.42 0.36 0.06 0.04 
ENSG00000107014 chr9 RLN2 0.49 0.42 0.07 0.03 
ENSG00000207200 chr11 RNU6-45P 0.89 0.91 -0.03 0.04 
ENSG00000104237 chr8 RP1 0.79 0.86 -0.07 0.03 
ENSG00000163993 chr4 S100P 0.96 0.95 0.01 0.04 
ENSG00000174326 chr17 SLC16A11 0.88 0.84 0.05 0.05 
ENSG00000171790 chr1 SLFNL1 0.93 0.95 -0.02 0.04 
ENSG00000109208 chr4 SMR3A 0.48 0.64 -0.16 0.00 
ENSG00000209582 chr17 SNORA48 0.70 0.72 -0.01 0.05 
ENSG00000238317 chr2 SNORD11 0.93 0.95 -0.02 0.04 
ENSG00000214929 chr9 SPATA31D1 0.48 0.58 -0.11 0.00 
ENSG00000166211 chr12 SPIC 0.43 0.57 -0.14 0.01 
ENSG00000159516 chr1 SPRR2G 0.24 0.29 -0.05 0.04 
ENSG00000241186 chr3 TDGF1 0.94 0.95 -0.01 0.05 
ENSG00000137462 chr4 TLR2 0.82 0.86 -0.04 0.03 
ENSG00000165091 chr9 TMC1 0.88 0.91 -0.03 0.02 
ENSG00000181634 chr9 TNFSF15 0.72 0.77 -0.05 0.04 
ENSG00000211701 chr7 TRGV1 0.92 0.88 0.04 0.03 
ENSG00000233306 chr7 TRGV2 0.18 0.24 -0.06 0.02 
ENSG00000166007 chr11 TRIM51HP 0.23 0.30 -0.07 0.02 
ENSG00000243197 chr3 TUSC7 0.84 0.88 -0.04 0.05 
ENSG00000220205 chr17 VAMP2 0.55 0.52 0.03 0.04 
ENSG00000146469 chr6 VIP 0.24 0.23 0.01 0.03 
ENSG00000146007 chr5 ZMAT2 0.92 0.94 -0.02 0.05 
ENSG00000147117 chrX ZNF157 0.88 0.93 -0.04 0.02 
ENSG00000158805 chr16 ZNF276 0.09 0.10 -0.01 0.05 
ENSG00000197857 chr19 ZNF44 0.32 0.38 -0.06 0.05 
ENSG00000176083 chr1 ZNF683 0.80 0.85 -0.06 0.01 
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142 coding promoters differentially methylated by vitamin D in DLD1 
id Chromosome symbol DLD_CTRL DLD_VIT_D diff comb.p.val 
ENSG00000123165 chrX ACTRT1 0.268119 0.412335 -0.14422 0.015769 
ENSG00000159322 chr15 ADPGK 0.566053 0.66238 -0.09633 0.024263 
ENSG00000186471 chrX AKAP14 0.789977 0.825109 -0.03513 0.027671 
ENSG00000125363 chrX AMELX 0.960124 0.970782 -0.01066 0.043623 
ENSG00000163297 chr4 ANTXR2 0.944883 0.963396 -0.01851 0.013948 
ENSG00000243478 chr2 AOX2P 0.831792 0.867926 -0.03613 0.017628 
ENSG00000134817 chr11 APLNR 0.303875 0.331675 -0.0278 0.045655 
ENSG00000103375 chr16 AQP8 0.608477 0.660297 -0.05182 0.034385 
ENSG00000067842 chrX ATP2B3 0.627358 0.674478 -0.04712 0.049484 
ENSG00000126895 chrX AVPR2 0.431314 0.468286 -0.03697 0.048653 
ENSG00000160862 chr7 AZGP1 0.623527 0.681335 -0.05781 0.018188 
ENSG00000172530 chr16 BANP 0.973481 0.97887 -0.00539 0.037396 
ENSG00000215277 chr14 C14orf164 0.735496 0.783247 -0.04775 0.026107 
ENSG00000198854 chr1 C1orf68 0.123195 0.167465 -0.04427 0.030614 
ENSG00000172247 chr11 C1QTNF4 0.367616 0.40647 -0.03885 0.035893 
ENSG00000181215 chr4 C4orf50 0.072308 0.101396 -0.02909 0.045844 
ENSG00000164898 chr7 C7orf55 0.978067 0.985144 -0.00708 0.028063 
ENSG00000021852 chr1 C8B 0.549816 0.519557 0.030259 0.033205 
ENSG00000164972 chr9 C9orf24 0.915525 0.915877 -0.00035 0.044452 
ENSG00000196954 chr11 CASP4 0.20436 0.158919 0.045441 0.013583 
ENSG00000163492 chr2 CCDC141 0.894329 0.921638 -0.02731 0.022452 
ENSG00000108700 chr17 CCL8 0.046012 0.059461 -0.01345 0.03329 
ENSG00000074276 chr5 CDHR2 0.330226 0.385556 -0.05533 0.027157 
ENSG00000147883 chr9 CDKN2B 0.035039 0.036181 -0.00114 0.048728 
ENSG00000135346 chr6 CGA 0.700712 0.761037 -0.06032 0.010915 
ENSG00000141076 chr16 CIRH1A 0.84252 0.79634 0.04618 0.021222 
ENSG00000166509 chr16 CLEC3A 0.376825 0.378551 -0.00173 0.04046 
ENSG00000005243 chr17 COPZ2 0.214389 0.223038 -0.00865 0.027487 
ENSG00000135047 chr9 CTSL 0.888645 0.908279 -0.01963 0.021891 
ENSG00000265766 chr18 CXADRP3 0.071327 0.117699 -0.04637 0.011852 
ENSG00000088782 chr20 DEFB127 0.812053 0.843311 -0.03126 0.04188 
ENSG00000147570 chr8 DNAJC5B 0.647765 0.682541 -0.03478 0.017367 
ENSG00000116675 chr1 DNAJC6 0.92351 0.889422 0.034087 0.004101 
ENSG00000128886 chr15 ELL3 0.123064 0.158223 -0.03516 0.036676 
ENSG00000188833 chr9 ENTPD8 0.214838 0.237948 -0.02311 0.045144 
ENSG00000138018 chr2 EPT1 0.978474 0.973838 0.004636 0.049655 
ENSG00000164283 chr5 ESM1 0.097093 0.093093 0.004 0.027124 
ENSG00000151327 chr14 FAM177A1 0.192457 0.120102 0.072355 0.015011 
ENSG00000122378 chr10 FAM213A 0.123501 0.145752 -0.02225 0.042932 
ENSG00000151474 chr10 FRMD4A 0.534981 0.527373 0.007608 0.032248 
ENSG00000158089 chr2 GALNT14 0.560335 0.522311 0.038024 0.007729 
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ENSG00000182512 chr14 GLRX5 0.230337 0.180164 0.050174 0.00315 
ENSG00000205336 chr16 GPR56 0.961592 0.972036 -0.01044 0.010327 
ENSG00000113088 chr5 GZMK 0.097093 0.093093 0.004 0.027124 
ENSG00000213934 chr11 HBG1 0.765661 0.807311 -0.04165 0.017351 
ENSG00000029993 chrX HMGB3 0.736788 0.782406 -0.04562 0.019695 
ENSG00000179362 chr15 HMGN2P46 0.725235 0.798017 -0.07278 0.012664 
ENSG00000203859 chr1 HSD3B2 0.901618 0.897865 0.003753 0.048058 
ENSG00000137142 chr9 IGFBPL1 0.898942 0.918342 -0.0194 0.030544 
ENSG00000168685 chr5 IL7R 0.968973 0.975379 -0.00641 0.026621 
ENSG00000177301 chr1 KCNA2 0.112966 0.081357 0.031609 0.022879 
ENSG00000170871 chr4 KIAA0232 0.955217 0.970662 -0.01545 0.016532 
ENSG00000186965 chr21 KRTAP19-2 0.06671 0.097344 -0.03063 0.01748 
ENSG00000204571 chr11 KRTAP5-11 0.143076 0.194623 -0.05155 0.004144 
ENSG00000235106 chr9 LINC00094 0.288663 0.301341 -0.01268 0.041821 
ENSG00000196553 chr14 LINC00238 0.897722 0.919781 -0.02206 0.046946 
ENSG00000231674 chr13 LINC00410 0.919336 0.936639 -0.0173 0.049423 
ENSG00000241469 chr3 LINC00635 0.776074 0.796176 -0.0201 0.027645 
ENSG00000243629 chr3 LINC00880 0.942882 0.960811 -0.01793 0.028091 
ENSG00000242385 chr3 LINC00901 0.121934 0.068443 0.053491 0.043745 
ENSG00000261742 chr16 LINC00922 0.374622 0.381563 -0.00694 0.039737 
ENSG00000259361 chr15 LINC00927 0.112917 0.1302 -0.01728 0.046628 
ENSG00000259150 chr15 LINC00929 0.2759 0.320122 -0.04422 0.019221 
ENSG00000253138 chr8 LINC00967 0.033288 0.045818 -0.01253 0.038215 
ENSG00000134569 chr11 LRP4 0.551964 0.572881 -0.02092 0.04095 
ENSG00000161572 chr17 LYZL6 0.502666 0.533645 -0.03098 0.042634 
ENSG00000166986 chr12 MARS 0.855032 0.866679 -0.01165 0.036424 
ENSG00000185231 chr18 MC2R 0.533305 0.562099 -0.02879 0.040556 
ENSG00000207939 chrX MIR223 0.104488 0.132764 -0.02828 0.041636 
ENSG00000207621 chrX MIR224 0.217749 0.296859 -0.07911 0.013031 
ENSG00000253008 chr2 MIR2355 0.978667 0.984314 -0.00565 0.007131 
ENSG00000264139 chr22 MIR3667 0.315901 0.36543 -0.04953 0.044154 
ENSG00000265432 chr14 MIR4308 0.969646 0.976111 -0.00647 0.046815 
ENSG00000264302 chr17 MIR4723 0.960193 0.970451 -0.01026 0.047725 
ENSG00000266459 chr17 MIR4724 0.534389 0.557531 -0.02314 0.049925 
ENSG00000265438 chr19 MIR4751 0.940463 0.963243 -0.02278 0.002835 
ENSG00000265329 chr20 MIR4758 0.937303 0.957732 -0.02043 0.022978 
ENSG00000207738 chr19 MIR520C 0.503432 0.526322 -0.02289 0.026045 
ENSG00000207815 chr3 MIR563 0.628087 0.680134 -0.05205 0.047943 
ENSG00000266099 chr12 MIR5700 0.032037 0.043344 -0.01131 0.006025 
ENSG00000144029 chr2 MRPS5 0.951075 0.957776 -0.0067 0.048597 
ENSG00000105835 chr7 NAMPT 0.071108 0.040707 0.030401 0.002679 
ENSG00000160703 chr11 NLRX1 0.170003 0.2147 -0.0447 0.037491 
ENSG00000105954 chr7 NPVF 0.759824 0.782873 -0.02305 0.034067 
ENSG00000124657 chr6 OR2B6 0.782589 0.853815 -0.07123 0.023023 
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ENSG00000177489 chr1 OR2G2 0.505475 0.501366 0.004109 0.016502 
ENSG00000177233 chr1 OR2M1P 0.202822 0.170352 0.03247 0.029729 
ENSG00000176253 chr14 OR4K13 0.46141 0.527169 -0.06576 0.016651 
ENSG00000181963 chr11 OR52K2 0.310231 0.335517 -0.02529 0.048551 
ENSG00000181023 chr11 OR56B1 0.035284 0.046282 -0.011 0.019716 
ENSG00000183303 chr11 OR5P2 0.268317 0.28487 -0.01655 0.022626 
ENSG00000188324 chr12 OR6C6 0.096432 0.147209 -0.05078 0.019371 
ENSG00000181689 chr11 OR8K3 0.100092 0.145729 -0.04564 0.048779 
ENSG00000172199 chr11 OR8U1 0.09099 0.067832 0.023158 0.034863 
ENSG00000181631 chr3 P2RY13 0.945726 0.949485 -0.00376 0.042059 
ENSG00000072682 chr5 P4HA2 0.030954 0.021289 0.009664 0.048931 
ENSG00000249504 chr5 PCDHA14 0.725271 0.728933 -0.00366 0.032048 
ENSG00000159763 chr7 PIP 0.526587 0.563795 -0.03721 0.033992 
ENSG00000105171 chr19 POP4 0.937016 0.921895 0.015121 0.027256 
ENSG00000137709 chr11 POU2F3 0.050516 0.067457 -0.01694 0.016511 
ENSG00000146250 chr6 PRSS35 0.080082 0.051166 0.028916 0.034691 
ENSG00000258223 chr7 PRSS58 0.047446 0.070099 -0.02265 0.023822 
ENSG00000188921 chr9 PTPLAD2 0.979361 0.984447 -0.00509 0.02913 
ENSG00000124839 chr2 RAB17 0.79142 0.832721 -0.0413 0.023383 
ENSG00000011454 chr9 RABGAP1 0.093705 0.071937 0.021768 0.030827 
ENSG00000160439 chr19 RDH13 0.496431 0.503315 -0.00688 0.021404 
ENSG00000172023 chr2 REG1B 0.180739 0.253316 -0.07258 0.030453 
ENSG00000143954 chr2 REG3G 0.100432 0.116551 -0.01612 0.040039 
ENSG00000067560 chr3 RHOA 0.111628 0.145472 -0.03384 0.044758 
ENSG00000267128 chr17 RNF157-AS1 0.680614 0.691131 -0.01052 0.019211 
ENSG00000184719 chr10 RNLS 0.853768 0.871178 -0.01741 0.03977 
ENSG00000120341 chr1 SEC16B 0.52214 0.543815 -0.02167 0.024303 
ENSG00000100095 chr22 SEZ6L 0.485717 0.514707 -0.02899 0.016525 
ENSG00000089060 chr12 SLC24A6 0.560444 0.589673 -0.02923 0.002054 
ENSG00000183780 chr1 SLC35F3 0.911124 0.915399 -0.00428 0.047524 
ENSG00000151812 chr14 SLC35F4 0.505161 0.561587 -0.05643 0.028139 
ENSG00000211584 chr12 SLC48A1 0.955994 0.968726 -0.01273 0.016732 
ENSG00000171790 chr1 SLFNL1 0.928723 0.963179 -0.03446 0.019056 
ENSG00000163206 chr1 SMCP 0.396033 0.432362 -0.03633 0.020646 
ENSG00000201700 chr14 SNORD113-3 0.023757 0.035532 -0.01178 0.048891 
ENSG00000202142 chr14 SNORD114-18 0.036346 0.059959 -0.02361 0.045662 
ENSG00000199942 chr14 SNORD114-19 0.036346 0.059959 -0.02361 0.045662 
ENSG00000199390 chr14 SNORD114-7 0.721162 0.747362 -0.0262 0.021287 
ENSG00000199970 chr15 SNORD115-3 0.439074 0.493546 -0.05447 0.045339 
ENSG00000202188 chr15 SNORD115-31 0.258897 0.281237 -0.02234 0.013137 
ENSG00000173898 chr11 SPTBN2 0.93745 0.970733 -0.03328 0.01164 
ENSG00000113387 chr5 SUB1 0.123035 0.184695 -0.06166 0.008114 
ENSG00000132872 chr18 SYT4 0.118384 0.145328 -0.02694 0.032213 
ENSG00000121314 chr12 TAS2R8 0.578823 0.666617 -0.08779 0.047418 
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ENSG00000122145 chrX TBX22 0.097592 0.10431 -0.00672 0.018616 
ENSG00000145850 chr5 TIMD4 0.230878 0.289551 -0.05867 0.036731 
ENSG00000065717 chr19 TLE2 0.355402 0.377419 -0.02202 0.041378 
ENSG00000163762 chr3 TM4SF18 0.211306 0.32227 -0.11096 0.000475 
ENSG00000123610 chr2 TNFΑIP6 0.850479 0.87758 -0.0271 0.030854 
ENSG00000120337 chr1 TNFSF18 0.809958 0.851456 -0.0415 0.028445 
ENSG00000167460 chr19 TPM4 0.067351 0.089832 -0.02248 0.010034 
ENSG00000108448 chr17 TRIM16L 0.066939 0.094141 -0.0272 0.018539 
ENSG00000167118 chr9 URM1 0.031323 0.043951 -0.01263 0.01835 
ENSG00000146469 chr6 VIP 0.239673 0.207967 0.031706 0.018681 
ENSG00000166415 chr15 WDR72 0.227076 0.109069 0.118008 0.042173 
ENSG00000010539 chr16 ZNF200 0.034947 0.048366 -0.01342 0.036302 
ENSG00000261221 chr19 ZNF865 0.233945 0.297343 -0.0634 0.017926 
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12 – Vitamin D differentially methylated single sites CaCO2 (array 1, 
experiment 2). Used for pathway analysis 
 
gene cgid CACO_CTRL CACO_VIT_D mean.diff diffmeth.p.val 
NF cg24928333 0.94 0.84 0.10 0.02 
PLCXD3 cg09499856 0.94 0.70 0.23 0.02 
NF cg17526103 0.93 0.83 0.10 0.04 
TTBK1 cg27363327 0.88 0.78 0.10 0.00 
DIP2C cg15551781 0.87 0.77 0.10 0.00 
ALOXE3 cg18700133 0.85 0.73 0.12 0.01 
IDUA cg05327835 0.85 0.74 0.11 0.02 
NF cg27179866 0.84 0.68 0.16 0.00 
NF cg03543893 0.82 0.72 0.10 0.00 
NF cg21503053 0.81 0.70 0.11 0.05 
KCNIP4 cg07204550 0.81 0.71 0.10 0.02 
BCL2L10 cg14540387 0.81 0.69 0.12 0.00 
ZNF655 cg05165378 0.79 0.68 0.11 0.00 
TMEM140 cg21363348 0.79 0.68 0.11 0.02 
NF cg10883069 0.79 0.69 0.10 0.01 
RPS6KA3 cg12456011 0.78 0.64 0.14 0.00 
NF cg12322450 0.77 0.66 0.11 0.01 
NF cg18266853 0.76 0.65 0.11 0.03 
TTC23L cg11183001 0.74 0.63 0.11 0.01 
FBXO47 cg10600889 0.74 0.62 0.12 0.01 
TEKT3 cg02016419 0.73 0.63 0.11 0.04 
ELOVL4 cg04107099 0.73 0.62 0.10 0.03 
NF cg26331343 0.72 0.60 0.12 0.03 
C8orf84 cg04367680 0.71 0.59 0.12 0.04 
HPCA cg05660436 0.71 0.51 0.19 0.01 
SPINK1 cg14452346 0.71 0.61 0.10 0.03 
NF cg03730474 0.71 0.60 0.10 0.01 
KLHL4 cg07897414 0.70 0.56 0.14 0.02 
ZNF350 cg18649745 0.70 0.59 0.11 0.01 
NF cg16005540 0.69 0.57 0.13 0.02 
NF cg23601397 0.69 0.57 0.12 0.01 
ATP2A1 cg16606674 0.68 0.57 0.11 0.01 
HPCA cg02631838 0.67 0.57 0.11 0.00 
CECR2 cg13762691 0.66 0.55 0.12 0.01 
GFI1 cg25320328 0.65 0.54 0.11 0.03 
NF cg00241427 0.64 0.54 0.10 0.01 
NF cg26645509 0.64 0.52 0.12 0.01 
MGC2889 cg08376864 0.64 0.51 0.13 0.01 
NF cg10098888 0.63 0.52 0.11 0.03 
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PCDH19 cg26401825 0.63 0.52 0.11 0.01 
MAP3K15 cg00072587 0.63 0.49 0.14 0.00 
RAB9B cg02547323 0.63 0.49 0.14 0.01 
MAGEC1 cg24761827 0.62 0.49 0.14 0.01 
HLA-DQB1 cg18902440 0.62 0.51 0.11 0.02 
SLMO1 cg07207726 0.61 0.50 0.10 0.01 
SLMO1 cg20984502 0.61 0.45 0.16 0.00 
NF cg16324725 0.60 0.41 0.19 0.03 
FRMD7 cg06647694 0.59 0.46 0.13 0.00 
NF cg07916101 0.59 0.48 0.11 0.01 
NF cg00188409 0.58 0.47 0.11 0.02 
NF cg02603022 0.58 0.45 0.13 0.02 
LPGAT1 cg13064658 0.57 0.05 0.52 0.00 
BCL11B cg12961080 0.57 0.44 0.13 0.03 
FHL1 cg12623328 0.56 0.45 0.12 0.03 
CACNA2D cg15603311 0.56 0.46 0.10 0.02 
TTC23L cg07895169 0.55 0.45 0.10 0.03 
GGN cg25922163 0.54 0.38 0.16 0.01 
CYB5R2 cg18791121 0.54 0.40 0.14 0.00 
NOL4 cg22287067 0.54 0.40 0.14 0.01 
PRKCB cg05632631 0.54 0.40 0.13 0.00 
CNPY1 cg26388509 0.53 0.42 0.11 0.04 
BCL2L10 cg19114050 0.52 0.41 0.10 0.04 
RBM23 cg01529538 0.51 0.40 0.12 0.05 
UNC5D cg08701686 0.51 0.39 0.12 0.00 
TRPM3 cg21171320 0.51 0.30 0.21 0.00 
EDA2R cg10153260 0.51 0.40 0.11 0.04 
PRICKLE3 cg04675919 0.51 0.39 0.12 0.00 
BIN3 cg07164659 0.50 0.40 0.11 0.01 
CADPS cg21534264 0.50 0.39 0.12 0.01 
RNLS cg06079710 0.50 0.37 0.13 0.00 
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The End 
